

INTERNATIONAL SOCIETY FOR
HEART AND LUNG TRANSPLANTATION

FINAL PROGRAM

Prague

PRAHA, CZECH REPUBLIC
PRAGUE CONGRESS CENTRE



32nd Annual Meeting &
Scientific Sessions April 18-21, 2012

FINAL PROGRAM

32nd Annual Meeting
& Scientific Sessions
April 18-21, 2012

EXPLORING
where it matters most



A long-standing
commitment to
cardiopulmonary
research

INSIDE FRONT COVER
FOR POSITION ONLY

TABLE OF CONTENTS

About ISHLT	2
Board of Directors	4
Scientific Program Committee	6
Abstract Reviewers	7
Committees	15
Scientific Councils	19
Past Presidents	22
Award Recipients	24
Daily Schedule Foldouts	between 24-37
Corporate Partners	30
Continuing Medical Education	32
Scientific Session Highlights	36
Meeting Rooms Floor Plan	50
ISHLT Academy Program	53
Program At a Glance	64
Scientific Program	80
List of Exhibiting Companies	228
Exhibit Hall and Poster Floor Plan	230
Exhibitors	232



ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.



THE PURPOSES OF THE SOCIETY ARE:

- 1.** To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
- 2.** To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
- 3.** To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
- 4.** To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
- 5.** To establish and maintain an international registry for heart and lung transplantation.
- 6.** To award research grants and establish endowments for the study of these disciplines.

2011-2012 BOARD OF DIRECTORS

OFFICERS

Lori J. West, MD, DPhil, President
University of Alberta, Edmonton, Alberta, Canada

David O. Taylor, MD, President-Elect
Cleveland Clinic, Cleveland, OH, USA

John Dark, MB, FRCS, Past President
Freeman Hospital, Newcastle upon Tyne,
United Kingdom

Duane Davis, MD, Secretary-Treasurer
Duke University Medical Center, Durham, NC, USA

DIRECTORS

Raymond L. Benza, MD
Allegheny General Hospital, Pittsburgh, PA, USA

Susan M. Chernenko, RN, MN, NP
Toronto General Hospital, Toronto, Ontario, Canada

Maria G. Crespo-Leiro, MD
Hospital Universitario A Coruna, La Coruna, Spain

James F. George, PhD
University of Alabama at Birmingham,
Birmingham, AL, USA

Allan R. Glanville, MBBS, MD, FRACP
St. Vincent's Hospital, Sydney, Australia

Richard Kirk, MA FRACP, FRCPC
Freeman Hospital, Newcastle upon Tyne,
United Kingdom

Patricia A. Uber, PharmD
University of Maryland, Baltimore, MD, USA

J. David Vega, MD
Emory Clinic, Atlanta, GA, USA

Geert M. Verleden, MD, PhD
University Hospital Gasthuisberg, Germany

Florian M. Wagner, MD
University Heart Center Hamburg,
Hamburg, Germany

George M. Wieselthaler, MD
University of California San Francisco, CA, USA

EX OFFICIO BOARD MEMBERS

Mandeep R. Mehra, MD, Editor-in-Chief,
Journal of Heart and Lung Transplantation
Brigham & Women's Hospital, Boston, MA, USA

Marshall I. Hertz, MD,
Thoracic Transplant Registry Medical Director
University of Minnesota, Minneapolis, MN, USA

Stuart C. Sweet, MD, PhD,
2012 Scientific Program Chair
St. Louis Children's Hospital, St. Louis, MO, USA

Heather J. Ross, MD, MHSc, FRCP(c),
Development Committee Chair
Toronto General Hospital, Toronto, CANADA,

Amanda W. Rowe, ISHLT Executive Director

STAFF

Amanda W. Rowe
Executive Director

Phyllis Glenn
Director of Membership Services

Lisa A. Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

Susie Newton
Communications Manager
Webmaster



14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.isHLT.org

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

PROGRAM CHAIR:

Stuart C. Sweet, MD, PhD, St. Louis, MO, USA

PRESIDENT:

Lori J. West, MD, DPhil, Edmonton, Alberta, Canada

Allan R. Glanville, MD, FRACP, Sydney, Australia

Carla C. Baan, MD, Rotterdam, The Netherlands

Mark L. Barr, MD, Los Angeles, CA, USA

Gerald J. Berry, MD, Stanford, CA, USA

Stephen C. Clark, MD, Newcastle Upon Tyne, United Kingdom

Lara Danziger-Isakov, MD, MPH, Cleveland, OH, USA

Marc De Perrot, MD, Toronto, ON, Canada

Marion Delcroix, MD, Leuven, Belgium

Annette J. DeVito Dabbs, RN, PhD, Pittsburgh, PA, USA

Stephan M. Ensminger, MD, PhD, Erlangen, Germany

Melanie D. Everitt, MD, Salt Lake City, UT, USA

Reda Girgis, MB, BCh, Baltimore, MD, USA

Daniel R. Goldstein, MD, New Haven, CT, USA

Cynthia J. Gries, MD, MSc, Pittsburgh, PA, USA

Richard Kirk, MA FRCP FRCPC,
Newcastle Upon Tyne, United Kingdom

Lorriana E. Leard, MD, San Francisco, CA, USA

Deborah J. Levine, MD, San Antonio, TX, USA

Bronwyn J. Levvey, RN, Grad Dip, Melbourne, Australia

Joren C. Madsen, MD, DPhil, Boston, MA, USA

Kenneth R. McCurry, MD, Cleveland, OH, USA

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Baltimore, MD, USA

Soon J. Park, MD, Rochester, MN, USA

Richard N. Pierson, III, MD, Baltimore, MD, USA

Evgenij V. Potapov, MD, PhD, Berlin, Germany

Luciano Potena, MD, PhD, Bologna, Italy

Eulalia Roig, MD, Barcelona, Spain

Heather J. Ross, MD, MHSc, FRCP(c), Toronto, ON, Canada

Josef Stehlik, MD, PhD, Salt Lake City, UT, USA

Lynne W. Stevenson, MD, Boston, MA, USA

David O. Taylor, MD, Cleveland, OH, USA

Dirk Van Raemdonck, MD, PhD, Leuven, Belgium

Erik A. M. Verschuuren, MD, PhD, Groningen, The Netherlands

Glen P. Westall, FRACP, PhD, Melbourne, Australia

ABSTRACT REVIEWERS

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria
Arezu Z. Aliabadi, MD, Medical University of Vienna, Vienna, Austria

Claus B. Andersen, MD, D.M.Sci, Rigshospitalet, Copenhagen, Denmark

Annalisa Angelini, MD, University of Padua, Padova, Italy

Samantha J. Anthony, PhD, MSW, Hospital for Sick Children/
McMaster University, Toronto, ON, Canada

Christopher J. Arendt, PharmD, RPh, Mayo Clinic,
Rochester, MN, USA

Agnes M. Azimzadeh, PhD, University of Maryland,
Baltimore, MD, USA

Aditya Bansal, MD, Ochsner Clinic Foundation,
New Orleans, LA, USA

David A. Baran, MD, FACC, Newark Beth Israel Medical Center,
Newark, NJ, USA

Christian Benden, MD, St. Vincent's Hospital, Sydney, Australia

Elizabeth Clark Benedetti, PharmD, Baptist Memorial Hospital,
Memphis, TN, USA

Raymond L. Benza, MD, Allegheny General Hospital,
Pittsburgh, PA, USA

Sangeeta Bhorade, MD, University of Chicago Medical Center,
Chicago, IL, USA

Eliane Billaud, PhD, APHP, Universite Paris Descartes-Hopital
European Georges Pompidou, Paris, France

Filio Billia, MD, PhD, FRCPC, University Health Network,
Toronto, ON, Canada

Emma Birks, MD, PhD, FRCP, University of Louisville/Jewish
Hospital, Louisville, KY, USA

Arie Blitz, MD, University Hospitals Case Medical Center,
Cleveland, OH, USA

Annette Boehler, MD, University Hospital Zurich, Zurich,
Switzerland

Michael Bowdish, MD, University of Southern California Keck
School of Medicine, Los Angeles, CA, USA

Patrick Bruneval, MD, Universite Paris Descartes-Hopital
European Georges Pompidou, Paris, France

Marie M. Budev, DO, MPH, The Cleveland Clinic, Cleveland,
OH, USA

Clare L. Burdett, MBBS, MRCS, Freeman Hospital, Newcastle
upon Tyne, United Kingdom

Margaret M. Burke, FRCPath, Royal Brompton and Harefield
NHS Foundation Trust, Middlesex, United Kingdom

Charles E. Canter, MD, St. Louis Children's Hospital, St. Louis,
MO, USA

Javier Carbone, MD, PhD, Gregorio Maranon Hospital,
Madrid, Spain

Michael P. Carboni, MD, Duke University Medical Center/Duke
Children's Hospital, Durham, NC, USA

Joern Carlsen, MD, PhD, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark

Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor,
MI, USA

Murali Chakinala, MD, Washington University School of Medicine, St. Louis, MO, USA

Daniel C. Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Queensland, Australia

Susan Chambers, MSN, CRNP, University of Pennsylvania, USA

Kevin M. Chan, MD, University of Michigan, Ann Arbor, MI, USA

Cecilia Chaparro, MD, Toronto General Hospital, Toronto, ON, Canada

Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, UHN, Toronto, ON, Canada

Anson W. Cheung, MD, St. Paul's Hospital, Vancouver, BC, Canada

Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

Tamara Claridge, PharmD, BCPS, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Adam B. Cochrane, PharmD, BCPS, Inova Fairfax Hospital, Arlington, VA, USA

Bernice Coleman, PhD, ACNP-BC, Cedars Sinai Med Center, Los Angeles, CA, USA

Jennifer Conway, MD, FRCPC, The Hospital for Sick Children, Toronto, ON, Canada

Hannah Copeland, MD, University of California San Diego School of Medicine, San Diego, CA, USA

Jennifer Cowger, MD, MS, University of Michigan Medical Center, Ann Arbor, MI, USA

Barbara Czarska, MD, Florida Hospital Transplant Center, Orlando, FL, USA

Hiroshi Date, MD, Kyoto University, Kyoto, Japan

Kyle L. Dawson, PharmD, BCPS, The Methodist Hospital, Houston, TX, USA

Teresa De Marco, MD, FACC, University of California, San Francisco, San Francisco, CA, USA

Roel A. de Weger, PhD, University Medical Center, Utrecht, The Netherlands

Juan F. Delgado Jimenez, MD, 12 de Octubre Universitare Hospital, Madrid, Spain

Smita A. Desai, DO, Southern California Permanente Group (Kaiser Permanente), San Diego, CA, USA

Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Francesco Di Chiara, MD, University of Padua, Padova, Italy

Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada

Daniel Dilling, MD, FACP, FCCP, Loyola University, Chicago, IL, USA

Anne I. Dipchand, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada

Fabienne Dobbels, PhD, Katholieke Universiteit Leuven, Leuven, Belgium

Robert D. Dowling, MD, University of Louisville, Louisville, KY, USA

Stavros G. Drakos, MD, Utah Cardiac Transplant Program, Salt Lake City, UT, USA

Lieven J. Dupont, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

Peter M. Eckman, MD, University of Minnesota, Minneapolis, MN, USA

Jeffrey D. Edelman, MD, University of Washington, Seattle, WA, USA

Thomas M. Egan, MD, University of North Carolina, Durham, NC, USA

Howard J. Eisen, MD, Drexel University College of Medicine and Hahnemann University Hospital, Philadelphia, PA, USA

Christopher R. Ensor, PharmD, BCPS-CV, The Johns Hopkins Hospital, Baltimore, MD, USA

Eric Epailly, MD, Les Hôpitaux Universitaires de Strasbourg, France

Michiel E. Erasmus, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands

Michele Estabrook, Washington University School of Medicine, St. Louis, MO, USA

Patrick Evrard, MD, PhD, CHU Mont-Godinne, Universite Catholique de Louvain, Belgium

Gregory A. Ewald, MD, Washington University School of Medicine, St. Louis, MO, USA

Albert Faro, MD, Washington University, St. Louis, MO, USA

Marny Fedrigo, MD, PhD, University of Padua, Padua, Italy

Brian Feingold, MD, MS, Children's Hospital of Pittsburgh of UPMS, Pittsburgh, PA, USA

David S. Feldman, MD, PhD, Minneapolis Heart Institute, Minneapolis, MN, USA

Erika D. Feller, MD, University of Maryland, Baltimore, MD, USA

Arnt E. Fiane, MD, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Ashi Firouzi, Royal Brompton & Harefield Hospital, Middlesex, United Kingdom

Michael S. Firstenberg, MD, The Ohio State University Medical Center, Columbus, OH, USA

Michael C. Fishbein, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Andrew J. Fisher, PhD, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Katrina Ford, BSc Bpharm MSc MRPS, Great Ormond Street Hospital NHS Trust, London, United Kingdom

Veronica Franco, MD, MSPH, Ohio State University, Columbus, OH, USA

Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA

Darren H. Freed, MD, PhD, FRCSC, University of Manitoba, Winnipeg, MB, Canada

Robert J. Gajarski, MD, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI, USA

Kimberly L. Gandy, MD, PhD, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA

Lois J. Geist, University of Iowa, Iowa City, IA, USA

Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA

James F. George, PhD, University of Alabama at Birmingham, Birmingham, AL, USA

Michael M. Givertz, MD, Brigham and Women's Hospital, Boston, MA, USA

Martin J. Goddard, BA, BM, ChB, FRCS, FRCPath, Papworth Hospital NHS Trust, Cambridge, United Kingdom

Samuel B. Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

Gonzalo V. Gonzalez-Stawinski, MD, Cleveland Clinic, Cleveland, OH, USA

Jeffrey G. Gossett, MD, Children's Memorial Hospital, Chicago, IL, USA

Kate Gould, MBBS, MRCP, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Paolo Antonio Grossi, MD, PhD, University of Insubria, Italy

Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

Finn Gustafsson, MD, PhD, DMSci, Rigshospitalet, Copenhagen, Denmark

Denis Hadjiliadis, MD, MHS, University of Pennsylvania, Philadelphia, PA, USA

Marc Halushka, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

M. Elizabeth H. Hammond, MD, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT, USA

Michelle L. Harkess, MCN, St. Vincent's Hospital, Sydney, Australia

Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Nicola E. Hiemann, MD, FACC, Deutsches Herzzentrum, Berlin, Germany

Greg Hodge, PhD, Royal Adelaide Hospital, Adelaide, Australia

William L. Holman, MD, University of Alabama at Birmingham, Birmingham, AL, USA

Mark Holmes, MBBS, MD, FRACP, Royal Adelaide Hospital, Adelaide, Australia

Peter M. Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia

Ed Horn, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA

Shahid Husain, MD, MS, Toronto General Hospital, Toronto, ON, Canada

Claire Irving, MBChB, MRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Miriam S. Jacob, MD, University of Maryland Medical Center, Baltimore, MD, USA

George Javorsky, MBBS, FRACP, CSANZ, The Prince Charles Hospital, Brisbane, Australia

Mylvaganam Jeyakanthan, MBChB, MRCS, University of Alberta, Edmonton, Canada

Annemarie Kaan, CSN, RN, MCN, St. Paul's Hospital, Vancouver, BC, Canada

Tomoko S. Kato, MD, PhD, National Cerebral and Cardiovascular Center, Osaka, Japan

Tam H. Khuu, PharmD, BCPS, University of California, Los Angeles, Los Angeles, CA, USA

Thomas Krabatsch, MD, PhD, Deutsches Herzzentrum Berlin, Berlin, Germany

Daniel Kreisel, MD, PhD, Washington University in St. Louis, St. Louis, MO, USA

Christiane Kugler, PhD, Hannover Medical School, Hannover, Germany

Shimon Kusne, MD, Mayo Clinic, Phoenix, AZ, USA

Johanna M. Kwakkel-van Erp, MD, PhD, Universitary Medical Center Utrecht, Utrecht, The Netherlands

Jaap Lahpor, MD, University Medical Center Utrecht, Utrecht, The Netherlands

Jacqueline M. Lamour, MD, Children's Hospital at Montefiore, Bronx, NY, USA

Stephen R. Large, MA, MS, FRCS, FRCP, MBA, Papworth Hospital, Cambridge, United Kingdom

David J. Lederer, MD, MS, Columbia University, New York, NY, USA

Timothy D. G. Lee, PhD, Dalhousie Medical School, Halifax, NS, Canada

Angeline S. Leet, MD, Alfred Hospital, Melbourne, VC, Australia

Karl B. Lemstrom, MD, PhD, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

Kimberly Y. Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Shu S. Lin, MD, PhD, Duke University Medical Center, Durham, NC, USA

Ugolino Livi, MD, FECS, University Hospital, Udine, Udine, Italy

Matthias Loebe, MD, PhD, The Methodist Hospital, Houston, TX, USA

Antonio Loforte, MD, San Camillo Hospital, Rome, Rome, Italy

James L. Lordan, MB, MRCP, PhD, FRCP, DCH, DME, Dobs, BSc Hons, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN, USA

Charles C. Marboe, MD, Columbia University Medical Center, New York, NY, USA

Kenneth B. Margulies, MD, University of Pennsylvania, Philadelphia, PA, USA

Spencer T. Martin, PharmD, New York-Presbyterian Hospital/ Columbia University Medical Center, New York City, NY, USA

Stanley I. Martin, MD, The Ohio State University Medical Center, Columbus, OH, USA

Tereza Martinu, MD, Duke University, Durham, NC, USA

David P. Mason, MD, Cleveland Clinic, Cleveland, OH, USA

Vicki McCalmont, RN, MS, ANP/GNP, APRN-BC, CNS, CCTC, Sharp Memorial Hospital, CA, USA

Michael A. McDonald, MD, FRCP(c), University of Toronto, Toronto, ON, Canada

Edwin C. McGee, Jr., MD, Northwestern Memorial Hospital, Chicago, IL, USA

Stephen H. McKellar, MD, MSc, Mayo Clinic, Rochester, MN, USA

Tanya J. McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand

Gerard J. Meachery, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Federica Meloni, MD, PhD, University of Pavia, Pavia, Italy

Dylan Miller, MD, Utah Cardiac Transplant Program, Murray, UT, USA

Sonia Mirabet Perez, MD, Hospital de Sant Pau, Barcelona, Spain

Nader Moazami, MD, Minneapolis Heart Institute at Abbott

Northwestern Hospital, Minneapolis, MN USA
Susan D. Moffatt-Bruce, MD, PhD, The Ohio State University, Columbus, OH, USA
Paul J. Mohacsi, MD, eMBA, University Hospital Bern, Bern, Switzerland
Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Virginia Beach, VA, USA
Matthew R. Morrell, MD, University of Pittsburgh, Pittsburgh, PA, USA
Michiel Morshuis, MD, Heart and Diabetic Center North-Rhine Westphalia, Bad Oeynhausen, Germany
Roland G. Nador, MD, University of Alberta, Edmonton, AB, Canada
Nandini Nair, MD, PhD, FSV, FACC, FACP, Scott and White Hospital, Temple, TX, USA
Takeshi Nakatani, MD, PhD, National Cerebral and Cardiovascular Center, Osaka, Japan
Desley Neil, MBBS, PhD, BMedSC, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
Ivan, Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Arne Neyrinck, MD, University Hospitals Leuven, Kesseloo, Belgium
Fabrizio Oliva, MD, Ospedale Niguarda, Milan, Italy
Takahiro Oto, MD, Okayama University, Okayama, Japan
Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA
Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA
Robert L. Page, II, PharmD, MSPH, FCCP, FAHA, BCPS, University of Colorado School of Medicine and Pharmacy, Denver, CO, USA
Elfriede Pahl, MD, Heart Transplantation Institution: Children's Memorial Hospital, Northwestern Feinberg School of Medicine, Wilmette, IL, USA
Scott M. Palmer, MD, MHS, Duke University Medical Center, Durham, NC, USA
Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA
Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Beverly Hills, CA, USA
Daniel F. Pauly, MD, PhD, University of Florida, Gainesville, FL, USA
Felix Perez-Villa, MD, PhD, Hospital Clinic Barcelona, Spain
Michael G. Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA
Si M. Pham, MD, University of Miami/Jackson Memorial Hospital, Miami, FL, USA
Jan Pirk, MD, IKEM Praha Czech Rep., Prague, Czech Republic
Guatam V. Ramani, MD, University of Maryland, Baltimore, MD, USA
J. Eduardo Rame, MD, DPhil, University of Pennsylvania, Philadelphia, PA, USA
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg Eppendorf, Hamburg, Germany
Monica P. Revelo, MD, PhD, University of Utah, Murray, UT, USA

Alexandra Rice, FRCPath, Harefield Hospital, London, United Kingdom
Jonathan D. Rich, MD, University of Chicago Medical Center, Chicago, IL, USA
E. Rene Rodriguez, MD, Cleveland Clinic Foundation, Cleveland, OH, USA
Stuart Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA
Zeenat Safdar, MD, FCCP, FACP, Baylor College of Medicine, Houston, TX, USA
Marc G. Schecter, MD, Baylor College of Medicine, Houston, TX, USA
Robert J. Schilz, DO, PhD, University Hospitals, Case Medical Center, Cleveland, OH, USA
Christof Schmid, MD, University Medical Center Regensburg, Regensburg, Germany
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Stanford, CA, USA
Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals Foundation Trust/Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Martin Schweiger, MD, Medical University, Graz, Austria
Javier Segovia, MD, PhD, Hospital Universitario Puerta De Hierro, Madrid, Spain
Keyur B. Shah, MD, Virginia Commonwealth University, Richmond, VA, USA
Monica R. Shah, MD, MHS, MSJ, National Heart Lung and Blood Institute, McLean, VA, USA
Pali D. Shah, MD, Johns Hopkins, Baltimore, MD, USA
Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA, USA
Sara J. Shumway, MD, University of Minnesota, Minneapolis, MN, USA
Fernanda P. Silveira, MD, MS, Univ of Pittsburgh, Pittsburgh, PA, USA
Marc A. Simon, MD, MS, University of Pittsburgh, Pittsburgh, PA, USA
Jonathan P. Singer, MD MS, University of California San Francisco, San Francisco, CA, USA
Tajinder P. Singh, MD, MSc, Children's Hospital of Boston, Boston, MA, USA
Cumara C. Sivathanan, MBBS, FRCS, FAMS, National Heart Centre, Singapore, Singapore
Nikolaos Skartsis, MD, Brigham and Women's Hospital, Boston, MA, USA
Jacqueline M. Smits, MD, PhD, Eurotransplant, Leiden, The Netherlands
Gregory I. Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia
Amparo Sole, MD, PhD, Hospital Universitario y Politecnico la Fe, Valencia, Spain
Alexander Stepanenko, MD, German Heart Institute, Berlin, Germany
Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Valentina Stosor, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Sean M. Studer, MD, MSc, Newark Beth Israel Medical Center, Newark, NJ, USA

Benjamin Sun, MD, Minneapolis Heart Institute, Minneapolis, MN, USA

W. H. Wilson Tang, MD, Cleveland Clinic, Gates Mills, OH, USA

Josef Thul, MD, Kinderherzzentrum Universitat, Giessen, Germany

Yoshiya Toyoda, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Patricia A. Uber, PharmD, University of Maryland, School of Medicine, Baltimore, MD, USA

Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC, USA

Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

Caroline Van De Wauwer, MD, University Medical Center, Groningen, The Netherlands

Wim van der Bij, MD, PhD, University Hospital Groningen, Groningen, The Netherlands

Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

Wickii T. Vigneswaran, MD, FACS, University of Chicago, Chicago, IL, USA

Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

Rajat Walia, MD, FCCP, St. Joseph's Hospital & Medical Center, Phoenix, AZ, USA

Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

David Weill, MD, Stanford University Medical Center, Stanford, CA, USA

Robert G. Weintraub, MB BS FRACP FACC, Royal Children's Hospital, Parkville, Australia

Michel White, MD, FRCPC, FACC, FESC, Montreal Heart Institute, Montreal, QC, Canada

Connie White-Williams, PhD, RN, FAAN, University of Alabama at Birmingham, Birmingham, AL, USA

Christopher H. Wigfield, MD, FRCS, Loyola University Medical Center, Maywood, IL, USA

Markus J. Wilhelm, MD, University Hospital Zurich, Zurich, Switzerland

Keith M. Wille, MD, University of Alabama at Birmingham, Birmingham, AL, USA

Gayle L. Winters, MD, Brigham and Women's Hospital, Boston, MA, USA

Stephanie T. Yerkovich, PhD, The Prince Charles Hospital, Brisbane, Australia

Nizar Yonan, MB ChB, MD, FRCS(CTh), University Hospital of South Manchester, S. Manchester, United Kingdom

Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA

Phillip C. Zakowski, MD, Cedars Sinai Medical Center, Los Angeles, CA, USA

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria



EDUCATION COMMITTEE

Allen S. Anderson, MD, FACC, Chair and Heart Failure Workforce Leader

Stuart C. Sweet, MD, PhD, 2012 Scientific Program Chair

Heather J. Ross, MD, MHSc, FRCP(c), Basic Science & Translational Research-to be determined

David Baran, MD, Heart Failure & Transplant Medicine, Council Workforce Leader

Fernanda Silveira, MD, Infectious Diseases, Council Workforce Leader

Matthew Morrell, MD, Junior Faculty and Trainees, Council Workforce Leader

Roberta C. Bogaev, MD, FACC, FACP, Mechanical Circulatory Support Council Workforce Leader

Michael Petty, PhD, RN, CCNS, CNS, Nursing Health Sciences & Allied Health Council Workforce Leader

E. Rene Rodriguez, MD, Pathology Council Workforce Leader

Daphne Hsu, MD, Pediatric Transplantation, Council Workforce Leader

Dana McGlothlin, MD, Pulmonary Hypertension Council Workforce Leader

Christopher H. Wigfield, MD, FRCS, Pulmonary Transplantation Council Workforce Leader

Beatriz Diaz Molina, MD, At Large Member

Keith McNeil, FRACP, At Large Member

Andreas O. Zuckermann, MD, At Large Member

GRANTS AND AWARDS COMMITTEE

Duane Davis, MD, Chair

Mark L. Barr, MD, Past Chair

Lori J. West, MD, DPhil, Reviewers

Carla C. Baan, PhD, Reviewers

Marshall I. Hertz, MD, Reviewers

Judy A. Currey, PhD, Reviewers

JHLT EDITORIAL BOARD

Mandeep R. Mehra, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Michelle Kraft, Journal Office Manager
Maria Rosa Costanzo, MD (Editor Emeritus, 1995-1999)
Consulting Editor
James K. Kirklin, MD (Editor Emeritus 2000-2009)
Consulting Editor
James F. George, PhD, Editorial Office Consultants
Jonathan B. Orens, MD (USA), Editorial Office Consultants
Jayan Parameshwar, FRCP (UK), Editorial Office Consultants
Richard N. Pierson, III, MD (USA), Editorial Office Consultants
Hector O. Ventura, MD (USA), Editorial Office Consultants
Claus B. Andersen, MD, D.M.Sc (Denmark), Editorial
Board Consultants
Annalisa Angelini, MD (Italy), Editorial Board Consultants
Marcelo Cantarovich, MD (Canada), Editorial Board Consultants
Charles E. Canter, MD (USA), Editorial Board Consultants
Pablo F. Castro, MD (Chile), Editorial Board Consultants
John V. Conte, MD (USA), Editorial Board Consultants
Paul A. Corris, MB FRCP (UK), Editorial Board Consultants
Duane Davis, MD (USA), Editorial Board Consultants
John Dark, MB, FRCS (UK) Editorial Board Consultants
Mary Amanda Dew, PhD (USA) Editorial Board Consultants
Fabienne Dobbels, MSc, PhD (Belgium), Editorial
Board Consultants
Howard J. Eisen, MD (USA), Editorial Board Consultants
Roger W. Evans, PhD (USA), Editorial Board Consultants
Michael C. Fishbein, MD (USA), Editorial Board Consultants
Edward R. Garrity, Jr., MD (USA), Editorial Board Consultants
Alan R. Glanville, MD, FRACP (Australia), Editorial
Board Consultants
Kate Gould, FRCPath (UK), Editorial Board Consultants
Shahid Husain, MD, MS (Canada), Editorial Board Consultants
Valluvan Jeevanandam, MD (USA), Editorial Board Consultants
Maryl R. Johnson, MD (USA), Editorial Board Consultants
Shaf Keshavjee, MD, FRCSC (Canada), Editorial Board Consultants
Jon Kobashigawa, MD (USA), Editorial Board Consultants
JoAnn Lindenfeld, MD (USA), Editorial Board Consultants
Bruce McManus, MD, PhD (Canada), Editorial Board Consultants
Bruno M. Meiser, MD (Germany), Editorial Board Consultants
Martha L. Mooney, MD (USA), Editorial Board Consultants
Jonah Odum, MD, (USA) Editorial Board Consultants
Francesco Parisi, MD (Italy), Editorial Board Consultants
Myung H. Park, MD (USA), Editorial Board Consultants
Evgenij V. Potapov, MD, PhD (Germany), Editorial Board
Consultants
Luciano Potena, MD, PhD (Italy), Editorial Board Consultants
Joseph G. Rogers, MD (USA), Editorial Board Consultants
Heather J. Ross, MD, MHSc, FRCP(c)(Canada), Editorial
Board Consultants
Lewis J. Rubin, MD (USA), Editorial Board Consultants
Stephan Schueler, MD, PhD, FRCS (UK), Editorial Board
Consultants

Keyur B. Shah, MD (USA), Editorial Board Consultants
Mark S. Slaughter, MD (USA), Editorial Board Consultants
Randall C. Starling, MD, MPH (USA), Editorial Board Consultants
Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultants
Geert Verleden, MD, PhD, (Belgium) Editorial Board Consultants
Aaron B. Waxman, MD, PhD (USA), Editorial Board Consultants
Steve A. Webber, MB ChB, MRCP (USA), Editorial Board
Consultants
Lori J. West, MD, D.Phil (Canada), Editorial Board Consultants
Michael Zaklinczynski, MD, (Poland), Editorial Board Consultants

PROFESSIONAL STANDARDS AND GUIDELINES COMMITTEE

James K. Kirklin, MD, Chair
Maria Rosa Costanzo, MD, Past Chair
Naveen Periera, MDm, Heart Failure Workforce Leader
Amparo Sole, MD, PhD, Infectious Diseases Workforce Leader
Susan D. Moffatt-Bruce, MD, PhD, Junior Faculty & Trainee
Workforce Leader
David S. Feldman, MD, PhD, FACC, FAHA, Mechanical
Circulatory Support Workforce Leader
Connie White-Williams, PhD, RN, FAAN, Nursing, Health
Sciences & Allied Health Workforce Leader
Carmela D. Tan, MD, Pathology Workforce Leader
Robert J. Boucek, Jr. MD, Pediatric Transplantation
Workforce Leader
Evelyn Horn, MD, Pulmonary Hypertension Workforce Leader
David Weill, MD, Pulmonary Transplantation Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

REGISTRIES AND DATABASES COMMITTEE

Marshall I. Hertz, MD, Chair
Josef Stehlik, MD, Heart Failure
Paolo A. Grossi, MD, PhD, Infectious Diseases Workforce Leader
Shahid Husain, MD, MS, Infectious Diseases Workforce Leader
Jennifer A. Cowger, MD, MS,
Junior Faculty & Trainee Workforce Leader
Jaap Lahpor, MD, PhD,
Mechanical Circulatory Support Workforce Leader
Fabienne Dobbels, PhD, Nursing, Health Sciences & Allied
Health Workforce Leader
Robert F. Padera, MD, PhD, Pathology Workforce Leader
Richard E. Chinnock, MD, Pediatric Transplantation
Workforce Leader
Mardi Gomberg-Maitland, MD, MSc,
Pulmonary Hypertension Workforce Leader
Fernando Torres, MD, PA, Pulmonary Hypertension
Workforce Leader
Shaf Keshavjee, MD, Pulmonary Transplantation Workforce Leader

Roger D. Yusen, MD, MPH, Outcomes Specialists
Maria G. Crespo-Leiro, MD, Outcomes Specialists
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison Workforce Leader

THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE

Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD, Associate Medical Director, Lung/
Heart-Lung
Richard Kirk, MA, FRCP, FRCPC, Senior Associate Medical
Director, Pediatric Heart
Anne I. Dipchand, MD, Associate Medical Director, Pediatric
Lung/Heart-Lung
Christian Benden, MD, Associate Medical Director, Pediatric Lung
Fabienne Dobbels, PhD, Associate Medical Director, Outcomes
Axel Rahmel, MD, Associate Medical Director, OEO Relations
Leah Edwards, PhD, Associate Medical Director, Biostatistics
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician

LINKS NEWSLETTER EDITORIAL STAFF

Vincent G. Valentine, MD, Editor-in-Chief
Susie Newton, Managing Editor
Roger W. Evans, PhD, Senior Associate Editor
Allan R. Glanville, MBBS, MD, FRACP, Senior Associate Editor
Maryl R. Johnson, MD, Senior Associate Editor
Lori J. West, MD, DPhil, Senior Associate Editor
Emma Birks, FRCP, PhD, Associate Editor-Cardiology
Stavros G. Drakos, MD, Associate Editor-Cardiology
Lee R. Goldberg, MD, MPH, Associate Editor-Cardiology
Nancy P. Blumenthal, CRNP, Associate Editor-Nursing
Daniel Dilling, MD, Associate Editor-Junior Faculty & Trainees
Stanley I. Martin, MD, Associate Editor-Infectious Diseases
Tereza Martinu, MD, Associate Editor-Pulmonary
Javier Carbone, MD, PhD, International Correspondents
Board, Spain
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, International
Correspondents Board, Australia
Takeshi Nakatani, MD, PhD, International Correspondents
Board, Japan
Luciano Potena, MD, PhD, International Correspondents
Board, Italy
Stephan Schubert, MD, International Correspondents
Board, Germany
Andreas Zuckermann, MD, International Correspondents
Board, Austria

SCIENTIFIC COUNCIL OPERATING BOARDS



BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Kimberly L. Gandy, MD, Chair
Sonja Schrepfer, MD, PhD, Vice Chair
Lori J. West, MD, DPhil, Board Liaison
James F. George, PhD, Board Liaison

MECHANICAL CIRCULATORY SUPPORT

Francis D. Pagani, MD, PhD, Chair
Jeffrey J. Teuteberg, MD, Vice Chair
Emma J. Birks, MRCP, PhD, Past Chair
J. David Vega, MD, Board Liaison
George M. Wieselthaler, MD, Board Liaison
Soon J. Park, MD, Annual Program Committee Representative
Evgenij V. Potapov, MD, PhD, Annual Program Committee
Representative
Josef Stehlik, MD, MPH, Annual Program Committee
Representative
David S. Feldman, MD, PhD, FACC, FAHA, Standards &
Guidelines Workforce Leaders
Robert C. Bogaev, MD, FACC, Education Workforce Leaders
Jaap Lahpor, MD, PhD, Registries & Databases Workforce Leaders
Evgenij V. Potapov, MD, Communications Workforce Leaders
Mario C. Deng, MD, Development Liaison

HEART FAILURE AND TRANSPLANT MEDICINE

Lee R. Goldberg, MD, MPH, Chair
David Brad Dyke, MD, Vice Chair
David A. Baran, MD, Past Chair
David O. Taylor, MD, Board Liaison
Maria G. Crespo-Leiro, MD, Board Liaison
Lynne W. Stevenson, MD, Annual Program Committee
Representative

Luciano Potena, MD, PhD, Annual Program Committee Representative
Eulalia Roig, MD, Annual Program Committee Representative
Joren C. Madsen, MD, DPhil, Annual Program Committee Representative
Naveen Pereira, MD, Standards & Guidelines Workforce Leader
David A. Baran, MD, Education Workforce Leader
Josef Stehlik, MD, Registries & Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader
Robert C. Bourge, MD, Development Liaison

INFECTIOUS DISEASES

Lara Danziger-Isakov, MD, MPH, Chair
Martha L. Mooney, MD, Past Chair
Patricia A. Uber, PharmD, Board Liaison
Erik A.M. Verschuuren, MD, PhD, Annual Program Committee Representative
Lara Danziger-Isakov, MD, MPH, Annual Program Committee Representative
Amparo Sole, MD, PhD, Standards & Guidelines Workforce Leader
Fernanda Silveira, MD, Education Workforce Leader
Paolo A. Grossi, MD, PhD, Registries & Databases Workforce Leader
Shahid Husain, MS, MBBS, MD, Registries & Databases Workforce Co-Leader
Stanley I. Martin, MD, Communications Workforce Leader

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Nancy P. Blumenthal, CRNP, Chair
Annemarie Kaan, MCN, RN, Vice Chair
Bernice L. Coleman, RN, PhD, Past Chair
Susan M. Chernenko, RN, MN, NP, Board Liaison
Annette J. Devito-Dabbs, RN, PhD, FAAN, Annual Program Committee Representative
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Annual Program Committee Representative
Connie White-Williams, MSN, Standards & Guidelines Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Education Workforce Leader
Fabienne Dobbels, PhD, Registries & Databases Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Communications Workforce Leader
Arzellra K. Walters, RN, MA, Clinical Coordinator

PATHOLOGY

Gerald J. Berry, MD, Chair
Patrick Bruneval, Vice Chair
Annalisa Angelini, MD, Past Chair
James F. George, PhD, Board Liaison
Gerald J. Berry, MD, Chair, Annual Program Committee Representative

Carmela D. Tan, MD, Standards & Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD, Registries & Databases Workforce Leader
James B. Atkinson, MD, PhD, Communications Workforce Leader

PEDIATRIC TRANSPLANTATION

Beth Kaufman, MD, Chair
Melanie Everitt, MD, Vice Chair
Elfriede Pahl Schuette, MD, Past Chair
Richard Kirk, MA, FRCP, FRCPC, Board Liaison
Melanie Everitt, MD, Annual Program Committee Representative
Richard Kirk, MA, FRCP, FRCPC, Annual Program Committee Representative
Robert J. Boucek, Jr., MD, Standards & Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnock, MD, Registries and Databases Workforce Leader
Kimberly L. Gandy, MD, Communications Workforce Leader

PULMONARY HYPERTENSION

Myung Park, MD, Chair
Robert P. Frantz, MD, Vice Chair
Raymond L. Benza, MD, Past Chair
Raymond L. Benza, MD, Board Liaison
Marc De Perrot, MD, Annual Program Committee Representative
Marion Delcroix, MD, Annual Program Committee Representative
Reda Girgis, MB, BCh, Annual Program Committee Representative
Evelyn Horn, MD, Standards & Guidelines Workforce Leader
Dana P. McGlothlin, MD, Education Workforce Leader
Mardi Gomberg-Maitland, MD, MSc, Registries & Databases Workforce Leader
Fernando Torres, MD, PA, Registries & Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Workforce Leader

PULMONARY TRANSPLANTATION

Lianne G. Singer, MD, FRCPC, Chair
David Weill, MD, Vice Chair
Michael Mulligan, MD, Vice Chair-Elect/Secretary
Geert M. Verleden, MD, PhD, Past Chair
Duane Davis, MD, Board Liaison
Deborah J. Levine, MD, Annual Program Committee Liaison
Mark L. Barr, MD, Annual Program Committee Liaison
Glen P. Westall, FRACP, PhD, Annual Program Committee Liaison
Stephen C. Clark, MD, Annual Program Committee Liaison
Lorriana Leard, MD, Annual Program Committee Liaison
David Weill, MD, Standards & Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS, Education Workforce Leader
Shaf Keshavjee, MD, Registries & Databases Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison Workforce Leader

JUNIOR FACULTY AND TRAINEE COUNCIL

Daniel Dilling, MD, Chair
Pali D. Shah, MD, Vice Chair
David W. Markham, MD, Past Chair
John Dark, MB, FRCS, Board Liaison
Florian M. Wagner, MD, Board Liaison
Lorriana E. Leard, MD, Annual Program Committee Representative
Cynthia J. Gries, MD, MSc, Annual Program Committee Representative
Susan D. Moffatt-Bruce, MD, PhD, Standards & Guidelines Workforce Leader
Matthew Morrell, MD, Education Workforce Leader
Jennifer A. Cowger, MD, Registries & Databases Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison

PAST PRESIDENTS

1981-1982 Michael Hess, MD
1982-1984 Jack Copeland, MD
1984-1986 Terence English, FRCS
1986-1988 Stuart Jamieson, MD
1988-1990 Bruno Reichart, MD
1990-1991 Margaret Billingham, MD
1991-1992 Christian Cabrol, MD
1992-1993 John O'Connell, MD
1993-1994 Eric Rose, MD
1994-1995 John Wallwork, FRCS
1995-1996 Sharon Hunt, MD
1996-1997 William Baumgartner, MD
1997-1998 Leslie Miller, MD
1998-1999 Alan Menkis, MD, FRCS(C)
1999-2000 Robert L. Kormos, MD
2000-2001 Anne Keogh, MBBS, MD
2001-2002 James B. Young, MD
2002-2003 Stephan Schueler, MD
2003-2004 Jon Kobashigawa, MD
2004-2005 Alec Patterson, MD
2005-2006 Mark L. Barr, MD
2006-2007 Robert C. Robbins, MD
2007-2008 Paul A. Corris, MB FRCP
2008-2009 Mandeep R. Mehra, MD
2009-2010 James K. Kirklin, MD
2010-2011 John Dark, MB, FRCS

PAST SCIENTIFIC PROGRAM CHAIRS

1981 San Francisco, CA Edward B. Stinson, MD and Michael L. Hess, MD
1982 Phoenix, AZ Michael Kaye and Bernard Gersh
1983 New Orleans, LA Stuart W. Jamieson, MD and Mark E. Thompson, MD
1984 New York, NY Randall B. Griep, MD
1985 Anaheim, CA Terence A. H. English and Hillel Laks
1986 New York, NY
1987 New Orleans, LA
1988 Los Angeles, CA John C. Baldwin, MD
1989 Munich, Germany Bruno Reichart, MD
1990 San Diego, CA D. Glenn Pennington, MD
1991 Paris, France John B. O'Connell, MD
1992 San Diego, CA Eric A. Rose, MD
1993 Boca Raton, FL Maria Rosa Costanzo, MD
1994 Venice, Italy John Wallwork, MBChB, FRCS
1995 San Francisco, CA Leslie W. Miller, MD
1996 New York, NY William A. Baumgartner, MD
1997 London, England Stephan Schueler, MD
1998 Chicago, IL James B. Young, MD
1999 San Francisco, CA Mark L. Barr, MD
2000 Osaka, Japan Jon Kobashigawa, MD
2001 Vancouver, Canada David O. Taylor, MD
2002 Washington, DC Robert C. Robbins, MD
2003 Vienna, Austria Bruce R. Rosengard, MD
2004 San Francisco, CA Mandeep R. Mehra, MD
2005 Philadelphia, PA Shaf Keshavjee, MD
2006 Madrid, Spain John Dark, MB, FRCS
2007 San Francisco, CA Duane Davis, MD
2008 Boston, MA Lori J. West, MD, DPhil
2009 Paris, France Randall C. Starling, MD, MPH
2010 Chicago, IL Hermann Reichenspurner, MD, PhD
2011 San Diego, CA Richard N. Pierson, III, MD

PAST EDITORS, JOURNAL OF HEART AND LUNG TRANSPLANTATION

1981-1985 Jacques G. Losman, MD
1986-1994 Michael P. Kaye, MD
1995-1999 Maria Rosa Costanzo, MD
2000-2009 James K. Kirklin, MD
2010-PRESENT Mandeep R. Mehra, MD

MEDICAL DIRECTORS, THORACIC ORGAN TRANSPLANT REGISTRY

1987-1993 Michael P. Kaye, MD
1993-2001 Jeffrey D. Hosenpud, MD
2001-PRESENT Marshall I. Hertz, MD

Award Recipient

LIFETIME ACHIEVEMENT AWARD

1996 Norman Shumway, MD
1999 Keith Reemtsma, MD
2004 Sir Magdi Yacoub, MD
2010 Margaret Billingham, MD

LIFETIME SERVICE AWARD

1996 Michael P. Kaye, MD
1997 Jacques G. Losman, MD

PIONEERS IN TRANSPLANTATION LECTURE

2000 Christiaan Barnard, MD
Joel D. Cooper, MD
Norman E. Shumway, MD
2002 Michael DeBakey, MD
Bruce A. Reitz, MD
2006 Leonard L. Bailey, MD
2008 Richard E. Lower, MD
2009 Christian E. A. Cabrol, MD
2011 Elizabeth Hammond, MD

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD

2000 Gordon D. Wu, MD (supported by Roche)
2002 Anthony Azakie, MD (supported by Roche)
2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
2008 Glen Westall, MD, PhD (supported by Roche)
2010 Sonja Schrepfer, MD, PhD (supported by Astellas)

WEDNESDAY

TIME	CONGRESS HALL	FORUM HALL	MEETING HALL 1	PANORAMA HALL	MEETING HALL 4
8:00 AM		PRE-MEETING SYMPOSIUM 1 Mechanical Circulatory Support Outcomes	PRE-MEETING SYMPOSIUM 2 Rejection Surveillance	PRE-MEETING SYMPOSIUM 3 Lung Tx Dysfunction	PRE-MEETING SYMPOSIUM 4 Cardiogenic Shock Before & After Heart Tx
9:30 AM		BREAK	BREAK	BREAK	BREAK
9:45 AM		PRE-MEETING SYMPOSIUM 7 New Devices New Approaches	PRE-MEETING SYMPOSIUM 8 ABCs of AMR	PRE-MEETING SYMPOSIUM 9 Ex-Vivo Lung Perfusion	PRE-MEETING SYMPOSIUM 10 Right Ventricular and Pulmonary Vascular Load
11:15 AM		BREAK	BREAK	BREAK	BREAK
11:30 AM		PRE-MEETING SYMPOSIUM 13 Chronic MCS Management	PRE-MEETING SYMPOSIUM 14 DEFs of AMR	PRE-MEETING SYMPOSIUM 15 Advances in LTx Surgery	PRE-MEETING SYMPOSIUM 16 Thoracic Organ Donors
1:00 PM		LUNCH BREAK	LUNCH BREAK	MCS COUNCIL MEETING	LUNCH BREAK
3:00 PM		CONCURRENT SESSION 1 VADs and Community	CONCURRENT SESSION 2 Advanced Heart Failure Decision Making	CONCURRENT SESSION 3 BOS Animal Models	CONCURRENT SESSION 4 Juggling Donor Risk
4:15 PM		BREAK	BREAK	BREAK	BREAK
4:45 PM	OPENING PLENARY SESSION Overcoming Political Barriers				
6:00 PM					
7:00 PM					

MEETING HALL 5	NORTH HALL	CONGRESS HALL FOYERS	CLUB B	CLUB C	CLUB D	TIME
PRE-MEETING SYMPOSIUM 5 Neurocognitive, Psychosocial Issues in Children	PRE-MEETING SYMPOSIUM 6 PH Potpourri	EXHIBIT BOOTH SET-UP 8:00 am – 4:30 pm POSTER HALL SET-UP 8:00 am – 1:00 pm				8:00 AM
BREAK	BREAK					9:30 AM
PRE-MEETING SYMPOSIUM 11 MCS in Congenital Heart Disease & Pediatrics	PRE-MEETING SYMPOSIUM 12 Viruses in Thoracic Transplantation					9:45 AM
BREAK	BREAK					11:15 AM
PRE-MEETING SYMPOSIUM 17 Innate Immunity in Cardiothoracic Transplantation	PRE-MEETING SYMPOSIUM 18 PH in Peds and Adults					11:30 AM
NHSAH COUNCIL MEETING	LUNCH BREAK	SCIENTIFIC POSTER MOUNT 1:00 pm – 4:45 pm	PH COUNCIL MEETING	PED COUNCIL MEETING	PTH COUNCIL MEETING	1:00 PM
CONCURRENT SESSION 5 LVAD Optimization	CONCURRENT SESSION 6 Managing Infection					3:00 PM
BREAK	BREAK					4:15 PM
		EXHIBITS AND POSTERS OPEN POSTER 4:45 pm – 7:00 pm				4:45 PM
		WELCOME RECEPTION 6:00 pm – 7:00 pm			LTX COUNCIL QOL WORK-FORCE MTG.	6:00 PM
						7:00 PM

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS

- 1995** Frances L. Johnson, MD
(supported by Ortho-Biotech)
- 1996** Tuija S. Ikonen, MD *(supported by Roche)*
Andrew F. Pierre, MD *(supported by Ortho-Biotech)*
- 1997** Jonathan Chen, MD *(supported by Roche)*
Alyssa M. Krasinskas, MD *(supported by Astellas)*
Owen T. Lawrence, MD *(supported by Ortho-Biotech)*
Anne K. Raisanen-Sokolowski, MD
(supported by Roche)
- 1998** Kelly S.A. Blair, MD *(supported by Roche)*
A.M. El Gamel, MD *(supported by Roche)*
Christine L. Lau, MD *(supported by Wyeth-Ayerst)*
Scott D. Ross, MD
Margaret L. Schwarze, MD *(supported by Novartis)*
- 1999** George Juang, MD *(supported by Novartis)*
Sivasai Krovvidi, PhD *(supported by Roche)*
Satoshi Saito, MD *(supported by Novartis)*
Donald Wong, PhD *(supported by Roche)*
- 2000** Richard S. Lee, MD *(supported by Novartis)*
Christopher H. Wigfield, FRCS *(supported by Roche)*
- 2001** Arnar Geirsson, MD *(supported by Roche)*
Matteo Vatta, PhD *(supported by Roche)*
- 2002** Ruediger Hoebelt, MD *(supported by Roche)*
- 2003** Ewout J. van den Bos, MD *(supported by Astellas)*
Felix Fernandez, MD *(supported by Roche)*
- 2004** Christian A. Gleissner, MD *(supported by Astellas)*
Tsuyoshi Shoji, MD, PhD *(supported by Actelion)*
Kendra N. Taylor, PhD *(supported by Roche)*
Monica Zwierzchnieuska, MD *(supported by XDx)*
- 2005** Ryan C. Fields, MD *(supported by Chiron)*
Arne Neyrinck, MD *(supported by Astellas)*
Ahmad Saad, MD *(supported by Roche)*

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS Continued

- 2006** Rachel L. Anderson, MBBS *(supported by Roche)*
Zhaohui Li, PhD *(supported by Transmedics)*
Heather E. Merry, MD *(supported by Encysive)*
Edward N. Seung, PhD *(supported by XDx)*
Matthew J. Weiss, MD *(supported by Novartis)*
- 2007** J. Raymond Fitzpatrick, III, MD *(supported by Encysive)*
Howard J. Huang, MD *(supported by Transmedics)*
Mylvganam Jeyakanthan, MD *(supported by XDx)*
Timothy M. Millington, MD *(supported by Novartis)*
Satish N. Nadig, MD *(supported by Roche)*
Takeshi Oyaizu, MD, PhD *(supported by Actelion)*
Sonja Schrepfer, MD *(supported by Astellas)*
- 2008** Jonathan Choy, PhD *(supported by XDx)*
Satoshi Itoh, MD *(supported by Transmedics)*
Tereza Martinu, MD *(supported by Novartis)*
Deepti Saini, PhD *(supported by Gilead)*
Atsushi Shiozaki, MD, PhD *(supported by Astellas)*
Seiichiro Sugimoto, MD, PhD *(supported by Roche)*
- 2009** Hua Shen, MD, PhD *(supported by Astellas)*
Tobias Deuse, MD, PhD *(supported by Novartis)*
Masahiro Miyajima, MD, PhD *(supported by XDx)*
Shin Hirayama, MD, PhD *(supported by Gilead)*
- 2010** Esme Dijke, PhD *(supported by Novartis)*
Smita Sihag, MD *(supported by Genentech)*
Sumiharu Yamamoto, MD *(supported by Gilead)*
Khurram Shahzad, MD
(supported by United Therapeutics)
Nina Pilat, MSc, PhD *(supported by XDx)*
- 2011** Alejandro Bribriesco, MD *(supported by Astellas)*
Alexey Dashkevich, MD *(supported by XDx)*
Patricia E. de Almeida, DVM, MS, PhD
Tiago Machuca, MD, PhD

ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD (FORMERLY JUNIOR FACULTY AWARD)

- 2007** Beth D. Kaufman, MD
- 2008** Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
- 2010** Jennifer Conway, MD, FRCPC
Kiran K. Khush, MD, MAS
- 2011** Jose Nativi, MD
- 1997** Eileen Collins, RN, PhD
- 1998** Katherine St. Clair, RN, MSN
- 1999** Jeanne Salyer, PhD
- 2000** Nancy M. Albert, MSN, RN
- 2001** Lynn Doering, RN, DNSc
- 2002** Annette J. De Vito Dabbs, RN, MN, PhD
- 2003** Diane H. Leloudis, RN, MSN
Janet E. Madill, PhD
- 2004** Deidre E. Logan, PhD
- 2005** Annemarie F. Kaan, MCN
- 2006** Thierry Troosters, PhD
- 2007** Mi-Kyung Song, PhD
- 2008** Stacey M. Pollock-BarZiv, PhD
- 2009** Jane MacIver, RN, MSc
- 2010** Heike Spaderna, PhD
Gerdi Weidner, PhD
- 2011** Christiane Kugler, PhD
Hilde Bollen, RN

- 1983** Robbin G. Cohen, MD
- 1984** Hermann Reichenspurner, MD
- 1985** Michael A. Breda, MD
- 1986** Stuart J. Knechtle, MD
- 1987** Wim Van Der Bij, MD
- 1988** Charles D. Fraser, Jr., MD
- 1989** A.M. Wood, MD
- 1990** Andres J. Duncan, MD
- 1991** A. Jimenez, MD
- 1992** David P. Kapelanski, MD
- 1993** David Marshman, MD
- 1994** Jobst Winter, MD
Alain Chapelier, MD
- 1995** Elizabeth A. Davis, MD
- 1996** Moninder S. Bhabra, MD
- 1997** Simon D. Eiref, MD
- 1998** Carla C. Baan, MD
- 1999** Joerg Koglin, MD
- 2000** Michael P. Fischbein, MD
- 2001** Alexander S. Krupnick, MD
- 2002** Peter Blaha, MD
- 2003** Sigrid Sandner, MD
- 2004** M.D. Peterson, MD
- 2005** Sigrid Sandner, MD
Frank D'Ovidio, MD
- 2006** Gregor Warnecke, MD
- 2007** Heather E. Merry, MD
- 2008** Satish N. Nadig, MD
- 2009** Howard Huang, MD
- 2010** Tobias Deuse, MD, PhD
- 2011** Ankit Bharat, MD

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

- 2005 Mary Amanda Dew, PhD
- 2006 Kathleen L. Grady, PhD, RN
- 2007 Christianne Kugler, PhD
- 2008 Annette DeVito Dabbs, RN, PhD
- 2009 Connie White-Williams, MSN
- 2010 Bronwyn Levvey, RN
- 2011 Samantha J. Anthony, PhD, MSW

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS PAPER AWARD

- 2009 Nishant Shah, MD *(supported by Thoratec)*
- 2010 Jose N. Nativi, MD *(supported by Thoratec)*

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT

- 2009 Sasa D. Borovic, MD *(supported by Thoratec)*
- 2010 Iki Adachi, MD *(supported by Thoratec)*
- 2011 Dan Spiegelstein, MD *(supported by Thoratec)*

The International Society for Heart and Lung Transplantation is Most Grateful for the Educational Grants and Support of:

Gold Level Partner
UNITED THERAPEUTICS EUROPE

Silver Level Partner
ACTELION
ASTELLAS PHARMA
GILEAD SCIENCES
THORATEC

Bronze Level Partner
ONE LAMBDA
NOVARTIS PHARMA

Corporate Level Partner
BAYER
(in support of the Pulmonary Hypertension Sessions)
HEARTWARE

Toward this 32nd Annual Meeting and Scientific Sessions



CONTINUING MEDICAL EDUCATION INFORMATION

ACCREDITATION STATEMENT

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

ISHLT designates this live activity for a maximum of 28 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

FRIDAY

TIME	CONGRESS HALL	FORUM HALL	MEETING HALL 1	PANORAMA HALL	MEETING HALL 4
8:00 AM	CONCURRENT SESSION 25 VAD Future	CONCURRENT SESSION 26 HTx Immunosuppression Trials	CONCURRENT SESSION 27 LTx Basic Science	CONCURRENT SESSION 28 Right Ventricle Function	CONCURRENT SYMPOSIUM 11 Failing Fontan
9:00 AM					
9:15 AM	ANNUAL BIZ MTG	BREAK	BREAK	BREAK	BREAK
9:45 AM	PLENARY SESSION Aging Imperative				
11:15 AM	BREAK	BREAK	BREAK	BREAK	BREAK
11:45 AM	CONCURRENT SYMPOSIUM 12 MCS Recovery	CONCURRENT SYMPOSIUM 13 HTx Immunosuppression	CONCURRENT SYMPOSIUM 14 Following the RV	CONCURRENT SYMPOSIUM 15 Pathology Cases	CONCURRENT SYMPOSIUM 16 Bad Bugs
1:00 PM					
1:15 PM		LUNCH BREAK	CONCURRENT SYMPOSIUM 19 ISHLT/ESOT	MINI ORAL SESSION 4 MCS 2	MINI ORAL SESSION 5 HTx and PEDS
2:45 PM					
3:00 PM		PLENARY SESSION New Horizons			
4:30 PM	BREAK	BREAK	BREAK	BREAK	BREAK
5:00 PM		CONCURRENT SESSION 31 Right Ventricle	CONCURRENT SESSION 32 Congenital Heart Disease	CONCURRENT SESSION 33 Outcomes Post LTx	CONCURRENT SESSION 34 Donor Lungs
6:15 PM					
7:00 PM					
7:30 PM	PRESIDENT'S COCKTAIL RECEPTION • 7:30 PM – 8:30 PM • PRAGUE MUNICIPAL HOUSE				
8:30 PM					

MEETING HALL 5	NORTH HALL	CONGRESS HALL FOYERS	CLUB B	CLUB C	CLUB D	MEETING HALL 2	TIME
CONCURRENT SESSION 29 Physical Activity Pre/Post Tx	CONCURRENT SESSION 30 Innate Immunity	POSTER VIEWING 8:00 am – 5:00 pm					8:00 AM
		EXHIBIT HALL OPEN 9:00 am – 5:00 pm					9:00 AM
BREAK	BREAK						9:15 AM
							9:45 AM
BREAK	BREAK						11:30 AM
CONCURRENT SYMPOSIUM 17 PH in Chronic Parenchymal Lung Diseases	CONCURRENT SYMPOSIUM 18 PED LTx						12:00 PM
							1:00 PM
MINI ORAL SESSION 6 LTx, ID, Donor Mgmt	MINI ORAL SESSION 7 Basic Sci HTx, ID		JHLT LUNCH MEETING	BSTR COUNCIL MEETING	JFT COUNCIL MEETING	COUNCIL CHAIRS LUNCH	1:15 PM
							3:00 PM
							3:15 PM
BREAK	BREAK						4:30 PM
CONCURRENT SYMPOSIUM 20 Self-Management	CONCURRENT SESSION 35 CAVES Presentations	EXHIBIT STRIKE POSTER STRIKE 5:00 pm – 11:59 pm					5:00 PM
							6:15 PM
							7:00 PM
PRESIDENT'S COCKTAIL RECEPTION • 7:30 PM – 8:30 PM • PRAGUE MUNICIPAL HOUSE							7:30 PM
							8:30 PM

EDUCATIONAL OBJECTIVES

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

EDUCATIONAL GOALS

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

TARGET AUDIENCE

The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.



LEARNING OBJECTIVES

At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of:

1. Understanding organ donor selection and management, organ allocation, procurement, preservation and ex-vivo treatment, and their implications for organ viability and recipient outcomes.
2. Understanding the state-of-the-art treatment approaches to clinical left heart failure, right heart failure and lung failure, including criteria for and outcome implications of transplant versus non-transplant therapies as well as management of psychosocial problems and end of life situations.
3. Comparing and evaluating the advantages and disadvantages of various mechanical circulatory and respiratory support systems and their associated patient selection criteria.
4. Understanding the underlying pathophysiology of and state-of-the-art treatment for pulmonary hypertension.
5. Evaluating and treating infectious and treatment-related complications of VAD therapy and heart and lung transplantation.
6. Comparing and evaluating the advantages and disadvantages of various pharmacologic, non-pharmacologic and biologic immunosuppression techniques.
7. Evaluating and developing patient specific strategies for post-heart and lung transplant treatment that maximize patient outcomes and minimize immunosuppression-related side-effects.
8. Understanding methods to maximize patient outcomes by diagnosing, monitoring and treating immunologic complications of heart and lung transplantation, including antibody mediated rejection and chronic forms of allograft dysfunction.
9. Evaluating issues of controversy in the selection of candidates for heart and lung transplantation, such as age, prior transplantation and co-morbidities.
10. Describing and assessing the impact of psychosocial and behavioral issues on clinical post-transplant outcomes and quality of life for patients.
11. Identifying current animal and other laboratory models relevant to the basic science of transplant immunobiology and understanding their application to the transplant setting.
12. Understanding the importance and utilization of techniques to detect and quantify HLA and non HLA antibodies in the immunobiology of donor and recipient matching and subsequent post-transplant management.
13. Evaluating pediatric specific aspects of heart and lung failure and thoracic transplantation, including pharmacotherapy, developmental issues and unique psychosocial situations.

SESSION HIGHLIGHTS



Karel Schwarzenberg
Czech Republic Minister of Foreign Affairs



Ministerstvo zahraničních věcí České republiky
Ministry of Foreign Affairs of the Czech Republic

PLENARY SESSIONS

Wednesday **OVERCOMING POLITICAL BARRIERS:**

Prague serves as a showcase for the positive changes that have occurred in Eastern Europe following the demise of the iron curtain. You will be welcomed by ISHLT President Lori West and Czech Republic Minister of Foreign Affairs Karel Schwarzenberg, who will bestow official patronage to the ISHLT meeting. Then you will be entertained by a historical perspective of Prague through the years and enlightened by a description of the successful development of a lung transplant program in Prague. Finally, you will be stimulated to consider the impact of politics on scientific advancement by internationally acclaimed physicist, commentator and essayist Lawrence Krauss.

Thursday ISHLT TRADITIONS:

Following tradition, Thursday's plenary will include the annual Thoracic Organ Transplant and Mechanical Circulatory Support Registry Reports. Then we will be challenged as transplant professionals to aid in the efforts led by the World Health Organization to raise awareness of access, safety and ethical issues in cell, tissue and organ transplantation by Luc Noel MD of the World Health Organization. The plenary session will close with presentation of the Lifetime Achievement award to Sharon Hunt for her many roles in Heart Transplantation Medicine beginning with its birth at Stanford and continuing today as well as her ongoing contributions to the ISHLT.

Friday Morning THE AGING IMPERATIVE: ETHICS, ECONOMICS AND RESOURCE ALLOCATION

The aging of our population impacts health care in multiple domains and is increasingly affecting delivery of care to patients with heart and lung failure. Mi-Kyung Song PhD, RN, University of North Carolina, will teach us about how to help aging patients make health care decisions and Axel Rahmel, Medical Director of Eurotransplant will provide a systems perspective. The session will also include presentations on aging and immunobiology, assessment of "frailty" in elderly patients and the ethics of allocation of scarce resources.

Friday Afternoon NEW HORIZONS:

Prepare for a glimpse of future research in key areas of our society. Harald Ott, MD, Massachusetts General Hospital, will tantalize us with descriptions and images of bio-artificial organs. The session will continue with talks on the use of functional imaging to assess graft function, the future of stem cell research and the pursuit of tolerance and will close with a discussion of the importance of pulsatile flow in mechanical circulatory support by Mandeep Mehra, MD.



Saturday INCORPORATING INFORMATION TECHNOLOGY INTO PRE AND POST-TRANSPLANT CARE:

Information technology in health care is expanding in multiple dimensions, including personal and system-based electronic health records, the use of social networking to improve patient communication and the use of information technology to provide more efficient and effective care. Cleveland Clinic Chief Information Officer C. Martin Harris MD will provide a broad overview of the impact IT is having on health care, followed by presentations on the use of technology in the care of heart failure patients, those receiving mechanical circulatory support and transplant recipients.

JOINTLY SPONSORED SESSIONS

Beginning with the pre-meeting symposia, joint symposia that bring together speakers and members from various disciplines will be spread throughout the program – a highlight will be two consecutive symposia: *AMR Part 1: The ABCs of AMR: Antibodies, B Cells, and Complement* and *AMR Part 2: The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy and Finally, the Patient*. These two sessions will bring together pathologists, immunologists and experts in clinical heart and lung transplantation. Other symposia will feature experts in pulmonary hypertension, heart failure and mechanical circulatory support to shed light on the right ventricle.

SESSION HIGHLIGHTS

Pediatricians will share the podium with their adult colleagues in several sessions, including *Management of the Failing Fontan Patient Across the Age Spectrum*, *Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients* and *MCS in Congenital Heart Disease & Pediatrics*.

DONOR MANAGEMENT, ORGAN PRESERVATION AND ALLOCATION

Highlights of sessions related to donor and organ management include an update on the use of ex-vivo techniques in *Ex-Vivo Perfusion of Heart and Lungs – Why, With What and How?*, a cutting edge session entitled: *Thoracic Organ Donors: Optimal Management and New Avenues* and finally a timely session co-sponsored by the infectious disease council – *Risky Business: Infectious Risk in Donors and Recipients*, featuring Camille Kotton, MD, FIDSA, Massachusetts General Hospital/Harvard Medical School, presenting on *The ‘Well-Travelled’ Donor: What are the Risks?* These sessions will provide attendees with important new information about managing donors and donor organs.

HEART FAILURE AND TRANSPLANTATION

As one of the core disciplines of ISHLT, Heart Failure and Transplant Medicine will be among the most prominent topics discussed in Prague. Clinical handling of advanced heart failure and heart transplant patients will remain the nucleus of the six dedicated concurrent symposia, two of which have been designed to foster interactivity between panel discussants and the audience. However, the invited speakers will additionally provide a broad perspective towards the basic mechanisms of the pathological processes to understand practical applicability of molecular biology techniques, clinical relevance of the novel immuno-biology processes involved in graft rejection and a multidisciplinary outlook of patient’s care, involving LVAD and pharmacological management of PH. The cutting edge of cellular and antibody-mediated acute rejection will be covered in three consecutive Satellite Symposia. The first, *Past, Present and Future of Cardiac Allograft Surveillance* will deal with the changing patterns and clinical manifestations of acute rejection, the role of endomyocardial biopsy monitoring in the

modern era and the clinical reliability of novel non-invasive tools based on molecular biology techniques. The second and third symposia, focusing on AMR, will discuss novel targets for treatment and updates of the pathological classification. Thursday’s Satellite Symposium session, *Tough Situations in Cardiac Transplantation*, will offer the audience the possibility to interact with an expert panel chaired by Man-deep Mehra on two controversial clinical scenarios in the management of long-term heart transplant recipients. A novel perspective on CAV, moving beyond the mere concept of coronary intimal thickening, will be provided in the Satellite session, *Large and Small Vessels Disease in Cardiac Transplantation*, covering the concept of vascular remodeling, morphology and function of coronary microvasculature and therapeutic targets and tools. On Friday, the Satellite session *The Leading Edge of Immunosuppression In Heart Transplantation: Evidence, Perspectives and Clinical Practice*, will grant insights from clinical trials and clinical practice of modern immunosuppression. This rich international menu of concurrent symposia, seasoned by oral abstract sessions, is expected to fully feed transplant cardiologists hunger for cutting-edge education, within the heart of old Europe.

RESPIRATORY FAILURE AND LUNG TRANSPLANTATION

Another of the core disciplines at the foundation of our society, management of respiratory failure and pulmonary replacement therapy, will be prominent topics throughout the meeting. In addition to the pulmonary aspects of antibody mediated rejection to be included in the pre-meeting AMR sessions, the first pre-meeting symposium devoted to lung transplantation, *Evolving Concepts Of Chronic Lung Allograft Dysfunction*, will review new concepts of chronic lung allograft dysfunction and will reflect some of the conclusions and recommendations reached by the joint ISHLT/ATS/ERS task force on care of the lung transplant recipient. *Advances In Pulmonary Transplant Surgery*, another pre-meeting symposium, will include presentations on airway complications, mechanical bridging and ex-vivo lung perfusion.

Concurrent symposia on Thursday and Friday include the session, *Special Considerations: Cystic Fibrosis and Lung Trans-*

SESSION HIGHLIGHTS

plantation, which will review the complicated microbiology, surgical considerations and psychosocial issues associated with transplant of the CF patient. An international review of *Lung Transplantation for Pulmonary Arterial Hypertension* will focus on the impact that regional variability in listing status, organ allocation and the type of organ transplantation have on outcomes, and finally a session on *Challenges in Pediatric Lung Transplant* that will close with a presentation on transition of the pediatric lung transplant recipient to adult care.



INFECTIOUS DISEASES

Infectious Diseases will be significantly highlighted during a variety of symposia during the meeting. In *CMV & Beyond* we will highlight emerging viruses in thoracic transplantation as well as discuss developing issues with cytomegalovirus. *Bad Bugs – What Can We Do?* includes discussions of the impact of multi-drug resistant gram negative organisms, VRE and MRSA and *Clostridium difficile*, with a focus on prevention. Infectious diseases will also be woven into sessions sponsored by other councils, including talks on infections in Mechanical Circulatory Support and in transplant candidates with Cystic Fibrosis. Finally, we will have the opportunity to evaluate the Risky Business of Transplantation, focusing on candidates and donors with chronic hepatitis and history of international travel.

NURSING, HEALTH SCIENCE AND ALLIED HEALTH

The 2012 NHSAH program highlights include a presentation for the *Incorporating Information Technology into Pre- and Post-Transplant Care* plenary session titled, *Using Technology to Promote Self-Monitoring and Health Outcomes after Transplantation*. The NHSAH council also played a major role in developing the plenary *Aging Demographic Imperative: Ethics, Economics & Resource Allocation* and three key symposia.

Children and adolescents frequently face significant developmental challenges from the time of transplant through the time they transition to adult programs. *Neurocognitive, Psychosocial and Behavioral Issues in Children and Adolescents* is a pre-meeting symposium jointly facilitated by pediatric and nursing councils to address non-clinical issues (psychosocial, behavioral and neurocognitive) in children after thoracic transplantation.

Caregivers are a crucial component to successful outcomes for our patients, thus in the *Focus on Caregivers – Investing in our Patients’ Future* symposium, a panel of experts will outline unique approaches to address needs of caregivers so they can continue to provide optimal care to transplant recipients and MCS patients.

In recognizing that transplantation is a chronic condition, development of self-management strategies is a key component to improving long-term outcomes post thoracic transplantation. Presenters in the symposium *Self Management in End-Stage Heart Lung Disease and Transplantation* will describe important principles of ‘self-management,’ including management of the medical and pharmaceutical regimens, emotions and new life roles for both adult and pediatric patients.

MECHANICAL CIRCULATORY SUPPORT

The mechanical circulatory support field continues to grow, and so will its representation at the 32nd Annual Meeting and Scientific Sessions. A comprehensive MCS program will start on Tuesday with the ISHLT Academy dedicated to mechanical support.

SESSION HIGHLIGHTS

During pre-meeting symposia, didactic sessions will include *Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support*, providing an overview of different RV risk assessment approaches before LVAD implant. *Cardiogenic Shock Before and After Heart Transplantation* will review options, from ECMO to total artificial heart, that are available for patients in severe cardiogenic shock before and after heart transplantation. *New Devices, New Approaches* will explore new developments in LVADs and their clinical applications. Current approaches to MCS in children will be highlighted in *MCS in Congenital Heart Disease & Pediatrics*. The final pre-meeting symposium will be *The Longer The Better – Chronic Medical Management of MCS* focusing on how to optimize long-term MCS.

During the main meeting, the MCS Concurrent symposia on Thursday and Friday will include *MCS: When Is It Too Soon or Too Late?* providing the latest information on patient selection for device therapy at both ends of the heart failure spectrum – specifically when is a patient too sick to receive a VAD and how early in the HF disease trajectory can we consider VAD implant, and on Friday, *MCS Recovery – How Do We Get There*, intended to showcase our understanding of this process and possible approaches that could make myocardial recovery a treatment goal.

A number of abstract sessions, mini-orals and poster sessions with focus on MCS will provide ample opportunity for discussing new research as well as pondering old problems. Finally, topics with direct relevance to the MCS field will be addressed at a closing plenary session titled *Incorporating Information Technology into Pre- and Post-Transplant Care*.

PEDIATRICS

Forget the sight-seeing! Every day of the 2012 scientific meeting in Prague is packed with sessions of interest to the pediatric transplant specialist. This year's symposia promote crosstalk between specialists of shared interests through collaborative sessions related to pulmonary hypertension in the session, *Congenital Heart Disease: PH Dilemmas in Pediatric and Adult Patients*, lung transplant challenges specific to the child and young adult in the session, *Challenges in Pediatric*



Lung Transplant, pediatric mechanical circulatory support in everyday practice in the session, *MCS in Congenital Heart Disease & Pediatrics* as well as not-so-basic information needed for a basic understanding of transplant immunology in infants. You may discover some gems about managing the adolescent transplant patient's cognitive, psychosocial and behavioral dilemmas in the Czech Republic that can be more broadly applied to other adolescents in your life – *Neurocognitive, Psychosocial and Behavioral Issues in Children and Adolescents*. And just when you need respite from the castle-

laden landscape and the never-ending night life of Eastern Europe, the featured session on the failing Fontan will entice you back to matters of importance with the session, *Management of the Failing Fontan Patient Across the Age Spectrum*. Whether your goal is to decide once and for all how to treat AMR or to reach a consensus in pediatric transplantation with IPTA, your trip to the ISHLT meeting in Prague will be an enriching experience.



PULMONARY HYPERTENSION

Again this year, the members of the Program Committee representing pulmonary hypertension have put together a diverse and exciting series of pre-meeting and concurrent symposia highlighting cutting edge pathophysiology of, and treatment for, advanced pulmonary hypertension. Invited speakers include key members of our society complemented by some of the leading authorities in the world.

The meeting will open with three pre-meeting symposia devoted to aspects of pulmonary hypertension. First, *Potpourri of Special Topics in Pulmonary Hypertension* will include a series of topics on pulmonary hypertension that are less understood and of interest to cardiologists, pulmonary/ critical care specialists, anesthesiologists and surgeons, including a presentation on *Schistosomiasis: Possibly the Most Common Worldwide Cause of Pulmonary Hypertension*. A state-of-the-art understanding of right ventricular (RV) function in health, exercise, resting pulmonary hypertension and right heart failure will be presented in *The Right Ventricle and Pulmonary Vascular Load in Health and Disease*. The pre-meeting symposia will close with *Congenital Heart Disease: Pulmonary*

Hypertension Dilemmas in Pediatric and Adult Patients providing useful information on the management of patients with pulmonary hypertension associated with congenital systemic to pulmonary shunts, particularly those with unrepaired shunts.

Concurrent symposia on Thursday and Friday will open with a worldwide tour of *Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel Discussion*, focusing on the impact that regional variability in listing status, organ allocation and the type of organ transplantation (lung versus heart-lung) have on outcomes. On Friday, *Following the RV Through Thick and Thin* will provide a thorough overview of the problem of RV dysfunction in patients with CHF due to LV diseases, with a pathophysiological overview of PH secondary to LV dysfunction and finally *Pulmonary Hypertension in Chronic Parenchymal Lung Diseases: Does it Matter?* will highlight increasing recognition of pulmonary hypertension as a serious complication of chronic obstructive and interstitial lung diseases.

PATHOLOGY

Again this year, pathologists will be front and center with two pre-meeting symposia focused on all aspects for antibody mediated rejection in clinical heart and lung transplantation – *AMR Part 1: The ABCs of AMR: Antibodies, B Cells and Complement* and *AMR Part 2: The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy and Finally, the Patient*.

The pre-meeting symposia will open with *Past, Present and Future of Cardiac Allograft Surveillance* a session intended to review the usefulness and pitfalls of endomyocardial biopsy monitoring in current clinical practice, including practical information regarding the use of genomics and proteomics-based methodologies.

Concurrent symposia on Thursday and Friday will include *Large and Small Vessels Disease in Heart Transplantation* reviewing the importance of pathological features involving large epicardial and small intramyocardial vessels in cardiac allograft vasculopathy and a case-based discussion *Solving the Enigmatic: Cases in Heart and Lung Transplantation*.

BASIC SCIENCE

This year the Program Committee made an effort to complement important clinical symposia with presentations from members of the newly formed Basic Science and Translational Research council. This is particularly evident in the *Past, Present and Future of Cardiac Allograft Surveillance* and *AMR Part 1: The ABCs of AMR: Antibodies, B Cells and Complement* sessions.

Another pre-meeting symposium, *Innate Immunity in Cardiothoracic Transplantation* will provide information on emerging innovative modalities for studying innate immunity and the concurrent symposium *Coagulation and Transplantation – The Clot Thickens* will review the role platelets and complement may play in immune stimulation following thoracic transplantation.

Basic science and translational research will also be highlighted in plenary sessions on stem cells (Sonja Schrepfer) and tolerance (Sophie Brouard) as well as the joint ISHLT/ESOT symposium including presentations on T-reg (Carla Baan), clinical experience with belatacept and the relationship between ABO incompatibility and HLA antibodies.

Finally, the *Caves Award* competition session will continue to highlight original research by our young academic scientists, who present their most compelling experimental and clinical research to a jury of senior scientists and interested members.

PHARMACY AND PHARMACOLOGY

Members of the new Pharmacy and Pharmacology Council will be featured Thursday morning in the inaugural symposium in a series entitled *A Lifecycle Journey in...* sponsored by the ISHLT Pharmacy and Pharmacology Council. This series, focusing on therapeutic aspects that uniquely involve emerging or established knowledge in the pharmacology and pharmacy, envisions using an enduring case to create a panel facilitated and audience supported best practice based discussion at predefined key “journey intervals.”

In this session the focus will be on the lifecycle of Advanced Heart Failure and Cardiac Transplantation with special em-

phasis on the “journey points” of Mechanical Circulatory Support and anticoagulation, post-transplant development of Antibody Mediated Rejection and late complications that demand innovative immunosuppressive strategies.




JUNIOR FACULTY AND TRAINEES


Again this year, Junior Faculty and Trainees are encouraged to submit cases for the popular *Clinical Case Dilemmas in Thoracic Transplantation* session where tough cases are presented by junior faculty to expert discussants (these cases must be submitted via the standard abstract submission process, the deadline is November 18).

We are also planning to reprise the “Mentor Lunch,” on Thursday. In this setting, junior faculty and trainees can learn about *Getting Your Next Job, Balancing Work and Family* and other topics of special interest (pre-registration is required and limited).


PRAGUE CONGRESS CENTRE



2ND FLOOR



1ST FLOOR





Created in response to goals developed at the ISHLT 2006-2007 Strategic Planning Meeting, the **ishlt academy** draws on the wealth of experience and expertise within the society to deliver high quality educational experiences with the goal of enabling our members to improve and maintain the highest possible standards in the care of patients with advanced heart and lung disease and those undergoing heart or lung transplantation.

The ishlt academy represents the ‘brand name’ that will be associated with the educational opportunities offered by the ISHLT to its members and interested non-members.

The purpose of the **ishlt academy** is to develop an enduring resource of education in core competencies in the field of cardiopulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. These educational endeavors will complement the ISHLT’s existing activities in the promulgation of new science, registry analyses, guideline statements and monograph series as a consolidated activity designed to train and educate young clinicians, trainees and those looking for a refresher course in clinical practice mandates in the field.

The opportunities provided by the **ishlt academy** will be multi-modality and multi-disciplinary and will be guided by the identified educational needs or ‘practice gaps’ of ISHLT members. When available, core curriculum and competency documents for different disciplines within the society will guide content of ishlt academy activities. The activities of the academy will run throughout the societies interface with its members with material provided in written format via articles in the Journal of Heart and Lung Transplantation, via the ISHLT Monograph series, and via educational meetings.

On Tuesday, April 17, 2012, a day prior to the 2012 Annual Meeting, we are conducting the third ishlt academy: Core Competencies in Mechanical Circulatory Support.

The **ishlt academy: Core Competencies in Mechanical Circulatory Support** will provide a concise review of clinical knowledge and essential professional skills to facilitate the surgical and medical management of patients with advanced heart failure who are being assessed for and who have received durable mechanical circulatory support. The course consists of focused presentations covering a broad array of topics for both inpatient and outpatient management with an emphasis on a practical approach to patient care, implementing best practices and clinical problem solving. All lectures will be delivered by internationally recognized experts in the field and include cardiologists, cardiac surgeons, critical care physicians and VAD coordinators.

Audience participation and interaction with the faculty will be actively encouraged throughout the Academy with Question and Answer sessions following each major topic and by limiting the enrollment to 200 participants.

The educational workforce of the Mechanical Circulatory Support Counsel of the ISHLT is confident this will be the most comprehensive and valuable summary for practitioners in the field of mechanical circulatory support.

ISHLT ACADEMY: Core Competencies In Mechanical Circulatory Support



CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 9.0 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Learning Objective

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Recognize the various types of mechanical circulatory support, their outcomes, and rates of adverse events.
2. Identify the clinical signs and risk factors of advanced heart failure in order to optimally time implantation.
3. Recognize the medical and social factors which impact patient outcomes on MCS.
4. Optimize implantation techniques and pump selection.
5. Manage patients after MCS in the intensive care unit, as an inpatient and as an outpatient.
6. Diagnose and manage common clinical dilemmas and adverse events in patients after MCS.

Educational Goals

The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of mechanical circulatory support.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training, are part of a new program or desire an update on the current state of the field.

TUESDAY, APRIL 17, 2012

ISHLT ACADEMY: Core Competencies In Mechanical Circulatory Support (MEETING HALL 1)

CHAIRS: Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA, Andreas Zuckermann, MD, University of Vienna, Austria, and David S. Feldman, MD, PhD, FAHA, FACC, Minneapolis Heart Institute, Minneapolis, MN, USA

Introduction

7:30 AM-7:45 AM

Welcome and Brief Overview, Jeffrey Teuteberg, MD, University of Pittsburgh, USA

SECTION 1: Review of the Current State of MCS

7:45 AM -8:00 AM

Technology 101: Review of Current Technologies, Types of Flow, Pump Parameters, Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

8:00 AM – 8:15 AM

BTT/Long-Term Support/Recovery: Review State of Outcomes and Adverse Events with Current Technologies, Andreas Zuckermann, MD, University of Vienna, Austria

8:15 AM – 8:30 AM

Shock – Role of Biventricular Support, TAH, and ECMO, Alain Pavie, MD, La Pitié Hospital, Paris, France

8:30 AM – 8:45 AM

Q & A

SECTION 2: Patient Selection

8:45 AM – 9:00 AM

Worrisome Signals – Risk Factors which Presage Patient Decline: Renal Function, Intolerance of Medications, Hospitalizations, Nicholas Banner, FRCP, Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom

9:00 AM – 9:15 AM

Risk Prediction Models – Review of Risk Prediction, What They Can and Can't Tell Us: MV02, SHRM, etc., Keith D. Aaronson, MD, University of Michigan, Ann Arbor, MI, USA

9:15 AM – 9:30 AM

Timing of Implantation – When is the Patient “Sick Enough” to Implant MCS; Andrew J. Boyle, MD, Aurora St. Luke's Medical Center of Aurora Health Care Metro, Inc, Milwaukee, WI, USA

9:30 AM – 9:45 AM

Q & A

9:45 AM – 10:00 AM

BREAK

SECTION 3: Medical Considerations

10:00 AM – 10:15 AM

RV Assessment and Prediction – Brief Overview of Impact of RV Failure, Pre-Operative Assessment and Management of the RV, Risk Prediction; Case Examples, David S. Feldman, MD, PhD, FAHA, FACC, Minneapolis Heart Institute, Minneapolis, MN, USA

10:15 AM – 10:30 AM

End-Organ Assessment – Review of Organ Recoverability: Renal, Hepatic, Vascular, Overall Medical Candidacy, Lee R. Goldberg, MD, MPH, Hospital of University of Pennsylvania, Philadelphia, PA, USA

10:30 AM – 10:45 AM

Infection: ISHLT Consensus – Overview of the ISHLT Consensus Guideline Definition of Infections, Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

10:45 AM – 11:00 AM

Q & A

SECTION 4: Surgical Considerations

11:00 AM – 11:15 AM

Implantation 101 – Overview of the Most Crucial Surgical Considerations: Inflow Cannula/Pump Placement, Driveline, etc., Nader Moazami, MD, Minneapolis Heart Institute, Minneapolis, USA

11:15 AM – 11:30 AM

How Much Else is Too Much? – Concomitant Operative Procedures: TV, Aortic Valve, Prior Dor, Congenitals, Roland Hetzer, MD, PhD, Berlin Heart Institute, Germany

11:30 AM – 11:45 AM

Matching Pumps to Patients – Considerations for Device Type, Type of Flow Based Upon Patient Factors, Mark S. Slaughter, MD, University of Louisville, Louisville, KY, USA

11:45 AM – NOON

Q & A

NOON – 1:15 PM

LUNCH This time is meant to provide an opportunity for participants and speakers to interact.

SECTION 5: Pediatric Considerations

1:15 PM – 1:30 PM

Pediatric Perspective – On Current State of Technology, Patient/Device Selection, Medicals/Surgical Considerations, David L.S. Morales, MD, Texas Children's Hospital, Houston, TX, USA

SECTION 6: Post-Op

1:30 PM – 1:45 PM

Post-Op Pearls in the ICU – Managing the Patient in the Immediate Post-Operative Period, Angela Rajek, MD, University of Vienna, Austria

1:45 PM – 2:00 PM

Managing the RV – Post-Operative Approach to the RV: Surgical Considerations, Pump Speed, INO, Inotropes, etc., Martin Strueber, MD, Hannover Medical School, Hannover, Germany

2:00 PM – 2:15 PM

Anticoagulation – Overview of the Timing and Type of Anticoagulation, Means to Monitor State of Anticoagulation, Anticoagulation Management for Elective Procedures, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

2:15 PM – 2:30 PM

Q & A

SECTION 7: Transition of Home

2:30 PM – 2:45 PM

Teaching/Patient Assessment – Outline of Approach to Teaching Patient and Their Family Community, Michael G. Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, MN, USA

2:45 PM – 3:00 PM

Keeping Patients at Home – Community Support, Restrictions, Role of Local Providers, Karl E. Nelson, RN, MBA, Integris Baptist Medical Center, Oklahoma City, OK, USA

3:00 PM – 3:15 PM

Quality of Life and Functionality Capacity – The Need For, Timing Of and Measures To Assess, Kathleen L. Grady, PhD, APN, Northwestern University, Chicago, IL

3:15 PM – 3:30 PM

Q & A

3:30 PM – 3:45 PM

BREAK

SECTION 8: Long-Term Management

3:45 PM – 4:00 PM

GI Bleeding – Review of Pathophysiology, Incidence and Diagnostic/Therapeutic Approach, Daniel J. Goldstein, MD, Montefiore-Einstein Medical Center, Bronx, NY

4:00 PM – 4:15 PM

Driveline Infections – Definition (ISHLT Consensus Statement), Prevention, Treatment, Evgenij Potapov, MD, PhD, Berlin Heart Institute, Berlin, Germany

4:15 PM – 4:30 PM

Outpatient Management – Clinic Structure, Typical Items Addressed, Focused Medical Management (BP, Rhythms, Etc), Rehab, Joseph G. Rogers, MD, Duke University Medical Center, Durham, NC, USA

4:30 PM – 4:45 PM

Role of Imaging – Echo: Basic Views, How to Assess Functionality, Set Speed, How Often, Case Presentation; CT: When it is Useful, What can Really be Assessed, Case Presentations, Shashank S. Desai, Inova Fairfax Hospital, Falls Church, VA, USA

4:45 PM – 5:00 PM

End of Life Considerations – Cause of Death on MCS, Establishing Goals, End-of-Life Care, Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, AL, USA

5:00 PM – 5:15 PM

Q & A

SECTION 9: Trouble Shooting – Case Presentations

5:15 PM – 5:25 PM

RV Function, Michele Pilato, MD, ISMETT, Palermo, Italy

5:25 PM – 5:35 PM

Driveline, Chris Salerno, MD, St. Vincent Medical Center, Indianapolis, IN

5:35 PM – 5:45 PM

Hemolysis/Bleeding, Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY, USA

5:45 PM – 5:55 PM

Thrombus, George M. Wieselthaler, MD, University of California San Francisco, CA, USA

SECTION 10: Review

6:00 PM – 6:15 PM

ISHLT MCS Guidelines, Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA, Andreas Zuckermann, MD, University of Vienna, Austria, and David S. Feldman, MD, PhD, FAHA, FACC, Minneapolis Heart Institute, Minneapolis, MN, USA

6:15 PM – 6:45 PM

RECEPTION



President's Cocktail Reception

PRAGUE MUNICIPAL HOUSE

The President's Cocktail Reception will be held Friday evening at the Prague Municipal House, which is often referred to as "the Art-Nouveau Jewel of Prague." One ticket to this event is included with all scientific session registration fees. Additional tickets may be purchased. As always, you can expect plenty of food, drink, music and friends.



Breathe in life

The only EMA-approved inhaled treatment for pulmonary arterial hypertension (PAH).



VENTAVIS
iloprost trometamol
Proven inhaled efficacy

Prescribing Information

VENTAVIS 10 microgram/ml nebuliser solution. **Composition:** 1 ml solution contains 10 micrograms iloprost (as iloprost trometamol). Ampoules with 1 or 2 ml solution containing 10 or 20 micrograms iloprost are available. **Excipient:** Ethanol 96% 0.81 mg per ml. **Therapeutic indications:** Treatment of patients with primary pulmonary hypertension, classified as NYHA functional class III, to improve exercise capacity and symptoms. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Conditions where the effects of Ventavis on platelets might increase the risk of haemorrhage (e.g. active peptic ulcers, trauma, intracranial haemorrhage); Severe coronary heart disease or unstable angina. Major infections within the last 6 months; Decompensated heart failure within the last 3 months; Severe liver disease; Severe renal impairment; Severe arrhythmias; Cerebrovascular events; Myocardial infarction within the last 3 months; Significant bleeding; Significant laboratory relevant myocardial function disorders not related to pulmonary hypertension; Pregnancy; Lactation. Undesirable effects:** In addition to local effects resulting from administration of iloprost by inhalation such as increased cough, adverse reactions with iloprost are related to the pharmacological properties of prostacyclins. Most common adverse reactions seen in clinical trials: vasodilatation (including hypotension), headache, increased cough. **Very common adverse events ($\geq 1/100$):** headache, vasodilatation, bleeding events, chest discomfort (chest pain, cough increased, nausea, pain in jaw/strismus). **Common adverse events ($\geq 1/100$ to $< 1/100$):** dizziness, syncope, hypotension, dyspnoea, pharyngolaryngeal pain and throat irritation, diarrhoea, vomiting, mouth and tongue irritation, rash. **Adverse events with unknown frequency are:** hypersensitivity, bronchospasm/wheezing and dysgeusia. **Syncope** is a common symptom of the disease itself, but can also occur under therapy. The increased occurrence of syncope can be related to the deterioration of the disease or insufficient effectiveness of the product. **Peripheral oedema** is a very common symptom of the disease itself, but can also occur under therapy. It can be related to the deterioration of the disease or insufficient effectiveness of the product. **Bleeding events (mostly haematomata)** were common as expected in this patient population with a high proportion of patients taking anticoagulant co-medication. **Special warnings and precautions for use:** Not recommended in patients with unstable pulmonary hypertension, with advanced right heart failure. In case of deterioration or worsening of right heart failure transfer to other medicinal products should be considered. Blood pressure should be checked while initiating Ventavis. In patients with low systemic blood pressure and in patients with postural hypotension or receiving drugs known to reduce blood pressure levels, care should be

taken to avoid further hypotension. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Physicians should be alert to the presence of concomitant conditions or drugs that might increase the risk of hypotension and syncope. The pulmonary vasodilatory effect of inhaled iloprost is of short duration (one to two hours). Syncope is a common symptom of the disease itself and can also occur under therapy. Patients who experience syncope in association with pulmonary hypertension should avoid any exceptional straining, for example during physical exertion. Before physical exertion it might be useful to inhale. The increased occurrence of syncope can reflect therapeutic gaps, insufficient effectiveness and/or deterioration of the disease. The need to adjust and/or change the therapy should be considered. **Precautions for use:** Caution might entail the risk of inducing bronchospasm, especially in patients with bronchial hyperactivity. **Warnings:** Caution should be exercised when Ventavis is administered in patients with pulmonary hypertension. **Concomitant acute pulmonary infections, COPD and severe asthma** should be carefully monitored. Should signs of pulmonary oedema when inhaled iloprost is administered in patients with pulmonary hypertension, the possibility of associated pulmonary veno-occlusive disease should be considered. The treatment should be stopped. In case of interruption of Ventavis therapy, the risk of rebound effect is not formally excluded. Careful monitoring of the patient should be performed, when inhaled iloprost therapy is stopped and an alternative treatment should be considered in critically ill patients. Data with intravenously administered iloprost indicated that the elimination is reduced in patients with hepatic dysfunction and in patients with renal failure requiring dialysis. A cautious initial dose titration using dosing intervals of at least 3 hours is recommended. Prolonged oral treatment with iloprost dathrate in dogs up to one year was associated with slightly increased fasted serum glucose levels. It cannot be excluded that this is also relevant to man on prolonged Ventavis therapy. To minimise accidental exposure, it is recommended to use Ventavis with nebulisers with inhalation-triggered systems (such as HaloLite/Prodose, I-Web), and to keep the room well ventilated. Ventavis nebuliser solution should not come into contact with skin and eyes; oral ingestion of Ventavis solution should be avoided. During nebulisation sessions a facial mask must be avoided and only a mouthpiece should be used. **Marketing authorisation numbers:** EU/1/03/255/001-008. **Preparation date:** June 2011. **Please note:** For current prescribing information refer to the package insert and/or contact your local Bayer HealthCare organisation. Bayer Pharma AG, D-13342 Berlin, Germany.

FOR POSITION ONLY
Bayer/Ventavis Ad

cmky

SCIENTIFIC PROGRAM AT A GLANCE

32nd Annual Meeting
& Scientific Sessions
April 18-21, 2012

FPO

End of 4/C
Section

TUESDAY, APRIL 17, 2012

7:30 AM – 6:45 PM

**ISHLT ACADEMY: CORE COMPETENCIES IN
MECHANICAL CIRCULATORY SUPPORT**
(MEETING HALL 1)

8:00 AM – 2:00 PM

ISHLT BOARD OF DIRECTORS MEETING
(MEETING HALL 2)

9:00 AM – NOON

CARDIAC AMR WORKSHOP
(CLUB B)

1:00 PM – 5:00 PM

PULMONARY AMR WORKSHOP
(CLUB B)

2:00 PM – 4:00 PM

**ISHLT COMMITTEE ON INTERNATIONAL and
INTER-SOCIETY POLICY MEETING**
(MEETING HALL 2)

IMACS STEERING COMMITTEE MEETING
(CLUB C)

**THORACIC TRANSPLANT REGISTRY
STEERING COMMITTEE MEETING**
(CLUB D)

3:00 PM – 6:00 PM

REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

4:00 PM – 6:00 PM

EDUCATION COMMITTEE MEETING
(CLUB C)

REGISTRIES & DATABASES COMMITTEE MEETING
(CLUB D)

**STANDARDS AND GUIDELINES
COMMITTEE MEETING**
(MEETING HALL 2)

6:00 PM – 7:00 PM

DCD REGISTRY STEERING COMMITTEE MEETING
(CLUB D)

6:30 AM – 6:30 PM

SPEAKER READY ROOM OPEN
(CLUB H)

WEDNESDAY, APRIL 18, 2012**7:00 AM – 6:00 PM****SPEAKER READY ROOM OPEN**
(CLUB H)**7:00 AM – 7:00 PM****REGISTRATION DESK OPEN**
(CONGRESS HALL FOYER)**8:00 AM – 4:30 PM****EXHIBIT BOOTH SET-UP**
(CONGRESS HALL FOYER)**8:00 AM – 1:00 PM****POSTER HALL SET-UP**
(CONGRESS HALL FOYER)**8:00 AM – 9:30 AM****PRE-MEETING SYMPOSIUM 1:**
Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support
(FORUM HALL)**PRE-MEETING SYMPOSIUM 2:***Past, Present and Future of Cardiac Allograft Surveillance*
(MEETING HALL 1)**PRE-MEETING SYMPOSIUM 3:***Evolving Concepts of Chronic Lung Allograft Dysfunction*
(PANORAMA HALL)**PRE-MEETING SYMPOSIUM 4:***Cardiogenic Shock Before and After Heart Transplantation*
(MEETING HALL 4)**PRE-MEETING SYMPOSIUM 5:***Neurocognitive, Psychosocial and Behavioral Issues in Children*
(MEETING HALL 5)**PRE-MEETING SYMPOSIUM 6:***Potpourri of Special Topics in Pulmonary Hypertension*
(This session is supported by an educational grant from Gilead.)
(NORTH HALL)**9:00 AM – 7:00 PM****PRESS OFFICE OPEN**
(MEETING ROOM 2.4)**9:30 AM – 9:45 AM****COFFEE BREAK**
(CONGRESS HALL FOYER)**9:45 AM – 11:15 AM****PRE-MEETING SYMPOSIUM 7:**
New Devices, New Approaches
(FORUM HALL)**PRE-MEETING SYMPOSIUM 8:***The ABCs of AMR: Antibodies, B Cells and Complement/Coagulation*
(MEETING HALL 1)**PRE-MEETING SYMPOSIUM 9:***Ex Vivo Perfusion of Heart and Lungs – Why, with What and How?*
(PANORAMA HALL)**PRE-MEETING SYMPOSIUM 10:***The Right Ventricle and Pulmonary Vascular Load in Health and Disease*
(MEETING HALL 4)**PRE-MEETING SYMPOSIUM 11:***MCS in Congenital Heart Disease & Pediatrics*
(MEETING HALL 5)**PRE-MEETING SYMPOSIUM 12:***CMV and Beyond: Important Viruses in Thoracic Transplantation*
(NORTH HALL)**11:15 AM – 11:30 AM****COFFEE BREAK**
(CONGRESS HALL FOYER)**11:30 AM – 1:00 PM****PRE-MEETING SYMPOSIUM 13:**
The Longer the Better – Chronic Medical Management of MCS
(FORUM HALL)**PRE-MEETING SYMPOSIUM 14:***The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy, and Finally, the Patient*
(MEETING HALL 1)

PRE-MEETING SYMPOSIUM 15:

Advances in Pulmonary Transplant Surgery
(PANORAMA HALL)

PRE-MEETING SYMPOSIUM 16:

Thoracic Organ Donors: Optimal Management and New Avenues
(MEETING HALL 4)

PRE-MEETING SYMPOSIUM 17:

Innate Immunity in Cardiothoracic Transplantation
(MEETING HALL 5)

PRE-MEETING SYMPOSIUM 18:

Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients
(NORTH HALL)

1:00 PM – 1:30 PM

BOX LUNCH PICK-UP

(BUFFET, 1ST FLOOR)

1:00 PM – 3:00 PM

LUNCH BREAK

1:00 PM – 3:00 PM

MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING

(PANORAMA HALL)

NURSING, HEALTH SCIENCES and ALLIED HEALTH COUNCIL MEETING

(MEETING HALL 5)

PULMONARY HYPERTENSION COUNCIL MEETING

(CLUB B)

PEDIATRIC TRANSPLANT COUNCIL MEETING

(CLUB C)

PATHOLOGY COUNCIL MEETING

(CLUB D)

1:00 PM – 4:45 PM

POSTER MOUNTING

(CONGRESS HALL FOYER)

3:00 PM – 4:15 PM

CONCURRENT SESSION 1:

How VADs Impact Our Community
(FORUM HALL)

CONCURRENT SESSION 2:

Decision Making in Advanced Heart Failure: Bridge, Recover, Transplant
(MEETING HALL 1)

CONCURRENT SESSION 3:

What Do Animal Models Teach Us About BOS?
(PANORAMA HALL)

CONCURRENT SESSION 4:

The Right Donor at the Right Time: Juggling the Risk
(MEETING HALL 4)

CONCURRENT SESSION 5:

Optimizing the LVAD Experience
(MEETING HALL 5)

CONCURRENT SESSION 6:

An Ounce of Prevention and Managing Infection
(NORTH HALL)

4:15 PM – 4:45 PM

COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS

(CONGRESS HALL FOYER)

4:45 PM – 7:00 PM

EXHIBIT HALL OPEN and POSTER VIEWING

(CONGRESS HALL FOYER)

4:45 PM – 6:00 PM

OPENING PLENARY SESSION:

Overcoming Political Barriers
(CONGRESS HALL)

6:00 PM – 7:00 PM

PULMONARY TRANSPLANT COUNCIL QOL WORKFORCE MEETING

(CLUB D)

6:00 PM – 7:00 PM

**EXHIBIT HALL OPEN and POSTER VIEWING
OPENING RECEPTION**

(CONGRESS HALL FOYER)

THURSDAY, APRIL 19, 2012

7:00 AM – 7:00 PM
SPEAKER READY ROOM OPEN
 (CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
 (CONGRESS HALL FOYER)

8:00 AM – 7:00 PM
PRESS OFFICE OPEN
 (MEETING ROOM 2.4)

8:00 AM – 7:00 PM
POSTER VIEWING
 (CONGRESS HALL FOYER)

8:00 AM – 9:15 AM
CONCURRENT SYMPOSIUM 1:
A Lifecycle Journey in Advanced Heart Failure and Transplantation
 (MEETING HALL 4)

CONCURRENT SESSION 7:
The Dark Side of VADs
 (CONGRESS HALL)

CONCURRENT SESSION 8:
Heart Transplantation: Trends in Complications and Risk Factors
 (FORUM HALL)

CONCURRENT SESSION 9:
Lessons from Lung Transplant Database Analysis
 (MEETING HALL 1)

CONCURRENT SESSION 10:
Pulmonary Hypertension: Advances in Diagnosis and Therapy
 (PANORAMA HALL)

CONCURRENT SESSION 11:
Tolerance: To the Bench and Back
 (MEETING HALL 5)

CONCURRENT SESSION 12:
Bad Bugs: Donors, Recipients and the Consequences
 (NORTH HALL)

9:00 AM – 7:00 PM
EXHIBIT HALL OPEN
 (CONGRESS HALL FOYER)

9:15 AM – 9:45 AM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
 (CONGRESS HALL FOYER)

9:45 AM – 11:30 AM
PLENARY SESSION:
ISHLT Traditions
 (CONGRESS HALL)

11:30 AM – NOON
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
 (CONGRESS HALL FOYER)

NOON – 1:15 PM
CONCURRENT SYMPOSIUM 2:
Focus on Caregivers: Investing in Our Patients' Future
 (MEETING HALL 5)

CONCURRENT SESSION 13:
MCS: Balancing on the Razor's Edge
 (CONGRESS HALL)

CONCURRENT SESSION 14:
What's New in Immune Surveillance in Heart Transplantation
 (FORUM HALL)

CONCURRENT SESSION 15:
Clinical Aspects of Lung Transplantation
 (MEETING HALL 1)

CONCURRENT SESSION 16:
Bringing Hearts Alive and Kicking
 (PANORAMA HALL)

CONCURRENT SESSION 17:
B-Cells, Antibodies and Graft Injury
 (MEETING HALL 4)

CONCURRENT SESSION 18:
AMR in Thoracic Transplantation: Are We Making Progress?
 (NORTH HALL)

1:15 PM – 1:45 PM
BOX LUNCH PICK-UP
 (BUFFET, 1ST FLOOR)

1:15 PM – 3:15 PM
LUNCH BREAK

1:15 PM – 3:15 PM**JUNIOR FACULTY MENTOR LUNCH**

(CLUB A)

PULMONARY TRANSPLANTATION COUNCIL MEETING

(NORTH HALL)

**HEART FAILURE AND TRANSPLANT MEDICINE
COUNCIL MEETING**

(CLUB B)

PHARMACY AND PHARMACOLOGY COUNCIL MEETING

(CLUB C)

INFECTIOUS DISEASES COUNCIL MEETING

(CLUB D)

1:30 PM – 3:00 PM**MINI ORAL SESSION 1:***Mechanical Circulatory Support*

(MEETING HALL 1)

MINI ORAL SESSION 2:*Heart and Pediatric Transplantation*

(MEETING HALL 4)

MINI ORAL SESSION 3:*Pulmonary Hypertension and
Lung Transplantation*

(MEETING HALL 5)

3:15 PM – 4:30 PM**CONCURRENT SYMPOSIUM 3:***Mechanical Circulatory Support:
When is it Too Soon or Too Late?*

(FORUM HALL)

CONCURRENT SYMPOSIUM 4:*Large and Small Vessels Disease in Heart
Transplantation*

(FORUM HALL)

CONCURRENT SYMPOSIUM 5:*Tough Situations in Cardiac Transplantation:
Bring in the Experts*

(MEETING HALL 1)

CONCURRENT SYMPOSIUM 6:*Lung Transplantation for Pulmonary Arterial
Hypertension – A Review and Panel Discussion*

(PANORAMA HALL)

CONCURRENT SYMPOSIUM 7:*Special Considerations: Cystic Fibrosis
and Lung Transplantation*

(MEETING HALL 4)

CONCURRENT SYMPOSIUM 8:*Risky Business: Infectious Risk in Donors
and Recipients*

(MEETING HALL 5)

CONCURRENT SYMPOSIUM 9:*Coagulation and Transplantation –
The Clot Thickens*

(NORTH HALL)

4:30 PM – 5:00 PM**COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING**

(CONGRESS HALL FOYER)

5:00 PM – 6:15 PM**CONCURRENT SYMPOSIUM 10:***Joint ISHLT/IPTA Symposium*

(NORTH HALL)

CONCURRENT SESSION 19:*MCS: Desired Outcomes – Can We Get There*

(CONGRESS HALL)

CONCURRENT SESSION 20:*Advanced Heart Failure: When is a Contraindication
Not a Contraindication to Transplant*

(FORUM HALL)

CONCURRENT SESSION 21:*Therapeutics of Lung Transplantation*

(MEETING HALL 1)

CONCURRENT SESSION 22:*Pulmonary Hypertension: Assessment
and Prognosis*

(PANORAMA HALL)

CONCURRENT SESSION 23:*Clinical Case Dilemmas in Thoracic
Transplantation*

(MEETING HALL 4)

CONCURRENT SESSION 24:*Heart Failure: Back to Basics*

(MEETING HALL 5)

6:15 PM – 7:00 PM**PAST PRESIDENT'S COUNCIL MEETING and
RECEPTION**

(CLUB B)

6:15 PM – 7:00 PM**EXHIBIT HALL RECEPTION AND POSTER VIEWING**

(CONGRESS HALL FOYER)

FRIDAY, APRIL 20, 2012**7:00 AM – 6:00 PM****REGISTRATION DESK OPEN**
(CONGRESS HALL FOYER)**7:00 AM – 6:30 PM****SPEAKER READY ROOM OPEN**
(CLUB H)**8:00 AM – 5:00 PM****POSTER VIEWING**
(CONGRESS HALL FOYER)**8:00 AM – 7:00 PM****PRESS OFFICE OPEN**
(MEETING ROOM 2.4)**8:00 AM – 9:15 AM****CONCURRENT SYMPOSIUM 11:**
*Management of the Failing Fontan Patient
Across the Age Spectrum?*
(MEETING HALL 4)**CONCURRENT SESSION 25:***VAD Future: Recovery and New Devices?*
(CONGRESS HALL)**CONCURRENT SESSION 26:***Heart Transplant Immunosuppression:
What Can We Learn from Clinical Trials*
(FORUM HALL)**CONCURRENT SESSION 27:***Basic Science of Lung Transplantation*
(MEETING HALL 1)**CONCURRENT SESSION 28:***Right Ventricle Function*
(PANORAMA HALL)**CONCURRENT SESSION 29:***Role of Physical Activity in the Pre and
Post-Transplant Setting*
(MEETING HALL 5)**CONCURRENT SESSION 30:***Innate Immunity and Ischemia Reperfusion Injury*
(NORTH HALL)**9:00 AM – 5:00 PM****EXHIBIT HALL OPEN**
(CONGRESS HALL FOYER)**9:15 AM – 9:45 AM****ANNUAL BUSINESS MEETING**
(CONGRESS HALL)**9:15 AM – 9:45 AM****COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING**
(CONGRESS HALL FOYER)**9:45 AM – 11:15 AM****PLENARY SESSION:**
*The Aging Imperative: Ethics, Economics
and Resource Allocation*
(CONGRESS HALL)**11:15 AM – 11:45 AM****COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS**
(CONGRESS HALL FOYER)**11:45 AM – 1:00 PM****CONCURRENT SYMPOSIUM 12:**
MCS Recovery – How Do We Get There
(CONGRESS HALL)**CONCURRENT SYMPOSIUM 13:***The Leading Edge of Immunosuppression in
Heart Transplantation: Evidence, Perspectives
and Clinical Practice*
(FORUM HALL)**CONCURRENT SYMPOSIUM 14:***Following the RV Through Thick and Thin*
(MEETING HALL 1)**CONCURRENT SYMPOSIUM 15:***Solving the Enigmatic: Cases in Heart and
Lung Transplantation*
(PANORAMA HALL)**CONCURRENT SYMPOSIUM 16:***Bad Bugs – What Can We Do?*
(MEETING HALL 4)**CONCURRENT SYMPOSIUM 17:***Pulmonary Hypertension in Chronic Parenchymal
Lung Diseases: Does it Matter?*
(MEETING HALL 5)**CONCURRENT SYMPOSIUM 18:***Challenges in Pediatric Lung Transplant*
(NORTH HALL)

1:00 PM – 1:30 PM
BOX LUNCH PICK-UP
 (BUFFET, 1ST FLOOR)

1:00 PM – 3:00 PM
LUNCH BREAK

1:00 PM – 3:00 PM
**JHLT EDITORIAL BOARD MEETING
 AND LUNCH**
 (CLUB B)

**BASIC SCIENCE AND TRANSLATIONAL
 RESEARCH COUNCIL MEETING**
 (CLUB C)

**JUNIOR FACULTY AND TRAINEE
 COUNCIL MEETING**
 (CLUB D)

COUNCIL CHAIRS LUNCH MEETING
 (MEETING HALL 2)

1:15 PM – 2:15 PM
CONCURRENT SYMPOSIUM 19:
Joint ISHLT/ESOT Symposium
 (MEETING HALL 1)

1:15 PM – 2:45 PM
MINI ORAL SESSION 4:
Mechanical Circulatory Support II
 (PANORAMA HALL)

MINI ORAL SESSION 5:
Heart Transplantation
 (MEETING HALL 4)

MINI ORAL SESSION 6:
*Lung Transplantation, Infectious Diseases
 and Donor Management*
 (MEETING HALL 5)

MINI ORAL SESSION 7:
*Basic Science and Immunobiology, Heart
 Transplantation and Infectious Diseases*
 (NORTH HALL)

3:00 PM – 4:30 PM
PLENARY SESSION:
New Horizons
 (FORUM HALL)

4:30 PM – 5:00 PM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
 (CONGRESS HALL FOYER)

4:30 PM – 5:00 PM
2013 SCIENTIFIC PROGRAM COMMITTEE MEETING
 (CLUB B)

5:00 PM – 11:59 PM
EXHIBIT HALL TEAR DOWN
 (CONGRESS HALL FOYER)

5:00 PM – 11:59 PM
POSTER HALL TEAR DOWN
 (CONGRESS HALL FOYER)

5:00 PM – 6:15 PM
CONCURRENT SYMPOSIUM 20:
*Self Management in End Stage Heart and Lung
 Disease and Transplantation*
 (MEETING HALL 5)

CONCURRENT SESSION 31:
Right Ventricle – Staying Alive
 (FORUM HALL)

CONCURRENT SESSION 32:
*End Stage Congenital Heart Disease:
 Opportunities and Challenges*
 (MEETING HALL 1)

CONCURRENT SESSION 33:
Stealing Beauty after Lung Transplantation
 (PANORAMA HALL)

CONCURRENT SESSION 34:
Fishing Lungs from the Donor Pool
 (MEETING HALL 4)

CONCURRENT SESSION 35:
Philip K. Caves Award Candidate Presentations
 (NORTH HALL)

7:30 PM – 8:30 PM
PRESIDENT'S COCKTAIL RECEPTION
 PRAGUE MUNICIPAL HOUSE

SATURDAY, APRIL 21, 2012**7:00 AM – 11:30 AM****REGISTRATION DESK OPEN**

(CONGRESS HALL FOYER)

7:00 AM – 1:00 PM**SPEAKER READY ROOM OPEN**

(CLUB H)

8:00 AM – 9:15 AM**CONCURRENT SESSION 36:***Pediatric Mechanical Circulatory Support*

(FORUM HALL)

CONCURRENT SESSION 37:*Heart Transplantation: Outcomes with Patients with CAV and/or Alloantibody*

(MEETING HALL 1)

CONCURRENT SESSION 38:*From BOS to CLAD and Beyond!*

(PANORAMA HALL)

CONCURRENT SESSION 39:*'Hitting the Right Spot' – New Targets in Immunosuppression*

(MEETING HALL 4)

CONCURRENT SESSION 40:*Secondary (Non-PAH) Pulmonary Hypertension*

(MEETING HALL 5)

CONCURRENT SESSION 41:*Getting Back To Basics*

(NORTH HALL)

9:15 AM – 9:30 AM**COFFEE BREAK**

(CONGRESS HALL FOYER)

9:30 AM – 11:15 AM**PLENARY SESSION:***Incorporating Information Technology into Pre and Post-Transplant Care*

(FORUM HALL)

11:15 AM – 11:30 AM**COFFEE BREAK**

(CONGRESS HALL FOYER)

11:30 AM – 12:45 PM**CONCURRENT SESSION 42:***Featured Abstracts*

(FORUM HALL)

CONCURRENT SESSION 43:*Bad VADs*

(MEETING HALL 1)

CONCURRENT SESSION 44:*Heart Transplantation: What Can We Learn from Registry Data*

(PANORAMA HALL)

CONCURRENT SESSION 45:*Growing Up with a Heart Transplant: Adolescence, Antibodies and Pharmacogenetics*

(MEETING HALL 4)

CONCURRENT SESSION 46:*Mechanisms of Acute Injury and Organ Preservation*

(MEETING HALL 5)

CONCURRENT SESSION 47:*Evolving Infections in a New Era*

(NORTH HALL)

12:45 PM – 1:15 PM**BOX LUNCH PICK-UP**

(BUFFET – 1ST FLOOR)

12:45 PM – 2:15 PM**COUNCIL AND COMMITTEE REPORTS TO THE BOARD AND MEMBERSHIP**

(MEETING HALL 4)

2:30 PM – 7:00 PM**ISHLT BOARD OF DIRECTORS MEETING**

(MEETING HALL 2)

SCIENTIFIC PROGRAM

32nd Annual Meeting
& Scientific Sessions
April 18-21, 2012

All meetings and activities will take place at the Prague Congress Centre unless otherwise specified. All papers will be presented in English.

TUESDAY, APRIL 17, 2012

7:30 AM – 6:45 PM

ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT
(MEETING HALL 1)

8:00 AM – 2:00 PM

ISHLT BOARD OF DIRECTORS MEETING
(MEETING HALL 2)

9:00 AM – NOON

CARDIAC AMR WORKSHOP
(CLUB B)

1:00 PM – 5:00 PM

PULMONARY AMR WORKSHOP
(CLUB B)

2:00 PM – 4:00 PM

ISHLT COMMITTEE ON INTERNATIONAL and INTER-SOCIETY POLICY MEETING
(MEETING HALL 2)

IMACS STEERING COMMITTEE MEETING
(CLUB C)

THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE MEETING
(CLUB D)

3:00 PM – 6:00 PM

REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

4:00 PM – 6:00 PM

EDUCATION COMMITTEE MEETING
(CLUB C)

REGISTRIES & DATABASES COMMITTEE MEETING
(CLUB D)

STANDARDS AND GUIDELINES COMMITTEE MEETING
(MEETING HALL 2)

6:00 PM – 7:00 PM

DCD REGISTRY STEERING COMMITTEE MEETING
(CLUB D)

6:30 AM – 6:30 PM

SPEAKER READY ROOM OPEN
(CLUB H)

WEDNESDAY, APRIL 18, 2012

7:00 AM – 6:00 PM
SPEAKER READY ROOM OPEN
 (CLUB H)

7:00 AM – 7:00 PM
REGISTRATION DESK OPEN
 (CONGRESS HALL FOYER)

8:00 AM – 4:30 PM
EXHIBIT BOOTH SET-UP
 (CONGRESS HALL FOYER)

8:00 AM – 1:00 PM
POSTER HALL SET-UP
 (CONGRESS HALL FOYER)

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 1 (FORUM HALL)*****Optimizing Outcomes in Patients with Right Heart Failure in Need of Mechanical Circulatory Support***

CHAIRS: David S. Feldman, MD, PhD, FAHA, FACC and Ugolino Livi, MD, FECTS

8:00 AM *Predicting Right Heart Failure after LVAD Implant*, Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospitals Trust, United Kingdom

8:15 AM *RV Dysfunction in MCS: What is the Transcript Signature of RV/LV in Mechanically Assisted Patients*, J. Eduardo Rame, MD, MPhil, University of Pennsylvania, Philadelphia, Philadelphia, PA

8:30 AM *Three Perspectives: Patient with a Failing RV*

8:30 AM *Triage with Medicines*, Michael M. Givertz, MD, Brigham & Women's Hospital, Boston, MA

8:40 AM *Triage with BiVADs*, Thomas Krabatsch, MD, PhD, Deutsches Herzzentrum Berlin, Germany

8:50 AM *TAH Is It*, Vigneshwar Kasirajan, MD, Virginia Commonwealth University Medical Center, Richmond, VA

9:00 AM *Right Heart Failure Late after LVAD Implant*, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada

9:15 AM *Panel Discussion*

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 2 (MEETING HALL 1)*****Past, Present and Future of Cardiac Allograft Surveillance***

CHAIRS: Maria Frigerio, MD and Keyur B. Shah, MD

8:00 AM *The Changing Epidemiology of Acute Rejection*, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

8:20 AM *The Genomics of Rejection*, Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

8:40 AM *The Proteomics of Rejection*, Bruce McManus, MD, PhD, RCS, FCAHS, James Hogg Research Centre, Vancouver, Canada

9:00 AM *Integrating Invasive and Non-Invasive Tools: A Clinician's Perspective*, Sharon A. Hunt, MD, Stanford University Medical Center, Palo Alto, CA

9:20 AM *Questions and Answers*

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 3 (PANORAMA HALL)*****Evolving Concepts of Chronic Lung Allograft Dysfunction***

CHAIRS: Keith C. Meyer, MD, MS and Paul A. Corris, MB, FRCP

8:00 AM *BOS: Definitions and Emerging Phenotypes*, Geert Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

8:25 AM *Emerging Pathways in BOS: Autoimmunity*, David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN

8:45 AM *Emerging Pathways in BOS: Epithelial – Mesenchymal Transition*, Daniel C. Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

9:05 AM *Future Therapies for BOS*, Andrew J. Fisher, PhD, FRCP, Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 4 (MEETING HALL 4)*****Cardiogenic Shock Before and After Heart Transplantation***

CHAIRS: Nader Moazami, MD and Nicholas G. Smedira, MD

8:00 AM *Cardiogenic Shock – How Long Should Be the ECMO Bridge?*, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA

8:12 AM *What is the Direction of the Bridge in Cardiogenic Shock?*, Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere, Paris, France

- 8:24 AM** *Extracorporeal Mechanical Support and the Community Hospitals: How to Make it Work*, Christoph Schmid, MD, University Medical Center Regensburg, Germany
- 8:36 AM** *What is the Best Surgical Option in the Setting of Primary Graft Failure?*, Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 8:48 AM** *Surgical Technique of ECMO Placement – Balance between Invasiveness and Effectiveness*, Arnt E. Fiane, MD, Rikshospitalet, Oslo, Norway
- 9:00 AM** *TAH – Standard Solution in Shock?*, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany
- 9:12 AM** *Panel Discussion*

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 5: (MEETING HALL 5)***Neurocognitive, Psychosocial and Behavioral Issues in Children*

CHAIRS: Kathleen L. Grady, PhD, APN and Susan M. Chernenko, RN, MN, NP

- 8:00 AM** *Neurocognition: What Happens after Thoracic Transplantation in Children and Adolescents?*, Richard E. Chinock, MD, Loma Linda University Children's Hospital, Loma Linda, CA
- 8:12 AM** *Helping Children Make Psychosocial and Educational Adjustments after Transplantation*, Connie White-Williams, RN, PhD, FAAN, University of Alabama at Birmingham, AL
- 8:24 AM** *Adolescence and Adherence: "The Perfect Storm,"* Sabina De Geest, RN, PhD, University of Basel, Switzerland
- 8:36 AM** *Parenting Children with Thoracic Transplantation: Stress, Coping and Letting Go*, Diana A. Shellmer, PhD, Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh, PA
- 8:48 AM** *No Longer a Child – Not Quite an Adult: How to Help the Adolescent Recipient Transition to Adulthood*, Elfriede Pahl, MD, Children's Memorial Hospital, Chicago, IL
- 9:00 AM** *Quality Of Life In Pediatric Thoracic Transplantation: Trading One Illness For Another*, Jo Wray, PhD, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
- 9:12 AM** *Panel Discussion*

8:00 AM – 9:30 AM**PRE-MEETING SYMPOSIUM 6 (NORTH HALL)***Potpourri of Special Topics in Pulmonary Hypertension*

(This session is supported by an educational grant from Gilead.)

CHAIRS: Raymond L. Benza, MD and Fernando Torres, MD

- 8:00 AM** *Schistosomiasis: Possibly the Most Common Worldwide Cause of Pulmonary Hypertension – What is It and How Do We Diagnose and Treat It?*, Rogerio Souza, MD, University of Sao Paulo Medical School, Sao Paulo, Brazil
- 8:18 AM** *Understanding the Many Faces of Sarcoidosis and Its Relationship to Pulmonary Hypertension*, Christopher F. Barnett, MD, MPH, University of California San Francisco/San Francisco General Hospital, San Francisco, CA
- 8:36 AM** *Pre-Operative Evaluation and Intra-Operative Management of the Pulmonary Hypertensive Patient*, Dana P. McGlothlin, MD, University of California San Francisco Medical Center, San Francisco, CA
- 8:54 AM** *Critical Care Management of the Pulmonary Hypertensive Patient: Optimal Use of Inotropes, Pressors, and Pulmonary Vasodilators*, Myung H. Park, MD, University of Maryland School of Medicine, Baltimore, MD
- 9:12 AM** *Future of Pulmonary Arterial Hypertension Treatment – Should We Really Be Thinking Like the Oncologists?*, Marc Humbert, MD, PhD, University Paris-Sud, Paris, France

9:00 AM – 7:00 PM**PRESS OFFICE OPEN**

(MEETING ROOM 2.4)

9:30 AM – 9:45 AM**COFFEE BREAK**

(CONGRESS HALL FOYER)

9:45 AM – 11:15 AM**PRE-MEETING SYMPOSIUM 7 (FORUM HALL)***New Devices, New Approaches*

CHAIRS: Matthias Loebe, MD, PhD and Martin Strueber, MD

- 9:45 AM** *Axial vs. Centrifugal Pumps*, Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI
- 9:57 AM** *LVAD: Partial vs. Full Flow Support?*, Bartley P. Griffith, MD, University of Maryland School of Medicine, Baltimore, MD
- 10:09 AM** *VAD Therapy in Heart Failure with Preserved Systolic Function*, Soon J. Park, MD, Mayo Clinic, Rochester, MN
- 10:21 AM** *Machine or Biology? The Future for a Patient with a Failing Heart is with Machines*, James K. Kirklin, MD, University of Alabama at Birmingham, AL
- 10:33 AM** *Machine or Biology? The Future for a Patient with a Failing Heart is with Stem Cells*, Andre Terzic, MD, PhD, Mayo Clinic, Rochester, MN
- 10:45 AM** *Machine or Biology? The Future for a Patient with a Failing Heart is with Xenotransplantation*, Christopher G. A. McGregor, MB, FRCS, MD(Hons), Mayo Clinic and University College London, Rochester, MN, USA and London, United Kingdom
- 10:57 AM** *Panel Discussion*

9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 8 (MEETING HALL 1)**The ABCs of AMR: Antibodies, B Cells and Complement/Coagulation****CHAIRS:** Gerald J. Berry, MD and Thalachallour Mohanakumar, PhD**9:45 AM Clinical Context Case Presentations****9:45 AM** Luciano Potena, MD, PhD, University of Bologna, Italy**9:50 AM** Todd L. Astor, MD, Massachusetts General Hospital, Boston, MA**9:55 AM B Cells / Plasma Cells**, Esme Dijke, PhD, University of Alberta, Edmonton, Canada**10:15 AM Complement and Coagulation**, Steven Sacks, MD, PhD, MRC Centre for Transplantation, King's College London, United Kingdom**10:35 AM A Rational Approach To Treatment Strategies**, Richard Kirk, MA FRCP FRCPC, Freeman Hospital, Newcastle Upon Tyne, United Kingdom**11:05 AM Discussion**

9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 9 (PANDRAMA HALL)**Ex Vivo Perfusion of Heart and Lungs – Why, with What and How?****CHAIRS:** Dirk Van Raemdonck, MD, PhD and Steven S.L. Tsui, MD, FRCS**9:45 AM Part I: Kidney – Ex Vivo Machine Perfusion of Kidneys**, Rutger J. Ploeg, MD, PhD, FRCS, University of Oxford, United Kingdom**10:00 AM Part II: Heart – Ex Vivo Perfusion of Hearts with the Transmedics Device – European Experience**, Christoph Knosalla, MD, PhD, MHBA, German Heart Institute, Berlin, Germany**10:15 AM Ex Vivo Perfusion of Hearts with the Transmedics Device – U.S. Experience**, Abbas Ardehali, MD, David Geffen School of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA**10:30 AM Part III: Lung – Clinical Experience with Warm Asanguinous Ex-Vivo Lung Perfusion in Toronto**, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Canada**10:45 AM Clinical Experience with Asanguinous Ex-Vivo Lung Perfusion Utilizing the Vivoline System**, Stephen C. Clark, BMedSci(Hons), BM, BS, DM, FRCSC(Th), Freeman Hospital, Newcastle Upon Tyne, United Kingdom**10:57 AM Clinical Experience with Warm Blood Lung Perfusion – Transmedics**, Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany**11:09 AM Discussion**

9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 10 (MEETING HALL 4)**The Right Ventricle and Pulmonary Vascular Load in Health and Disease****CHAIRS:** Marc Humbert, MD, PhD and John T. Granton, MD**9:45 AM The Pulmonary Vasculature and Right Ventricular Afterload**, Ryan J. Tedford, MD, Johns Hopkins Medical Institutions, Baltimore, MD**10:05 AM The Right Ventricle in Exercise**, Rajeev Sagar, MD, Heart-Lung Institute, St. Joseph Hospital & Medical Center, Phoenix, AZ**10:20 AM Pathophysiology of RV Failure**, Stephen C. Mathai, MD, MHS, Johns Hopkins University, Baltimore, MD**10:35 AM Assessment and Management of RV Failure**, Anton Vonk-Noordegraaf, MD, PhD, VU Medisch Centrum, Amsterdam, The Netherlands**11:00 AM Panel Discussion**

9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 11 (MEETING HALL 5)**MCS in Congenital Heart Disease & Pediatrics****CHAIRS:** Ivan M. Rebeyka, MD and Christopher S. Almond, MD, MPH**9:45 AM Implantable VADs in Children and Adults with Congenital Heart Disease**, David L. S. Morales, MD, Texas Children's Hospital and Baylor College of Medicine, Houston, TX**9:57 AM Is Two Better than One? Indications for Bi iVAD vs. LVAD Placement in Children**, Holger W. Buchholz, MD, University of Alberta, Stollery Children's Hospital and Mazankowski Alberta Heart Institute, Edmonton, Canada**10:09 AM Beyond the Surgery – Preventing Thromboembolic Complications During Long-term VAD Support**, M. Patricia Massicotte, MSc, MD, MHSc, University of Alberta, Stollery Children's Hospital, Edmonton, Canada**10:21 AM VAD Options for the Single Ventricle Patient**, Olaf Reinhartz, MD, Stanford University, Stanford, CA**10:33 AM Heart Transplant or VAD in Children and Adults with Congenital Heart Disease – Strategies for Improving Transplant Outcome**, Robert Jaquiss, MD, Duke University School of Medicine, Durham, NC**10:45 AM Going Home: Hospital Discharge on VAD Support in Children**, William Neil Wrightson, RN, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, United Kingdom**10:57 AM Panel Discussion**

9:45 AM – 11:15 AM

PRE-MEETING SYMPOSIUM 12 (NORTH HALL)***CMV and Beyond: Important Viruses in Thoracic Transplantation*****CHAIRS:** Martha L. Mooney, MD and Martin R. Zamora, MD**9:45 AM** ***EBV Infection and PTLTD: Beyond the Viral Load***, Steven A. Webber, MBChB, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA**10:00 AM** ***Respiratory Viruses: Beyond RSV***, Peter M. Hopkins, MBBS FRACP HONOURS, The Prince Charles Hospital, Brisbane, Australia**10:15 AM** ***Beyond Abdominal Organs: HIV+ Thoracic Transplant Candidates***, Paolo Antonio Grossi, MD, PhD, University of Insubria, Varese, Italy**10:30 AM** ***Beyond HSV: Human Herpes Viruses in Transplantation***, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH**10:45 AM** ***Beyond Prophylaxis: CMV Immune Monitoring***, Martina Sester, PhD, Saarland University, Homburg, Germany**11:00 AM** ***Panel Discussion: CMV & Beyond: Clinical Dilemmas in Thoracic Transplant Recipients*****MODERATORS:** Martin R. Zamora, MD and Camille N. Kotton, MD, FIDSA

11:15 AM – 11:30 AM

COFFEE BREAK

(CONGRESS HALL FOYER)

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 13 (FORUM HALL)***The Longer the Better – Chronic Medical Management of MCS*****CHAIRS:** Evgenij V. Potapov, MD, PhD and Sudhir S. Kushwaha, MD**11:30 AM** ***Fine Tuning Pump Performance***, Mark S. Slaughter, MD, University of Louisville, Louisville, KY**11:42 AM** ***Arrhythmia Management: Beyond Amiodarone***, Salpy V. Pamboukian, MD, MSPH, University of Alabama at Birmingham, AL**11:54 AM** ***Aortic Insufficiency: An Achilles Heel for Long-Term Support?***, Roland Hetzer, MD, PhD, German Heart Institute, Berlin, Germany**12:06 PM** ***Long-Term Infection Prevention***, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland**12:18 PM** ***G.I. Bleeding: What is the Optimal Strategy for Diagnosis and Management?***, Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA**12:30 PM** ***Getting Back to Life: Sex, Driving and Rock-n-Roll – What, if any, Restrictions are Reasonable?***, Karl E. Nelson, RN, MBA, Integris Baptist Medical Center, Oklahoma City, OK**12:42 PM** ***Panel Discussion***

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 14 (MEETING HALL 1)***The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy, and Finally, the Patient*****CHAIRS:** Allan R. Glanville, MBBS, MD, FRACP and Jon Kobashigawa, MD**11:30 AM** ***Antibody Detection***, Dolly B. Tyan, PhD, D(ABHI) Stanford University, Palo Alto, CA**12:00 PM** ***Pathology: New Nomenclature / Classification***, Charles C. Marboe, MD, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY**12:30 PM** ***Clinical Correlate: What Does It All Mean? What are the Big Unanswered Questions?*****12:30 PM** ***Lung***: Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark**12:40 PM** ***Heart***: A. G. Kfoury, MD, FACC, Intermountain Medical Center, UTAH Cardiac Transplant Program, Murray, UT

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 15 (PANDRAMA HALL)***Advances in Pulmonary Transplant Surgery*****CHAIRS:** Stephen C. Clark, BMedSci(Hons), BM, BS, DM, FRCS(C-Th) and Christopher H. Wigfield, MD, FRCS**11:30 AM** ***Airway Complications***, Michael S. Mulligan, MD, University of Washington School of Medicine, Seattle, WA**12:00 PM** ***Mechanical Bridging to Lung Transplantation***, Martin Strueber, MD, Hannover Medical School, Hannover, Germany**12:30 PM** ***Practical Issues with EVLP***, Shaf Keshavjee, MD, FRCS, Toronto General Hospital, Toronto, Canada

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 16 (MEETING HALL 4)***Thoracic Organ Donors: Optimal Management and New Avenues*****CHAIRS:** Kenneth R. McCurry, MD and Gregory I. Snell, MD**11:30 AM** ***The Impact of Brain Death in Thoracic Organ Donor***, Arne P. Neyrinck, MD, University Hospitals Leuven, Belgium**11:40 AM** ***Hormonal Therapy in Thoracic Organ Donor: Does It Work?***, Robert S. Bonser, MD, FRCS, FRCP, Queen Elizabeth Hospital Birmingham, United Kingdom**12:00 PM** ***Ventilatory Strategies and Inhaled Therapies to Increase Donor Lung Yield***, Lorraine B. Ware, MD, Vanderbilt University, Nashville, TN

12:20 PM *The Agonal Phase in Controlled Donation after Cardiac Death: Does it Matter?* Bronwyn Lewvey, RN, BEd, Stu Grad Dip Clin Epi, The Alfred Hospital, Melbourne, Australia

12:40 PM *Potential for Heart Transplantation from Donors after Cardiac Death?* Ayyaz Ali, MD, PhD, Papworth Hospital, Cambridge, United Kingdom

12:30 PM *Balancing the Risks of Transplantation for CHD Today: Should we be Reserving this Therapy as a Last Resort or Consider Earlier Referral over Multiple Palliative Procedures?* Jonathan M. Chen, MD, New York Presbyterian, New York, NY

12:45 PM *Panel Discussion*

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 17 (MEETING HALL 5)

Innate Immunity in Cardiothoracic Transplantation

CHAIRS: Andrew Gelman, PhD and Daniel R. Goldstein, MD

11:30 AM *Acute Lung Injury after Lung Transplantation*, Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO

11:50 AM *Imaging the Innate Immune System after Lung Transplantation*, Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO

12:10 AM *Clinical Markers of Innate Immunity after Lung Transplantation*, Jason D. Christie, MD, MS, University of Pennsylvania School of Medicine, PA

12:30 AM *Role of NK Cells and Neutrophils in Cardiac Allograft Dysfunction*, Joren C. Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA

12:50 AM *Panel Discussion*

1:00 PM – 3:00 PM
LUNCH BREAK

1:00 PM – 1:30 PM
BOX LUNCH PICK-UP
(BUFFET, 1ST FLOOR)

1:00 PM – 3:00 PM
MECHANICAL CIRCULATORY SUPPORT
COUNCIL MEETING
(PANORAMA HALL)

1:00 PM – 3:00 PM
NURSING SCIENCE, HEALTH SCIENCES and
ALLIED HEALTH COUNCIL MEETING
(MEETING HALL 5)

1:00 PM – 3:00 PM
PULMONARY HYPERTENSION COUNCIL MEETING
(CLUB B)

1:00 PM – 3:00 PM
PEDIATRIC TRANSPLANT COUNCIL MEETING
(CLUB C)

1:00 PM – 3:00 PM
PATHOLOGY COUNCIL MEETING
(CLUB D)

1:00 PM – 4:45 PM
POSTER MOUNTING
(CONGRESS HALL FOYER)

11:30 AM – 1:00 PM

PRE-MEETING SYMPOSIUM 18 (NORTH HALL)

Congenital Heart Disease: Pulmonary Hypertension Dilemmas in Pediatric and Adult Patients

CHAIRS: Christian Benden, MD and
Mardi Gomberg-Maitland, MD, MSC

11:30 AM *Congenital Heart Disease and Pulmonary Hypertension: Classification and Understanding Why All Defects are Not the Same*, Ian Adatia, MBChB, MRCP, FRCPC(C), University of Alberta, Edmonton, Canada

11:45 AM *Unrepaired Systemic to Pulmonary Shunts and PAH: To Close Or Not to Close? That is the Question*, Daphne T. Hsu, MD, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY

12:00 PM *Medical Management of CHD Associated PAH: Do's and Don'ts for this Challenging Population*, Richard Krasuski, MD, The Cleveland Clinic Foundation, Cleveland, OH

12:15 PM *Use of PAH Directed Therapies in Patients with Single Ventricles*, Brian D. Hanna, MD, PhD, Children's Hospital of Pennsylvania, Philadelphia, PA

3:00 PM – 4:15 PM

CONCURRENT SESSION 1

(FORUM HALL)

How VADs Impact Our Community

CHAIRS: Leslie W. Miller, MD and Heather J. Ross, MD, MHSc, FRCP(c)

- 3:00 PM (1) Initial Results of the Destination Therapy Post-FDA-Approval Study with a Continuous Flow Left Ventricular Assist Device: A Prospective Study Using the INTERMACS Registry;** U.P. Jorde,¹ S.S. Kushwaha,² A.J. Taloos,³ Y. Naka,¹ G. Bhat,³ J.W. Long,⁴ D.A. Horstmannshof,⁴ R.L. Kormos,⁵ J.J. Teuteberg,⁵ M.S. Slaughter,⁶ E.J. Birks,⁶ D.J. Farrar,⁷ S.J. Park,² ¹Columbia University Medical Center, New York, NY; ²Mayo Clinic, Rochester, MN; ³Advocate Christ Medical Center, Oak Lawn, IL; ⁴Integrus Baptist, Oklahoma City, OK; ⁵University of Pittsburgh, PA; ⁶University of Louisville, Louisville, KY; ⁷Thoratec Corporation, Pleasanton, CA.
- 3:12 PM (2) Improved Survival of Patients on UNOS Waiting List Is Associated with Increased LVAD Use;** E.S. Shao, R. Garberich, K. Hryniewicz, B. Sun, N. Moazami, B. Cabuay, D. Feldman. Minneapolis Heart Institute, Minneapolis, MN.
- 3:24 PM (3) Implant Strategies for Continuous Flow LVAD Therapy in INTERMACS – Impact on Outcomes and Variability over Time;** J.J. Teuteberg,¹ G. Stewart,² M. Jessup,³ R.L. Kormos,¹ B. Sun,⁴ O.H. Frazier,⁵ D. Naftel,⁶ L. Stevenson,² ¹Heart and Vascular Institute, University of Pittsburgh, PA; ²Cardiology, Brigham and Women's Hospital, Boston, MA; ³Cardiology, University of Pennsylvania, Philadelphia, PA; ⁴Cardiovascular Surgery, Abbott Northwestern, Minneapolis, MN; ⁵Cardiology, Texas Heart Institute, Dallas, TX; ⁶Cardiology, University of Alabama, Birmingham, AL.
- 3:36 PM (4) Outcomes of Patients Implanted with a Left Ventricular Assist Device at Non-Transplant Open Heart Surgery Centers;** M.R. Katz,¹ E.M. Horn,² M.G. Dickinson,³ G.R. Zeevi,¹ A. Salemi,² J.P. Slater,⁴ ¹Cardiac Surgery/Advanced Heart Failure Center, Bon Secours Heart & Vascular Institute, Richmond, VA; ²Division of Cardiology/Dept Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY; ³Richard DeVos Heart and Lung Transplant Program, Frederik Meijer Heart & Vascular Institute Spectrum Health, Grand Rapids, MI; ⁴Department of Cardiovascular Medicine, Morristown Memorial Hospital, Morristown, NJ.
- 3:48 PM (5) High Event Rates in Medically Managed Advanced Heart Failure Patients Followed at VAD Centers;** G.C. Stewart,¹ M.M. Kittleson,² J. Cowger,³ C. Patel,⁴ F. Johnson,⁵ M. Mountis,⁶ P. Patel,⁷ E. Rame,⁸ J. Testani,⁹ M. Guglin,⁹ J. Teuteberg,¹⁰ L.W. Stevenson,¹ ¹Brigham and Women's Hospital, Boston, MA; ²Cedars Sinai Heart Institute, Los Angeles, CA; ³University of Michigan, Ann Arbor, MI; ⁴Duke University, Durham, NC; ⁵University of Iowa, Iowa City, IA; ⁶Cleveland Clinic, Cleveland, OH; ⁷University of Texas Southwestern, Dallas, TX; ⁸University of Pennsylvania, Philadelphia, PA; ⁹University of South Florida, Tampa, FL.
- 4:00 PM (6) Impact of Physical Deconditioning on Daily Life Activities in Patients with Left Ventricular Assist Device;** U. Tegtbur,¹ D. Malehsa,² E. Gützlaff,² B. Christoph,² S. Jan,² K. Christiane,² S. Martin,² ¹Sportsmedicine, Hannover Medical School, Hannover, Germany; ²Heart, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

3:00 PM – 4:15 PM

CONCURRENT SESSION 2

(MEETING HALL 1)

Decision Making in Advanced Heart Failure: Bridge, Recover, Transplant

CHAIRS: Fabrizio Oliva, MD and Peter Eckman, MD

- 3:00 PM (7) Outcomes after Heart Transplantation in Adult Recipients Based on Medical Urgency Status/Criteria: Implications for Heart Allocation in the USA;** D. Vega,¹ L.B. Edwards,² ¹Surgery, Emory University School of Medicine, Atlanta, GA; ²Research, UNOS, Richmond, VA.
- 3:12 PM (8) Can the Seattle Heart Failure Model Help in Predicting Death in a Cohort of High Urgent and Urgent Heart Transplant Candidates?;** J.M. Smits,¹ E. de Vries,¹ A. Rahmel,¹ B. Meiser,² H. Reichenspurner,³ M. Strueber,⁴ ¹Eurotransplant, Leiden, Netherlands; ²University Hospital Munich, Munich, Germany; ³University Hospital Effendorf, Hamburg, Germany; ⁴Hannover Medical School, Hannover, Germany.
- 3:24 PM (9) Outcomes in Destination Therapy VAD and Extended Criteria Cardiac Transplantation Stratified by HeartMate Risk Score;** C.B. Patel, M.A. Daneshmand, A.A. Simeone, A.F. Hernandez, G.M. Felker, P.B. Rosenberg, L.J. Blue, C.A. Milano, J.G. Rogers. Duke University Medical Center, Durham, NC.
- 3:36 PM (10) Successful Use of Percutaneously Placed Axillary-Subclavian Intra-Aortic Balloon Pumps That Permit Ambulation as a Bridge to Heart and Multi-Organ Transplantation;** J.D. Estep,¹ A.M. Cordero-Reyes,¹ A. Bhimaraj,¹ M. Loebe,¹ B. Bruckner,¹ S. Scheinin,¹ B. Ramlawi,¹ G. Torre-Amione,^{1,2} ¹The Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX; ²Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.
- 3:48 PM (11) Advanced Heart Failure Requiring Emergency Surgical Therapy: Emergency Heart Transplantation with Marginal Donors vs. LVAD Implant;** A. Forni, B. Chiominto, A. Mazzucco, G. Faggian. Cardiac Surgery, University Hospital of Verona, Verona, Italy.
- 4:00 PM (12) Outcomes with Use of Continuous Outpatient Milrinone Infusions in Patients with Advanced Heart Failure (AHF);** P. Muthusamy,^{1,2} S. Madan,³ K. Mowers,³ D.E. Langholz,¹ J.D. Call,¹ M.B. Hanrahan,⁴ A.T. Davis,^{2,3} H. Pahwa,² M.G. Dickinson,¹ ¹Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; ²Grand Rapids Medical Education Partners, Grand Rapids, MI; ³Michigan State University/College of Human Medicine, Grand Rapids, MI; ⁴Coram Home Infusion Group, Grand Rapids, MI.

3:00 PM – 4:15 PM

CONCURRENT SESSION 3 (PANORAMA HALL)**What Do Animal Models Teach Us About BOS?****CHAIRS:** Marshall I. Hertz, MD and Annette Boehler, MD**(13) WITHDRAWN**

3:00 PM (294) Alpha 1-Antitrypsin Improves Lung Function in a Rat Lung Transplantation Model; W. Gao,^{1,3} M. Chen,³ M. Jhaji,³ M. Cypel,^{2,3} S. Keshavjee,^{2,3} M. Liu.^{1,2,3} ¹Physiology, University of Toronto, Toronto, ON, Canada; ²Surgery, University of Toronto, Toronto, ON, Canada; ³Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada.

3:12 PM (14) Administration of Antibodies to Self Antigens (K 1 Tubulin and Collagen V) Results in Obliterative Bronchitis after Syngeneic Mouse Lung Transplantation; V. Subramanian,¹ M. Takenaka,¹ V. Tiriveedhi,¹ N. Benschoff,¹ S. Yamamoto,¹ A.E. Gelman,¹ A. Patterson,¹ T. Mohanakumar.^{1,2} ¹Surgery, Washington University, St. Louis, MO; ²Pathology and Immunology, Washington University, St. Louis, MO.

3:24 PM (15) The Pro-Inflammatory Cytokine IL-17 Acts Directly on Bronchiolar Epithelium – Implications for Chronic Lung Allograft Dysfunction Pathogenesis; S.T. Yerkovich,^{1,2} M.E. Tan,¹ K.A. Sinclair,¹ A. Fiene,¹ P.M. Hopkins,^{1,2} D.C. Chambers.^{1,2} ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; ²School of Medicine, The University of Queensland, Brisbane, Australia.

3:36 PM (16) Release of ATP by Injured Pulmonary Cells Triggers Th17 Dependent Lung Allograft Rejection; S. Sugimoto, D. Kreisel, A.S. Krupnick, A.E. Gelman. Surgery, Washington University in Saint Louis, Saint Louis, MO.

3:48 PM (17) Zinc Suppresses Pathogenesis of Bronchiolitis Obliterans Via Inhibition of IL-6 Receptor; T. Nakagiri, Y. Shintani, M. Inoue, M. Minami, N. Sawabata, M. Okumura. Departments of General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita-City, Osaka, Japan.

4:00 PM (18) Prolonged Ischemic Time Exacerbates the Development of Chronic Gastric Fluid Aspiration-Associated Bronchiolitis Obliterans in Rat Pulmonary Allografts; J.-C. Chang,^{1,2,3} T. Tang,^{1,4} J. Leung,¹ M.G. Hartwig,¹ W. Parker,¹ R.D. Davis,¹ S.S. Lin.^{1,2,5} ¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Department of Pathology, Duke University Medical Center, Durham, NC; ³Division of Thoracic and Cardiovascular Surgery, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; ⁴The Thoracic and Cardiovascular Surgery, The Second Xiangya Hospital, Changsha, Hunan, China; ⁵Department of Immunology, Duke University Medical Center, Durham, NC.

3:00 PM – 4:15 PM

CONCURRENT SESSION 4 (MEETING HALL 4)**The Right Donor at the Right Time: Juggling the Risk****CHAIRS:** Melanie Everitt, MD and Beth D. Kaufman, MD

3:00 PM (19) Pediatric Heart Transplantation from Donors with Depressed Ventricular Function: An Analysis of the United Network of Organ Sharing Database; J.W. Rossano,¹ K.Y. Lin,¹ S.M. Paridon,¹ J.W. Gaynor,² R.E. Shaddy,¹ B.D. Kaufman.¹ ¹Cardiology, The Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA; ²Cardiothoracic Surgery, The Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA.

3:12 PM (20) The Effect of Oversizing Donor Cardiac Allografts on In-Hospital Outcomes in Pediatric Heart Transplant Recipients; E.D. McFeely,¹ R.K. Singh,² M.E. Richmond,² W.A. Zuckerman,² T.M. Lee,² L. Gilmore,² R. Rodriguez,² J.M. Chen,³ L.J. Addonizio.² ¹Columbia University College of Physicians and Surgeons, New York, NY; ²Pediatric Cardiology, Columbia University Medical Center, New York, NY; ³Pediatric Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

3:24 PM (21) Risk Factors for and Risk of Graft Loss after Pediatric Heart Retransplantation: Analysis of the ISHLT Registry; J. Conway,¹ L.B. Edwards,² R. Kirk,³ B. McCrindle,¹ C. Manliot,¹ A.I. Dipchand.¹ ¹Labatt Family Heart Center, The Hospital for Sick Children, Toronto, ON, Canada; ²International Society of Heart and Lung Transplant Registry, Addison, TX; ³Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

3:36 PM (22) Is Lung Transplantation Survival Better in Infants? Analysis of over 80 Infants; M.S. Khan,¹ J.S. Heinle,¹ I. Adachi,¹ B. Shirkey,² M.G. Schecter,³ G.B. Mallory,³ D.L.S. Morales.¹ ¹Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Congenital Heart Surgery, Texas Children's Hospital, Houston, TX; ³Pulmonology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.

3:48 PM (23) Risk-Stratification and Transplant Benefit in Children Listed for Heart Transplant; T.P. Singh, C.S. Almond, G. Piercey, K. Gauvreau. Cardiology, Children's Hospital Boston, Boston, MA.

4:00 PM (24) Predicting 1-Year Survival in Pediatric Heart Transplant Candidates with Cardiomyopathy: An Analysis of the PHTS Database; K.R. Schumacher,¹ D. Nafte,² M. Tresler,² R. Kirk,³ C. Almond,⁴ T.P. Singh,⁴ R. Spicer,⁵ T.M. Hoffman,⁶ D. Hsu,⁷ C. Canter,⁸ M. Zamberlan,¹ R.J. Gajarski.¹ ¹Congenital Heart Center, University of Michigan, CS Mott Children's Hospital, Ann Arbor, MI; ²University of Alabama, Birmingham, AL; ³Freeman Hospital, Newcastle Upon Tyne, United Kingdom; ⁴Boston Children's Hospital, Boston, MA; ⁵Children's Hospital Medical Center, Cincinnati, OH; ⁶Nationwide Children's Hospital, Columbus, OH; ⁷The Children's Hospital at Montefiore, New York, NY; ⁸St. Louis Children's Hospital, St. Louis, MO.

3:00 PM – 4:15 PM

CONCURRENT SESSION 5 (MEETING HALL 5)**Optimizing the LVAD Experience**

CHAIRS: Bernice Coleman, PhD, ACNP-BC and Michelle Harkess, RN, MCN

3:00 PM (25) LVAD Family Caregivers: Impact of Social Support (SS) on Perceived Burden and Quality of Life (QOL); M. Petty,¹ K. Savik,² ¹Nursing, University of Minnesota Medical Center, Fairview, Minneapolis, MN; ²School of Nursing, University of Minnesota, Minneapolis, MN.

3:12 PM (26) Predictors of Health-Related Quality of Life at 6 Months after Left Ventricular Assist Device Implantation: Findings from INTERMACS; S. Wissman,¹ D.C. Naftel,² S.L. Myers,² J.K. Kirklín,² A. Moskowitz,³ A. Gelijns,³ F.D. Pagani,⁴ J.B. Young,⁵ K.L. Grady,⁵ ¹Surgery, Ohio State University, Columbus, OH; ²Surgery, University of Alabama, Birmingham, AL; ³Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY; ⁴Surgery, University of Michigan, Ann Arbor, MI; ⁵Medicine, Cleveland Clinic, Cleveland, OH; ⁶Surgery/Cardiac Surgery, Northwestern University, Chicago, IL.

3:24 PM (27) Improving Patient Satisfaction in Wound Care of Left Ventricular Assist Device Exit Sites; N. Robinson Smith, N. Wrightson, G. MacGowan, T. Butt, F. Oezalp, K. Gould, S. Schueler. Mechanical Circulatory Support for Advanced Heart Failure Team, The Newcastle upon Tyne NHS Foundation Trust Freeman Hospital, Newcastle upon Tyne, United Kingdom.

3:36 PM (28) Improvement in Quality of Life after Left Ventricular Assist Device Implant Is Similar, Regardless of Baseline Severity of Heart Failure; K.L. Grady,¹ D.C. Naftel,² L. Stevenson,³ M.A. Dew,⁴ G. Weidner,⁵ F.D. Pagani,⁶ J.K. Kirklín,² S. Myers,² J.T. Baldwin,⁷ M.R. Shah,⁷ J.B. Young,⁸ ¹Surgery/Cardiac Surgery, Northwestern University, Chicago, IL; ²Surgery, University of Alabama, Birmingham, AL; ³Medicine, Brigham and Women's Hospital, Boston, MA; ⁴Psychiatry, University of Pittsburgh, PA; ⁵Biology, San Francisco State University, Tiburon, CA; ⁶Surgery, University of Michigan, Ann Arbor, MI; ⁷National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; ⁸Medicine, Cleveland Clinic, Cleveland, OH.

3:48 PM (29) Quality of Life Is Higher in Destination Therapy Compared with Bridge to Transplantation Patients Following Ventricular Assist Device Implantation; F.M. McNeil,¹ C.S. Lee,¹ H.K. Song,² A.Y. Kim,² A. Rosenfeld.¹ ¹School of Nursing, Oregon Health & Science University, Portland, OR; ²School of Medicine, Oregon Health & Science University, Portland, OR.

4:00 PM (30) After Hour VAD Coverage: VAD Training Is Not Required; M.K. Saraswat, S.L. Ullrich, R.L. Fioretti, T.J. George, C.A. Beaty, J.V. Conte, G.J. Whitman. The Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

3:00 PM – 4:15 PM

CONCURRENT SESSION 6 (NORTH HALL)**An Ounce of Prevention and Managing Infection**

CHAIRS: Shahid Husain, MD, MS and Alexander Stepanenko, MD

3:00 PM (31) Pump-Related Infections (PRI) after Implantation of Continuous-Flow Left Ventricular Devices (CF LVADs): Analysis of 2900 Patients from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS); F. Kamdar,¹ P. Eckman,¹ D. Goldstein,² C. Sai-Sudhaker,³ S. Aggarwal,⁴ F. Pagani,⁵ R. John,¹ ¹University of Minnesota, Minneapolis, MN; ²Montefiore Medical Center, Bronx, NY; ³Ohio State University Medical Center, Columbus, OH; ⁴Mid America Heart and Vascular Institute, Kansas City, MO; ⁵University of Michigan, Ann Arbor, MI.

3:12 PM (32) Modified HeartMate II Driveline Externalization Technique Significantly Decreases Incidence of Infection and Improves Long-Term Survival; S.A. Akhter,¹ M.J. Russo,¹ A. Singh,¹ T.B. Valeroso,¹ E.M. Johnson,¹ A.S. Anderson,² S.E. Fedson,² G. Kim,² J. Rich,² V. Jeevanandam,¹ ¹Surgery, University of Chicago Medical Center, Chicago, IL; ²Medicine, University of Chicago Medical Center, Chicago, IL.

3:24 PM (33) Prevention of Driveline Infection after Left Ventricular Assist Device Implantation: Are Prophylactic Antibiotics Necessary?; J.M. Stulak,¹ S. Maltais,² J. Cowger,³ L.D. Joyce,¹ R.C. Daly,¹ S.J. Park,¹ K. Aaronson,³ F.D. Pagani,³ ¹Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN; ²Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN; ³Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI.

3:36 PM (34) Impact of Driveline Material and Size on Exit Site Healing Time in Left Ventricular Assist Devices; R.A. Merchel, B.B. Reid, S.P. McCandless, W.T. Caine, I.D. Ledford, S.E. Clayson, A.K. Carter, B. Rasmussen, S. Stoker, D. Budge, R.A. Alharethi, A.G. Kfoury. Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, UT.

3:48 PM (35) Classification of Ventricular Assist Device Infections According to ISHLT Formulation and Device Generation; C. Guerrero-Miranda, D.A. Baran, O. Emmanuel, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, M.J. Zucker, S. Pardi, E. Bishburg. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.

4:00 PM (36) Right-to-Left Hemispheric Predominance of Cerebrovascular Lesions and Its Association with Systemic Infection in Patients Undergoing Left Ventricular Assist Device Implantation; T.S. Kato,¹ T. Ota,² P.C. Schulze,¹ M. Farr,¹ N. Uriel,¹ U. Jorde,¹ H. Akashi,² H. Takayama,² Y. Naka,² T. Yamashita,³ D. Mancini.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ³Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY.

4:15 PM – 4:45 PM**COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS**

(CONGRESS HALL FOYER)

4:45 PM – 7:00 PM**EXHIBIT HALL OPEN/POSTER VIEWING**

(CONGRESS HALL FOYER)

4:45 PM – 6:00 PM**OPENING PLENARY SESSION** (CONGRESS HALL)*Overcoming Political Barriers***CHAIRS:** Jan Pirk, MD, John H. Dark, MB, FRCS and
John B. O'Connell, MD**4:45 PM** *Introduction and Welcome*, Lori J. West, MD, DPhil,
FRCPC, ISHLT President, University of Alberta, Edmonton,
Canada**4:50 PM** *Welcome*, Karel Schwarzenberg, Deputy Prime Minister and
Minister of Foreign Affairs, Prague, Czech Republic**5:00 PM** *Bringing Down the Walls: An Historical Perspective*,
Josef Stehlik, MD, MPH, University of Utah School of Medicine,
Salt Lake City, UT**5:15 PM** *After the Iron Curtain: Successes of Regional Collabora-
tion in Thoracic Transplantation*, Walter Klepetko, MD,
Medical University of Vienna, Austria**5:25 PM** *Political Influence and Scientific Advancement*, Lawrence
Krauss, PhD, School of Earth and Space Exploration, Arizona
State University, Tempe, AZ**6:00 PM – 7:00 PM****EXHIBIT HALL OPENING RECEPTION
AND POSTER VIEWING**

(CONGRESS HALL FOYER)

6:00 PM – 7:00 PM**PULMONARY TRANSPLANT COUNCIL
QOL WORKFORCE MEETING**

(CLUB D)

THURSDAY, APRIL 19, 2012**7:00 AM – 7:00 PM****SPEAKER READY ROOM OPEN**

(CLUB H)

7:00 AM – 7:00 PM**REGISTRATION DESK OPEN**

(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM**PRESS OFFICE OPEN**

(MEETING ROOM 2.4)

8:00 AM – 7:00 PM**POSTER VIEWING**

(CONGRESS HALL FOYER)

8:00 AM – 9:15 AM**CONCURRENT SYMPOSIUM 1** (MEETING HALL 4)*A Lifecycle Journey in Advanced Heart Failure
and Transplantation***CHAIRS:** Patricia A. Uber, PharmD and Andreas Zuckermann, MD**8:00 AM** *Pre-Transplant Journey: Advanced Heart Failure with
BTT MCS and Malfunction Due to Thrombosis*, Paul E.
Nolan, Jr., PharmD, University of Arizona, Tucson, AZ**8:20 AM** *Early Post-Transplant Journey: Primary Graft Failure
at 1 Week*, David O. Taylor, MD, Cleveland Clinic Foundation,
Cleveland, OH**8:40 AM** *Late Post-Transplant Journey: Development of Skin
Cancer and Pre-cancerous Colon Polyp*, Michael Shullo,
BS, PharmD, University of Pittsburgh Medical Center, Pitts-
burgh, PA**9:00 AM** *Panel and Audience Questions and Answers***PANEL DISCUSSANTS:**

Patricia A. Uber, PharmD, University of Maryland, Baltimore, MD

Andreas Zuckermann, MD, University of Vienna, Austria

Paul E. Nolan, Jr., PharmD, University of Arizona, Tucson

David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

Michael Shullo, PharmD, University of Pittsburgh Medical Center,
Pittsburgh, PA

Robert L. Page, II, PharmD, MSPH, University of Colorado, Denver, CO

Walter E. Uber, PharmD, Medical University of South Carolina,
Charleston, SC

8:00 AM – 9:15 AM

CONCURRENT SESSION 7 (CONGRESS HALL)*The Dark Side of VADs***CHAIRS:** Tomoko S. Kato, MD, PhD and Nader Moazami, MD

8:00 AM (37) Optimal Medical Management and Lowering LVAD Speed Prevents Progression of Aortic Insufficiency; K. Hryniewicz, N. Moazami, M. Lillyblad, E.S. Shao, D. Feldman, C. Maxfield, B. Cabuay, E. Carter, B. Sun. Minneapolis Heart Institute, Minneapolis, MN.

8:12 AM (38) Incidence and Impact of De Novo Aortic Insufficiency Following Continuous Flow LVADs Implantation; A. Mano, J. Gorcsan, J.J. Teuteberg, C.A. Bermudez, J.K. Bhama, D.M. McNamara, R. Ramani, M.A. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

8:24 AM (39) Development of Aortic Insufficiency after Heart Mate II Left Ventricular Assist Device Implantation in 71 Patients; A. Aggarwal,¹ R. Raghuvir,¹ G. Macaluso,¹ R. Pant,² C. Gallagher,¹ A. Tatrooles,³ P. Pappas,³ G. Bhat.¹ ¹Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Chicago; ²Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago; ³Cardiothoracic Surgery, Advocate Christ Medical Center, Chicago.

8:36 AM (40) Clinician Attitudes toward Ventricular Assist Device Deactivation at Life's End; K.M. Swetz,¹ K.E. Cook,¹ A.L. Ottenberg,¹ N. Chang,² P.S. Mueller.¹ ¹Mayo Clinic, Rochester, MN; ²Augsburg College, Minneapolis, MN.

8:48 AM (41) Ventricular Assist Device (VAD) Device Malfunction: It's All about the Peripheral Components and Not the Pump; C.E. Eckert, R. Schaub, K. Lockard, G.C. O'Shea, J.A. Zaldonis, M.A. Kormos, C. Bermudez, J.K. Bhama, J.J. Teuteberg, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

9:00 AM (42) Predictors of Hospital Length of Stay Following Implantation of a Left Ventricular Assist Device: An Analysis of the INTERMACS Registry; W.G. Cotts,¹ K.L. Grady,¹ E. McGee,¹ D.C. Naftel,² J.B. Young,³ J.K. Kirklin,² F.D. Pagani.⁴ ¹Cardiovascular Disease, Bluhm Cardiovascular Institute, Northwestern University, Chicago, IL; ²Surgery, University of Alabama, Birmingham, AL; ³Endocrinology and Metabolism Institute, Cleveland Clinic Foundation, Cleveland, OH; ⁴Cardiac Surgery, University of Michigan, Ann Arbor, MI.

8:00 AM – 9:15 AM

CONCURRENT SESSION 8 (FORUM HALL)*Heart Transplantation: Trends in Complications and Risk Factors***CHAIRS:** Maryl Johnson, MD and J. David Vega, MD

8:00 AM (43) Have Risk Factors Changed over the Last 20 Years of Cardiac Transplantation? S.V. Pamboukian,¹ R.N. Brown,² J.K. Kirklin,² J.A. Tallaj,¹ J.F. George.² ¹Medicine, University of Alabama, Birmingham, AL; ²Surgery, University of Alabama, Birmingham, AL.

8:12 AM (44) The Revised Pathologic Diagnosis of AMR Identifies Patients at Risk of Cardiovascular Mortality; J. Stehlik, M.P. Revelo, G.L. Snow, D. Miller, K. Brunisholz, F.M. Bader, R. Alharethi, B.B. Reid, C.G. Selzman, D. Budge, E.M. Gilbert, S.G. Drakos, M. Everitt, M.E. Hammond, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

8:24 AM (45) Application of Immunosuppression Clinical Trial Results in Reducing the Incidence of Heart Transplant Rejection – Bridging the New Millennium; J. Patel, R. Shiozaki, M. Rafiei, L. Stern, M. Kittleson, D. Chang, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

8:36 AM (46) The Policy of Placing Older Donors into Older Recipients: Is It Worth It? J. Patel, M. Kittleson, L. Czer, M. Rafiei, L. Stern, D. Patel, A. Hage, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

8:48 AM (47) Parametric Prediction Model Using Preoperative Serum Albumin Concentration for Survival Estimation in Patients Undergoing Heart Transplantation; I.S. Kato,¹ F.H. Cheema,² Y. Kawano,¹ H. Akashi,² J. Yang,² H. Takayama,² Y. Naka,² M. Farr,¹ D. Mancini,¹ P.C. Schulze.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

9:00 AM (48) Consequences of First-Year Rejection after Heart Transplantation: Is the Worse yet To Come? L. Czer, J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, D. Luthringer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

8:00 AM – 9:15 AM

CONCURRENT SESSION 9 (MEETING HALL 1)*Lessons from Lung Transplant Database Analysis***CHAIRS:** Jason D. Christie, MD, MS and Leah B. Edwards, PhD

8:00 AM (49) Five Years of Lung Transplantation Since the Implementation of the Lung Allocation Score: A Comparative Analysis of Patient Characteristics and Outcomes; J.M. Schaffer,¹ S.K. Singh,² R.R. Sista,³ R.C. Robbins,¹ H.R. Mallidi.⁴ ¹Cardiac Surgery, Stanford University Medical Centre, Palo Alto, CA; ²Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada; ³Pulmonary Medicine, Baylor School of Medicine, Houston, TX; ⁴Cardiac Surgery, Baylor School of Medicine, Houston, TX.

8:12 AM (50) Ipsilateral, Contralateral, or Double? Procedure Incidence and Associated Outcomes in a Retrospective UNOS Review of Re-Transplantation Following Prior Single Lung Transplantation; Z.N. Kon, G. Bittle, B. Wehman, B.P. Griffith, R.N. Pierson III. Surgery/Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD.

8:24 AM (51) Branching out To Refine the Lung Allocation Score: Does Pre-Transplant Diagnosis Matter?; C.J. Gries,¹ S.Y. Park,² L.P. Douglas,² S. Norihisa,³ J.M. Pilewski.¹ ¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pittsburgh, PA; ²Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, PA; ³Division of Cardiothoracic Transplant, Department of Cardiothoracic Surgery, University of Pittsburgh, PA.

8:36 AM (52) Impact of Lung Transplantation in the US Lung Allocation Score System on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease; B. Mittler, K. Brown, R.D. Yusem. Medicine, Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO.

8:48 AM (53) Geographic Disparities in Access to Lung Transplantation in the United States; D.J. Lederer,¹ D.L. Segev,² E.R. Peterson,¹ S. Ravichandran,¹ J.R. Sonett,¹ S.M. Arcasoy.¹ ¹Columbia University Medical Center, New York, NY; ²Johns Hopkins University School of Medicine, Baltimore, ME.

9:00 AM (54) Institutional Volume Affects Ten-Year Survival in Lung Transplantation; A. Kilić,¹ E.S. Weiss,¹ J.V. Conte,¹ C.A. Merlo,² A.S. Shah.¹ ¹Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; ²Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD.

8:00 AM – 9:30 AM

CONCURRENT SESSION 10 (PANORAMA HALL)*Pulmonary Hypertension: Advances in Diagnosis and Therapy***CHAIRS:** Evelyn Horn, MD and George Javorsky, MBBS, FRACP, FCSANZ

8:00 AM (55) RePHerral Study: A Multi-Center Study on the Referral of Pulmonary Hypertension Patients; R.C. Deaño,¹ A. Frost,² S. Visovatti,³ C. Glassner,¹ V. McLaughlin,³ M. Rubenfire,³ M. Gomberg-Maitland.¹ ¹Section of Cardiology, University of Chicago, IL; ²Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX; ³Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI.

8:12 AM (56) Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension; K.M. Chin,¹ D.B. Badesch,² I.M. Robbins,³ V.F. Tapson,⁴ H. Palevsky,⁵ N.H. Kim,⁶ S.M. Kawut,⁵ A. Frost,⁷ W.W. Benton,⁸ J.C. Lemarie,⁹ F. Bodin,¹⁰ L.J. Rubin,⁵ V.V. McLaughlin.¹¹ ¹UT Southwestern, Dallas, TX; ²University of Colorado, Denver, CO; ³Vanderbilt University Medical Center, Nashville, TN; ⁴Duke University Medical Center, Durham, NC; ⁵University of Pennsylvania Medical Center, Philadelphia, PA; ⁶University of California at San Diego, San Diego, CA; ⁷Baylor College of Medicine, Houston, TX; ⁸Actelion Pharmaceuticals US, Inc., South San Francisco, CA; ⁹Effi-Stat, Paris, France; ¹⁰Actelion Pharmaceuticals, Ltd., Allschwil, Switzerland; ¹¹University of Michigan, Ann Arbor, MI.

8:24 AM (57) ATHENA-1: Long Term Clinical Improvements Following the Addition of Ambrisentan to Background PDE5i Therapy in Patients with Pulmonary Arterial Hypertension; S. Shapiro,¹ H. Gillies,² M. Allard,² C. Blain,² R.J. Oudiz.³ ¹West Los Angeles VA HealthCare UCLA School of Medicine, Los Angeles, CA; ²Gilead Sciences Inc., Foster City, CA; ³LA Biomedical Research Institute at Harbor-UCLA, Torrance, CA.

8:36 AM (58) An Open Label Non-Randomized Pilot Study To Evaluate the Safety of the GeNO Nitrosyl Delivery System in Patients Being Evaluated for Heart Transplantation; A.J. Boyle,¹ M.F. Tector,¹ D.H. Fine,² M.M. Miller,¹ M.R. Rush,² C.A. Zywicki,¹ A.J. Tector.¹ ¹Aurora Cardiovascular Services, Aurora St. Luke's Medical Center, Milwaukee, WI; ²GeNO LLC, Cocoa, FL.

8:48 AM (59) Is There a Role for Cardiac Resynchronization Therapy in Pediatric Pulmonary Hypertension?; K.S. Motonaga, C.Y. Miyake, R. Punn, D.N. Rosenthal, J.A. Feinstein, A.M. Dubin. Pediatric Cardiology, Stanford University, Palo Alto, CA.

9:00 AM (60) Patient and Clinician Perceptions of Palliative Care in Pulmonary Arterial Hypertension; K.M. Swetz, T.D. Shanafelt, J.A. Sloan, P.J. Novotny, R.P. Frantz, M.D. McGoon. Mayo Clinic, Rochester, MN.

8:00 AM – 9:30 AM

CONCURRENT SESSION 11 (MEETING HALL 5)**Tolerance: To the Bench and Back****CHAIRS:** Sangeeta Bhorade, MD and Sonja Schrepfer, MD, PhD

8:00 AM **Invited Lecture: Costimulation Blockade in Transplantation: Back to the Bench**, Mohamad H. Sayegh, MD, Brigham and Women's Hospital and Children's Hospital Boston, MA.

8:25 AM **(61) PHD (Prolyl-Hydroxylase)-Inhibitor Activating Hypoxia-Inducible Transcription Factors (HIFs) Reduces Levels of Transplant Arteriosclerosis in a Murine Aortic Allograft Model**; C. Heim,¹ S. Aghayeva,¹ Z. Wang,² B. Motsch,¹ N. Koch,¹ N. Burzlaff,³ M. Weyand,¹ W. Bernhardt,² K.-U. Eckardt,² S.M. Ensminger.¹ ¹Department of Cardiac Surgery, University Hospital, Erlangen, Germany; ²Department of Nephrology, University Hospital, Erlangen, Germany; ³Department of Inorganic and Analytical Chemistry, University Hospital, Erlangen, Germany.

8:37 AM **(62) T-bet Deficiency in Mouse Orthotopic Lung Transplant**; E.A. Lendermon,¹ J.M. Dodd-o,² H.L. Miller,³ G. Zhong,¹ J.F. McDyer.³ ¹Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; ²Anesthesiology, Johns Hopkins University, Baltimore, MD; ³Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, PA.

8:49 AM **(63) Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation**; J. Salman,¹ W. Sommer,¹ A.-K. Knöfel,¹ C. Kühn,¹ M. Avsar,¹ G. Buechler,¹ T. Fuehner,² J. Gottlieb,² T. Welte,² A. Haverich,¹ G. Warnecke.¹ ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; ³Department of Gastroenterology, Hannover Medical School, Hannover.

9:01 AM **(64) High Expression of the B-Cell Inhibitory Molecule CD22 on Memory B-Cells in Early Life May Contribute to Better Transplant Outcomes**; K. Derkatz, E. Dijke, L. West. Pediatrics, University of Alberta, Edmonton, AB, Canada.

8:00 AM – 9:30 AM

CONCURRENT SESSION 12 (NORTH HALL)**Bad Bugs: Donors, Recipients and the Consequences****CHAIRS:** Erik AM Verschuuren, MD, PhD and Margaret Hannan, MD

8:00 AM **(65) Cardiac Transplantation from Bacteremic Donors: Is It Safe?**; S.J. Forest,¹ D. Goldstein,¹ P. Friedmann,¹ R. Bello,¹ V. Muggia,² D. D'Alessandro.¹ ¹Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY; ²Department of Medicine, Montefiore Medical Center, Bronx, NY.

8:12 AM **(66) Donor-Derived Infections in Heart Transplantation**; A. Ehsan,¹ S. Taranto,³ S.H. Covington,³ R.A. Miller,⁴ K.H. Taylor,³ K.B. Parker,³ B.S. Friedman,⁷ M.D. Green,⁵ P. Ruiz,⁶ E.A. Blumberg.² ¹Surgery, Tufts Medical Center, Boston, MA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³United Network for Organ Sharing, Richmond, VA; ⁴Medicine, University of Iowa, Iowa City, IA; ⁵Pediatrics, University of Pittsburgh, PA; ⁶Pathology, University of Miami, FL; ⁷University of Minnesota, Minneapolis, MN.

8:24 AM **(67) Donor-Derived Infections in Lung Transplantation**; A. Ehsan,¹ S. Taranto,³ S.H. Covington,³ R.A. Miller,⁴ K.H. Taylor,³ K.B. Parker,³ B.S. Friedman,⁷ M.D. Green,⁵ P. Ruiz,⁶ E.A. Blumberg.² ¹Surgery, Tufts Medical Center, Boston, MA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³United Network for Organ Sharing, Richmond, VA; ⁴Medicine, University of Iowa, Iowa City, IA; ⁵Pediatrics, University of Pittsburgh, PA; ⁶Pathology, University of Miami, FL; ⁷University of Minnesota, Minneapolis, MN.

8:36 AM **(68) Distinct Microbial Signatures of Healthy and Failing Lung Allografts**; D. Willner,¹ P. Hugenholtz,¹ M.E. Tan,² S.T. Yerkovich,^{2,3} P.M. Hopkins,^{2,3} D.C. Chambers.^{2,3} ¹Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia; ²Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; ³School of Medicine, The University of Queensland, Brisbane, Australia.

8:48 AM **(69) Impact of Cardiotropic Viruses on Alloimmune Response and Microvasculopathy in Cardiac Transplant Recipients**; N.E. Hiemann,¹ E. Wellenhofer,² K. Klingel,³ R. Kandolf,³ C. Proch,¹ C. Knosalla,¹ H. Lehmkuhl,¹ R. Hetzer,¹ R. Meyer.¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; ³Department of Molecular Pathology, Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany.

9:00 AM **(70) Cardiac Allograft Vasculopathy and Survival after Heart Transplantation for Chagas' Heart Disease**; M. Diez,¹ L. Favaloro,¹ A. Bertolotti,¹ C. Vighiano,¹ M. Peradejordi,¹ A. Schijman,² R. Favaloro.¹ ¹Intrathoracic Transplant Unit, University Hospital Favaloro Foundation, Ciudad Autónoma de Buenos Aires, Argentina; ²Molecular Biology Laboratory of Chagas' Disease, INGEBI-CONICET, Ciudad Autónoma de Buenos Aires, Argentina.



9:00 AM – 7:00 PM
EXHIBIT HALL OPEN
 (CONGRESS HALL FOYER)

9:15 AM – 9:45 AM
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
 (CONGRESS HALL FOYER)

9:45 AM – 11:30 AM

PLENARY SESSION (CONGRESS HALL)

ISHLT Traditions

CHAIRS: Stuart C. Sweet, MD, PhD and Lori J. West, MD, DPhil

9:45 AM *Welcome and Program Chair's Report*, Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO

9:55 AM *President's Address*, Lori J. West, MD, DPhil, FRCPC, ISHLT President, University of Alberta, Edmonton, Canada

10:05 AM *Thoracic Registry Report*, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

10:25 AM *MCS Registry Reports*, James K. Kirklin, MD, University of Alabama at Birmingham, AL

10:35 AM *The Responsibility of Transplantation Specialists in the World Health Assembly's Vision for Transplantation*, Luc Noel, MD, Coordinator of Clinical Procedures, World Health Organization, Geneva, Switzerland

10:55 AM *Lifetime Achievement Award*, Sharon Hunt, MD Stanford University, Palo Alto, CA

11:30 AM – NOON
COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
 (CONGRESS HALL FOYER)

NOON – 1:15 PM

CONCURRENT SYMPOSIUM 2 (MEETING HALL 5)

Focus on Caregivers: Investing in Our Patients' Future

CHAIRS: Michael G. Petty, PhD, RN, CCNS, CNS and Sharon Beer, RN, MSc

NOON *Family Caregivers of Mechanical Circulatory Support Patients*, Judy A. Currey, PhD, Alfred/Deakin Nursing Research Center, Melbourne, Australia

12:12 PM *Family Caregivers of Heart Transplant Candidates and Recipients*, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA

12:24 PM *Family Caregivers of Lung Transplant Candidates and Recipients*, Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

12:36 PM *Family Caregivers of Children with End Stage Heart and Lung Disease and Thoracic Transplant*, Paula A. Kofflin, RN, BSN, CPTC, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN

12:48 PM *Burdens of Family Caregivers as Surrogate Decision-Makers*, Denise Dudzinski, PhD, MTS, University of Washington, Seattle, WA

1:00 PM *Panel Discussion*

NOON – 1:15 PM

CONCURRENT SESSION 13 (CONGRESS HALL)**MCS: Balancing on the Razor's Edge****CHAIRS:** Evgenij V. Potapov, MD, PhD and Josef Stehlik, MD, MPH

- NOON (71) Heparin May Not Be Needed as a Transition to Long Term Warfarin Therapy in LVAD Destination Therapy Patients;** R.M. Adamson,¹ R. John,² D. Goldstein,³ S.J. Park,⁴ C.A. Milano,⁵ A.J. Tatrooles,⁶ K.S. Sundareswaran,⁷ D.J. Farrar,⁷ M.S. Slaughter,⁸ ¹Sharp Memorial Hospital, San Diego, CA; ²University of Minnesota, Minneapolis, MN; ³Montefiore Medical Center, New York, NY; ⁴Mayo Clinic, Rochester, MN; ⁵Duke University, Durham, NC; ⁶Advocate Christ Medical Center, Chicago, IL; ⁷Thoratec Corporation, Pleasanton, CA; ⁸University of Louisville, Louisville, KY.
- 12:12 PM (72) Reduced Pulsatility in Patients Supported with the Continuous-Flow Left Ventricular Assist Device HeartMate II Is Associated with Increased Bleeding Events;** Q. Wever-Pinzon, A. Saidi, N. Mehta, C.H. Selzman, S.G. Drakos, R. Alharethi, E.M. Gilbert, M. Labedi, D. Budge, B.B. Reid, A.G. Kfoury, J. Stehlik, F. Bader. UTAH Cardiac Transplant Program, Salt Lake City, UT.
- 12:24 PM (73) Gastrointestinal Bleeding and Subsequent Risk of Thromboembolic Events during Support with a Left Ventricular Assist Device;** J.M. Stulak,¹ D. Lee,² M.A. Romano,² J.W. Haft,² J. Cowger,² K.D. Aaronson,² S.J. Park,¹ L.D. Joyce,¹ R.C. Daly,¹ F.D. Pagani,² ¹Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN; ²Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI.
- 12:36 PM (74) Gastrointestinal Bleeding Is Not Associated with Pump Speed and Aortic Valve Opening in Patients Supported with the HeartMate II LVAD;** S.R. Patel,¹ A. Rivera,¹ J. Patel,¹ Q. Saeed,¹ M. Camacho-Rivera,² S. Maybaum,¹ D. Goldstein,¹ ¹Montefiore Medical Center, Bronx, NY; ²Harvard School of Public Health, Boston, MA.
- 12:48 PM (75) von Willebrand Factor in Recipients of Different VAD Systems and Its Clinical Relevance;** N. Dranishnikov, A. Stepanenko, A. Frumkin, J. Vierecke, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany.
- 1:00 PM (76) Thrombus Formation at the Pump Inflow Area in Heart Mate II Patients;** M.E.I. Schipper,¹ A. Vink,¹ H.F.J. Dulens,¹ R.A. de Weger,¹ N. de Jonge,² J.R. Lahpor,³ ¹Department of Pathology, University Medical Centre, Utrecht, Netherlands; ²Department of Cardiology, University Medical Centre, Utrecht, Netherlands; ³Department of Cardio-Thoracic Surgery, University Medical Centre, Utrecht, Netherlands.

NOON – 1:15 PM

CONCURRENT SESSION 14 (FORUM HALL)**What's New in Immune Surveillance in Heart Transplantation****CHAIRS:** Annalisa Angelini, MD and Howard Eisen, MD

- NOON (77) Impact of Time Post Transplant on Gene Expression Profile Scores, an Analysis of 34,567 Tests;** B.A. Austin,¹ E. Wang,² P.J. Arnold,² A. Kao,¹ ¹Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO; ²Expression Diagnostics, Brisbane, CA.
- 12:12 PM (78) Are Donor-Specific Antibodies Detected after Heart Transplant All Bad?;** J. Patel, M. Kittleson, L. Czer, M. Rafiei, L. Stern, F. Esmailian, N. Reinsmoen, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.
- 12:24 PM (79) Intentional ABO-Incompatible Heart Transplantation;** G. Tydén,¹ L. Hagerman,² K.-H. Grinnemo,³ P. Svenarud,³ J. van der Linden,³ G. Kumlien,⁴ A. Wernerson,⁵ ¹Transplantation Surgery, Karolinska Institute, Stockholm, Sweden; ²Cardiology, Karolinska Institute, Stockholm, Sweden; ³Cardiothoracic Surgery and Anaesthesiology, Karolinska Institute, Stockholm, Sweden; ⁴Transfusion Medicine, Karolinska Institute, Stockholm, Sweden; ⁵Pathology, Karolinska Institute, Stockholm, Sweden.
- 12:36 PM (80) Clinical Relevance of Preformed Complement- and Non-Complement-Fixing HLA Alloreactivity in Cardiac Transplantation;** S.L. Mahr,¹ M. Wahrmann,² A. Zuckermann,¹ G. Böhmig,² ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
- 12:48 PM (81) Prediction of Allograft Clinical Outcomes and Risk of Acute Cellular Rejection with a Non-Invasive Gene-Expression Profiling Test (AlloMap): Results from the Cargo 2 European-Based Multicenter Trial;** M.G. Crespo-Leiro,¹ U. Schulz,² A. Zuckermann,³ C. Bara,⁴ P. Mohacsí,⁵ R. Bogaev,¹⁶ A. Boyle,⁶ H. Ross,⁷ J. Parameshwar,⁸ M. Zakliczynski,⁹ R. Fiocchi,¹⁰ J. Stypmann,¹¹ D. Hoefler,¹² H. Lehmkühl,¹³ M.C. Deng,¹⁴ P. Leprince,¹⁵ J.P. Yee,¹⁷ J. Vanhaecke,¹⁸ ¹Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruña, La Coruña, Spain; ²Heart Center North Rhine-Westphalia, Department of Thoracic and Cardiovascular Surgery, Ruhr University of Bochum, Bad Oeynhausen, Germany; ³Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ⁴Department of Cardiovascular, Thoracic, and Transplant Medicine, Hannover Medical School, Hannover, Germany; ⁵Department of Cardiology, Swiss Cardiovascular Centre Bern, University Hospital Bern, Bern, Switzerland; ⁶Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; ⁷Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, Canada; ⁸Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; ⁹Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland; ¹⁰Cardiovascular Department-Transplant Section, Ospedali Riuniti di Bergamo, Bergamo, Italy; ¹¹Department of Cardiology and Angiology, University Hospital Muenster, Muenster, Germany; ¹²Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria; ¹³Deutsches Herzzentrum, Berlin, Germany; ¹⁴College of Physicians and Surgeons, Columbia University Medical Center, New York, NY; ¹⁵Department of Cardiothoracic Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; ¹⁶Texas Heart Institute, St. Luke's Episcopal Hospital, Houston,

TX; ¹⁷XDx, Inc., Brisbane, CA; ¹⁸Department of Cardiology, University Hospital of Leuven, Leuven, Belgium.

1:00 PM (82) Blood-Based Biomarker Panels for Diagnosis of Acute Heart Allograft Rejection; J.E. Wilson-McManus,¹ Z. Hollander,^{1,2} G. Cohen Freue,^{1,4} R. Balshaw,^{1,4} C. Borchers,^{5,6} R. Davies,⁷ D. Delgado,⁸ H. Haddad,⁷ A. Ignaszewski,⁹ D. Isaac,⁹ D. Kim,¹⁰ A. Mui,¹¹ M. Rajda,¹² L. West,¹³ M. White,¹⁴ S. Zieroth,¹⁵ P. Keown,³ R. McMaster,¹⁶ R. Ng,^{1,17} B. McManus.^{1,2} ¹PROOF Centre of Excellence, Vancouver, BC, Canada; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; ³Medicine, University of British Columbia, Vancouver, BC, Canada; ⁴Statistics, University of British Columbia, Vancouver, BC, Canada; ⁵Biochemistry, University of Victoria, Victoria, BC, Canada; ⁶UVic Genome BC Proteomics Centre, Victoria, BC, Canada; ⁷Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada; ⁸Medicine, Toronto General Hospital, University Health Network, Toronto, ON, Canada; ⁹Medicine, University of Calgary, Calgary, AB, Canada; ¹⁰Medicine, University of Alberta, Edmonton, AB, Canada; ¹¹Surgery, University of British Columbia, Vancouver, BC, Canada; ¹²Medicine, QEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada; ¹³Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, AB, Canada; ¹⁴Medicine, Montreal Heart Institute, Montreal, QC, Canada; ¹⁵Medicine, University of Manitoba, Winnipeg, MB, Canada; ¹⁶Medical Genetics, University of British Columbia, Vancouver, BC, Canada; ¹⁷Computer Science, University of British Columbia, Vancouver, BC, Canada.



NOON – 1:15 PM

CONCURRENT SESSION 15

(MEETING HALL 1)

Clinical Aspects of Lung Transplantation

CHAIRS: Stephen C. Clark, BMed Sci(Hons), BM, BS, DM, FRCS(C-Th) and Frank D' Ovidio, MD, PhD

NOON (83) Lung Transplantation in Patients with Scleroderma: Long-Term Follow Up and Risk Factors for Poor Survival; M.M. Crespo,¹ D. Zaldonis,² C. Bermudez,² B. Johnson,¹ S. Haider,¹ M. Morrell,¹ J. Bhama,² Y. Toyoda,³ N. Shigemura,² P. George,¹ J.M. Pilewski.¹ ¹Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Cardiothoracic, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

12:12 PM (84) Increased Frequency of Donor Specific HLA Antibody in Lung Transplant Recipients with Acute Cellular Rejection: Spectrum of Alloantibody and the Impact on Histopathology; A. Zeevi, D. Zaldonis, K. Spichty, C. Gries, M. Morrell, M. Crespo, J. Pilewski, C. Bermudez, S. Yousem. University of Pittsburgh, PA.

12:24 PM (85) Lung Transplantation Is an Effective Treatment Option for Patients over the Age of 70; M.G. Hartwig,¹ Z.A. Hashmi,¹ D. Albon,² J.T. Martin,¹ A.W. Castleberry,¹ L.D. Snyder,² S.M. Palmer,² S.S. Lin,¹ R.D. Davis.¹ ¹Surgery, Duke University Medical Center, Durham, NC; ²Medicine, Duke University Medical Center, Durham, NC.

12:36 PM (86) Preoperative Mild or Moderate Coronary Artery Disease (CAD) Does Not Affect Long-Term Outcomes of Lung Transplantation; G. Zanotti,¹ M.G. Hartwig,¹ A. Castleberry,¹ J.T. Martin,¹ Z.A. Hashmi,¹ M. Horvath,² S.S. Lin,¹ R.D. Davis.¹ ¹Surgery, Duke University Medical Center, Durham, NC; ²Duke Health Technology Solutions, Duke University, Durham.

12:48 PM (87) Coronary Revascularization in Lung Transplant Recipients with Concomitant Coronary Artery Disease; J.T. Martin, M.G. Hartwig, Z.A. Hashmi, A.W. Castleberry, G. Zanotti, L.K. Shaw, J.B. Williams, S.S. Lin, S.L. Reddy, R.D. Davis. Thoracic and Cardiovascular Surgery, Duke University Medical Center, Durham, NC.

1:00 PM (88) Acute Rejection after Lung Transplantation Is Associated with Daily Changes in Air Pollution; S.E. Verleden,¹ H. Scheers,² T.S. Nawrot,² F. Fierens,² R. Vos,¹ R. Geenens,¹ J. Yserbyt,¹ S. Wauters,¹ J. Somers,¹ D. Rutten,¹ A. Van Eylen,¹ E.K. Verbeken,¹ B. Nemery,² D.E. Van Raemdonck,¹ G.M. Verleden,¹ B.M. Vanaudenaerde.¹ ¹Lung Transplant Unit, KULeuven and UZ Gasthuisberg, Leuven, Belgium; ²Department of Public Health, KULeuven and UHasselt, Leuven, Belgium.

NOON – 1:15 PM

CONCURRENT SESSION 16 (PANORAMA HALL)**Bringing Hearts Alive and Kicking****CHAIRS:** Bart Meyns, MD and J. David Vega, MD**NOON (89)** *Continuous Crystalloid Microperfusion Provides Excellent Preservation for Transplantation of Donation after Cardiocirculatory Death Hearts*; F.L. Rosenfeldt, R.F. Salamonsen, R. Ou, D.S. Esmore, J. Byrne. Cardiothoracic Surgery, Alfred Hospital, Melbourne, VIC, Australia.**12:12 PM (90)** *Additional Intraoperative Blood Cardioplegia To Improve Donor Heart Ischemic Tolerance – A Single Center Prospective Cohort Study*; F.M. Wagner,¹ T. Deuse,¹ P. Marcsek,¹ H. Treede,¹ M. Kubik,¹ A. Jaeckle,² H. Reichenspurner.¹ ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Cardiology, University Heart Center Hamburg, Hamburg, Germany.**12:24 PM (91)** *Equivalent Long Term Survival of Heart Transplant Patients Receiving Resuscitated Donor Hearts*; S.R. Hosmane, M. Devbhandari, S. Williams, R. Venkateswaran, N. Yonan. Transplant Department, University Hospital of South Manchester, Manchester, United Kingdom.**12:36 PM (92)** *Donor Treatment with Simvastatin and Methylprednisolone Targets Microvascular-Myelomonocyte Interactions and Improves Cardiac Allograft Survival*; R. Tuuminen,¹ S. Syrjäälä,¹ R. Krebs,¹ R. Arnaudova,¹ E. Rouvinen,¹ A.I. Nykänen,^{1,2} K.B. Lemström.^{1,2} ¹Transplantation Laboratory, Haartman Institute, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland; ²Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland.**12:48 PM (93)** *Activation of Aldehyde Dehydrogenase Type 2 (ALDH2) by Alda-1 Significantly Enhances the Function of the DCD Heart*; F.J. Taghavi,^{1,2} P.K. Thanaporn,² C.E. Woods,² A. Ali,² S.R. Large,¹ D. Mochly-Rosen,² E. Ashley,² C. Chen.² ¹Department of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA; ²Department of Cardiothoracic Surgery, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.**1:00 PM (94)** *Ex Vivo Assessment of DCD Hearts with STEEN Solution Is Associated with Less Myocardial Edema and Improved Cardiac Function*; A. Ali,³ C. White,¹ B. Xiang,² S. Colah,³ P. Mundt,¹ R. Arora,^{1,2} T. Lee,^{1,2} S. Tsui,³ S. Large,³ G. Tian,² D. Freed.^{1,2} ¹Surgery, University of Manitoba, Winnipeg, MB, Canada; ²Institute of Biodiagnostics, National Research Council of Canada, Winnipeg, MB, Canada; ³Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom.

NOON – 1:15 PM

CONCURRENT SESSION 17 (MEETING HALL 4)**B-Cells, Antibodies and Graft Injury****CHAIRS:** Lori J. West, MD, DPhil, FRCPG and Karl B. Lemstrom, MD, PhD**NOON** *Invited Lecture: B-Cell Biology: A New Frontier in Understanding and Preventing Thoracic Transplant Injury*, Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD**12:24 PM (95)** *Antibodies to MHC Induce Autoimmunity Leading to Obliterative Airway Disease: Definition of Mechanisms*; V. Tiriveedhi,¹ M. Takenaka,¹ V. Subramanian,¹ A. Gelman,³ G.A. Patterson,³ T. Mohanakumar.^{1,2} ¹Surgery, Washington University School of Medicine, St. Louis, MO; ²Pathology & Immunology, Washington University School of Medicine, St. Louis, MO; ³Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.**12:36 PM (96)** *Spleen Tyrosine Kinase Modulates Obliterative Bronchiolitis Associated Lymphoid Neogenesis after Lung Transplantation*; Y. Matsuda,¹ M. Liu,¹ M. Sato,¹ X. Wang,² G. Zehong,¹ S. Keshavjee,¹ C.-W. Chow.² ¹Department of Thoracic Surgery, University of Toronto, Toronto, ON, Canada; ²Division of Respiratory, Department of Medicine, University of Toronto, Toronto, ON, Canada.**12:48 PM (97)** *Non-HLA Antibodies in Heart Transplant Recipients with AMR: Profiling with Antigen Microarrays*; A. Chruscinski, F. Huang, K. Tinckam, V. Rao, G. Levy, H. Ross. Multi Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.**1:00 PM (98)** *Determining Developmental Immaturity in B-Cell Receptor Signaling*; L.A. Ryan, L.J. West, S. Urschel. University of Alberta, Edmonton, AB, Canada.

NOON – 1:15 PM

CONCURRENT SESSION 18 (NORTH HALL)

AMR in Thoracic Transplantation: Are We Making Progress?

CHAIRS: Charles C. Marboe, MD and Dylan V. Miller, MD

NOON (99) Interpretation of C4d and C3d in the Diagnosis of Antibody Mediated Rejection in Hearts. Can Accommodation Be Diagnosed? A 51 Month Experience with 550 Patients; E.R. Rodriguez, C.D. Tan. Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

12:12 PM (100) Intracapillary Macrophages in Cardiac Allograft Biopsies for Diagnosis of Antibody-Mediated Rejection (AMR); M. Fedrigo,¹ G. Feltrin,² E. Benazzi,³ F. Poli,³ A. Frigo,⁴ F. Tona,² A. Caforio,² C. Castellani,¹ G. Toscano,² A. Gambino,² G. Gerosa,² G. Thiene,¹ A. Angelini.¹ ¹Medico-Diagnostic and Special Therapies, University of Padua, Padua, Italy; ²Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy; ³Regenerative Medicine Transplant Immunology, IRCCS Cà Granda, Policlinic Hospital, Milan, Italy; ⁴Environmental Medicine and Public Health, University of Padua, Padua, Italy.

12:24 PM (101) C4d Positive Biopsy without Dysfunction: Relevance and Outcome in Heart Transplant Recipients; C.D. Tan, E. Rene Rodriguez. Anatomic Pathology, Cleveland Clinic, Cleveland, OH.

12:36 PM (102) Macrophage Density of Cardiac Allograft Biopsies Reflects Complement Staining by C4d and Is Strongly Associated with Alloantibodies to HLA Antigens; L. Xu, C. Drachenberg, E. Feller, A. Burke. University of Maryland, Baltimore, MD.

12:48 PM (103) Pathologic Diagnosis of Antibody-Mediated Rejection of the Lung Allograft; M.M. DeNicola,¹ S.S. Weigt,² J.A. Belperio,² D.J. Ross,² W.D. Wallace.¹ ¹Pathology, University of California, Los Angeles, CA; ²Medical-Pulmonology/Critical Care, University of California, Los Angeles, CA.

1:00 PM (104) Evaluation of Antibody Mediated Rejection in Lung Transplant Recipients; M.L. Bissonnette,¹ S. Marino,¹ S. Bhorade,² A. Husain.¹ ¹Pathology, University of Chicago; ²Pulmonary and Critical Care, University of Chicago.

**1:15 PM – 1:45 PM
BOX LUNCH PICK-UP
(BUFFET, 1ST FLOOR)**

**1:15 PM – 3:15 PM
LUNCH BREAK**

**1:15 PM – 3:15 PM
JUNIOR FACULTY MENTOR LUNCH
(CLUB A)**

**1:15 PM – 3:15 PM
PULMONARY TRANSPLANTATION COUNCIL MEETING
(NORTH HALL)**

**1:15 PM – 3:15 PM
HEART FAILURE AND TRANSPLANT MEDICINE
COUNCIL MEETING
(CLUB B)**

**1:15 PM – 3:15 PM
PHARMACY AND PHARMACOLOGY COUNCIL
MEETING
(CLUB C)**

**1:15 PM – 3:15 PM
INFECTIOUS DISEASES COUNCIL MEETING
(CLUB D)**

**1:30 PM – 3:00 PM
MINI ORAL SESSION 1 (MEETING HALL 1)
*Mechanical Circulatory Support***

CHAIRS: Soon J. Park, MD and Robert D. Dowling, MD

1:30 PM (105) Alterations in Flow and Shear Stress in the Thoracic Aorta with a Continuous-Flow Left Ventricular Assist Device; D. Gupta,¹ M. Piccinelli,³ T. Passerini,³ A. Veneziani,³ L. Brewster,⁴ S.R. Laskar,¹ D.G. Nguyen,² J.D. Vega,² W.R. Taylor.¹ ¹Cardiology, Emory University School of Medicine, Atlanta, GA; ²Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; ³Mathematics, Emory University, Atlanta, GA.

1:35 PM (106) Serial Echocardiographic Evaluation Using 2-Dimensional Speckle Tracking Imaging in Monitoring Right Ventricular Failure Development Following Left Ventricular Assist Device Implantation; T.S. Kato,¹ P.C. Schulze,¹ J. Jiang,¹ J. Yang,² L. Gillam,¹ H. Takayama,² U. Jorde,¹ Y. Naka,² D. Mancini,¹ M. Farr.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

1:40 PM (107) Cost and Length of Stay for Implant of Continuous Flow Left Ventricular Assist Device (CF-LVAD) in Patients with INTERMACS Profiles 4-6 Are Lower Than Patients with INTERMACS Profiles 1-3; P.M. Eckman,¹ A. Rosenbaum,¹ S. Duval,² F. Kamdar,¹ B. Milavitz,³ R. John.⁴ ¹Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN; ²Lillehei Clinical Research Unit, University of Minnesota, Minneapolis, MN; ³Cardiovascular Service Line, University of Minnesota Medical Center, Fairview, Minneapolis, MN; ⁴Division of Cardiac Surgery, University of Minnesota, Minneapolis.

- 1:45 PM (108) A New M-Mode Parameter To Assess Ventricular Unloading in the LVAD Patient: Slope of the Anterior Mitral Leaflet (SLAM);** S.C. Martinez,¹ E.A. Bradley,¹ E.L. Novak,¹ R. Rasalingam,¹ S.C. Silvestry,² G.A. Ewald,¹ S.M. Joseph.¹ ¹Internal Medicine, Cardiovascular Division, Washington University School of Medicine, Saint Louis, MO; ²Surgery, Cardiothoracic Division, Washington University School of Medicine, Saint Louis, MO.
- 1:50 PM (109) End-of-Life Care in Recipients of Magnetically Levitated Centrifugal-Flow Pump;** L.K. Soni,¹ D.L. Jones,¹ S.R. Cedola,¹ J. Cogan,¹ B. Shulman,¹ A. Kossar,¹ J. Jiang,¹ M. Koeckert,¹ H. Yerebakan,¹ Y. Naka,¹ H. Takayama.¹ ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Columbia University Medical Center, New York, NY.
- 1:55 PM (110) Blood Urea Nitrogen to Creatinine Ratio Identifies Heart Failure Patients Likely To Experience Substantial Improvement in Renal Function Post-LVAD Placement: Insights from the INTERMACS Registry;** M.A. Brisco,¹ S.E. Kimmel,² M. Jessup,¹ J.M. Testani.¹ ¹Department of Medicine, Cardiovascular Division, University of Pennsylvania School of Medicine, Philadelphia, PA; ²Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA.
- 2:00 PM (111) Outcomes of Patients with Anthracycline Cardiomyopathy Treated with Mechanical Circulatory Support: Data from the INTERMACS Registry;** G.H. Oliveira,¹ D. Matthias,¹ D.C. Naftel,² Y. Yuan,² S.L. Meyers,² D. Schmulh,¹ M.M. Mountis,¹ N. Smedira,¹ W.W.H. Tang,¹ G. Gonzalez-Stawinski,¹ D.O. Taylor,¹ R.C. Starling.¹ ¹Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH; ²Department of Biostatistics, University of Alabama, Birmingham, AL.
- 2:05 PM (112) Identification of Non-HLA Antibodies in Ventricular Assist Device Recipients;** M.J. Barten,¹ D. Dragun,² S. von Salisch,¹ M.-T. Dieterlen,¹ J. Garbade,¹ S. Klein,¹ S. Dhein,¹ F.W. Mohr,¹ H.B. Bittner.¹ ¹Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany; ²Clinic for Nephrology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- 2:10 PM (113) Improvement in Functional Capacity after Left Ventricular Assist Device Therapy Can Be Limited by Preoperative Comorbidities;** M.S. Kiernan,¹ D.T. Pham,¹ N.K. Kapur,¹ N.L. Pereira,² K.S. Sundareswaran,³ M. Stueber,⁵ D.J. Farrar,³ D. DeNofrio,¹ J.G. Rogers.⁴ ¹Cardiology, Tufts Medical Center, Boston, MA; ²Cardiology, Mayo Clinic, Rochester, MN; ³Thoratec Corporation, Pleasanton, CA; ⁴Cardiology, Duke University Medical Center, Durham, NC; ⁵Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
- 2:15 PM (114) Pre-Implantation Echocardiographic Indices of Right Ventricular Adverse Remodeling Predict Death and Right Ventricular Failure in Patients with Continuous-Flow Left Ventricular Assist Devices;** R.P. Vivo,¹ M. Aldeiri,¹ U. Gamar,¹ A.M. Cordero-Reyes,¹ B. Elias,¹ M. Loebe,¹ B. Bruckner,¹ G. Torre-Amione,¹ A. Bhimaraj,¹ J.D. Estep.¹ The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX.
- 2:20 PM (115) Bivalirudin Is a Safe and Effective Anticoagulant for Post-Operative Bridging to Warfarin in LVAD Patients;** N. Moazami,¹ L.B. Richardson,² B. Sun,¹ B. Cabuay,² E. Shao,² K.M. Hryniewicz,² D. Feldman.² ¹Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN; ²Cardiology, Minneapolis Heart Institute, Minneapolis, MN.
- 2:25 PM (116) Gastrointestinal Bleeding Risk in Patients with Ventricular Assist Devices;** J.B. French,¹ S.V. Pamboukian,² G.B. Smallfield,³ S. Peter,³ J.A. Tallaj,² R.N. Brown,⁴ M.C. Smallfield,² J.K. Kirklin,⁴ J.F. George.⁴ ¹Graduate Medical Education Department of Internal Medicine Residency Program, University of Alabama, Birmingham, AL; ²Department of Medicine: Division of Cardiovascular Disease, University of Alabama, Birmingham, AL; ³Department of Medicine: Division of Gastroenterology and Hepatology, University of Alabama, Birmingham, AL; ⁴Department of Surgery, Cardiovascular/Surgery, University of Alabama, Birmingham, AL.
- 2:30 PM (117) Patient Selection for Ventricular Assist Device Therapy in the Elderly: Application of the HeartMate II Risk Score;** J.A. Cowger,¹ K. Sundareswaran,² J.G. Rogers,³ S.S. Kushwaha,⁴ F.D. Pagani,¹ A. Tatoes,⁵ R.M. Adamson,⁶ M.S. Slaughter,⁷ D.J. Farrar.² ¹Univ. of Michigan Health System, Ann Arbor, MI; ²Thoratec Corporation, Pleasanton, CA; ³Duke University Medical Center, Durham, NC; ⁴Mayo Clinic, Rochester, MN; ⁵Advocate Christ Medical Center, Oak Lawn, IL; ⁶Sharp Memorial Hospital, San Diego, CA; ⁷Univ. of Louisville, Jewish Hospital, and St. Mary's HealthCare, Louisville, KY.
- 2:35 PM (118) Effectiveness of Platelet Aggregation Inhibitor (Tirofiban) in Treating Continuous Flow Ventricular Assist Device (VAD) Thrombus;** K.M. Lam,¹ H. Hayes,¹ J. Barber,¹ G. Green,² L. Dembo,¹ G. O'Driscoll.³ ¹Advanced Heart Failure and Cardiac Transplant Unit, Royal Perth Hospital, Perth, WA, Australia; ²Cardiology, Royal Perth Hospital, Perth, WA, Australia; ³Notre Dame University, Fremantle, WA, Australia.
- 2:40 PM (119) Proposed Echocardiographic Algorithm To Predict Elevated Left Ventricular Filling Pressures in Patients Supported with Continuous-Flow Left Ventricular Assist Devices;** J.D. Estep,¹ R.P. Vivo,¹ J.H. Flores-Arredondo,¹ S.R. Krim,¹ M. Aldeiri,¹ B. Elias,¹ B. Kurchock,¹ M. Loebe,¹ B. Bruckner,¹ G. Torre-Amione,¹ A. Bhimaraj.¹ The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX.
- 2:45 PM (120) Derivation of IQ Flow Index as a Measure of LV Chamber Function in Patients Supported with Continuous Flow Centrifugal LVADs;** K. Muthiah,¹ D. Robson,¹ R. Walker,¹ P.S. Macdonald,¹ A.M. Keogh,¹ E. Kotlyar,¹ P. Spratt,² E. Granger,² K. Dhital,² P. Jansz,² C.S. Hayward.¹ ¹Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ²Cardiothoracic Surgery and Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia.
- 2:50 PM (121) Factors Associated with Anti-HLA Antibodies in Patients Supported with Continuous Flow Devices and Impact on Probability of Transplant;** A.C. Alba,¹ K. Tinckam,¹ L.M. Nelson,² F. Gustafsson,² K. Sander,² H. Bruunsgaard,² V. Rao,¹ D. Delgado,¹ H. Ross.¹ ¹Toronto General Hospital, Toronto, ON, Canada; ²Rigshospitalet, Copenhagen, Denmark.
- 2:55 PM (122) Pre Implant Noncompliance Does Not Predict Social Success in LVAD Recipients;** M. Malby,¹ M. Flattery,² A. Barclay,¹ V. Kasirajan,² D. Tang,² M. Hess,² S. Harton,² M.E. Olbrisch,³ K. Shah.² ¹Department of Social Work, Virginia Commonwealth University Health System, Richmond, VA; ²Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA; ³Department of Psychiatry, Virginia Commonwealth University, Richmond, VA.

1:30 PM – 3:00 PM

MINI ORAL SESSION 2

(MEETING HALL 4)

Heart and Pediatric Transplantation**CHAIRS:** Kimberly Gandy, MD, PhD and Randall C. Starling, MD, MPH**1:30 PM (123) Assessment of Unexplained Cardiomyopathy (CMP) — Clinical Utility of Delayed-Enhancement Cardiac Magnetic Resonance (DE-CMR) Compared to Endomyocardial Biopsy;** I. Sobol, E.M. Horn, A. Dele-Michael, F.Y. Lin, M. Yushak, F. Islam, P. Goyal, J.W. Weinsaft, N. Narula. Medicine, Weill Cornell Medical College, New York City, NY.**1:35 PM (124) Is Cardiac Resynchronization Therapy a Cost-Effective Strategy in Patients Whose Ultimate Destination Is a Left Ventricular Assist Device?;** P. Shah,¹ A.J. Rongione,² P.D. Hewitt,² C.M. Rosner,² C.W. May,² N.A. Burton,² S.S. Desai.² ¹Division of Cardiology, The George Washington University, Washington, DC; ²Heart Failure/Transplant, Inova Fairfax Hospital, Falls Church, VA.**1:40 PM (125) Reduced Skinfold Thickness Is an Independent Predictor of Adverse Outcome in Patients with Advanced Heart Failure;** V. Melenovsky, M. Kotrc, A. Jabor, I. Malek, J. Kautzner. Cardiology, Institute for Clinical and Experimental Medicine – IKEM, Prague, Czech Republic.**1:45 PM (126) Risk Stratification of Ambulatory Patients with Advanced Heart Failure Undergoing Evaluation for Heart Transplantation;** G.R. Stevens,¹ J. Jiang,² P.C. Schulze,² T. Kato,² N. Gukasyan,³ A. Levin,⁴ D. Mancini,² M. Farr.² ¹Center for Advanced Cardiac Therapy, Montefiore Medical Center, Bronx, NY; ²Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; ³Tulane University Medical Center, New Orleans, LA; ⁴Columbia College, New York, NY.**1:50 PM (127) Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients during Cardiopulmonary Exercise;** L. Rifai,¹ W. Taylor,¹ K. Key,¹ M.A. Silver.^{1,2} ¹Department of Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, IL; ²Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL.**1:55 PM (128) Redo Sternotomy in Patients Undergoing Heart Transplantation: A Propensity-Matched Survival Analysis of the United Network for Organ Sharing Database;** J.M. Schaffer,¹ S.K. Singh,² B.A. Reitz,¹ P.E. Oyer,¹ R.C. Robbins,¹ H.R. Mallidi,³ ¹Cardiac Surgery, Stanford University Medical Centre, Palo Alto, CA; ²Cardiac Surgery, McMaster University, Hamilton, ON, Canada; ³Cardiac Surgery, Baylor College of Medicine, Houston, TX.**2:00 PM (129) Familial Dilated Cardiomyopathy (FDCM) Prevalence in End-Stage Non-Ischemic Heart Failure (ESHF);** D.L. Jacoby,¹ E.C. DePasquale,¹ O. Laur,¹ P. Pomianowski,² W.J. McKenna.³ ¹Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; ²Department of Genetics, Yale University School of Medicine, New Haven, CT; ³Institute of Cardiovascular Science, University College London and The Heart Hospital, UCLH NHS Trust, London, United Kingdom.**2:05 PM (130) Extended Criteria Cardiac Transplantation Versus Destination Therapy Left Ventricular Assist Device Therapy in the Continuous Flow Era;** M.A. Daneshmand,¹C.B. Patel,² A.F. Hernandez,² G.M. Felker,² P.B. Rosenberg,² A.A. Simeone,¹ L.J. Blue,² J.G. Rogers,² C.A. Milano.¹ ¹Surgery, Duke University Medical Center, Durham, NC; ²Medicine, Duke University Medical Center, Durham, NC.**2:10 PM (131) Effects of Bosentan in Patients Considered Ineligible for Heart Transplantation Because of Severe Pulmonary Hypertension;** I. Tatjer, M. Farrero, M. Cardona, D. Penela, A. Castel, F. Perez-Villa. Heart Transplantation Unit, Hospital Clinic, Barcelona, Spain.**2:15 PM (132) Predicting Heart Failure Mortality Following Hospital Discharge: A Novel and Simple Risk Assessment Tool;** K.D. Brunisholz, B.D. Home, K.D. Rasmussen, T. Bair, O.W. Pinzon, R. Alharethi, D. Budge, J.L. Nixon, J.L. Anderson, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.**2:20 PM (133) Cardiac Allograft Vasculopathy (CAV) in Children: An 18 Year Pediatric Heart Transplant Study (PHTS) Analysis in 3120 Patients;** S.J. Kindel,¹ C. Chin,² Y. Law,³ M.M. Burch,⁴ J.K. Kirklin,⁵ D.C. Naftel,⁵ M.P. Carbone,⁶ A. Arens,¹ A.M. Atz,⁷ W.J. Dryer,⁸ E. Pahl.¹ ¹Division of Cardiology, Department of Pediatrics, Children's Memorial Hospital – Northwestern University Feinberg School of Medicine, Chicago, IL; ²The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ³The Heart Center, Seattle Children's Hospital Medical Center, Seattle, WA; ⁴Cardiology, Great Ormond Street Hospital, London, United Kingdom; ⁵University of Alabama, Birmingham, AL; ⁶Pediatric Cardiology, Duke University Medical Center, Durham, NC; ⁷Department of Pediatrics, Division of Cardiology, Medical College of South Carolina, Charleston, SC; ⁸Department of Pediatrics, Baylor College of Medicine, Houston, TX.**2:25 PM (134) Geographic Variation in Mortality Rates Following Pediatric Heart Transplantation;** R.R. Davies, S. Haldeman, C. Pizarro. Nemours Cardiac Center, A.I. duPont Hospital for Children, Wilmington, DE.**2:30 PM (135) Neuro-Cognitive Performance of Children Undergoing Heart Transplantation in the US Analysis of Data from the Organ Procurement and Transplant Network;** L.B. Smoot, C.J. VanderPluym, T.P. Singh, K. Gauvreau, H. Bastardi, E. Blume, K.P. Daly, M. Oliva, C.S. Almond. Cardiology, Children's Hospital Boston, Boston, MA.**2:35 PM (136) Central Aortic Stiffness, Hypertension and Coronary Allograft Vasculopathy in Children;** T. Hussain,² M. Burch,¹ A.J. Wiethoff,^{2,3} S.A. Peel,² M. Cecelja,² G.F. Greil,² R.M. Botnar,² M. Fenton.¹ ¹Paediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom; ²King's College London, London, United Kingdom; ³Philips Healthcare, UK, Guildford, United Kingdom.**2:40 PM (137) Risk Factors for Wait-List and Post-Transplant Mortality in Children with Dilated and Non-Dilated Cardiomyopathy in the Current Era;** T.P. Singh, C.S. Almond, G. Piercey, K. Gauvreau. Cardiology, Children's Hospital Boston, Boston, MA.**2:45 PM (138) Bortezomib for Management of Antibody-Mediated Rejection Following Pediatric Heart Transplantation;** W.T. Mahle, H. Henderson, A.M. Berg, K.R. Kanter. Children's Healthcare of Atlanta, Emory University, Atlanta, GA.**2:50 PM (139) Association between Renal Function and Genetic Polymorphisms in Pediatric Heart Transplant Recipients;** B. Feingold,¹ M.M. Brooks,² A. Zeevi,³ E.L. Ohmann,¹ G.J. Burckart,⁴ R.E. Ferrell,⁵ R. Chinnock,⁶ C. Canter,⁷ L. Addonizio,⁸ D. Bernstein,⁹ J.K. Kirklin,¹⁰ D.C. Naftel,¹⁰ S.A. Webber.¹ ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC,

Pittsburgh, PA; ²Epidemiology, University of Pittsburgh, PA; ³Pathology, University of Pittsburgh, PA; ⁴Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD; ⁵Human Genetics, University of Pittsburgh, PA; ⁶Pediatrics, Loma Linda University, Loma Linda, CA; ⁷Pediatric Cardiology, Washington University School of Medicine, St. Louis, MO; ⁸Pediatric Cardiology, Columbia University, New York, NY; ⁹Pediatric Cardiology, Stanford University, Palo Alto, CA; ¹⁰Surgery, University of Alabama, Birmingham, AL.

2:55 PM (140) Risk-Adjusted Waitlist Mortality Varies across Regions among Children Listed for Heart Transplant; R.R. Davies, S. Haldeman, C. Pizarro. Nemours Cardiac Center, Nemours/A.I. duPont Hospital for Children, Wilmington, DE.

1:30 PM – 3:00 PM

MINI ORAL SESSION 3

(MEETING HALL 5)

Pulmonary Hypertension and Lung Transplantation

CHAIRS: Florian Wagner, MD and Tereza Martinu, MD

1:30 PM (141) Feasibility and Effectiveness of a Telehealth Clinic for Lung Transplant Recipients; L.G. Singer,^{1,2} M. Binnie,^{1,2} C. Chaparro,^{1,2} S. Chernenko,¹ C.-W. Chow,^{1,2} M. Davies,¹ J. Duerr,¹ M.A. Hutcheon,^{1,2} S. Juvet,^{1,2} N. Marks.¹ ¹Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada; ²Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.

1:35 PM (142) Fifteen-Year Experience of Living Donor Lobar Lung Transplant: Update on the Outcomes and Pulmonary Function of Recipients; M. Yamane, M. Yoshikawa, K. Miyoshi, S. Sugimoto, T. Oto, S. Miyoshi. Cancer and Thoracic Surgery, Okayama University Hospital, Okayama, Japan.

1:40 PM (143) A Web-Based Pilot Study of Judgment of the Transplant Benefit by Transplant Experts in Comparison to the Lung Allocation Score: The Eurotransplant Experience; J. Gottlieb,¹ A. Rahmel,² J. Smits.² ¹Pulmonary Medicine, Hannover Medical School, Hannover, Germany; ²Eurotransplant International Foundation, Leiden, Netherlands.

1:45 PM (144) Does Age Matter in Lung Transplantation?; W. Sherman,¹ A. Chaudhry,¹ D. Klarin,¹ D. Ross,² J. Belperio,² J.P. Lynch,² R. Saggat,² C. Hunter,¹ M. Kwon,¹ D. Gjertson,³ A. Ardehali.¹ ¹Surgery, Division of Cardiothoracic Surgery, David Geffen School of Medicine at University of California – Los Angeles, CA; ²Medicine, Division of Pulmonary and Critical Care, David Geffen School of Medicine at University of California – Los Angeles, CA; ³Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California – Los Angeles, CA.

1:50 PM (145) Impact of Donor Weight on Lung Graft Survival in Multiorgan Transplantation; M.S. Khan,¹ J.S. Heinle,¹ B. Shirkey,² J.A. Goss,³ M.G. Schecter,⁴ D.L.S. Morales.¹ ¹Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Congenital Heart Surgery, Texas Children's Hospital, Houston, TX; ³Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ⁴Pulmonology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.

1:55 PM (146) The High Yield of Transbronchial Cryo-Biopsy in Lung Transplantation Patients; M.R. Kramer, L. Fridel, R. Yael, D. Rosengarten, F. Oren. The Pulmonary Division, Rabin Medical Center, Petah Tikva, Israel.

2:00 PM (147) Lung Transplantation for Chronic Graft Versus Host Disease after Allogeneic Stem Cell Transplantation; A.M. Holm,^{1,2} G.C. Riise,³ L. Hansson,⁴ Ø. Bjørtuft,¹ L. Brinch,⁵ S. Simonsen,⁶ Y. Fløisand.⁵ ¹Department of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; ²Faculty of Medicine, University of Oslo, Oslo, Norway; ³Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁴Department of Respiratory Medicine, Skåne University Hospital, Lund, Sweden; ⁵Section of Hematology, Department of Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; ⁶Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.

2:05 PM (148) Methicillin-Resistant Staphylococcus aureus (MRSA) Screening and Decolonization of Lung Transplant Recipients (LTR) Prevents Disease and Saves Costs; C.J. Clancy, S.M. Bartsch, M.H. Nguyen, D.R. Stuckey, R.K. Shields, B.Y. Lee. University of Pittsburgh Medical Center, Pittsburgh, PA.

2:10 PM (149) Ambulatory ECMO Provides a Superior Bridge to Lung Transplantation Compared to Conventional ECMO; M.G. Hartwig,¹ G. Zanotti,¹ K. Rehder,² D.A. Turner,² S.S. Lin,¹ R.D. Davis.¹ ¹Surgery, Duke University Medical Center, Durham, NC; ²Pediatrics, Duke University Medical Center, Durham, NC.

2:15 PM (150) Impact of Health Literacy on Adherence after Lung Transplantation; C.J. Gries,¹ M.A. Dew,² A.J. DeVito Dabbs,³ J.M. Pilewski,¹ D.B. White.⁴ ¹Division of Pulmonary Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, PA; ²Departments of Psychiatry, Psychology, Epidemiology, Biostatistics and Clinical and Translational Science, University of Pittsburgh, PA; ³School of Nursing, University of Pittsburgh, PA; ⁴Department of Critical Care, University of Pittsburgh, PA.

2:20 PM (151) Longitudinal Spirometry Progression and BOS Diagnosis Post Transplant: Impact of Reference Equation; P. Robinson,^{1,2} H. Spencer,² P. Aurora.² ¹Department of Pediatric Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; ²Department of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

2:25 PM (152) Post-Marketing Hepatic Safety Profile of Arbrisentan in Patients with Pulmonary Arterial Hypertension – 4 Year Update; D.B. Badesch,¹ T. Peschel,² D. Pizzuti,² H. Gillies,² M. Allard,² C. Blair,² M. Littman.² ¹Pulmonary Hypertension Center, University of Colorado, Denver, CO; ²Gilead Sciences, Inc., Foster City, CA.

2:30 PM (153) Systemic Endothelial Dysfunction in Children with Idiopathic Pulmonary Arterial Hypertension Correlates with Disease Severity; D. Friedman,¹ J. Szmuszkovicz,² M. Rabai,² J.A. Detterich,² J. Mentzer,² J.C. Wood.² ¹Pediatric Cardiology, Newark Beth Israel Medical Center, Newark, NJ; ²Pediatric Cardiology, Children's Hospital Los Angeles, Los Angeles, CA.

2:35 PM (154) Exercise Testing: Influence of Pulmonary Hypertension in Patients with Interstitial Lung Disease Awaiting Lung Transplantation; H.F. Armstrong,¹ P.C. Schulze,² D.J. Lederer,³ M.N. Bartels.¹ ¹Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; ²Department of Medicine, Division of Cardiology,

Columbia University Medical Center, New York, NY; ³Department of Surgery, Columbia University Medical Center, New York, NY.

- 2:40 PM (155) Could Health Care Reform Reduce the Gap in Racial Disparities in Pulmonary Hypertension Outcomes?**; K.A. Stackhouse, G. Devendra, S. Hart, W. Elmallah, J. Lee, R.A. Krasuski. Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH.
- 2:45 PM (156) Identifying High Risk Patients with Pulmonary Arterial Hypertension Undergoing Six Minute Walk Test**; H. Seale, J. Harris, H. Kathleen, F. Kermeen. Queensland Centre for Pulmonary Transplantation & Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia.
- 2:50 PM (157) Platelet-Activating Factor Acetylhydrolase (PAF-AH): A Predictor of Adverse Event in Medically Treated CTEPH Patients?**; R. Quarck,¹ H. Durand,² E. Ninio,² M. Delcroix,³ ¹Respiratory Diseases, Katholieke Universiteit Leuven, Leuven, Belgium; ²UMRS937, Institut National et de la Recherche Médicale, Paris, France; ³Center for Pulmonary Vascular Diseases, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
- 2:55 PM (158) Definition and Functional Correlates of Right Ventricular Reserve in a Model of Chronic Thromboembolic Pulmonary Hypertension**; J. Guihaire, F. Haddad, O. Mercier, D. Boulate, B. Decante, E. Flecher, P. Darteville, E. Fadel. Laboratory of Surgical Research, Marie Lannelongue Hospital, Le Plessis Robinson, France.

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 3 (CONGRESS HALL)

Mechanical Circulatory Support – When is It Too Soon or Too Late?

CHAIRS: Jan Pirk, MD and Stuart D. Russell, MD

- 3:15 PM Ambulatory Heart Failure Patient – When has Medical Therapy Failed?**, JoAnn Lindenfeld, MD, University of Colorado, Denver, CO
- 3:30 PM Patient Risk – Heart Failure and VAD Operation – Where is the ‘Sweet Spot’?**, Garrick C. Stewart, MD, Brigham & Women’s Hospital, Boston, MA
- 3:45 PM MCS in the Less Sick Patients – Where will REVIVE-IT Fit?**, Keith Aaronson, MD, MS, University of Michigan, Ann Arbor, MI
- 4:00 PM DEBATE: MCS Should Be the First Choice for Patients with End-Stage Heart Failure, Not Transplant**
- 4:00 PM PRO:** Joseph Woo, MD, University of Pennsylvania Health System, Philadelphia, PA
- 4:08 PM CON:** Andreas Zuckermann, MD, Medical University of Vienna, Austria
- 4:16 PM Discussion**

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 4 (FORUM HALL)

Large and Small Vessels Disease in Heart Transplantation

CHAIRS: A. G. Kfoury, MD, PhD and Javier Segovia, MD, PhD

- 3:15 PM Intimal Thickening vs. Remodeling: Clinical Significance of Volumetric Changes in Epicardial Coronary Arteries**, Luciano Potena, MD, PhD, University of Bologna, Italy
- 3:30 PM Microvasculopathy from Artifact to Prognostic Factor**, M. Elizabeth H. Hammond, MD, UTAH Cardiac Transplant Program, Intermountain Healthcare, Salt Lake City, UT
- 3:45 PM From Morphology to Function: Coronary Flow Reserve**, Francesco Tona, MD, PhD, University of Padua, Padova, Italy
- 4:00 PM How Can We Ameliorate Microvasculopathy?**, Nicola E. Hiemann, MD, FACC, Deutsches Herzzentrum, Berlin, Germany
- 4:15 PM Questions and Answers**

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 5 (MEETING HALL 1)

Tough Situations in Cardiac Transplantation: Bring in the Experts

CHAIR: Mandeep R. Mehra, MD, MBBS, FACC, FACP

- 3:15 PM Case Presentation**, Jennifer A. Cowger, MD, MS, University of Michigan Health Systems, Ann Arbor, MI
- 3:50 PM Case Presentation:** Arezu Z. Aliabadi, MD, Medical University of Vienna, Austria

PANELISTS:

- Juan F. Delgado Jimenez, PhD, “12 Octubre” University Hospital, Madrid, Spain
- Roberto Fiocchi, MD, PhD, Ospedali Riuniti di Bergamo, Italy
- Sharon A. Hunt, MD, Stanford University, Palo Alto, CA
- Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, MN,
- Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY
- Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Germany
- Marc J. Semigran, MD, Massachusetts General Hospital, Boston, MA

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 6 (PANDRAMA HALL)***Lung Transplantation for Pulmonary Arterial Hypertension – A Review and Panel Discussion*****CHAIRS:** Thomas K. Waddell, MD, MSc, PhD and Paul A. Corris, MB, FRCP**3:15 PM** *Lung and Heart-Lung Transplantation for PAH: Universal and Regional Issues of Timing of Referral, Listing Status, and Organ Allocation*, Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX**3:30 PM** *Bilateral Lung Versus Combined Heart-Lung Transplantation for PAH: What are the Considerations for the Type of Operation?*, Elie Fadel, MD, PhD, Marie Lannelongue, Paris-Sud University, Le Plessis Robinson, France**3:45 PM** *Bridging Strategies for Lung Transplant Candidates with PAH: Atrial Septostomy, ECMO, RVAD, and No-valung*, Duane Davis, MD, MBA, Duke University Medical Center, Durham, NC**4:00 PM** *Lung Transplantation for PAH: Panel Discussion with Transplant Physicians from Various Regions of The World – Learning from Each Other***4:15 PM** *Discussion: Learning from Each Other – How We Do It Around the World***PANELISTS:**

Deborah J. Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA

Elie Fadel, MD, Marie Lannelongue Hospital, Paris-Sud, France

Walter Klepetko, MD, Medical University of Vienna, Austria

Phillip Spratt, St. Vincent's Hospital, Sydney, Australia

Duane Davis, MD, Duke University Medical Center, Durham, NC, USA

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 7 (MEETING HALL 4)***Special Considerations: Cystic Fibrosis and Lung Transplantation*****CHAIRS:** Cecilia Chaparro, MD and Paul Aurora, MBBS, BSc(Hons), MSc, MRCP, PhD**3:15 PM** *Surgical Issues in Lung Transplantation for Cystic Fibrosis*, John H. Dark, MB, FRCS, Newcastle Upon Tyne University, United Kingdom**3:40 PM** *Microbiological Issues in Patients with Cystic Fibrosis Undergoing Lung Transplantation*, Shahid Husain, MD, MS, University Health Network, University of Toronto, Canada**4:05 PM** *Medical Management of the Lung Transplant Recipient with Cystic Fibrosis*, Denis Hadjiladis, MD, MHS, University of Pennsylvania, Philadelphia, PA

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 8 (MEETING HALL 5)***Risky Business: Infectious Risk in Donors and Recipients*****CHAIRS:** Valentina Stosor, MD and Kate Gould, FRCPATH**3:15 PM** *Hepatitis C: When is it a Contraindication?*, Minh-Hong T. Nguyen, MD, University of Pittsburgh, PA**3:35 PM** *Opening the Door to Hepatitis B Core Donors*, Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY**3:55 PM** *On the Horizon: Hepatitis E*, Erik A. M. Verschuuren, MD, PhD, University Medical Centre Groningen, The Netherlands**4:10 PM** *The 'Well-Travelled' Donor: What Are The Risks?*, Camille N. Kotton, MD, FIDSA, Massachusetts General Hospital/Harvard Medical School, Boston, MA

3:15 PM – 4:30 PM

CONCURRENT SYMPOSIUM 9 (NORTH HALL)***Coagulation and Transplantation – The Clot Thickens*****CHAIRS:** Joren C. Madsen, MD, DPhil and Stephan M. Ensminger, MD, PhD**3:15 PM** *The Role of Platelets in the Development of Arteriosclerosis – Relevant Aspects for Transplantation*, Steffen Massberg, MD, PhD, German Heart Center, Munich, Germany**3:40 PM** *Platelets and Leucocyte Adhesion*, Christian Weber, MD, Kreislaufinstitut, Munich, Germany**4:05 PM** *Complement and T Cell Alloimmunity*, Steven Sacks, MD, PhD, MRC Centre for Transplantation, King's College London, United Kingdom

4:30 PM – 5:00 PM

COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING
(CONGRESS HALL FOYER)



5:00 PM – 6:15 PM

CONCURRENT SYMPOSIUM 10 (NORTH HALL)**Joint ISHLT/IPTA Symposium****CHAIRS:** Shaf Keshavjee, FRCS(C) and Richard E. Chinnock, MD**Part I: Cardiac Transplant in Infancy – A Window into the Immune System****5:00 PM** *Insights into Immunological Development and Tolerance Drawn from Recipients of Heart Transplantation in Infancy*, Simon Urschel, MD, University of Alberta, Edmonton, Canada**5:15 PM** *Challenges to Achieving Tolerance*, Mohamad H. Sayegh, MD, Brigham and Women's Hospital & Children's Hospital, Boston, MA**5:30 PM** *Insights into Acquisition and Maintenance of Host Defense after Heart Transplantation in Infancy*, Jeffrey L. Platt, MD, University of Michigan, Ann Arbor, MI**5:45 PM** *Heart Transplantation Yields Insights into T Cell Dependent B Cell Responses to Infection, Vaccines and Regulation of Immunity*, Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI**Part II: Update on ISHLT / IPTA Consensus Process****6:00 PM** *Heart*, Elfriede Pahl, MD, Children's Memorial Hospital, Chicago, IL**6:05 PM** *Lung*, Samuel B. Goldfarb, MD, The Children's Hospital of Pennsylvania, Philadelphia, PA**6:10 PM** *Discussion*

5:00 PM – 6:15 PM

CONCURRENT SESSION 19 (CONGRESS HALL)**MCS: Desired Outcomes – Can We Get There****CHAIRS:** Edwin C. McGee, MD and Paul Mohasci, MD, eMBA**5:00 PM** **(159)** *Impact of Bridging with Ventricular Assist Devices on Long-Term Survival Following Heart Transplantation*; A. Kilic,¹ A.S. Shah,¹ D.D. Yuh,² W.A. Baumgartner,¹ J.V. Conte,¹ ¹Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; ²Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.**5:12 PM** **(160)** *Trends in Utilization and Costs of Left Ventricular Assist Device Therapy for Advanced Heart Failure in US – Results from the Nationwide Inpatient Sample 2005-2008*; A.R. Mahankali Sridhar,¹ S. Parasa,¹ W.B. Hille-gass,² G. Pranjat,³ ¹Department of Medicine, Washington Hospital Center, Washington, DC; ²Division of Cardiology, University of Alabama, Birmingham, AL; ³Division of Cardiology, Johns Hopkins University, Baltimore, MD.**5:24 PM** **(161)** *Patients with INTERMACS 4-7 Heart Failure Have Reduced Quality of Life*; P.C. Patel,¹ G.C. Stewart,² M.M. Kittleson,³ J.A. Cowger,⁴ C.B. Patel,⁵ M.M. Mountis,⁶ F.L. Johnson,⁷ J.E. Rame,⁸ J. Testani,⁹ M.E. Guglin,⁹ J.J. Teuteberg,¹⁰ M.H. Drazner,¹ ¹University of Texas, Southwestern, Dallas, TX; ²Brigham and Women's Hospital, Boston, MA; ³Cedars-Sinai Heart Institute, Los Angeles, CA; ⁴University of Michigan, Ann Arbor, MI; ⁵Duke University, Durham, NC; ⁶Cleveland Clinic, Cleveland, OH; ⁷University of Iowa, Iowa City, IA; ⁸University of Pennsylvania, Philadelphia, PA; ⁹University of South Florida, Tampa, FL; ¹⁰University of Pittsburgh, PA.**5:36 PM** **(162)** *Prediction of Events in Patients with Advanced Heart Failure: Application of the Seattle Heart Failure Model to the MEDAMACs Population*; J.J. Teuteberg,¹ M. Kittleson,² J. Cowger,³ C. Patel,⁴ G. Stewart,⁵ M. Mountis,⁶ F. Johnson,⁷ P. Patel,⁸ E. Rame,⁹ J. Testani,⁹ M. Guglin,¹⁰ L. Stevenson,⁵ R.L. Kormos,¹ ¹Heart and Vascular Institute, University of Pittsburgh, PA; ²Cardiology, Cedars Sinai, Los Angeles, CA; ³Cardiology, University of Michigan, Ann Arbor, MI; ⁴Cardiology, Duke University, Durham, NC; ⁵Cardiology, Brigham and Women's, Boston, MA; ⁶Cardiology, Cleveland Clinic, Cleveland, OH; ⁷Cardiology, University of Iowa, Ames, IA; ⁸Cardiology, UT Southwestern, Dallas, TX; ⁹Cardiology, University of Pennsylvania, Philadelphia, PA; ¹⁰Cardiology, University of South Florida, Tampa, FL.**5:48 PM** **(163)** *Increased LVAD Utilization Has Increased Waiting Time for Medically Bridged Patients*; E.S. Shao, R. Garberich, K. Hryniewicz, B. Sun, N. Moazami, B. Cabuay, D. Feldman. Minneapolis Heart Institute, Minneapolis, MN.**6:00 PM** **(164)** *Continuous Flow Mechanical Circulatory Support: Does It Really Improve Peak Oxygen Consumption (VO₂)?*; E.S. Leibner,¹ J. Cysyk,² K. Eleuteri,¹ E. Stephenson,¹ B. Soleimani,¹ A. El-Banayosy,¹ J.P. Boehmer,¹ W.E. Pae,¹ ¹Heart and Vascular Institute, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA; ²Division of Artificial Organs, Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA.

5:00 PM – 6:15 PM

CONCURRENT SESSION 20 (FORUM HALL)**Advanced Heart Failure: When is a Contraindication Not a Contraindication to Transplant****CHAIRS:** Luciano Potena, MD, PhD and Allen Anderson, MD

- 5:00 PM (165) Analysis of over 1000 Patients Listed for Combined Heart-Kidney Transplant in the Modern Era; J.M. Schaffer,¹ S.K. Singh,² B.A. Reitz,¹ P.E. Oyer,¹ R.C. Robbins,¹ H.R. Mallidi,³ ¹Cardiac Surgery, Stanford University Medical Centre, Palo Alto, CA; ²Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, ON, Canada; ³Cardiac Surgery, Baylor School of Medicine, Houston, TX.**
- 5:12 PM (166) High Transpulmonary Gradient Obtained at the Time of LVAD Implantation Is Associated with Worse Long Term 1 Year Survival after Cardiac Transplantation; N. Uriel,¹ D.B. Sims,¹ P.C. Colombo,¹ H. Takayama,² R. John,³ F.D. Pagani,⁴ Y. Naka,² K.S. Sundareswaran,⁵ D.J. Farrar,⁵ U.P. Jorde.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY; ³Surgery, University of Minnesota, Minneapolis, Mn; ⁴Surgery, University of Michigan, Ann Arbor, MI; ⁵Thoratec Corporation, Pleasanton, CA.**
- 5:24 PM (167) Follow-Up of Lung and Heart Transplant Recipients with Pre-Transplant Malignancies; V. Sigurdardottir,¹ O. Bjortuft,² H. Eiskjær,³ B. Ekmeahag,⁴ E. Gude,⁵ F. Gustafsson,⁶ I. Hagerman,⁷ M. Halme,⁸ J. Lommi,⁹ L. Mared,¹⁰ G.C. Riise,¹ S. Simonsen.⁵ ¹Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Department of Respiratory Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ³Department of Cardiology, Skejby University Hospital, Aarhus, Denmark; ⁴Department of Cardiology, Skåne University Hospital, Lund, Sweden; ⁵Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁶Department of Cardiology, Rigshospitalet Copenhagen, Copenhagen, Denmark; ⁷Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; ⁸Division of Respiratory Medicine, Helsinki University Central Hospital, Helsinki, Finland; ⁹Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland; ¹⁰Department of Respiratory Medicine, Skåne University Hospital, Lund, Sweden.**
- 5:36 PM (168) Experience of Sequential Heart and Bone Marrow Transplant for AL Amyloidosis: What Is the Optimal Waiting Time for Bone Marrow Transplant?; J.D. Estep, D.S. Medina, A.M. Cordero-Reyes, K. Youker, A. Bhimaraj, M. Loebe, G. Amione-Torre. The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX.**
- 5:48 PM (169) Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation; L. Potena, S. Martin-Suarez, V. Manfredini, M. Masetti, E. Pilato, G. Magnani, F. Fallani, F. Cocco, A. Russo, F. Fallani, F. Grigioni, A. Branzi, G. Arpesella. Cardiovascular Department, University of Bologna, Bologna, Italy.**
- 6:00 PM (170) Heart Transplantation in 11 Patients with End Stage Heart Failure Caused by Muscular Dystrophy; U. Fuchs, U. Schulz, B. Schulze, A. Zittermann, K. Hakim-Meibodi, J.F. Gummert. Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.**

5:00 PM – 6:15 PM

CONCURRENT SESSION 21 (MEETING HALL 1)**Therapeutics of Lung Transplantation****CHAIRS:** Deborah Jo Levine, MD and Andrew Fisher, PhD, FRCP

- 5:00 PM (171) 3-Year Results of the CeMyLungs Study, a 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing De Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (Using C2 Monitoring) and Corticosteroids for the Prevention of Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients; A.R. Glanville,¹ C. Aboyou,¹ W. Klepetko,² H. Reichenspurner,³ H. Treede,³ E.A. Verschuuren,⁴ A. Boehler,⁵ C. Benden,¹ P. Hopkins,⁶ P.A. Corris.⁷ ¹Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ²University of Vienna, Vienna, Austria; ³University Heart Center, Hamburg, Germany; ⁴University Medical Centre, Groningen, Netherlands; ⁵University Hospital, Zurich, Switzerland; ⁶The Prince Charles Hospital, Brisbane, Australia; ⁷Newcastle University, Newcastle, United Kingdom.**
- 5:12 PM (172) Cyclosporine Inhalation Solution Does Not Improve Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplant: Results from the CYCLIST Trial; B.A. Johnson,¹ M.R. Zamora,² M.M. Budev,³ R.M. Kotloff,⁴ A. Iacono,⁵ S.G. Dilly,⁶ W.J. Verret,⁶ J.A. Golden.⁷ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Colorado Health Sciences Center, Aurora, CO; ³Cleveland Clinic, Cleveland, OH; ⁴University of Pennsylvania Medical Center, Philadelphia, PA; ⁵University of Maryland Medical Center, Baltimore, MD; ⁶APT Pharmaceuticals, Inc., Burlingame, CA; ⁷University of California, San Francisco, CA.**
- 5:24 PM (173) A Randomised Controlled Trial of Azithromycin Therapy in Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplantation; P.A. Corris,^{1,2} T. Small,¹ V.A. Ryan,³ J. Lordan,¹ A.J. Fisher,^{1,2} G. Meachery,¹ G. Johnson,¹ C. Ward.² ¹Institute of Transplantation, Freeman Hospital – Newcastle Upon Tyne/UK, Newcastle upon Tyne, United Kingdom; ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne; ³Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom.**
- 5:36 PM (174) Everolimus Versus MMF in Lung Transplant Recipients; S. Martin, F. Thomas, W. Gregor, W. Tobias, H. Axel, G. Jens. Hannover Medical School, Hannover, Germany.**
- 5:48 PM (175) Alemtuzumab Induction in Lung Transplantation: Efficacy and Safety; P. Jaksch, A. Scheed, B. Zweytick, M. Ernst, V. Augustin, W. Klepetko. Thoracic Surgery, Medical University Vienna, Vienna, Austria.**
- 6:00 PM (176) Mesenchymal Stromal Cell Therapy for Bronchiolitis Obliterans Syndrome – Preliminary Data in Humans; D.C. Chambers,^{1,2} P.M. Hopkins,^{1,2} M. Sturm,^{3,4} S. Lawrence,⁵ D. Enever,¹ L. Sparks,⁶ K. Whitelaw,⁷ R. Herrmann,^{3,4} M. Musk.⁵ ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; ²School of Medicine, The University of Queensland, Brisbane, Australia; ³Cell & Tissue Therapies Western Australia, Royal Perth Hospital, Perth, Australia; ⁴Department of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; ⁵WA Lung Transplant Service, Royal Perth Hospital, Perth, Australia; ⁶Department of Oncology, The Prince Charles Hospital, Brisbane, Australia.**

5:00 PM – 6:15 PM

CONCURRENT SESSION 22 (PANORAMA HALL)**Pulmonary Hypertension: Assessment and Prognosis****CHAIRS:** Srinivas Murali, MD and Dana McGlothlin, MD

5:00 PM (177) 'Notching' of the Right Ventricular Outflow Tract Doppler Profile (DopplerRVOT) Is a Highly Sensitive and Specific Predictor of Pulmonary Vascular Disease among Patients with Systemic Sclerosis; R. Saggari,¹ R. Saggari,² A. Derhovanessian,² A.V. Fields,³ D. Khanna,⁴ P.R. Forfia,³ ¹Heart-Lung Institute, St. Joseph Hospital & Medical Center, Phoenix, AZ; ²Pulmonary & Critical Care, University of California, Los Angeles, CA; ³Heart Failure/Transplant Cardiology, Univ of Penn, Philadelphia, PA; ⁴Division of Rheumatology, Scleroderma Program, University of Michigan Scleroderma Program, Ann Arbor, MI.

5:12 PM (178) Reduced Resting Pulmonary Artery Compliance (Cpa) in Exercise-Induced Pulmonary Arterial Hypertension (EI-PAH) Associated with Systemic Sclerosis (SSc); R.E. Girgis, R.J. Tedford, S.C. Mathai, D.A. Kass, P.M. Hassoun. Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.

5:24 PM (179) Exercise Determinates of Pulmonary Hypertension in Patients with Interstitial Lung Disease: Which Is Better? H.F. Armstrong,¹ P.C. Schulze,² D.J. Lederer,³ M.N. Bartels.¹ ¹Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; ²Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ³Department of Surgery, Columbia University Medical Center, New York, NY.

5:36 PM (180) Exercise Hemodynamics Can Predict Otherwise Undetectable Left Heart Failure in Patients Referred Due to Suspicion of Pulmonary Arterial Hypertension; P. Lesny, M. Luknar, I. Varga, P. Solik, E. Goncalvesova. National Cardiovascular Institute, Bratislava, Slovakia (Slovak Republic).

5:48 PM (181) Hemodynamic Assessment of Pulmonary Hypertension in Grown-Up Congenital Heart Disease; M. Gerges, C. Gerges, M. Lang, I.M. Lang. Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.

6:00 PM (182) Validation of the REVEAL Score for Pulmonary Arterial Hypertension and Application of the Model To Predict Long Term Survival; R. Cogswell, D. McGlothlin, R. Shaw, T. DeMarco. Cardiology, University of California, San Francisco, CA.

5:00 PM – 6:15 PM

CONCURRENT SESSION 23 (MEETING HALL 4)**Clinical Case Dilemmas in Thoracic Transplantation****CHAIRS:** Pali D. Shah, MD and Geert M. Verleden, MD, PhD

5:00 PM (183) Dyspnea, Dizziness and Weakness 5 Years after Heart Transplantation; K.J. Lindley, A.K. Ravichandran, J. Schilling, S.M. Joseph. Cardiology, Washinton University in St. Louis, Saint Louis, MO.

5:07 PM EXPERT DISCUSSANT: Gerald J. Berry, MD, Stanford University, Palo Alto, CA

5:12 PM (184) Severe Exertional Dyspnea 1 Year after Lung Transplantation; D.M. Sayah, B.S. Schwartz, J. Kukreja, J.P. Singer, J.A. Golden, L.E. Leard. University of California, San Francisco.

5:19 PM EXPERT DISCUSSANT: Peter Hopkins, MBBS, FRACP, HONOURS, The Prince Charles Hospital Brisbane, Australia

5:24 PM (185) Renal Failure and Hemolysis 10 Days after Lung Transplantation; I. Sinapi,² P. Bulpa,^{1,2} M. Gonzalez,² M. Buche,¹ L. Delaunoy,¹ I. Michaux,² A. Dive,² P. Evrard.^{1,2} ¹Transplant Center, CHU Mont-Godinne, Yvoir, Belgium; ²Intensive Care, CHU Mont-Godinne, Yvoir, Belgium.

5:31 PM EXPERT DISCUSSANT: Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

5:36 PM (186) Long Term Mechanical Circulatory Support: What Are the Final Options? C.B. Patel,¹ M.L. Mackinnon,¹ A.D. Smith,¹ G.M. Felker,¹ D. Vikraman-Sushama,¹ D.L. Sudan,¹ P.B. Rosenberg,¹ A.F. Hernandez,¹ G.T. Delario,² C.A. Milano,¹ J.G. Rogers.¹ ¹Duke University Medical Center, Durham, NC; ²Carolina Donor Services, Durham, NC.

5:43 PM EXPERT DISCUSSANT: George M. Wieselthaler, MD, University of California San Francisco, CA

5:48 PM (187) Ventricular Dysfunction after Pediatric Heart Transplant: It's Not Always Rejection! E.L. Albers,¹ D.P. Bichell,² D.A. Dodd,¹ ¹Pediatric Cardiology, Vanderbilt University, Nashville, TN; ²Pediatric Cardiothoracic Surgery, Vanderbilt University, Nashville, TN.

5:55 PM EXPERT DISCUSSANT: Beth D. Kaufman, MD, Children's Hospital of Philadelphia, PA.

6:00 PM (188) Is the Use of Remodulin Safe for Pregnant and Breastfeeding Patients with Pulmonary Arterial Hypertension (PAH)? A Case Report; V. Franco, J. Mueller, C.J. Daniels. Cardiovascular Medicine, The Ohio State University, Columbus, OH.

6:07 PM EXPERT DISCUSSANT: Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA.

5:00 PM – 6:15 PM

CONCURRENT SESSION 24 (MEETING HALL 5)**Heart Failure: Back to Basics****CHAIRS:** Lee R. Goldberg, MD, MPH and Eric Epailly, MD**5:00 PM (189) Regulation of the Mitochondrial Proteins Mitofilin and Porin in Explanted Failing Human Hearts;** R.C. Gupta, S. Rastogi, M. Wang, P. Mohyl, H.N. Sabbah. Medicine, Henry Ford Hospital, Detroit, MI.**5:12 PM (190) Local Expression of Myocardial Galectin-3 Does Not Correlate with Its Serum Levels in Patients Undergoing Heart Transplantation;** A. Beiras-Fernandez,¹ J. Rothkopf,² S. Reinwand,³ I. Kaczmarek,² S. Kreth,³ F. Weis.³ ¹Thoracic and Cardiovascular Surgery, JW Goethe University, Frankfurt, Germany; ²Cardiac Surgery, LM-University, Munich, Germany; ³Anesthesiology, LM-University, Munich, Germany.**5:24 PM (191) Modulation of the Myocardial Expression of Neuregulin-1 and Its Receptor ErbB4 in Patients with Chronic Heart Failure;** J. Rothkopf,¹ F. Weis,² I. Kaczmarek,¹ S. Kreth,² A. Beiras-Fernandez.³ ¹Cardiac Surgery, LM-University of Munich, Munich, Germany; ²Anesthesiology, LM-University of Munich, Munich, Germany; ³JW-Goethe University, Frankfurt, Germany.**5:36 PM (192) Safety and Efficacy of Ixmyelocel-T, an Expanded Patient-Specific Mixed Cell Product, in Dilated Cardiomyopathy (IMPACT-DCM);** R.R. Bunge,¹ A.N. Patel,² B.L. Hamman,⁴ O.M. Lattouf,³ N.G. Smedira,⁵ R.L. Bartel,⁶ S. Watling,⁶ B.A. Bruckner.¹ ¹Cardiovascular Surgery, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX; ²Cardiothoracic Surgery, University of Utah, Salt Lake City, UT; ³Cardiothoracic Surgery, Emory Crawford Long Hospital, Atlanta, GA; ⁴Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX; ⁵Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; ⁶Aastrom Biosciences Inc., Ann Arbor, MI.**5:48 PM (193) Biomarkers of Recovered Heart Function;** Z. Holander,^{1,2} M. Lazárová,³ A. Ignaszewski,⁴ V. Chen,¹ R.T. Ng,^{1,5} J.E. Wilson-McManus,¹ R. Balshaw,^{1,6} R.W. McMaster,^{1,7} P.A. Keown,^{1,2,4} B.M. McManus.^{1,2,4,8,9} ¹PROOF Centre of Excellence, Vancouver, Canada; ²Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, Canada; ³Internal Medicine – Cardiology, University Hospital Olomouc, Olomouc, Czech Republic; ⁴Medicine, The University of British Columbia, Vancouver, Canada; ⁵Computer Science, The University of British Columbia, Vancouver, Canada; ⁶Statistics, The University of British Columbia, Vancouver, Canada; ⁷Medical Genetics, The University of British Columbia, Vancouver, Canada; ⁸UBC James Hogg Research Centre, Vancouver, Canada; ⁹Institute for Heart + Lung Health, Vancouver, Canada.**6:00 PM (194) End-Stage Human Failing Hearts Increase Cardiac Progenitor Cells by Switching to a Developmental Program;** S. Kaushal,¹ D. Simpson,¹ R. Mishra,¹ S. Sharma,¹ E. Pahl.² ¹Cardiothoracic Surgery, University of Maryland, Baltimore, MD; ²Cardiology, Childrens Memorial Hospital, Chicago, IL.

6:15 PM – 7:00 PM

PAST PRESIDENT'S COUNCIL MEETING AND RECEPTION

(CLUB B)

6:15 PM – 7:00 PM

EXHIBIT HALL RECEPTION AND POSTER VIEWING

(CONGRESS HALL FOYER)

FRIDAY, APRIL 20, 2012

7:00 AM – 6:00 PM

REGISTRATION DESK OPEN

(CONGRESS HALL FOYER)

7:00 AM – 6:30 PM

SPEAKER READY ROOM OPEN

(CLUB H)

8:00 AM – 5:00 PM

POSTER VIEWING

(CONGRESS HALL FOYER)

8:00 AM – 7:00 PM

PRESS OFFICE OPEN

(MEETING ROOM 2.4)

8:00 AM – 9:15 AM

CONCURRENT SYMPOSIUM 11 (MEETING HALL 4)**Management of the Failing Fontan Patient Across the Age Spectrum?****CHAIRS:** W. Robert Morrow, MD and Aditya Kaza, MD**8:00 AM** *How and Why Does the Fontan Circuit Fail?*, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Canada**8:10 AM** *Is Fontan Conversion a Good Alternative to Transplantation?*, Carl Lewis Backer, MD, Children's Memorial Hospital, Chicago, IL**8:20 AM** *When to list the Failing Fontan Patient for Transplantation?*, Daniel Bernstein, MD, Stanford University and Packard Children's Hospital at Stanford, Palo Alto, CA**8:30 AM** *Plumbing Matters in the Failing Fontan Circulation!*, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom**8:40 AM** *Challenges in the ICU Post-Transplant*, Jane V. Cassidy, MRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom**8:50 AM** *What are the Post-transplant Outcomes for the Failing Fontan Patient?*, Steven D. Zangwill, MD, Children's Hospital of Wisconsin, Milwaukee, WI

8:00 AM – 9:15 AM

CONCURRENT SESSION 25 (CONGRESS HALL)**VAD Future: Recovery and New Devices?**

CHAIRS: George M. Wieselthaler, MD and Michael McDonald, MD, FRCP(C)

8:00 AM (195) A New Treatment Option for Intermacs Profile 4, 5 and 6 Patients with the Circulite® Synergy® System; B. Meyns,¹ F. Rega,¹ M. Strueber,² A. Barbone,³ E. Vitali,³ D. Burkhoff.⁴ ¹University Hospital Leuven, Leuven, Belgium; ²Hannover Medical School, Hannover, Germany; ³Istituto Clinico Humanitas, Milan, Italy; ⁴CircuLite, Inc., Saddle Brook, NJ.

8:12 AM (196) The Role of ST-2 as a Novel Heart Failure Biomarker during Mechanical Unloading and Recovery in MCS Patients; C.C.O. Oezpeker, G.G.E. Erkilet, M.M.M. Morshuis, J.J.G. Gummert, H.H.M. Milting. Cardiothoracic Surgery, Heart Center North-Rhine-Westphalia, Bad Oeynhausen, NRW, Germany.

8:24 AM (197) First Clinical Evaluation of a Novel Percutaneous Right Ventricular Assist Device: The Impella RP; A. Cheung,¹ D. Freed,² D. Raess,⁴ P. LePrince.³ ¹University of British Columbia, Vancouver, Canada; ²University of Manitoba, Winnipeg, Canada; ³Pitie Salpetriere Hospital, Paris, France; ⁴Abiomed Inc, Danvers.

8:36 AM (198) Cardiac Power Output Predicts Myocardial Recovery and Successful Explanation of Left Ventricular Assist Device; J.K. George, F. Raissi Shabari, A.H. Abdul-Jabbar, J. Gazzala, G. Rossell, P. Odegaard, A.M. Segura, R.M. Delgado. Texas Heart Institute, Houston, TX.

8:48 AM (199) Reverse Remodelling with the Use of the Circulite® Synergy® Circulatory Assist System; J. Geens,¹ P. Claus,² S. Jacobs,¹ M. Martin,³ I. Van Tichelen,¹ F. Rega,¹ D. Burkhoff,³ B. Meyns.¹ ¹Dept. of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium; ²Dept. of Medical Imaging, University Hospitals Leuven, Leuven, Belgium; ³CircuLite, Inc., Saddle Brook, NJ.

9:00 AM (200) Does Prolonged Continuous-Flow LVAD Unloading Induce Hypertrophy Regression to the Point of Atrophy in the Failing Human Heart?; S.G. Drakos,^{1,2,4} N.A. Diakos,^{2,4} A.G. Kfoury,¹ C.H. Selzman,¹ B.B. Reid,¹ D.V. Miller,¹ M.P. Revelo,¹ D.R. Verma,¹ O. Wever-Pinzon,¹ K. Brunisholz,¹ R. Alharethi,¹ C. Myrick,³ M. Salama,² E.M. Gilbert,¹ E.H. Hammond,¹ J. Stehlik,¹ D.Y. Li.² ¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²University of Utah Molecular Medicine & ARUP, Salt Lake City, UT; ³Intermountain Donor Services, Salt Lake City, UT; ⁴rd Division of Cardiology, University of Athens, Athens, Greece.

8:00 AM – 9:15 AM

CONCURRENT SESSION 26 (FORUM HALL)**Heart Transplant Immunosuppression: What Can We Learn from Clinical Trials**

CHAIRS: Eulalia Roig, MD and Donna Mancini, MD

8:00 AM (201) Multicenter Randomized Trial of Everolimus vs. Mycophenolate Mofetil in Heart Transplantation: Final 24 Month Analysis of Efficacy and Safety; J. Kobashigawa,¹ D. Pauly,² A. Kfoury,³ H. Ross,⁴ S.-S. Wang,⁵ B. Cantin,⁶ A. van Bakel,⁷ R.C. Starling,⁸ S. Hirt,⁹ G. Dong,¹⁰ C. Panis,¹⁰ P. Lopez,¹¹ H. Eisen.¹² ¹Cedars-Sinai Heart Institute, Los Angeles; ²University of Florida College of Medicine, Gainesville; ³Intermountain Medical Center, Salt Lake City; ⁴University Health Network, Toronto General Hospital, Toronto, Canada; ⁵National Taiwan University, Taipei, Taiwan; ⁶Quebec Heart Institute, Quebec, Canada; ⁷Medical University of South Carolina, Charleston; ⁸Cleveland Clinic Foundation, Cleveland; ⁹Universitaetsklinikum Regensburg, Regensburg, Germany; ¹⁰Novartis Pharmaceuticals, East Hanover; ¹¹Novartis Pharma AG, Basel, Switzerland; ¹²Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia.

8:12 AM (202) Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Four Year Outcomes; J.J. Teuteberg,¹ R. Zomak,¹ C. Yost,¹ C. Newman,¹ M. Navoney,¹ J.K. Bhama,¹ D. McNamara,¹ C. Bermudez,¹ R.L. Kormos,¹ M.A. Shullo.² ¹Heart and Vascular Institute, University of Pittsburgh, PA; ²Pharmacy and Therapeutics, University of Pittsburgh, PA.

8:24 AM (203) Prospective Randomized 3-Arm Trial Comparing Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus with Calcineurin Inhibitor-Free Immunosuppression (Sirolimus/MMF) after Heart Transplantation: 5-Year Results; L. Kaczmarek,¹ M.-M. Zaruba,² S. Sadoni,³ A. Bigdeli,³ R. Schramm,¹ B. Meiser.¹ ¹Transplantation Center, Ludwig-Maximilians-University, Munich, Germany; ²Cardiology, Ludwig-Maximilians-University, Munich, Germany; ³Cardiac Surgery, Ludwig-Maximilians-University, Munich, Germany.

8:36 AM (204) Long-Term Benefit of Tacrolimus over Cyclosporine Preventing Cardiac Allograft Vasculopathy (CAV) after Heart Transplantation: 10-Year Results of a Prospective Randomized Trial Comparing Tacrolimus Versus Cyclosporine Both in Combination with Mycophenolate Mofetil; S. Guethoff,¹ B. Meiser,² R. Schramm,¹ P. Ueberfuhr,¹ C. Hagl,¹ B. Reichart,¹ I. Kaczmarek.^{1,2} ¹Department of Cardiac Surgery, University of Munich, Munich, Germany; ²Transplantation Center Munich, Munich, Germany.

8:48 AM (205) A Survey of Current Practice for Antibody Mediated Rejection in Heart Transplantation To Guide Treatment Standardization; S. Chih,¹ K. Tinckam,² H.J. Ross.¹ ¹Division of Cardiology and Cardiac Transplant, Toronto General Hospital-University Health Network, Toronto, ON, Canada; ²Division of Nephrology and Multi-Organ Transplant, Toronto General Hospital-University Health Network, Toronto, ON, Canada.

9:00 AM (206) Effect of Everolimus in Patients with Established Cardiac Allograft Vasculopathy: Results of a Randomized, Multicenter Intravascular Ultrasound Study; J. Segovia,¹ M. Gómez-Bueno,¹ J. Goicolea,¹ J. Elizaga,² J. Fernández-Yáñez,² J. Palomo,² F. González-Vílchez,³ L. Alonso-Pulpón.¹ ¹Hospital Puerta de Hierro, Madrid, Spain; ²Hospital Gregorio Marañón, Madrid, Spain; ³Hospital Marqués de Valdecilla, Santander, Spain.

8:00 AM – 9:15 AM

CONCURRENT SESSION 27 (MEETING HALL 1)**Basic Science of Lung Transplantation**

CHAIRS: Thomas Waddell, MD, MSc, PhD and Daniel C. Chambers, MBBS, MRCP, FRACP, MD

8:00 AM (207) Plasma RAGE Levels Measured 24 Hours after Lung Transplantation Are Associated with Bronchiolitis Obliterans Syndrome (BOS); R.J. Shah,¹ J.M. Diamond,¹ S. Kawut,¹ E. Cantu,³ N. Wickersham,² L.B. Ware,² J.D. Christie,¹ ¹Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia; ²Division of Allergy, Pulmonary, and Critical Care, Vanderbilt University, Nashville; ³Division of Surgery, University of Pennsylvania, Philadelphia.

8:12 AM (208) IL-23R Locus Polymorphism Is Associated with Higher Mortality, after Lung Transplantation; D. Rutgens,¹ S.E. Verleden,¹ E. Wauters,² A. Vaneylen,¹ V. Robin,¹ D. Lambrechts,² D. Van Raemdonck,¹ G.M. Verleden,¹ B.M. Vanaudenaerde,¹ ¹Lung Transplantation Unit, Lab of Pneumology, KUL, University Hospital Gasthuisberg Leuven, Belgium; ²Vesalius Research Centrum, University Hospital Gasthuisberg, Leuven, Belgium.

8:24 AM (209) Functional TLR4 Polymorphisms Are Associated with Lower Risk of Primary Graft Dysfunction (PGD) after Lung Transplantation; J.M. Diamond,¹ R. Feng,¹ N.J. Meyer,¹ R. Shah,¹ S.M. Kawut,¹ D.J. Lederer,² J.C. Lee,¹ V. Aha,¹ E. Cantu,¹ A. Weinacker,³ S. Bhorade,⁴ V.N. Lama,⁵ J.B. Orens,⁶ J. Sonett,² K.M. Wille,⁷ M. Crespo,⁸ D. Weill,³ B. Kohl,¹ S.M. Arcasoy,² A.S. Shah,⁹ P.D. Shah,⁹ E. Demissie,¹ J.M. Reynolds,¹⁰ J.A. Belperio,¹¹ D. Wilkes,¹¹ L.B. Ware,⁹ S.M. Palmer,¹² J.D. Christie,¹ ¹University of Pennsylvania, Philadelphia, PA; ²Columbia University, New York, NY; ³Stanford University, Palo Alto, CA; ⁴University of Michigan, Ann Arbor, MI; ⁵University of Chicago, IL; ⁶Johns Hopkins University Hospital, Baltimore, MD; ⁷University of Alabama, Birmingham, AL; ⁸University of Pittsburgh, PA; ⁹Vanderbilt University Medical Center, Nashville, TN; ¹⁰Indiana University School of Medicine, Indianapolis, IN; ¹¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ¹²Duke University, Durham, NC.

8:36 AM (210) Toll-Like Receptor 4 Polymorphisms and the Risk of Primary Graft Dysfunction after Lung Transplantation; S. Wauters,¹ E. Wauters,² D. Rutgens,³ J. Somers,¹ S.E. Verleden,³ B.M. Vanaudenaerde,³ D. Lambrechts,² J. van Loon,⁴ G.M. Verleden,^{3,5} D.E. Van Raemdonck,^{1,6} ¹Laboratory for Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium; ²Vesalius Research Center, KU Leuven, Leuven, Belgium; ³Laboratory of Pneumology, KU Leuven, Leuven, Belgium; ⁴Division of Neurosurgery, UZ Leuven, Leuven, Belgium; ⁵Division of Pneumology, UZ Leuven, Leuven, Belgium; ⁶Division of Thoracic Surgery, UZ Leuven, Leuven, Belgium.

8:48 AM (211) WITHDRAWN

9:00 AM (212) Direct Evidence of Chronic Epithelial Injury and Dysregulated Repair in the Lung Allograft; B. Banerjee,^{1,5} M. Musk,² P. Hopkins,⁴ S.M. Stick,^{1,3,5} D.C. Chambers,⁴ A. Kicic,^{1,3,5} ¹Telethon Institute for Child Health Research, Subiaco, WA, Australia; ²Western Australia Lung Transplant Program, Royal Perth Hospital, Perth, WA, Australia; ³Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, WA, Australia; ⁴Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia; ⁵School of Paediatrics and Child Health, University of Western Australia, Nedlands, WA, Australia.

8:00 AM – 9:15 AM

CONCURRENT SESSION 28 (PANORAMA HALL)**Right Ventricle Function**

CHAIRS: Marc de Perrot, MD and Veronica Franco, MD, MSPH

8:00 AM (213) The Relationship between Right Ventricular Pulmonary Arterial Coupling and Right Ventricular Structure and Function in a Porcine Model of Pulmonary Hypertension; J. Guihaire, F. Haddad, O. Mercier, D. Boulate, B. Decante, E. Flecher, P. Darteville, E. Fadel. Laboratory of Surgical Research, Marie Lannelongue Hospital, Le Plessis Robinson, France.

8:12 AM (214) Improvement in Right Ventricular Function after Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension in a Porcine Model; J. Guihaire, O. Mercier, F. Haddad, D. Boulate, B. Decante, P. Dorfmueller, S. Eddahibi, E. Flecher, E. Fadel. Laboratory of Surgical Research, INSERM U999, Marie Lannelongue Hospital, Le Plessis Robinson, France.

8:24 AM (215) Independent Determinants of Septal Curvature in Patients with Pulmonary Arterial Hypertension; F. Haddad,¹ A.Y. Denault,² M. Shkiri,¹ J. Guihaire,³ O. Mercier,³ F. Gomari,¹ E. Ashley,¹ E. Fadel,³ R. Zamanian,¹ I. Schnitzger,¹ ¹Medicine, Stanford University, Stanford, CA; ²Intensive Care Medicine and Anesthesia, Montreal University, Montreal, QC, Canada; ³Surgery, Marie-Lannelongue Surgical Center, Paris, France.

8:36 AM (216) Right Ventricular Size and Function and Its Change over Time Independently Predict Survival in Pulmonary Hypertension; K.A. Stackhouse,¹ G. Devendra,¹ S. Hart,¹ W. Elmallah,¹ J. Lee,¹ T.M. Bashore,² R. Dweik,³ R.A. Krasuski,¹ ¹Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH; ²Cardiovascular Medicine, Duke University Medical Center, Durham, NC; ³Pulmonary Medicine, The Cleveland Clinic, Cleveland, OH.

8:48 AM (217) Echocardiographic Mortality Predictors in Idiopathic Pulmonary Fibrosis; B.N. Rivera-Lebron,¹ P.R. Forfia,² J. Holmes,³ M. Kreider,¹ J. Lee,¹ S.M. Kawut,^{1,3} ¹Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA; ²Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, PA; ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.

9:00 AM (218) Not the Right, but the Left Ventricle Causes the Problem after Lung Transplantation for Pulmonary Artery Hypertension – Awake ECMO for Postoperative LV Remodelling; I. Tudorache,¹ C. Kühn,¹ O. Wiesner,² K. Olsson,² J. Hadem,³ W. Sommer,¹ C. Bara,¹ T. Welte,² J. Gottlieb,² M. Hoepfer,² A. Haverich,¹ G. Warnecke,¹ ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; ³Department of Gastroenterology, Hannover Medical School, Hannover, Germany.

8:00 AM – 9:15 AM

CONCURRENT SESSION 29 (MEETING HALL 5)**Role of Physical Activity in the Pre and Post-Transplant Setting****CHAIRS:** Fabienne Dobbels, PhD and Katherine Hoercher, RN, FAHA**(219) WITHDRAWN**

8:00 AM (220) Comparison between Supervised and Unsupervised Exercise Program after Lung Transplantation; A. Rozanski,¹ F.A. Ferrante,¹ P.H.B. Alves,¹ R.T.B. Ribas,¹ M.L. Caramori,³ P.M. Pego-Fernandes,² M.I.Z. Feltrim.¹ ¹Department of Physical Therapy, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil; ²Department of Thoracic Surgery, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil; ³Department of Pneumology, Heart Institute (InCor), Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil.

8:12 AM (221) Better Event-Free Survival in Ambulatory Heart Transplant (HTx) Candidates Who Are Physically Active and in Good Mood; H. Spaderna,¹ G. Weidner,² V. Bunyamin,¹ For the Waiting for a New Heart Study Group. ¹Psychology, Johannes Gutenberg-University, Mainz, Germany; ²Biology, San Francisco State University, San Francisco, CA; ³Eurotransplant Interantional Foundation, Leiden, Netherlands.

8:24 AM (222) Effects of Exercise Training on Exercise Capacity and Quality of Life in Patients with a Left Ventricular Assist Device (LVAD): A Randomised Controlled Trial; K. Hayes,¹ A.S. Leet,^{1,2} S.J. Bradley,¹ A.E. Holland.^{1,3} ¹Alfred Health, Melbourne, VIC, Australia; ²Baker Heart Institute, Melbourne, Australia; ³La Trobe University, Melbourne, Australia.

8:36 AM (223) Evaluation of a Family Camp Intervention in Pediatric Heart Transplant; S. Urschel,¹ D. Nicholas,² B. Dodd,¹ K. Simard,¹ F. Dicke,³ L.J. West.¹ ¹Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada; ²Faculty of Social Work, University of Calgary, Calgary, AB, Canada; ³Pediatric Cardiology, Alberta Children's Hospital, Calgary, AB, Canada.

8:48 AM (224) Physical Capacity and Health Related Quality of Life before and One Year after Lung Transplantation; K. Heimborg, I. Skog, L. Hansson. Dept of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden.

8:00 AM – 9:15 AM

CONCURRENT SESSION 30 (NORTH HALL)**Innate Immunity and Ischemia Reperfusion Injury****CHAIRS:** Daniel Kreisler, MD, PhD and David S. Wilkes, MD

8:00 AM (225) Protective Effect of Anti-High-Mobility Group Box-1 (HMGB1) Antibody on Pulmonary Ischemia-Reperfusion Injury (IRI) in Miniature Swine; H. Sahara, A. Shimizu, M. Sekijima, K. Setoyama, M. Oku, H. Nishimura, K. Yamada. Xenotransplantation Surgery Section, Frontier Science Research Center, Kagoshima University, Kagoshima, Japan.

8:12 AM (226) Toll-Like Receptor-4 (TLR-4) Signaling in Alveolar Macrophages Undergoing Hypoxia and Reoxygenation; H.E. Merry, P.J. Phelan, M.S. Mulligan. Division of Cardiothoracic Surgery, University of Washington, Seattle, WA.

8:24 AM (227) Neutrophils Are Necessary and Sufficient To Exacerbate Allograft Vasculopathy in Murine Aortic Allografts Exposed to Prolonged Cold Ischemia; C.L. Hancock Friesen,^{1,2} M. So,² T.D.G. Lee.^{1,2,3} ¹Department of Pathology, Dalhousie University, Halifax, NS, Canada; ²Department of Surgery, Dalhousie University, Halifax, NS, Canada; ³Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.

8:36 AM (228) Therapeutic Effect of Surfactant Inhalation on Lungs Donated after Cardiac Death in a Canine Lung Transplantation Model; A. Ohsumi, F. Chen, J. Sakamoto, D. Nakajima, K. Hijiya, H. Motoyama, K. Okita, K. Horita, R. Kikuchi, T. Yamada, H. Sakai, T. Bando, H. Date. Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

8:48 AM (229) Lipopolysaccharide Preconditioning in Lung Ischemia-Reperfusion Injury Is TRAM Dependent; P.J. Phelan, H.E. Merry, M.S. Mulligan. Division of Cardiothoracic Surgery, University of Washington, Seattle, WA.

9:00 AM (230) Pharmacological Preconditioning of Lung with Monophosphoryl Lipid A: A Role of MyD88-Independent Signaling Pathway; A. Shimamoto, H. Fujii, M. Tomita, Y. Yajima, M. Takao, H. Shimpo. Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

9:00 AM – 5:00 PM

EXHIBIT HALL OPEN

(CONGRESS HALL FOYER)

9:15 AM – 9:45 AM

ANNUAL BUSINESS MEETING

(CONGRESS HALL)

9:15 AM – 9:45 AM

COFFEE BREAK/VISIT EXHIBITS/POSTER VIEWING

(CONGRESS HALL FOYER)

9:45 AM – 11:15 AM

PLENARY SESSION (CONGRESS HALL)*The Aging Imperative: Ethics, Economics and Resource Allocation***CHAIRS:** Robert L. Kormos, MD, FRCS(C) and Sharon A. Hunt, MD

9:45 AM *Featured Abstract Presentation (231) Ventricular Assist Device Implantation in the Elderly: Nationwide Outcomes;* A. Kilic,¹ D.D. Yuh,² A.S. Shah,¹ J.V. Conte.¹ ¹Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; ²Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

10:30 AM *The Impact of an Aging Population on Resources for Healthcare and Transplant,* Axel Rahmel, MD, Eurotransplant International Foundation, Leiden, The Netherlands

10:45 AM *Immunobiology – The Immune System from Birth Through End of Life,* Daniel R. Goldstein, MD, Yale New Haven Hospital, New Haven, CT

11:00 AM *How to Incorporate Measures of Frailty in Assessment for Cardiothoracic Surgery,* David J. Lederer, MD, MS, Columbia University, New York, NY

11:15 AM *Shared Decision Making in the Aging Population – How to Help Patient Make Decision Right for Them,* Mi-Kyung Song, RN, PhD, University of North Carolina at Chapel Hill, NC

11:30 AM *'Accountability for Reasonableness' as an Ethical Framework for Scarce Resource Allocation,* Heather J. Ross, MD, MHS, FRCP(c), Toronto General Hospital, Toronto, Canada

11:15 AM – 11:45 AM

COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS

(CONGRESS HALL FOYER)

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 12 (CONGRESS HALL)*MCS Recovery – How Do We Get There***CHAIRS:** Joseph G. Rogers, MD and Hans B. Lehmkuhl, MD

11:45 AM *Effects of LVAD Unloading on the Myocardial Function and Structure,* Stavros G. Drakos, MD, Utah Cardiac Transplant Program, Salt Lake City, UT

NOON *Targeted Adjuvant Therapies to Enhance LVAD-Induced Reverse Remodeling,* Emma Birks, MD, PhD, FRCP, University of Louisville, KY

12:15 PM *How to Monitor the Heart During LVAD Unloading,* Simon Maybaum, MD, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY

12:30 PM *Predictors of LVAD-Induced Sustained Myocardial Recovery,* Michael Dandel, MD, PhD, German Heart Institute, Berlin, Germany

12:45 PM *Panel Discussion*

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 13 (FORUM HALL)*The Leading Edge of Immunosuppression in Heart Transplantation: Evidence, Perspectives and Clinical Practice***CHAIRS:** Eulalia Roig, MD and Guatam V. Ramani, MD

11:45 AM *Recent Trials in Immunosuppression – 2, 3 or 1 Drugs?,* David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ

12:05 PM *mTOR Inhibitors as Rescue or First Line Strategy: A Balancing Act,* Luciano Potena, MD, PhD, University of Bologna, Italy

12:25 PM *Emerging Immunosuppression: Novel Molecules,* Marisa G. Crespo Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

12:45 PM *Putting it Together: A Case Based Moderated Discussion*

MODERATOR: Howard J. Eisen, MD, Drexel University Medical Center, Philadelphia, PA**PANELISTS AND AUDIENCE QUESTIONS AND ANSWERS:**

Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain

Guatam V. Ramani, MD, University of Maryland, Baltimore, MD

David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ

Luciano Potena, MD, PhD, University of Bologna, Italy

Marisa G. Crespo Leiro, MD, Hospital Universitario A Coruña, La Coruña, Spain

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 14 (MEETING HALL 1)*Following the RV Through Thick and Thin***CHAIRS:** Felix Perez-Villa, MD, PhD and Lynne W. Stevenson, MD

11:45 AM *Biventricular Failure and Pulmonary Hypertension: A Unique Pathophysiology,* Robert P. Frantz, MD, Mayo Clinic, Rochester, MD

NOON *Drugs in PH with Left Heart Failure: Role for PH Specific Novel Therapies,* Jean-Luc Vachieri, MD, Erasme University Hospital, Brussels, Belgium

12:15 PM *Treatment of RV Failure After LVAD or Transplant,* Mauro Rinaldi, MD, University of Turin, San Giovanni Battista "Molinette" Hospital, Torino, Italy

12:30 PM *Assessment of CRV Function During RV Support,* Marc A. Simon, MD, MS, University of Pittsburgh, PA

12:45 PM *Panel Discussion*

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 15 (PANORAMA HALL)*Solving the Enigmatic: Cases in Heart and Lung Transplantation***CHAIRS:** Lianne G. Singer, MD, FRCPC and Gerald J. Berry, MD**11:45 AM** *Cardiac Case #1*, Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA**12:05 PM** *Lung Case #1*, Alexandra Rice, FRCPath, Royal Brompton and Harefield Hospitals, London, United Kingdom**12:25 PM** *Lung Case #2*, Joseph J. Maleszewski, MD, Mayo Clinic, Rochester, MN**12:40 PM** *Cardiac Case #2*, Marny Fedrigo, MD, University of Padua, Italy

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 16 (MEETING HALL 4)*Bad Bugs – What Can We Do?***CHAIRS:** Shimon Kusne, MD and Stanley I. Martin, MD**11:45 AM** *Multi-Drug Resistant Gram Negative Infections: What Are The Options?*, Amparo Sole, MD, PhD, Hospital Universitario y Politécnico Ie Fe, Valencia, Spain**NOON** *VRE & MRSA: Can They Be Defeated?*, Stanley I. Martin, MD, The Ohio State University Medical Center, Columbus, OH**12:15 PM** *C. difficile: Can We Keep Our Patients Off the Toilet?*, Michele Estabrook, MD, Washington University School of Medicine, St. Louis, MO**12:30 PM** *Infection Prevention: Get The Bugs Before They Get You!*, Frauke Mattner, PhD, Kliniken der Stadt Koln gGmbH, Cologne, Germany**12:45 PM** *Panel Discussion*

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 17 (MEETING HALL 5)*Pulmonary Hypertension in Chronic Parenchymal Lung Diseases: Does it Matter?***CHAIRS:** Marion Delcroix, MD, PhD and Reda Girgis, MB, BCH**11:45 AM** *Cor Pulmonale in COPD: Not Just Blue Bloaters*, Omar A. Minai, MD, Cleveland Clinic Foundation, Cleveland, OH**NOON** *Importance of Pulmonary Hypertension in ILD*, Oksana Anatolia Shlobin, MD, Inova Fairfax Hospital, Heart and Vascular Institute, Falls Church, VA**12:15 PM** *The Impact of PH in the Lung Transplant Recipient*, Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada**12:30 PM** *Therapy for PH Associated with Lung Disease: What Is The Evidence?*, Pavel Jansa, MD, General University Hospital, Prague, Czech Republic**12:45 PM** *Panel Discussion*

11:45 AM – 1:00 PM

CONCURRENT SYMPOSIUM 18 (NORTH HALL)*Challenges in Pediatric Lung Transplant***CHAIRS:** Bart L. Rottier, MD and Melinda P. Solomon, MD, MSC, FRCPC(C)**11:45 PM** *Small But Not Forgotten*, Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO**NOON** *Second Chances: Re-Transplantation in Pediatric Lung Transplantation*, Christian Benden, MD, St. Vincent's Hospital, Sydney, Australia**12:15 PM** *Bridging to Lung Transplantation in Children*, Charles B. Huddleston, MD, Cardinal Glennon Hospital, St. Louis University School of Medicine, St. Louis, MO**12:30 PM** *Transition to Adult Care: What Could Pediatricians Do Better?*, Joseph M. Pilewski, MD, University of Pittsburgh Medical Center, Pittsburgh, PA**12:45 PM** *Panel Discussion*

1:00 PM – 1:30 PM

BOX LUNCH PICK-UP

(BUFFET, 1ST FLOOR)

1:00 PM – 3:00 PM

LUNCH BREAK

1:00 PM – 3:00 PM

JHLT EDITORIAL BOARD MEETING AND LUNCH

(CLUB B)

1:00 PM – 3:00 PM

**BASIC SCIENCE AND TRANSLATIONAL RESEARCH
COUNCIL MEETING**

(CLUB C)

1:00 PM – 3:00 PM

JUNIOR FACULTY AND TRAINEE COUNCIL MEETING

(CLUB D)

1:00 PM – 3:00 PM

COUNCIL CHAIRS LUNCH MEETING

(MEETING HALL 2)

1:15 PM – 2:15 PM

CONCURRENT SYMPOSIUM 19 (MEETING HALL 1)

Joint ISHLT/ESOT Symposium

CHAIRS: David O. Taylor, MD (ISHLT) and
Rutger J. Ploeg, MD (ESOT)

1:15 PM *Impact of DCD Donors for Thoracic Donation*, Darren
H. Freed, MD, PhD, FRCSC, University of Manitoba, Winnipeg,
Canada

1:30 PM *Are TRegs Ready for the Clinic?*, Carla C. Baan, PhD, Eras-
mus MC, University Medical Center, Rotterdam, The Netherlands

1:45 PM *Clinical Experience with Belatacept: A Balanced View*,
Josep M. Grinyó, MD, Hospital Universitari de Bellvitge,
Barcelona, Spain

2:00 PM *The Impact of ABO Incompatibility on De Novo HLA
Ab Production*, Simon Urschel, MD, University of Alberta, Ed-
monton, Canada



1:15 PM – 2:45 PM**MINI ORAL SESSION 4****(PANORAMA HALL)****Mechanical Circulatory Support II****CHAIRS:** Cumara Sivathanan, FRCS and Martin Schweiger, MD

1:15 PM (232) Improvement in Blood Sugar Control and Insulin Requirements in Patients with a Ventricular Assist Device; K.L. Eleuteri, C.D. Kline, A. El-Banayasy, W. Pae, S. Behzad, E. Stephenson. Penn State Milton S. Hershey Medical Center, Hershey, PA.

1:20 PM (233) Contemporary Continuous Flow Devices: How Much Does It Cost To Keep a Patient on Support for One Year? D.J. Goldstein, A. Sileo, L. Baker, K. Vandervoort, P. Cotter. Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY.

1:25 PM (234) Allosensitization Associated with Continuous Axial Flow Left Ventricular Assist Device Implantation Does Not Affect Outcomes after Heart Transplantation; N. Shankar, J. Geske, M. Gandhi, M. Timmons, B. Boilson, J. Schirger, A. Clavell, R. Frantz, R. Rodeheffer, R. Daly, L. Joyce, B. Edwards, W. Kremers, S.K. Kushwaha, S. Park, N.L. Pereira. Mayo Clinic, Rochester.

1:30 PM (235) Thrombus within the HeartMate II Left Ventricular Assist Device (LVAD): Are All Clots Created Equal?; I.D. Ledford, M. Labedi, A.G. Kfoury, J. Stehlik, R. Alharethi, B.B. Reid, D. Budge, C.H. Selzman, M.P. Revelo, S. Stoker, F. Bader, D.V. Miller. UTAH Cardiac Transplant Program, Salt Lake City, UT.

1:35 PM (236) Left Ventricular Assist Device Exchange Due to Driveline Failure after 1 Year of Support: Incidence, Operative Technique and Clinical Outcomes. Single-Center Experience; A. Stepanenko, N. Dranishnikov, E. Hennig, F. Kaufmann, J. Vierecke, B. Jurmann, T. Drews, H. Lehmkühl, Y. Weng, M. Pasic, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

1:40 PM (237) Reverse Remodeling (RR) Following Rotary Blood Pump Implantation: Is There a Difference between Axial (AFP) and Centrifugal Flow Pumps (CFP)?; K.L. Eleuteri, B. Soleimani, C. Brehm, E. Stephenson, W. Pae, A. El-Banayasy. Penn State Milton S. Hershey Medical Center, Hershey, PA.

1:45 PM (238) Driveline Staging System: Help in Managing Acute and Chronic Driveline Infections; K.L. Eleuteri, A. El-Banayasy, W. Suzanne. Mechanical Circulatory Support, Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA.

1:50 PM (239) Hospital Readmissions Are a Common Occurrence in the Current Era with Continuous Flow (CF) LVADs; E. Kamdar,¹ J. Rasmussen,¹ P. Eckman,¹ K. Liao,¹ B. Milavitz,² M. Colvin-Adams,¹ R. John.¹ ¹University of Minnesota, Minneapolis, MN; ²Fairview Health, Minneapolis, MN.

1:55 PM (240) Continuous Flow Left Ventricular Assist Devices Do Not Impair Central Sympathetic Nerve Traffic; J. Tank,¹ D. Malehsa,² K. Heusser,¹ K. Hegemann,¹ A. Diedrich,³ C. Bara,² J. Jordan,¹ M. Strueben.² ¹Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Lower Saxony, Germany; ²Dept. of Cardiac, Thoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Lower Saxony, Germany; ³Dept. of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN.

2:00 PM (241) Impact of Malnutrition on Early Outcomes Fol-

lowing Implantation of Continuous Flow Left Ventricular Assist Devices; D.J. Goldstein,¹ W. Holman,² N. Moazami,³ R. John,⁴ D. Naftel,² F. Pagani,⁵ ¹Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY; ²Cardiothoracic Surgery, University of Alabama, Birmingham, AL; ³Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis; ⁴Cardiothoracic Surgery, University of Minnesota, Minneapolis; ⁵Cardiothoracic Surgery, University of Michigan, Ann Arbor.

2:05 PM (242) Implantation of a Centrifugal Pump as Left Ventricular Assist Device (LVAD) through a Minimized Approach: Upper-Hemisternotomy Plus Anterior-Lateral-Thoracotomy; J.D. Schmitto, M. Avsar, N. Schuetz, S. Schwabe, D. Malehsa, U. Molitoris, A. Haverich, M. Strueber. Hannover Medical School, Hannover, Germany.

2:10 PM (243) Comparison of Outcomes for Heart Transplantation Following Continuous Versus Pulsatile Flow Ventricular Assist Device Bridging; A. Kilic,¹ J.V. Conte,¹ D.D. Yuh,² A.S. Shah.¹ ¹Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; ²Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

2:15 PM (244) VLAD: A Novel Approach to EMS Education Utilizing an Interactive VAD Medical Simulator; J.A. Gluck, B. Mendes, T. DeVoe, J. Radojevic, D. Wencker. Center for Advanced Heart Failure and Transplant, Hartford Hospital, Hartford, CT.

2:20 PM (245) Translatable Performance with the Total Artificial Heart: The U.S. Post-Market Study; M.J. Slepian,¹ R.G. Smith,¹ D. Covington,¹ M. Acker,² F.A. Arabia,³ S. Clayton,⁴ J.G. Copeland,¹ P.A. DeValeria,³ G.V. Gonzalez-Stawinski,⁵ I.D. Gregoric,⁶ J.W. Long,⁷ R. Morris,² W.E. Pae,⁸ F.D. Pagani,⁹ N.G. Smedira,⁶ C. Smith,¹ V. Kasirajan.¹⁰ ¹Sarver Heart Center, University of Arizona, Tucson, AZ; ²Cardiac Surgery, University of Pennsylvania, Philadelphia, PA; ³Cardiac Surgery, The Mayo Clinic Scottsdale, Scottsdale, AZ; ⁴Cardiac Surgery, Intermountain Medical Center, Salt Lake City, UT; ⁵Cardiac Surgery, The Cleveland Clinic Foundation, Cleveland, OH; ⁶Cardiac Surgery, The Texas Heart Institute, Houston, TX; ⁷Cardiac Surgery, Integris Baptist Medical Center, Oklahoma City, OK; ⁸Cardiac Surgery, Penn State Hershey Medical Center, Hershey, PA; ⁹Cardiac Surgery, The University of Michigan Medical Center, Ann Arbor, MI; ¹⁰Cardiac Surgery, Virginia Commonwealth Medical Center, Richmond, VA.

2:25 PM (246) BiVACOR® – A Magnetically Levitated Rotary Total Artificial Heart; B. Thomson,¹ J. Choudhary,¹ N. Greatrex,³ S. Gregory,² M. Stevens,² S. Diab,² C. McDonald,² K. Dunster,² N. Kurita.⁴ ¹Cardiac Surgery, The Prince Charles Hospital, Brisbane, Australia; ²Critical Care Research Group, The Prince Charles Hospital, Brisbane, Australia; ³Graduate School of Biochemical Engineering, University of New South Wales, Sydney, Australia; ⁴Mechanical Engineering, Gunma University, Kiryu, Japan.

2:30 PM (247) Peak Exercise Capacity in Continuous-Flow Left Ventricular Assist Device Recipients May Be Determined by Right Ventricular Performance; J. González-Costello,¹ N. Uriel,² L. Murray,² S. Shames,² A. Kozco,² D.B. Sims,² K. Morrison,² P.C. Colombo,² H. Takayama,³ Y. Naka,³ L. Gillam,² U.P. Jorde.² ¹Cardiology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain; ²Cardiology, Columbia University Medical Center, New York; ³Cardiothoracic Surgery, Columbia University Medical Center, New York.

2:35 PM (248) Right Ventricular Dysfunction Should Not Preclude Left Ventricular Assist Device Explantation in Patients Exhibiting Left Ventricular Recovery; M. Toma,¹ K. Josan,¹ R. Moss,¹ J. Bashir,² S. Cowan,¹ A. Kaan,¹ A. Ignaszewski,¹ A. Cheung.² ¹Cardiology, St. Paul's Hospital, Vancouver, BC,

Canada; ²Cardiac Surgery, St. Paul's Hospital, Vancouver, BC, Canada.

- 2:40 PM (249) Living with a Total Artificial Heart;** L.S. Savage,¹ M.P. Flattery,¹ J. Salyer.² ¹Department of Nursing, Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA; ²Adult Health and Nursing Systems, School of Nursing, Virginia Commonwealth University, Richmond, VA.

1:15 PM – 2:45 PM
MINI ORAL SESSION 5
Heart Transplantation

(MEETING HALL 4)

CHAIRS: Nicholas Banner, FRCP and Stephan Schueler, MD, PhD, FRCS

- 1:15 PM (250) The Likelihood of Acute Cardiac Rejection Can Be Predicted at Transplantation;** Z. Hollander,^{1,2} V. Chen,¹ R.T. Ng,^{1,3} R. Balshaw,^{1,4} J.E. Wilson-McManus,¹ A. Ignaszewski,⁵ R.W. McMaster,^{1,6} P.A. Keown,^{1,2,5} B.M. McManus.^{1,2,5,7,8} ¹PROOF Centre of Excellence, Vancouver, Canada; ²Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, Canada; ³Computer Science, The University of British Columbia, Vancouver, Canada; ⁴Statistics, The University of British Columbia, Vancouver, Canada; ⁵Medicine, The University of British Columbia, Vancouver, Canada; ⁶Medical Genetics, The University of British Columbia, Vancouver, Canada; ⁷UBC James Hogg Research Centre, Vancouver, Canada; ⁸Institute for Heart + Lung Health, Vancouver, Canada.

- 1:20 PM (251) Incidence, Determinants and Clinical Consequences of Acute Rejection after Conversion from Calcineurin-Inhibitor to Proliferation Signal Inhibitor in Maintenance Heart Transplant Recipients;** J.A. Vázquez de Prada,¹ J. Delgado,² M. Gomez-Bueno,³ M.J. Paniagua,⁴ F. Perez-Villa,⁵ S. Mirabet,⁶ J.M. Arizon,⁷ J.L. Lambert,⁸ L. Almenar,⁹ F. Gonzalez-Vilchez.¹ ¹Cardiology Service, University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain; ²Cardiology Service, University Hospital ¹² de Octubre, Madrid, Spain; ³Cardiology Service, University Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; ⁴Cardiology Service, University Hospital A Coruña, A Coruña, Galicia, Spain; ⁵Cardiology Service, Hospital Clinic, Barcelona, Cataluña, Spain; ⁶Cardiology Service, University Hospital Santa Creu i Sant Pau, Barcelona, Cataluña, Spain; ⁷Cardiology Service, University Hospital Reina Sofia, Cordoba, Andalucía, Spain; ⁸Cardiology Service, University Hospital Central de Asturias, Oviedo, Asturias, Spain; ⁹Cardiology Service, University Hospital La Fe, Valencia, Spain.

- 1:25 PM (252) Sirolimus Based Immunosuppression Attenuates Cardiac Allograft Vasculopathy Progression by Decreasing Fibrotic Component of Coronary Atherosclerotic Plaque;** E. Reichlin, Y. Matsuo, N.L. Pereira, B.S. Edwards, R.P. Frantz, A.L. Clavell, R.J. Rodeheffer, B.A. Boilson, J.A. Schirger, A. Lerman, S.S. Kushwaha. William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN; Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN; Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.

- 1:30 PM (253) Long-Term Renal Function in the TICTAC Trial: Outcomes beyond 5 Years;** D.A. Baran, C. Guerrero-Miranda, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, S. Pardi, M. Camacho, M.J. Zucker. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.

- 1:35 PM (254) Highly Sensitive Transplant Rejection Surveillance Using Targeted Detection of Donor Specific Cell Free**

DNA; M. Hidestrand,¹ S. Zangwill,^{2,4} A. Tomita-Mitchell,^{1,4} A. Oliphant,³ P. Hidestrand,^{2,4} C. Castleberry,² G. Stendahl,⁴ M. Otto,⁴ H. Liang,¹ M. Goetsch,¹ T. Ellis,⁵ B. Shames,¹ P. Simpson,¹ S. Bergen,^{2,4} J. Tweddell,^{1,2,4} M.E. Mitchell.^{1,4} ¹Surgery, Medical College of Wisconsin, Milwaukee, WI; ²Pediatrics, Medical College of Wisconsin, Milwaukee, WI; ³Aria Diagnostics, San Jose, CA; ⁴Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee, WI; ⁵Blood Center of Wisconsin, Milwaukee, WI.

- 1:40 PM (255) Predictors of Acute Rejection or Renal Function Improvement in Cardiac Transplant Patients with Renal Insufficiency;** A. Zuckermann,¹ H. Eisen,² S. See Tai,³ H. Li,³ C. Hahn,³ M.G. Crespo-Leiro.⁴ ¹AKH Wien, Vienna, Austria; ²Drexel University College of Medicine, Philadelphia, PA; ³Wyeth Pharmaceuticals (now Pfizer), Collegeville, PA; ⁴Hospital Universitario A Coruna, La Coruna, Spain.

- 1:45 PM (256) Use of Thymoglobulin after Heart Transplantation: Is There a Role in African American Patients?;** E. Coleman, J. Patel, L. Czer, J. Mirocha, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

- 1:50 PM (257) An Intensive Endomyocardial Biopsy (EMB) Surveillance Strategy Is Not Superior to a Conservative Strategy To Reduce Post Transplant Events: A 5-Year Follow-Up Study;** C.M. Orrego,¹ A.M. Cordero-Reyes,¹ J.D. Estep,¹ M. Loebe,¹ G. Torre-Amione.^{1,2} ¹The Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, TX; ²Cardiology, Hospital San Jose TEC de Monterrey, Monterrey, NL, Mexico.

- 1:55 PM (258) Panel Reactive Antibody in Bridge to Transplant Left Ventricular Assist Device Patients: Impact on Patient Survival after Cardiac Transplant;** J.R. Trivedi, M.S. Slaughter, K.C. McCants, E.J. Birks, A. Meyer, M.L. Williams. University of Louisville, Louisville, KY.

- 2:00 PM (259) The Clinical Outcomes of Prolonged Donor Ischemic Time in Adult Patients Undergoing Heart Transplantation. A Single Center Experiences in Canada;** M. Mutsuga,¹ S. Wang,² R. MacArthur,² J. Mullen,² D. Modry,² D. Ross,² S. Meyer.² ¹Cardiac Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; ²Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada.

- 2:05 PM * (260) Is Metabolic Syndrome Important in the Development of Cardiac Allograft Vasculopathy in Heart Transplantation Patients?;** I. Sanchez-Lazaro,¹ J.M. Sanchez-Gomez,¹ L. Martinez-Dolz,¹ L. Almenar-Bonet,¹ R. Cortes-Vergaz,² F. Buendia Fuentes, E. Rosello-Lleti,² M. Portoles-Sanz,² M. Rivera-Otero,² A. Salvador-Sanz.¹ ¹Heart Failure and Transplantation Unit, Cardiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; ²Research Center, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

*to be presented as poster in Poster Session 2

- 2:10 PM (261) Optical Coherence Tomography for Detection of Cardiac Allograft Vasculopathy (OCTCAV Study);** S.J. Khandhar,¹ H. Yamamoto,² J.J. Teuteberg,¹ M.A. Shullo,³ H.G. Bezerra,² M.A. Costa,² M. Ramratnam,¹ D.M. McNamara,¹ J.S. Lee,¹ O.C. Marroquin,¹ S.R. Mulukutla,¹ C. Toma.¹ ¹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH; ³Department of Pharmacy and Therapeutics, University of Pittsburgh, PA.

- 2:15 PM (262) Markov Chain Analysis of Time Dependent Changes in AMR Using the 2011 ISHLT pAMR Classification;** G. Snow, J. Stehlik, E.H. Hammond, K. Brunisholz, E. Gilbert,

R. Alharethi, M. Everitt, P. Revelo, D. Budge, F. Bader, D.V. Miller, K. Molina, A. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

2:20 PM (263) Multicentric Validation of RADIAL Score for Primary Graft Failure Prediction; M.D.G. Cosío,¹ J. Segovia,¹ M. Gómez Bueno,¹ L. Almenar,² J. Delgado,³ J.M. Arizon,⁴ F. Gonzalez-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹⁴ F. Perez Villa,⁷ J. Fernández-Yañez,⁸ J.L. Lambert,⁹ N. Manito,¹⁰ L. Fuente,¹¹ M.L. Sanz Julve,¹² D. Pascual,¹³ G. Rábago,¹⁵ L.A.A. Pulpón.¹ ¹Heart Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain; ²Hospital La Fe, Valencia, Spain; ³Hospital ¹² de Octubre, Madrid, Spain; ⁴Hospital Reina Sofía, Córdoba, Spain; ⁵Hospital Valdecilla, Santander, Spain; ⁶Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; ⁷Hospital Clínico, Barcelona, Spain; ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁹Hospital Universitario Central de Asturias, Oviedo, Spain; ¹⁰Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; ¹¹Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ¹²Hospital Miguel Servet, Zaragoza, Spain; ¹³Hospital La Arrixaca, Murcia, Spain; ¹⁴Hospital Sant Pau, Barcelona, Spain; ¹⁵Clinica Universitaria de Navarra, Navarra, Spain.

2:25 PM (264) Five-Year Survival Trends in Heart Transplantation Based on Recipient Age over Two Decades of Multi-Institutional Experience; J.F. George,¹ S.V. Pamboukian,² R.N. Brown,¹ J.K. Kirkin,¹ J.A. Tallaj,² ¹Surgery, University of Alabama, Birmingham, AL; ²Medicine, University of Alabama, Birmingham, AL.

2:30 PM (265) Tricuspid Regurgitation and Surgical Technique Influences Outcome after Heart Transplantation; M. Carlström,¹ S. Dahlin,¹ J. Gäbel,¹ R. Doanhu,¹ J. Hörnlige,¹ A. Jeppsson,¹ V. Sigurdardottir,² G. Dellgren.^{1,2} ¹Cardiothoracic Surgery and Anesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.

2:35 PM (266) High Intensity Interval Training Improves Muscle Strength and VO₂ peak in Heart Transplant Recipients; K. Nytrøen,¹ L.A. Rustad,^{1,2} I. Holm,³ S. Aakhus,¹ L. Gullestad.^{1,4} ¹Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; ³Division of Surgery and Clinical Neuroscience, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁴Faculty of Medicine, University of Oslo, Oslo, Norway.

2:40 PM (267) Health Behaviors as Correlates of Quality of Life in the Waiting for a New Heart Study; V. Bunyamin,¹ H. Spaderna,¹ G. Weidner,² For the Waiting for a New Heart Study Group. ¹Health Psychology, Institute of Psychology – Johannes Gutenberg-University Mainz, Mainz, Rheinland Pfalz, Germany; ²Department of Biology, San Francisco State University, Tiburon, CA.

1:15 PM – 2:45 PM

MINI ORAL SESSION 6

(MEETING HALL 5)

Lung Transplantation, Infectious Diseases and Donor Management

CHAIRS: Kenneth R. McCurry, MD and Vincent G. Valentine, MD

1:15 PM (268) Older Donor Lungs: A Neglected Source of Transplantable Organs; G.I. Snell, L.E. Mitchell, A.P. Griffiths, H.M.

Whitford, T.J. Williams, G.P. Westall, B.J. Lewey. Lung Transplant Service, Alfred Hospital, Melbourne, VIC, Australia.

1:20 PM (269) The Utilization of Donors Aged 65 and Older Is Associated with Decreased Survival Following Lung Transplantation; G.J. Bittle, P.G. Sanchez, Z.N. Kon, A.C. Watkins, J.P. Garcia, B.P. Griffith. Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD.

1:25 PM (270) Ex Vivo Treatment of Infection in Human Donor Lungs; R. Bonato,¹ T.N. Machuca,¹ M. Cypel,¹ J.C. Yeung,¹ T. Saito,¹ M. Liu,¹ D.M. Hwang,² S. Husain,² S. Keshavjee.¹ ¹Latter Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada; ²Department of Pathology, University Health Network, Toronto, ON, Canada; ³Division of Infectious Diseases and Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada.

1:30 PM (271) Non Heparinisation Does Not Impair Outcome of Lung Transplantation from Maastricht Category III Donation after Circulatory Death (DCD) Donors; A. Iyer, M. Harkess, A. Havryk, M. Plit, M. Malouf, P. Jansz, E. Granger, K. Dhital, P. Spratt, A.R. Glanville. Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia.

1:35 PM (272) Ex-Vivo Perfusion and Transplantation of Initially Rejected Donor Lungs; A. Wallinder,¹ S.-E. Ricksten,³ C. Hansson,³ G.C. Riise,² M. Silverborn,¹ H. Liden,¹ G. Dellgren.² ¹Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden; ³Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden.

1:40 PM (273) Seroconversion and Safety of H1N1 Vaccination in Lung Transplant Recipients: Data from the Brussels Lung Transplant Group; A. Hombrouck,¹ A. Lemy,² M. Dumoncaux,³ M. Estenne,³ A. Belhaj,⁴ B. Rondelet,⁴ I. Thomas,¹ C. Knoop.³ ¹Section Viral Diseases, Scientific Institute of Public Health, Brussels, Belgium; ²Nephrology, Erasme University Hospital, Brussels, Belgium; ³Chest Medicine, Erasme University Hospital, Brussels, Belgium; ⁴Heart and Lung Transplantation Surgical Clinic, Erasme University Hospital, Brussels, Belgium.

1:45 PM (274) Extensive- and Pandrug-Resistant (XDR/PDR) Acinetobacter baumannii (Ab) and KPC-Producing Klebsiella pneumoniae (KPC) Primarily Cause Pneumonia (PNA) among Lung and Heart Transplant (LTR, HTR) Recipients, and Outcomes May Be Improved by Treatment with a Carbenem + Colistin (CBM+COL); R.K. Shields, M.H. Nguyen, E.J. Kwak, F.P. Silveira, R.C. Abdel-Massih, J. Pilewski, M. Crespo, Y. Toyoda, C. Bermudez, J.K. Bhamra, C.J. Clancy. University of Pittsburgh Medical Center, Pittsburgh, PA.

1:50 PM (275) Early-Onset Staphylococcus aureus Disease (SA dz) Is Associated with Chronic Rejection and Death among Lung Transplant Recipients (LTR); R.K. Shields, C.J. Clancy, L. Mincec, E.J. Kwak, F.P. Silveira, R. Abdel-Massih, J. Pilewski, M. Crespo, Y. Toyoda, C. Bermudez, J.K. Bhamra, M.H. Nguyen. University of Pittsburgh Medical Center, Pittsburgh, PA.

1:55 PM (276) Paired Donor Lung Expression Suggest Key Effectors in Primary Graft Dysfunction; E. Cantu,¹ L. Erhunmwunsee,² R. Feng,³ N.J. Meyer,⁴ J.M. Diamond,⁵ R.J. Shah,⁵ S. Rao,⁶ S.S. Lin,² R.D. Davis,² J.D. Christie.⁴ ¹Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ²Department of Surgery, Duke University Medical Center, Durham, NC; ³Center for Clinical Epidemiology and Biostatistics,

University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ⁴Pulmonary, Allergy, and Critical Care Division, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ⁵Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; ⁶Penn Molecular Profiling Facility Bioinformatics Group, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

- 2:00 PM (277) Lung Transplant Surgery on Cardiocirculatory Support: Extracorporeal Membrane Oxygenation Outcompetes Cardiopulmonary Bypass;** F. Jus,¹ C. Kühn,¹ I. Tudorache,¹ W. Sommer,¹ M. Avsar,¹ T. Fuehner,² T. Welte,² J. Gottlieb,² A. Haverich,¹ G. Warnecke.¹ ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
- 2:05 PM (278) Grade 3 Primary Graft Dysfunction after Lung Transplantation: A Heterogeneous Population;** M. Cypel, R. Zamel, K. Yasufuku, A. Pierre, M. DePerrot, L.G. Singer, M. Liu, S. Keshavjee, T.K. Waddell. University of Toronto, Toronto, ON, Canada.
- 2:10 PM (279) Renal Function Preservation with Everolimus after Lung Transplant;** S. Schmeer,¹ Y. Raviv,¹ D. Rosengarten,¹ B. Medalion,² M.R. Kramer.¹ ¹Pulmonary Institute, Rabin Medical Center (RMC), Beilinson Campus, Petah Tiqwa, Israel; ²Thoracic Surgery Unit, Rabin Medical Center (RMC), Beilinson Campus, Petah Tiqwa, Israel.
- 2:15 PM (280) Pharmacokinetic Study of the Conversion from Tacrolimus to Tacrolimus Retard in Stable Lung Transplantation;** A. Méndez,¹ C. Berastegui,¹ M. López-Meseguer,¹ V. Monforte,¹ C. Bravo,¹ A. Blanco,² S. Camós,² L. Pou,² A. Roman.¹ ¹Pneumology, Hospital Universitari Vall d'Hebron, CIBERES, Barcelona, Spain; ²Pharmacy, Hospital Universitari Vall d'Hebron, CIBERES, Barcelona, Spain.
- 2:20 PM (281) Alemtuzumab (Amab) vs. Basiliximab (Bmab) Induction: Impact on Infectious and Non-Infectious Outcomes among Lung Transplant Patients (LT pts);** M.H. Nguyen, C.J. Clancy, M.M. Crespo, J. Pilewski, C. Bermudez, N. Shigemura, J.K. Bhamra, B. Johnson, M. Morrell, R.K. Shields, E.J. Kwak, F. Silveira, Y. Toyoda. University of Pittsburgh, PA.
- 2:25 PM (282) Alemtuzumab Minimizes Airway Ischemic Reperfusion Injury (aIRI), Which Is Associated with Graft Damage and Deaths Post-Lung Transplant (LT);** M.M. Crespo,¹ J.M. Pilewski,¹ C.J. Clancy,² B. Johnson,¹ C. Bermudez,³ J. Bhamra,³ Y. Toyoda,⁴ S.S. Haider,¹ M. Morrell,¹ N. Shigemura,³ M.H. Nguyen.² ¹Division of Pulmonary, Allergy and Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Division of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴Cardiothoracic, Temple University Hospital, Philadelphia, PA.
- 2:30 PM (283) A Comparative Study of Bronchial Artery Revascularization in Lung Transplantation;** K. Karam, L. Thuita, M.M. Budev, M.S. Machuzak, D.R. Johnston, K.R. McCurry, D.P. Mason, S.C. Murthy, E.H. Blackstone, G.B. Pettersson. Cleveland Clinic, Cleveland, OH.
- 2:35 PM (284) Evolution to Twice Daily Bolus Intravenous (IV) Tacrolimus (TAC): Optimizing Safety and Efficacy Early Post Lung Transplant (LTx);** L.E. Mitchell,¹ G.I. Snell,¹ S.P. Ivulich,² G.P. Westall,¹ B.J. Levey.¹ ¹Lung Transplant Service, The Alfred Hospital, Melbourne, VIC, Australia; ²Pharmacy, The Alfred Hospital, Melbourne, VIC, Australia.

- 2:40 PM (285) A Panel of Lung Injury Biomarkers Enhances the Definition of Primary Graft Dysfunction (PGD) after Lung Transplantation for Early Clinical Studies;** R.J. Shah,¹ J.M. Diamond,¹ S.M. Kawut,¹ J.C. Lee,¹ D.J. Lederer,² S. Bhorade,³ M. Crespo,⁴ E.J. Demissie,¹ J.A. Belperio,⁵ V.N. Lama,⁶ J.B. Orens,⁷ S.M. Palmer,⁸ J. Reynolds,⁹ A. Shah,⁷ P. Shah,¹⁰ K.M. Wille,¹¹ A. Weinacker,¹² D.S. Weill,¹² D. Wilkes,⁹ L.B. Ware,¹⁰ J.D. Christie.¹ ¹Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA; ²Columbia University, New York City; ³University of Chicago; ⁴University of Pittsburgh; ⁵University of California, Los Angeles; ⁶University of Michigan, Ann Arbor; ⁷Johns Hopkins University, Baltimore; ⁸Duke University, Durham; ⁹Indiana University, Indianapolis; ¹⁰Vanderbilt University, Nashville; ¹¹University of Alabama, Birmingham; ¹²Stanford University, Palo Alto.

1:15 PM – 2:45 PM

MINI ORAL SESSION 7

(NORTH HALL)

Basic Science and Immunobiology, Heart Transplantation and Infectious Diseases

CHAIRS: Roland G. Nador, MD and Bruce R. Rosengard, MD, FRCS

- 1:15 PM (286) Altered Naive and Effector FOXP3+ T-Cell Frequencies after Thymectomy and Heart Transplantation (HTx) in Infants;** E. Dijke,¹ S. Urschel,¹ I. Larsen,¹ K. Matthews,² E. Pahl,² R. Chincock,³ L. West.¹ ¹Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Pediatrics, Children's Memorial Hospital, Chicago, IL; ³Pediatrics, Loma Linda University and Children's Hospital, Loma Linda, CA.
- 1:20 PM (287) Xenotransplant Immunology; Impact on Bioprosthetic Materials;** C.G.A. McGregor,^{1,2} H. Kogelberg,² G.W. Byrne.^{1,2} ¹Institute of Cardiovascular Sciences, University College London, London, Westminster, United Kingdom; ²Department of Surgery, Mayo Clinic, Rochester, MN.
- 1:25 PM (288) Non-HLA Antibodies and Risk of Rejection after Heart Transplantation: Profiling with Antigen Microarrays;** A. Chruscinski,¹ F. Huang,¹ K. Tincam,¹ V. Rao,² G. Levy,¹ H. Ross.¹ ¹Multi Organ Transplant, UHN-Toronto General Hospital, Toronto, ON, Canada; ²Cardiovascular Surgery, UHN-Toronto General Hospital, Toronto, ON, Canada.
- 1:30 PM (289) In Situ Imaging of Neonatal Tolerance Induction: Donor Bone Marrow and Spleen Cells Home Differently and Induce Tolerance by Distinct/Overlapping Mechanisms;** R.A. Bascom, K. Tao, S.L. Tollenaar, L.J. West. Pediatrics, Surgery and Immunology, University of Alberta, Edmonton, Canada.
- 1:35 PM (290) Ferret Lung Transplant: An Orthotopic Model for Obliterative Bronchiolitis;** H. Sui, L. Brooks, J.A. Klesney-Tait, A. Olivier, D. Meyerholz, P. Sanchez, N. Zavazava, J.F. Engelhardt, K.R. Parekh. Carver College of Medicine, University of Iowa, Iowa City, IA.
- 1:40 PM (291) Immunogenicity of Umbilical Cord Lining-Derived Mesenchymal Stromal Cells;** M. Stubbendorff,¹ J. Kawalkowska,¹ T. Deuse,¹ T.T. Phan,² K. Bieback,³ K. Atkinson,⁴ T.H. Eiermann,⁵ H. Reichenspurner,¹ R.C. Robbins,⁶ S. Schrepfer.^{1,6} ¹ITSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Surgery, Yong Lin University, Singapore, China; ³Transfusion Medicine, University Mannheim, Mannheim, Germany; ⁴University Queensland, St.

Lucia, Australia; ⁵HLA Lab, University Hospital Hamburg, Hamburg, Germany; ⁶CT Surgery, Stanford University, Stanford.

- 1:45 PM (292) Physiologic and Biochemical Profile of Clinically Rejected Lungs on a Normothermic Ex Vivo Lung Perfusion Platform;** T.J. George,¹ G.J. Arnaoutakis,¹ C.A. Beaty,¹ S.K. Jandu,² D.E. Berkowitz,² L. Santhanam,² A.S. Shah.¹ ¹The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²The Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.
- 1:50 PM (293) Novel Nebulized Arginase Inhibitor Increases Human Lung Compliance during Normothermic Ex Vivo Lung Perfusion;** T.J. George,¹ G.J. Arnaoutakis,¹ C.A. Beaty,¹ S.K. Jandu,² L. Santhanam,² D.E. Berkowitz,² A.S. Shah.¹ ¹The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²The Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD.
- 1:55 PM (630) Donor Pharmacologically Induced Hypothermia with DADLE Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury through Akt, ERK1/2 Signaling;** A. Rungtatscher, A. Giacomazzi, D. Linardi, A. Mazzucco, G. Faggian. Department of Surgery, Section of Cardiac Surgery, University of Verona, Verona, Italy.
- 2:00 PM (295) Combined aGPIIb and aGPIIb/IIIa Blockade Prevents Platelet Sequestration in a Pig-to-Human Lung Perfusion Model;** L. Burdorf,¹ T. Zhang,¹ E. Rybak,¹ I.I. Salles,² K. Broos,² E. Welty,¹ C. Avon,¹ A. Laaris,¹ X. Cheng,¹ D. Ayares,³ H. Deckmyn,² A.M. Azimzadeh,¹ R.N. Pierson.¹ ¹Department of Surgery, University of Maryland, Baltimore, MD; ²Laboratory for Thrombosis Research, KU Leuven Campus Kortrijk, Leuven, Belgium; ³Revivicor, Inc., Blacksburg.
- 2:05 PM (296) Time-Course Microarray Analysis of Rejected Human Donor Lungs during 12 Hours of Acellular Normothermic Ex Vivo Lung Perfusion;** J.C. Yeung, P.C. Boutros, R. Zamel, M. Cypel, X.-H. Bai, Y. Matsuda, T.K. Waddell, M. Liu, S. Keshavjee. University of Toronto, Toronto, Canada.
- 2:10 PM (297) Non-HLA Antibody Screening after Heart Transplantation Identifies High Risk for Cardiac Allograft Vasculopathy;** M.J. Barten,¹ D. Dragun,² M.-T. Dieterlen,¹ S. von Salisch,¹ J. Gerbade,¹ S. Klein,¹ S. Dhein,¹ F.W. Mohr,¹ H.B. Bittner.¹ ¹Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany; ²Clinic for Nephrology and Intensive Care Medicine, Charite Campus Virchow Clinic, Berlin, Germany.
- 2:15 PM (298) Pre-Transplant Non-Cytotoxic Anti-HLA Antibodies Predict Multiple Adverse Events after Heart Transplantation;** L. Potena,¹ A. Bontadini,² F. Fruet,² S. Iannelli,² F. Barberini,¹ M. Nardoza,¹ V. Manfredini,¹ M. Masetti,¹ G. Magnani,¹ F. Grigioni,¹ A. Branzi.¹ ¹Cardiovascular Department, University of Bologna, Bologna, Italy; ²Immunogenetics Unit, Academic Hospital S. Orsola-Malpighi, Bologna, Italy.
- 2:20 PM (299) Cardiac Allograft Remodeling Is Associated with Increased Inflammatory Burden of Coronary Atherosclerotic Plaque;** E. Raichlin, Y. Matsuo, S.S. Kushwaha, A.L. Clavell, R.P. Frantz, R.J. Rodeheffer, B.S. Edwards, B.A. Boilsson, J.A. Schinger, A. Lerman, N.L. Pereira. William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN; Division of Cardiovascular Diseases, Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN; Division of Cardiovascular Diseases, University of Nebraska Medical Center, Omaha, NE.
- 2:25 PM (300) Low Absolute Lymphocyte Count at Six Months Post-Heart Transplantation Predictive of Late-Onset CMV;** T. Khuu,¹ R. Cheng,² A.S. Baas,² D. Cruz,² A. Nsair,² B.

Kubak,³ A. Ardehali,⁴ R.J. Shemin,⁴ A. Hickey,² M.C. Deng.² ¹Heart Transplant, University of California, Los Angeles, CA; ²Medicine, Division of Cardiology, University of California, Los Angeles, CA; ³Medicine, Division of Infectious Disease, University of California, Los Angeles, CA; ⁴Surgery, Division of Cardiothoracic Surgery, University of California, Los Angeles, CA.

- 2:30 PM (301) Infectious Complications of Desensitization Therapy: Is the Cure Worse Than the Disease?;** L. Czer, J. Patel, M. Kittleston, M. Rafiei, L. Stern, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.
- 2:35 PM (302) Heart Transplantation as Atherapeutic Intervention in Multi Drug Resistant Ventricular Assist Related Infections;** A. Gkouziouta, S. Xatzianastasiou, D. Zarkalis, A. Manginas, G. Karavoliag, G. Saroglou, S. Adamopoulos. Heart Transplant Unit, Onassis Cardiac Surgery Center, Athens, Greece.
- 2:40 PM (303) Pre-Transplant Antibodies to Self-Antigens and the Subsequent Development of Donor-Specific HLA Antibodies after Lung Transplantation;** R. Hachem,¹ V. Tiriveedhi,² A. Patterson,³ E. Trulock,¹ T. Mohanakumar.² ¹Pulmonary & Critical Care, Washington University School of Medicine, St. Louis, MO; ²Pathology & Immunology, Washington University School of Medicine, St. Louis, MO; ³Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.

3:00 PM – 4:30 PM

PLENARY SESSION

(FORUM HALL)

New Horizons

- CHAIRS:** James K. Kirklin, MD and Paul A. Corris, MB, FRCP
- 3:00 PM Bioartificial Organs – (Re)building A New Lung or Heart,** Harald C. Ott, MD, Massachusetts General Hospital, Boston, MA
- 3:15 PM Functional Imaging – New Windows into Allograft Function,** Markus Schwaiger, MD, Klinikum rechts der Isar der TU Muenchen, Munich, Germany
- 3:30 PM Stem Cells – Are We There Yet?,** Sonja Schrepfer, MD, PhD, University Heart Centre Hamburg, Germany
- 3:45 PM Allograft Tolerance: Can We Find the Path?** Sophie Brouard, PhD, CNRS/Nantes University, Nantes, France
- 4:05 PM Why is Pulsatile Flow Important – Is Pulsatility Needed?,** Mandep R. Mehra, MD, MBBS, FACC, FACP, Brigham and Women's Hospital, Boston, MA

4:30 PM – 5:00 PM

COFFEE BREAK/VISIT EXHIBITS/VIEW POSTERS
(CONGRESS HALL FOYER)

4:30 PM – 5:00 PM

2013 SCIENTIFIC PROGRAM COMMITTEE MEETING
(CLUB B)



5:00 PM – 11:59 PM
EXHIBIT HALL TEAR DOWN
 (CONGRESS HALL FOYER)

5:00 PM – 11:59 PM
POSTER HALL TEAR DOWN
 (CONGRESS HALL FOYER)

5:00 PM – 6:15 PM

CONCURRENT SYMPOSIUM 20 (MEETING HALL 5)

Self-Management in End Stage Heart and Lung Disease and Transplantation

CHAIRS: Bronwyn J. Lewey, RN, BEd Stu Grad Dip Clin Epi and Nancy P. Blumenthal, CRNP

5:00 PM *Self-Management as Part of Chronic Illness Management (CIM)*, Christiane Kugler, PhD, University Witten, Witten, Germany

5:15 PM *Health Care System Factors Related to Self Management*, Lut Berben, PhD, RN, Institute for Nursing Science, University of Basel, Switzerland

5:30 PM *Management of New Life Roles*, Michael G. Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center-Fairview, Minneapolis, MN

5:45 PM *Self-Management in Pediatrics*, Samantha Anthony, PhD, MSW, RSW, Hospital for Sick Children/McMaster University, Toronto, Canada

6:00 PM *Self-Management via the Virtual Heart Clinic*, Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, Canada

5:00 PM – 6:15 PM

CONCURRENT SESSION 31 (FORUM HALL)

Right Ventricle – Staying Alive

CHAIRS: Benjamin Sun and Antonio Loforte, MD

5:00 PM (304) *Clinical Use of the HeartWare HVAD for Biventricular Support*; M. Strueber,¹ J. Schmitto,¹ C. Fegbeutel,¹ K. Chorprenning,² M. Avsar,¹ D. Malehsa,¹ D. Tamez,² A. Haverich.¹ ¹Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Lower Saxony, Germany; ²HeartWare Inc., Miami Lakes.

5:12 PM (305) *Bridge to Transplant Using BiVAD or Total Artificial Heart: Is There a Survival Difference?*; A. Nguyen, M. Pozzi, C. Mastroianni, P. Iepince, P. Alain, P. Léger, M. Kirsch. Department of Cardiothoracic Surgery, La Pitié-Salpêtrière Hospital, Paris, France.

5:24 PM (306) *Concomitant Tricuspid Valve Procedure Reduces Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device (LVAD) Implantation*; V. Piacentino III,¹ A.M. Ganapathi,¹ M. Stafford-Smith,² C.B. Patel,³ A. Barbas,¹ A.J. Lodge,¹ A.A. Simeone,¹ J.G. Rogers,³ C.A. Milano.¹ ¹Cardiac and Thoracic Surgery, Duke University Medical Center, Durham, NC; ²Cardiothoracic Anesthesia, Duke University Medical Center, Durham, NC; ³Cardiology, Duke University Medical Center, Durham, NC.

5:36 PM (307) *Mechanical Circulatory Support for Right Ventricular Failure: The Tandem Heart in Right Ventricular Support (THRIVE) Registry*; N.K. Kapur,¹ V. Paruchuri,¹ A. Jagannathan,¹ J. Finley,² A.K. Chakrabarti,³ D. Steinberg,⁴ N.M. Orr,⁵ M. Tempelhof,⁶ M.S. Kiernan,¹ D.T. Pham,¹ D. DeNofrio.¹ ¹The Cardiovascular Center, Tufts Medical Center, Boston, MA; ²Interventional Cardiology, Thomas Jefferson University, Philadelphia, PA; ³Interventional Cardiology, Beth Israel Deaconess Medical Center, Boston, MA; ⁴Interventional Cardiology, Medical University of South Carolina, Charleston, SC; ⁵Cardiology, St. Francis Hospital, Roslyn, NY; ⁶Interventional Cardiology, Northwestern University, Chicago, IL.

5:48 PM (308) *Right Ventricular Failure in Patients with Continuous-Flow Left Ventricular Assist Devices: Incidence and Risk Factors from INTERMACS*; M.S. Kiernan,¹ N.K. Kapur,¹ D.T. Pham,¹ J.K. Kirklin,² D.C. Naftel,² F.D. Pagani,³ R.L. Kormos,⁴ D. DeNofrio.¹ ¹Cardiovascular Center, Tufts Medical Center, Boston, MA; ²Cardiovascular Division, University of Alabama, Birmingham, AL; ³Cardiac Surgery, University of Michigan, Ann Arbor, MI; ⁴Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

6:00 PM (309) *The Bad Oeynhausen Experience with Temporary Right Ventricular Assist Device*; N. Aissaoui, M. Morshuis, J. Bürgermann, K. Hakim, J. Gummert. Department of Thoracic and Cardiovascular Surgery, Heart & Diabetes Center North Rhine-Westphalia, Bad Oeynhausen, Germany.

5:00 PM – 6:15 PM

CONCURRENT SESSION 32 (MEETING HALL 1)**End Stage Congenital Heart Disease: Opportunities and Challenges****CHAIRS:** Daphne T. Hsu, MD and Michael P. Carboni, MD

5:00 PM (310) Heart Transplantation for Adults with Congenital Heart Disease: Results in the Modern Era; J.K. Bhama,¹ J. Shulman,¹ C.A. Bermudez,¹ A. Bansal,¹ D. Zaldonis,¹ R. Ramani,¹ J.J. Teuteberg,¹ M. Shullo,¹ D.M. McNamara,¹ R.L. Kormos,¹ Y. Toyoda.² ¹Heart & Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

5:12 PM (311) Late Mortality after Heart Transplantation in Adults with Congenital Heart Disease; L.J. Burchill,¹ L.B. Edwards,² M.B. Hertz,⁵ J.I. Stehlik,³ A.I. Dipchand,⁴ H.J. Ross.¹ ¹Division of Cardiology, University Health Network, Toronto, ON, Australia; ²International Society of Heart and Lung Transplantation, Addison, TX, Australia; ³Cardiology Division, University of Utah School of Medicine, Salt Lake City, UT, Australia; ⁴Cardiology, Hospital for Sick Children, Toronto, ON, Canada; ⁵PACC Medicine, University of Minnesota, Minneapolis, MN.

5:24 PM (312) Predicting 1-Year Survival in Pediatric Heart Transplant Candidates with Congenital Heart Disease: An Analysis of the PHTS Database; K.R. Schumacher,¹ D. Naftel,² M. Tresler,² R. Kirk,³ C. Almond,⁴ T.P. Singh,⁴ R. Spicer,⁵ T.M. Hoffman,⁶ D. Hsu,⁷ C. Canter,⁸ M. Zamberlan,¹ R.J. Gajarski.¹ ¹Congenital Heart Center, University of Michigan, Ann Arbor, MI; ²University of Alabama, Birmingham, AL; ³Freeman Hospital, Newcastle Upon Tyne, United Kingdom; ⁴Boston Children's Hospital, Boston, MA; ⁵Cincinnati Children's Hospital, Cincinnati, OH; ⁶Nationwide Children's Hospital, Columbus, OH; ⁷The Children's Hospital at Montefiore, New York, NY; ⁸St. Louis Children's Hospital, St. Louis, MO.

5:36 PM (313) The Fontan Outcomes Need To Be Assessed in Adults Now (FONTAN) Study: A Prospective Study; L.J. Burchill, A.H. Kovacs, R.M. Wald, A. Soufi, E.N. Oechslin, H.J. Ross. Toronto Congenital Cardiac Centre for Adults/Toronto General Hospital, University Health Network, Toronto, ON, Canada.

5:48 PM (314) Combined Heart-Liver Transplantation (HLT) for Failed Single Ventricle/Fontan Physiology; P. Vallabhajosyula,¹ C. Komlo,¹ M. Molina,² L. Roche,¹ Y. Kim,² L. Goldberg,² A. Pochettino.¹ ¹Cardiovascular Surgery, Hospital of University of Pennsylvania, Philadelphia, PA; ²Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA.

6:00 PM (315) Outcomes of Cardiac Transplantation in Single Ventricle Patients with Plastic Bronchitis – A Multi-Center Report; J.G. Gossett,¹ C. Almond,² R. Kirk,³ S. Zangwill,⁴ M.E. Richmond,⁵ P.F. Kantor,⁶ M.A. Tresler,⁷ S.M. Lenderman,⁷ D.C. Naftel,⁷ K.L. Matthews,¹ E. Pahl.¹ ¹Pediatric Cardiology, Siragusa Transplant Center, Children's Memorial Hospital, Chicago, IL; ²Pediatric Cardiology, Children's Hospital Boston, Boston, MA; ³Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ⁴Pediatric Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI; ⁵Pediatric Cardiology, Columbia University, Morgan Stanley Children's Hospital of New York, New York, NY; ⁶Pediatric Cardiology, Hospital for Sick Children, Toronto, ON, Canada; ⁷University of Alabama, Birmingham, AL.

5:00 PM – 6:15 PM

CONCURRENT SESSION 33 (PANORAMA HALL)**Stealing Beauty after Lung Transplantation****CHAIRS:** Lara Danziger-Isakov, MD, MPH and Todd L. Aster, MD

5:00 PM (316) Pseudomonas Infection Increases Risk of Death and BOS in Lung Transplant Recipients; A. Gregson,¹ X. Wang,² S. Weigt,¹ R. Elashoff,³ D. Ross,¹ R. Saggan,¹ B. Kubak,¹ G. Li,² J. Belperio.¹ ¹Medicine, UCLA, Los Angeles, CA; ²Biostatistics, UCLA, Los Angeles, CA; ³Biomathematics, UCLA, Los Angeles, CA.

5:12 PM (317) Invasive Aspergillosis (IA) in Cystic Fibrosis Patients Undergoing Lung Transplantation, 2006-2010; M.-L. Luong,^{1,2} C. Chaparro,^{1,2,3} A. Stephenson,³ L.G. Singer,^{1,2} S. Azad,¹ S. Keshavjee,¹ V. Waters,⁴ C. Rotstein,^{1,2} E. Tullis,³ S. Husain.^{1,2} ¹The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada; ²Medicine, University Health Network, University of Toronto, Toronto, ON, Canada; ³St. Michael's Hospital Adult Cystic Fibrosis Program, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; ⁴Department of Pediatrics- Division of Infectious Diseases, The Hospital for Sick Kids, Toronto, ON, Canada.

5:24 PM (318) Post Lung Transplant Outcome in Children Varies According to Mycobacterium abscessus Complex Species; P.D. Robinson,^{1,2} K. Harris,³ S. Jerkic,² P. Aurora,² J. Hartley,³ H. Spencer.² ¹Department of Pediatric Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; ²Department of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom; ³Department of Microbiology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

5:36 PM (319) Acidic Gastroesophageal Reflux May Not Predict Earlier Bronchiolitis Obliterans in Pediatric Lung Transplant; C. Towe, S. Sweet, R. Rothbaum, P. Michelson, A. Faro. Pediatrics, Washington University, St. Louis, MO.

5:48 PM (320) Quality of Life in Pediatric Lung Transplantation: Comparing Recipients to Population Mean Values; M. Mann,¹ D. Czyzewski,² J.K. Johnson,¹ J. Schnuck,² M. Mignogna,² G.B. Mallory,¹ M.G. Schechter.¹ ¹Department of Pediatric Pulmonary Medicine, Baylor College of Medicine, Houston, TX; ²Department of Psychology, Baylor College of Medicine, Houston, TX.

6:00 PM (321) Impact of Age on Health-Related Quality of Life Benefit of Lung Transplantation; L.G. Singer,^{1,2} N. Chowdhury,¹ C. Chaparro,^{1,2} S. Keshavjee.^{1,3} ¹Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada; ²Medicine, University of Toronto, Toronto, ON, Canada; ³Thoracic Surgery, University of Toronto, Toronto, ON, Canada.

5:00 PM – 6:15 PM

CONCURRENT SESSION 34 (MEETING HALL 4)**Fishing Lungs from the Donor Pool****CHAIRS:** Matthew G. Hartwig, MD and Florian Wagner, MD

5:00 PM (322) *The INSPIRE International Lung Trial with the Organ Care System Technology (OCS™)*; G. Warnecke,¹ A. Haverich,¹ G. Massard,² N. Santelmo,² F. Rea,³ C. Knosalla,⁴ R. Hetzer,⁴ G. Leseche,⁵ A. Ardehali,⁶ A.R. Simon,⁷ J. Kukreja,⁸ K. McCurrey.⁹ ¹Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Hopitaux Universitaires de Strasbourg, Strasbourg, France; ³University of Padua, Padua, Italy; ⁴German Heart Center, Berlin, Germany; ⁵Hopital Bichat, Paris, France; ⁶UCLA, Los Angeles; ⁷Harefield Trust, London, United Kingdom; ⁸UCSF, San Francisco; ⁹Cleveland Clinic, Cleveland.

5:12 PM (323) *Successful Transplantation of Unusable Donor Lungs Using Ex-Vivo Lung Perfusion: The Newcastle Experience*; J.H. Dark,^{1,2} D. Karamanou,¹ S. Clark,¹ P. Mahesh,¹ B. Watson,¹ P.A. Corris,^{1,2} A.J. Fisher.^{1,2} ¹Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.

5:24 PM (324) *Uncontrolled Non-Heart-Beating-Donors (NHBD): Clinical Experience and Results*; J.L. Campo-Cañaveral de la Cruz, D. Gómez de Antonio, S. Crowley Carrasco, D.A. Valdivia Concha, L. Macías Sotuela, J.M. Naranjo Gómez, F.J. Moradiellos Díez, M. Córdoba Peláez, A. Varela de Ugarte. Thoracic Surgery, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

5:36 PM (325) *5 Years Experience with Lung Donation after Cardiac Death*; M. Cypel, A. Pierre, K. Yasufuku, M. DePerrot, V. Leist, L.G. Singer, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.

5:48 PM (326) *A Randomized Trial of Nebulized Albuterol To Enhance Resolution of Pulmonary Edema in 506 Brain Dead Organ Donors*; L.B. Ware,¹ M. Landeck,² T. Koyama,¹ E. Johnson,² G.R. Bernard,¹ J.W. Lee,³ M.A. Matthay.³ ¹Vanderbilt University, Nashville, TN; ²California Transplant Donor Network, Oakland, CA; ³University of California, San Francisco, CA.

6:00 PM (327) *Good Lungs for Bad Recipients and Bad Lungs for Good Recipients – Follow Up on Eurotransplant Rescue Offers*; W. Sommer,¹ C. Kuehn,¹ I. Tudorache,¹ M. Avsar,¹ J. Salman,¹ J. Gottlieb,² A. Haverich,¹ G. Warnecke.¹ ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany; ²Respiratory Medicine, Hannover Medical School, Hannover, Germany.

5:00 PM – 6:15 PM

CONCURRENT SESSION 35 (NORTH HALL)**Philip K. Caves Award Candidate Presentations****CHAIRS:** Duane Davis, MD, MBA and Herman Reichenspurner, MD, PhD

5:00 PM (328) *Retention of IL-10+ Neutrophils May Be Essential To Limit Lung Graft Ischemia-Reperfusion Injury*; M. Ibrahim,¹ G. Macri,¹ H.J. Huang,³ S. Yamamoto,² D. Kreisel,² A.E. Gelman.² ¹Thoracic Surgery, University of Rome La Sapienza, Rome, Lazio, Italy; ²Surgery, Washington University in Saint Louis, Saint Louis, MO; ³Medicine, Washington University in Saint Louis, Saint Louis, MO.

5:15 PM (329) *CTLA4-Ig Promotes Lung Allograft Survival Following P. aeruginosa Infection by Blocking Neutrophil-Mediated Trans-Costimulation of Intra-graft CD4+ T Cells*; S. Yamamoto,¹ A.S. Krupnick,¹ R. Nava,¹ H.J. Huang,² D. Kreisel,¹ A.E. Gelman.¹ ¹Surgery, Washington University in Saint Louis, Saint Louis, MO; ²Medicine, Washington University in Saint Louis, Saint Louis, MO.

5:30 PM (330) *Regenerative Therapy after Myocardial Infarction: Role of mtDNA in SCNT Derived Embryonic Stem Cells*; X. Hua,¹ T. Deuse,¹ J. Velden,² O. Kirak,³ R. Jaenisch,⁴ I. Weissman,⁵ F. Ricklefs,¹ H. Reichenspurner,¹ R.C. Robbins,⁶ S. Schrepfer.^{1,6} ¹TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Pathology, University Hospital Hamburg, Hamburg, Germany; ³University Scribbs, San Diego; ⁴Whitehead Institute, Boston; ⁵Immunology, Stanford University, Stanford; ⁶CT Surgery, Stanford University, Stanford, Germany.

5:45 PM (331) *COMP-Ang1 Reduces Ischemia-Reperfusion Injury-Induced Microvascular Dysfunction and Chronic Rejection in Rat Cardiac Allografts*; S.O. Sryjala,¹ R. Tuominen,¹ A. Raissadati,¹ M.A. Keränen,¹ R. Krebs,¹ A.I. Nykänen,^{1,2} G.-Y. Koh,³ K. Alitalo,⁴ K.B. Lemström.^{1,2} ¹Cardiopulmonary Research Group, Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland; ²Department of Thoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland; ³Biomedical Research Center, Korea Advanced Institute of Science and Technology, Daejeon, Korea; ⁴Molecular/Cancer Biology Program, Institute for Molecular Medicine Finland, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.

6:00 PM (332) *Protein Kinase C delta (PKC δ) Mediating Inflammation and Cell Death in Ischemia-Reperfusion-Induced Lung Injury*; H. Kim,^{1,2} Y. Wang,¹ L. Turrell,^{1,3} Q. Zhang,¹ M. Chen,¹ W. Gao,^{1,2} D. Lee,^{1,7} H. Yang,¹ Z. Zhao,¹ X. Bai,¹ M. Li,^{1,4} M. Cypel,^{1,5,6} S. Keshavjee,^{1,5,6} M. Liu.^{1,2,6,7} ¹Latner Thoracic Research Laboratories, University of Health Network, Toronto, ON, Canada; ²Department of Physiology, University of Toronto, Toronto, ON, Canada; ³Biochemistry, Oxford University, Oxford, England, United Kingdom; ⁴Medicine, Shandong University, Jinan, Shandong, China; ⁵Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada; ⁶Department of Surgery, University of Toronto, Toronto, ON, Canada; ⁷Institute of Medical Science, University of Toronto, Toronto, ON, Canada.

7:30 PM – 8:30 PM

PRESIDENT'S COCKTAIL RECEPTION
PRAGUE MUNICIPAL HOUSE

SATURDAY, APRIL 21, 2012

7:00 AM – 11:30 AM

REGISTRATION DESK OPEN
(CONGRESS HALL FOYER)

7:00 AM – 1:00 PM

SPEAKER READY ROOM OPEN
(CLUB H)

8:00 AM – 9:15 AM

CONCURRENT SESSION 36 (FORUM HALL)

Pediatric Mechanical Circulatory Support

CHAIRS: David L.S. Morales, MD and Jennifer Conway, MD, FRCPC

8:00 AM (333) Congenital Heart Disease Patients Have Disproportionately Lower Use of Ventricular Assist Devices Prior to Transplantation: Impact on Organ Allocation; J.M. Gelow,¹ J.O. Mudd,¹ H.K. Song,² C.S. Borberg.¹ ¹Department of Medicine, Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR; ²Department of Surgery, Oregon Health and Science University, Portland, OR.

8:12 AM (334) The Use of Short-Term Ventricular Assist Devices in Children; I. Adachi,¹ J.S. Heinle,¹ E.D. McKenzie,¹ M.C. McGarry,³ A.G. Cabrera,² A. Jeewa,² C.D. Fraser, Jr.,¹ D.L.S. Morales.¹ ¹Michael E. DeBakey Department of Surgery, Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; ²Pediatrics-Cardiology, Baylor College of Medicine, Houston, TX; ³Cardiovascular Surgery, Texas Children's Hospital, Houston, TX.

8:24 AM (335) Hospital Costs for Supporting Children with Ventricular Assist Device in the United States; A.X. Samayoa,¹ B.S. Moffett,² M.S. Khan,¹ C.M. Mery,¹ J.S. Heinle,¹ D.L.S. Morales.¹ ¹Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Pharmacy, Texas Children's Hospital, Houston, TX.

8:36 AM (336) Cognitive Outcomes in Pediatric VAD and Transplant Recipients: A Pilot Study; M.L. Stein, J.L. Bruno, K.L. Konopacki, S. Kesler, O. Reinartz, D.N. Rosenthal. Stanford University, Stanford, CA.

8:48 AM (337) Mechanical Circulatory Support (MCS) as a Bridge to Paediatric Heart Transplant: Does the End Justify the Means?; J.V. Cassidy, A. Wagh, S. Haynes, R. Kirk, L. Ferguson, J. Smith, M. Guillen, Y. Thiru, M. Griselli, A. Hasan. Paediatric Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

9:00 AM (338) Outcomes of Pediatric Patients Supported by the Heartmate II LVAD in the USA; A.G. Cabrera,¹ K. Sundareswaran,² A.X. Samayoa,³ D.J. Farrar,² O.H. Frazier,⁴ D.L.S. Morales.³ ¹Pediatrics, Division of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Thoratec Corporation, Pleasanton, CA; ³Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ⁴Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, TX.

8:00 AM – 9:15 AM

CONCURRENT SESSION 37 (MEETING HALL 1)

Heart Transplantation: Outcomes with Patients with CAV and/or Alloantibody

CHAIRS: Joren C. Madsen, MD, DPhil and Bruce R. Rosengard, MD, FRCS

8:00 AM (339) Clinical Effects of Introducing Everolimus in the Immunosuppressive Regimen of Patients with Established Cardiac Allograft Vasculopathy (CAV): Efficacy Analysis of a Randomized, Multicenter Study; J. Segovia,¹ J. Fernández-Yáñez,² F.J. González-Vílchez,³ J. Delgado,⁴ S. Mirabet,⁵ N. Manito,⁶ E. Roig,⁵ G. Rábago,⁷ M. Gómez-Bueno,¹ L. Alonso-Pulpón.¹ ¹Heart Transplant Units, Hospital Puerta de Hierro, Madrid, Spain; ²Hospital Gregorio Marañón, Madrid, Spain; ³Hospital Marqués de Valdecilla, Santander, Spain; ⁴Hospital 12 de Octubre, Madrid, Spain; ⁵Hospital Sant Pau, Barcelona, Spain; ⁶Hospital Bellvitge, Barcelona, Spain; ⁷Clinica Universitaria de Navarra, Pamplona, Spain.

8:12 AM (340) Outcomes Validation of the New ISHLT Cardiac Allograft Vasculopathy Coronary Angiogram Grading Scale; J. Patel, M. Kittleson, P. Kansara, M. Rafiei, L. Stern, D. Chang, B. Azarbal, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

8:24 AM (341) Distal Pruning as an Important Factor for Outcome in the New ISHLT Cardiac Allograft Vasculopathy Grading Scale; L. Czer, J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, B. Azarbal, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

8:36 AM (342) Non-Stenotic Coronary Vasculopathy Is Associated with Reduced Survival after Heart Transplantation; N.E. Hiemann,¹ E. Wellnhofer,² C. Christian,¹ S. Kretschmer,¹ R. Meyer,¹ H. Valantine,³ R. Hetzer,¹ K.K. Khush.³ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Department of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany; ³Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford.

8:48 AM (343) First-Year Brain Natriuretic Peptide (BNP) as a Biomarker after Heart Transplant To Predict Severity of Cardiac Allograft Vasculopathy (CAV) as Per the New ISHLT CAV Scale; J. Patel, M. Kittleson, R. Shiozaki, M. Rafiei, L. Stern, B. Azarbal, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

9:00 AM (344) New ISHLT Pathologic Diagnosis of Suspicious AMR (pAMR1) Confers Increased Risk of Cardiovascular Mortality; D.V. Miller, P. Revelo, G. Snow, M. Eventt, J. Stehlik, K. Brunisholz, D. Budge, F. Bader, R. Alharethi, E. Gilbert, B. Reid, C. Selzman, A. Kfoury, E.H. Hammond. Cardiac Transplantation, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT.

8:00 AM – 9:15 AM

CONCURRENT SESSION 38 (PANORAMA HALL)**From BOS to CLAD and Beyond!****CHAIRS:** Keith C. Meyer, MD, MS and Daniel Dilling, MD

- 8:00 AM (345) Evaluation of FVC and FEV1 in Both Cohorts Previously Included in a Randomized Controlled Trial of Azithromycin To Prevent Bronchiolitis Obliterans Syndrome after Lung Transplantation;** R. Vos, B.M. Vanaudenaerde, S.E. Verleden, L.J. Dupont, D.E. Van Raemdonck, G.M. Verleden. Lung Transplant Unit, KULeuven and UZLeuven, Leuven, Belgium.
- 8:12 AM (346) Risk of Patient Death after CLAD Onset: BOS and RAS as Time-Dependent Covariates in a Cox Model;** M. Sato,¹ K. Ohmori-Matsuda,² L.G. Singer,³ S. Keshavjee,³ ¹Thoracic Surgery, Kyoto University, Kyoto-city, Japan; ²Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, ON, Canada; ³The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
- 8:24 AM (347) Running Out of Air: CLAD Phenotypes Post Lung Transplant;** M. Paraskeva,¹ M. Bailey,² T. Williams,¹ B. Levvey,¹ G. Snell,¹ G. Westall.¹ ¹Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; ²ANZIC-RC, Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Melbourne, VIC, Australia.
- 8:36 AM (348) Inter-Observer Variability on Diagnosing Bronchiolitis Obliterans Syndrome;** S. Bhorade,¹ A. Kapila,¹ V. Valentine,² M. Baz,³ On Behalf of the AIRSAC Investigators.¹ ¹Medicine, University of Chicago Medical Center, Chicago, IL; ²Medicine, University of Texas, Galveston, TX; ³Medicine.
- 8:48 AM (349) Air Pollution and the Development of Post-Transplant Bronchiolitis Obliterans Syndrome;** S. Bhinder,¹ H. Chen,² M. Sato,⁴ R. Copes,² G.J. Evans,³ C.-W. Chow,¹ L.G. Singer.¹ ¹Department of Medicine, University of Toronto, Toronto, ON, Canada; ²Public Health Ontario, Toronto, ON, Canada; ³Southern Ontario Centre for Atmospheric Aerosol Research, University of Toronto, Toronto, ON, Canada; ⁴Thoracic Surgery, Kyoto University, Kyoto, Japan.
- 9:00 AM (350) Biologic Subtyping of Human Chronic Lung Allograft Dysfunction;** T. Saito,¹ M. Sato,² S. Azad,¹ M. Binnie,³ S.E. Gilpin,¹ T. Machuca,¹ R. Bonato,¹ Y. Matsuda,¹ C.-W. Chow,³ M. Cypel,¹ M. Liu,¹ T.K. Waddell,¹ S. Keshavjee.¹ ¹Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada; ²Department of Thoracic Surgery, Kyoto University, Kyoto, Japan; ³Division of Respiriology, University of Toronto, Toronto, ON, Canada.

8:00 AM – 9:15 AM

CONCURRENT SESSION 39 (MEETING HALL 4)**'Hitting the Right Spot' – New Targets in Immunosuppression****CHAIRS:** Richard N. Pierson, III, MD and Carla C. Baan, PhD

- 8:00 AM (351) The JAK1/3-Inhibitor R507 Diminishes Acute and Chronic Rejection While Demonstrating Immune Cell Specificity;** T. Deuse,¹ X. Hua,¹ M. Stubbendorff,¹ T. Gossler,¹ J. Velden,² V. Taylor,³ G. Park,³ Y. Chen,³ H. Reichenspurner,¹ R.C. Robbins,⁴ S. Schrepfer.^{1,4} ¹TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Pathology, University Hospital Hamburg, Hamburg, Germany; ³Rigel Pharmaceuticals, San Francisco; ⁴CT Surgery, Stanford University School of Medicine, Stanford.
- 8:12 AM (352) Role of Mitochondrial Activity in the Development of Chronic Allograft Vasculopathy;** X. Hua,¹ T. Deuse,¹ M. Stubbendorff,¹ T. Gossler,¹ J. Velden,² R.C. Robbins,³ E. Michelakis,⁴ S. Schrepfer.^{1,3} ¹TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Pathology, University Hospital Hamburg, Hamburg, Germany; ³CT Surgery, Stanford University, Stanford; ⁴CV Medicine, University of Alberta, Edmonton, Canada.
- 8:24 AM (353) Clopidogrel Alone and Combined with Everolimus or Tacrolimus Substantially Reduces Obliterative Bronchiolitis (OB) in an Experimental Mouse Model;** R. Preidl, S. Eckl, M. Ramsperger-Gleixner, N. Koch, M. Weyand, S.M. Ensminger. Department of Cardiac Surgery, University Hospital, Erlangen-Nürnberg, Germany.
- 8:36 AM (354) Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease;** R. Krebs,¹ J. Tikkanen,¹ M. Hollmén,¹ Y. Wu,² B. Pytowski,² K. Lemström.¹ ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland; ²Department of Experimental Therapeutics, ImClone Systems, New York, NY.
- 8:48 AM (355) In Vivo Expansion of Regulatory T Cells with ATG and Inhibition of IL-6 Prolongs Non-Human Primate Lung Allografts Survival;** A. Aoyama,¹ M. Tonsho,¹ Y. Yamada,¹ T.M. Millington,¹ S. Boskovic,¹ S. Lee,¹ R.-N. Smith,² J.C. Madsen,³ T. Kawai,¹ J.S. Allan.⁴ ¹Transplant Surgery, Massachusetts General Hospital, Boston, MA; ²Pathology, Massachusetts General Hospital, Boston, MA; ³Transplant Center, Massachusetts General Hospital, Boston, MA; ⁴Thoracic Surgery, Massachusetts General Hospital, Boston, MA.
- 9:00 AM (356) Pyruvate Dehydrogenase Kinase 2 Controls Vascular Remodeling;** T. Deuse,¹ X. Hua,¹ F. Länger,² T. Gossler,¹ M. Stubbendorff,¹ A. Rakovic,³ C. Klein,³ G. Sutendra,⁴ P. Dromparis,⁴ L. Maegdefessel,⁵ P.S. Tsao,⁵ J. Velden,⁶ H. Reichenspurner,¹ R.C. Robbins,⁷ F. Haddad,⁵ E. Michelakis,⁴ S. Schrepfer.^{1,7} ¹TSI-Lab, Cardiovascular Surgery, University Heart Center, Hamburg, Germany; ²Pathology, University School of Medicine Hannover, Hannover, Germany; ³Neurology, University of Luebeck, Luebeck, Germany; ⁴CV Medicine, University of Alberta, Edmonton, Canada; ⁵CV Medicine, Stanford University, Stanford; ⁶Pathology, University Hospital Hamburg, Hamburg, Germany; ⁷CT Surgery, Stanford University, Stanford.

8:00 AM – 9:15 AM

CONCURRENT SESSION 40 (MEETING HALL 5)**Secondary (Non-PAH) Pulmonary Hypertension**

CHAIRS: Joren Carlsen, MD, DMSC and
J. Eduardo Rame, MD, MPH

8:00 AM (357) Comparative Effects of the Drugs Used for Pulmonary Hypertension Reversibility Testing: A Meta-Analysis; M. Guglin,¹ S. Mehra,² T. Mason,² ¹Cardiology, University of South Florida, Tampa, FL; ²College of Public Health, University of South Florida, Tampa, FL.

8:12 AM (358) Pulmonary Vascular Gradient: A Predictor of Prognosis in Pulmonary Hypertension Due to Left Heart Disease; C. Gerges,¹ M. Gerges,¹ M. Lang,¹ H. Heinzl,² P. Probst,¹ G. Maurer,¹ I. Lang,¹ ¹Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria; ²Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

8:24 AM (359) Long-Term Sildenafil Therapy in Advanced HF Patients with Severe PH Improves Hemodynamics and Prevents Weight Loss; A. Reichenbach, V. Melenovsky, H. Al-Hiti, I. Málek, J. Kautzner. Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

8:36 AM (360) Echo-Doppler Profile of Abnormal Right Ventricular-Pulmonary Arterial Interaction Is Associated with Beneficial Response to Sildenafil in Heart Transplant Recipients with Pulmonary Hypertension; M.R. Molina,¹ E.H. Ticehurst,² L. Goldberg,¹ D. Chojnowski,¹ N. Hornsby,¹ P. Forfia,³ ¹Heart Transplant & Heart Failure, Hosp of the Univ of Penn, Philadelphia, PA; ²Pharmacy, Hosp of the Univ of Penn, Philadelphia, PA; ³Pulmonary Hypertension, Hosp of the Univ of Penn, Philadelphia, PA.

8:48 AM (361) The REVEAL Score Predicts Prognosis in Patients with Multifactorial and Non-WHO Group I Pulmonary Hypertension; R. Cogswell, D. McGlothlin, R. Shaw, T. De Marco. Cardiology, University of California San Francisco, CA.

9:00 AM (362) Pulmonary Arterial Lesions in Explanted Lungs after Transplantation Correlate with Severity of Pulmonary Hypertension in End-Stage Chronic Obstructive Pulmonary Disease; J. Carlsen,¹ K.H. Andersen,¹ S. Boesgaard,¹ M. Iversen,¹ D. Steinbrüchel,² C.B. Andersen,³ ¹Department of Cardiology, Pulmonary Vascular Program, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Department of Cardiothoracic Surgery, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Department of Pathology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.

8:00 AM – 9:15 AM

CONCURRENT SESSION 41 (NORTH HALL)**Getting Back To Basics**

CHAIRS: Filio Billia, MD, PhD and Takeshi Nakatani, MD, PhD

8:00 AM (363) Apoptosis Occurs in Late Stages of Unloading Related Ventricular Remodeling; H.L. Brinks,¹ T.P. Carrel,¹ W.J. Koch,² H.T. Tevaearai,¹ M.-N. Giraud,¹ ¹Cardiac and Vascular Surgery, Inselspital University Hospital Bern, Bern, Switzerland; ²Center for Translational Medicine, Thomas Jefferson University, Philadelphia.

8:12 AM (364) Increased Vascular Expression of the Proinflammatory Adhesion Molecules VCAM and E-Selectin and Endothelial Depletion of vWF Following Continuous Flow Left Ventricular Assist Device Placement; T. Kato,² H. Takayama,¹ E. Collado,² H. Akashi,² S. Yi,² C.J. Chung,² D. Mancini,² Y. Naka,¹ P.C. Schulze,² ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY.

8:24 AM (365) Improved LVAD Haemocompatibility of Sintered Inflow Cannula by Endothelialization with Human Endothelial Cells; B. Wiegmann,¹ I. Birschmann,² A. Haverich,¹ M. Strüber,¹ ¹Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Clinic for Haematology, Haemostaseology and Oncology, Hannover Medical School, Hannover, Germany.

8:36 AM (366) Plasma NOx Decreases Following Continuous Flow Left Ventricular Assist Device Despite Lack of Change in Shear Stress; S. Hozayen,¹ A. Somani,² S. Nair,² D. Dengel,³ R. John,⁴ A. Hamel,¹ P.M. Eckman,¹ ¹Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN; ²Department of Pediatric Medicine, Critical Care Division, University of Minnesota, Minneapolis, MN; ³School of Kinesiology, University of Minnesota, Minneapolis, MN; ⁴Division of Cardiac Surgery, University of Minnesota, Minneapolis, MN.

8:48 AM (367) Augmentation of LV Wall Thickness by Selective Regional Injections of Alginate Hydrogel into Epivardial Cardiac Veins Improves LV Function and Reverses Chamber Remodeling in Dogs with Chronic Heart Failure; H.N. Sabbah,¹ M. Wang,¹ R.C. Gupta,¹ S. Rastogi,¹ S. Helgerson,² ¹Medicine, Henry Ford Hospital, Detroit, MI; ²Lonestar Heart, Inc., Laguna Hills, CA.

9:00 AM (368) Developing a Biohybrid Lung – Gas Exchange Membranes Endothelialized with Allogeneic MHC-Silenced Endothelial Cells To Prevent Transplant Rejection; B. Wiegmann,¹ C. Figueiredo,² V. Dewor,¹ S. Vahlsing,² R. Blasczyk,² A. Haverich,¹ ¹Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

9:15 AM – 9:30 AM**COFFEE BREAK**

(CONGRESS HALL FOYER)

9:30 AM – 11:15 AM**PLENARY SESSION**

(FORUM HALL)

Incorporating Information Technology into Pre and Post-Transplant Care**CHAIRS:** Allan R. Glanville, MD, FRACP and David O. Taylor, MD**9:30 AM** *Awards Presentations***9:45 AM** *Integrating Information Technology into Care: Challenges and Opportunities*, C. Martin Harris, MD, MBA, Cleveland Clinic Foundation, Cleveland, OH**10:15 AM** *Featured Abstract (369) Initial Experience of Cardiac Transplant Recipient Follow Up Using Telehealth*; S.C. McKenzie,¹ J. Maddicks-Law,¹ R. Gururajan,² M. Brown,¹ D. Platts,¹ A. Hickey,¹ G. Javorsky,¹ ¹The Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, Brisbane, QLD, Australia; ²School of Information Systems Faculty of Business, The University of Southern Queensland, Toowoomba, QLD, Australia.**10:30 AM** *Remote Hemodynamic Monitoring*, W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH**10:45 AM** *Using Technology to Promote Self-Monitoring and Health Outcomes after Transplant*, Annette J. DeVito-Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA**11:00 AM** *Remote Monitoring of Mechanical Circulatory Support Devices*, Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany**11:15 AM – 11:30 AM****COFFEE BREAK**

(CONGRESS HALL FOYER)

11:30 AM – 12:45 PM**CONCURRENT SESSION 42**

(FORUM HALL)

Featured Abstracts**CHAIRS:** Jack Copeland, MD and Jon Kobashigawa, MD**11:30 AM (370)** *Prognostic Indications of Serial Risk Score Assessments: A REVEAL Analysis*; R.L. Benza,¹ D.P. Miller,² A.J. Foreman,² A.E. Frost,³ D.B. Badesch,⁴ L.A. Meltzer,⁵ M.D. McGoon,⁶ ¹Allegheny General Hospital, Pittsburgh, PA; ²ICON Late Phase & Outcomes Research, San Francisco, CA; ³Baylor College of Medicine, Houston, TX; ⁴University of Colorado Denver, Aurora, CO; ⁵Actelion Pharmaceuticals US, Inc., South San Francisco, CA; ⁶Mayo Clinic, Rochester, MN.**11:42 AM (371)** *Is the Allocation Advantage for LVAD Supported Heart Transplant Candidates in the US Still Justified? An OPTN/UNOS Analysis*; O. Wever-Pinzon, S.G. Drakos, C. Selzman, R. Alharethi, E.M. Gilbert, M. Everitt, D. Budge, F. Bader, J. Nativi, B. Reid, K. Molina, K.D. Brunisholz, A. Kfoury, J. Stehlik. UTAH Cardiac Transplant Program, Salt Lake City, UT.**11:54 AM (372)** *The Eurotransplant (ET) Donor Heart Score: Can It Stand the Test of Real Life?*; A.Z. Aliabadi,¹ F.A. Eskandary,¹ M. Groemmer,¹ O. Salameh,¹ T. Haberl,¹ S.L. Mahr,¹ D. Wiedemann,¹ D. Zimpfer,¹ G. Lauffer,¹ J. Smiths,² A.O. Zuckermann,¹ ¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Eurotransplant Foundation, Leiden, Netherlands.**12:06 PM (373)** *First-in-Man Experience with a Superficial, Synchronous Partial Circulatory Support Device for Chronic Heart Failure Patients*; R. Cecere,¹ N. Giannetti,¹ R. Dowling,² D. Raess,³ E. Gratz,³ A. Cheung,⁴ ¹McGill University Health System, Montreal, Canada; ²DCI, Louisville, KY; ³Abiomed, Danvers; ⁴University of British Columbia, Vancouver, Canada.**12:18 PM (374)** *Psychiatric Predictors of 10-Year Outcomes after Lung Transplantation*; E.M. Rosenberger,¹ A.F. DiMartini,^{2,3} Y. Toyoda,⁴ J.M. Pilewski,^{5,6} C.A. Bermudez,⁷ A. DeVito Dabbs,⁸ M.A. Dew,^{1,2,9,10,11} ¹Clinical and Translational Sciences, University of Pittsburgh, PA; ²Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA; ³Transplantation Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴Surgery, Temple University, Philadelphia, PA; ⁵Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁶Cell Biology and Physiology, University of Pittsburgh, PA; ⁷Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁸School of Nursing, University of Pittsburgh, PA; ⁹Biostatistics, University of Pittsburgh, PA; ¹⁰Psychology, University of Pittsburgh, PA; ¹¹Epidemiology, University of Pittsburgh, PA.**12:30 PM (375)** *The Impact of High Recipient Acuity on Outcomes after Lung Transplantation*; T.J. George, C.A. Beaty, J.V. Conte, A.S. Shah. The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD.

11:30 AM – 12:45 PM

CONCURRENT SESSION 43 (MEETING HALL 1)**Bad VADs****CHAIRS:** Thomas Krabatsch, MD, PhD and TBD

11:30 AM (376) Durability of Left Ventricular Assist Devices (LVADs): INTERMACS 2006-2011; W.L. Holman,¹ D.C. Naftel,¹ C.E. Eckert,³ R.L. Kormos,³ D.J. Goldstein,² Y. Yuan,¹ J.K. Kirklin.¹ ¹Surgery, University of Alabama, Birmingham, AL; ²Surgery, Montefiore-Einstein Medical Center, Bronx, NY; ³Bioengineering and Surgery, University of Pittsburgh, PA.

11:42 AM (377) Survival to Transplant in Patients Undergoing Mechanical Circulatory Support as Bridge: Retrospective Analysis of LVAD, BiVAD and TAH Strategy; O.E. Pajaro,¹ A.V. Kalya,² R.S. Gopalan,² L.L. Staley,¹ K.L. Diane,¹ J.M. Spadafore,¹ C.N. Pierce,¹ B.N. Noble,³ C. Krishnaswamy,² R.L. Scott,² F.A. Arabia.¹ ¹Cardiovascular and Thoracic Surgery, Mayo Clinic, Phoenix, AZ; ²Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ; ³Department of Biostatistics, Mayo Clinic, Phoenix, AZ.

11:54 AM (378) Adverse Events and Complications Profile after HVAD LVAD Implantations in Adult Patients; T. Krabatsch,¹ M. Schweiger,^{1,2} J. Vierecke,¹ A. Stepanenko,¹ E. Potapov,¹ M. Hübler,¹ M. Kukcuka,¹ R. Hetzer.¹ ¹German Heart Institute Berlin, Clinic for Heart, Thotac and Vascular Surgery, Berlin, Germany; ²Medical University Graz, Division for Transplantations Surgery, Graz, Austria.

12:06 PM (379) Early Results from the SoundMate Study. Acoustic Analysis of a Thromboembolic Event in a Patient Treated with HeartMate II™, Mechanical Circulatory Support; L. Hubbert,¹ U.P. Jorde,³ B. Peterzén,¹ H. Granfeldt,¹ B. Kornhall,² K. Morrison,³ H. Ahn.¹ ¹Heart Centre at Linköping University Hospital, Departments of Medicine & Health at Linköping University, Linköping, Sweden; ²Division of Heart failure and Cardiac Valves, Skane University Hospital, Lund, Sweden; ³Columbia University Medical Center, New York Presbyterian Hospital, New York.

12:18 PM (380) Changes in Sexual Function Following Left Ventricular Assist Device (LVAD); V. Dhungel,¹ S.A. Mandras,² M.A. Brisco,³ S. Emani,⁴ J. Lindenfeld,⁵ N. Sulemanjee,⁶ G. Sokos,⁷ J.L. Feldman,⁸ P.M. Eckman.¹ ¹Cardiology Division, University of Minnesota, Minneapolis, MN; ²Cardiology Division, Ochsner Medical Center, New Orleans, LA; ³Cardiology Division, University of Pennsylvania, Philadelphia, PA; ⁴Cardiology Division, The Ohio State University Medical Center, Columbus, OH; ⁵Cardiology Division, University of Colorado, Aurora, CO; ⁶Transplant and Cardiology Clinics, Aurora Medical Group, Milwaukee, WI; ⁷The Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA; ⁸Department of Family Medicine, University of Minnesota, Minneapolis, MN.

12:30 PM (381) Morphologic Changes in the Aortic Wall after Support with a Nonpulsatile-Flow Left Ventricular Assist Device; A.M. Segura, I. Gregoric, R. Radovancevic, Z. Demirozu, L.M. Buja, O.H. Frazier. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

11:30 AM – 12:45 PM

CONCURRENT SESSION 44 (PANORAMA HALL)**Heart Transplantation: What Can We Learn from Registry Data****CHAIRS:** Finn Gustafsson, MD, PhD, DMSci and Gregory A. Ewald, MD

11:30 AM (382) Outcomes of Adults with Restrictive Cardiomyopathy (RCM) Post Heart Transplant (HT): UNOS Registry Analysis; E.C. DePasquale,¹ K. Nasir,¹ L. Bellumkonda,¹ A. Mangi,² D. Dries,¹ D.L. Jacoby.¹ ¹Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; ²Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

11:42 AM (383) ABO Blood Type Matching and Survival after Heart Transplantation: Analyze of the ISHLT Registry; J. Nilsson,¹ M. Ohlsson,² P. Höglund,³ B. Ekmeahag,⁴ B. Koul,¹ B. Andersson.⁵ ¹Clinical Sciences in Lund, Cardiothoracic Surgery, Lund University and Skåne University Hospital, Lund, Sweden; ²Computational Biology and Biological Physics, Lund University, Lund, Sweden; ³Competence Centre for Clinical Research, Lund University and Skåne University Hospital, Lund, Sweden; ⁴Clinical Sciences in Lund, Cardiology, Lund University and Skåne University Hospital, Lund, Sweden; ⁵Clinical Sciences in Lund, Surgery, Lund University and Skåne University Hospital, Lund, Sweden.

11:54 AM (384) Pre-Transplant Malignancy: An Analysis of Outcomes after Thoracic Organ Transplantation; C.A. Beaty, T.J. George, A. Kilic, J.V. Conte, A.S. Shah. The Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD.

12:06 PM (385) Predictors of Graft Survival in Heart Transplant Recipients with Peripartum Cardiomyopathy: Insights from the United Network for Organ Sharing (UNOS) Database; K. Rasmusson,¹ K. Brunisholz,¹ M. Labedi,¹ S. Knight,¹ D. Budge,¹ J. Stehlik,² R. Alharethi,¹ J. Nixon,¹ S. Frampton,¹ A. Kfoury.¹ ¹UTAH Cardiac Transplant Program, Intermountain Medical Center, Salt Lake City, UT; ²UTAH Cardiac Transplant Program, University of Utah Hospital, Salt Lake City, UT.

12:18 PM (386) Outcomes of Familial Dilated Cardiomyopathy (FDCM) Post Heart Transplant (HT); E.C. DePasquale,¹ D. Dries,¹ W.J. McKenna,² D.L. Jacoby.¹ ¹Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT; ²Institute of Cardiovascular Science, University College London and The Heart Hospital, UCLH NHS Trust, London, United Kingdom.

12:30 PM (387) Post-Transplant Survival of Patients in Need of Biventricular and Right-Ventricular Mechanical Bridge to Heart Transplantation. A Comparative Analysis of the ISHLT Transplant Registry. [Transplant Registry Early Career Award]; J.N. Nativi,¹ S.G. Drakos,¹ L.B. Edwards,² A.Y. Kucheryavaya,² C. Selzman,¹ A.G. Kfoury,⁴ F. Bader,¹ R. Alharethi,⁴ O. Wever-Pinzon,¹ S. Kushwaha,³ M.I. Hertz,³ J. Stehlik.¹ ¹University of Utah, Salt Lake City, UT; ²International Society for Heart and Lung Transplantation, Addison, TX; ³University of Minnesota, Minneapolis, MN; ⁴Intermountain Medical Center, Salt Lake City, UT; ⁵Mayo Clinic, Rochester, MN.

11:30 AM – 12:45 PM

CONCURRENT SESSION 45 (MEETING HALL 4)***Growing Up with a Heart Transplant: Adolescence, Antibodies and Pharmacogenetics***

CHAIRS: Richard Kirk, MA, FRCP, FRCPC and Robert E. Shaddy, MD

11:30 AM (388) Pharmacogenetics of Tacrolimus in Pediatric Solid Organ Transplant Recipients; K. McLean, V. Gijzen, A. Fung, T. Daljevic, N. Nalli, R. Parekh, B. Kamath, H. Grasmann, S. Ito, G. Koren, S. Mital. Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.

11:42 AM (389) Is Adolescence an Independent Risk Factor for Rejection in Pediatric Heart Transplantation, Independent of Age at Listing?; C.J. VanderPluym,¹ H. Bastardi,¹ J. Scheel,² B. Kaufman,³ J. Fricker,⁴ D. Schneider,⁵ D. Naftel,⁶ M. Tresler,⁶ B. Das,⁷ K. Gandy,⁸ E.D. Blume.¹ ¹Cardiology, Children's Hospital Boston, Boston, MA; ²Cardiology, Johns Hopkins Hospital, Baltimore, MD; ³Cardiology, Children's Hospital of Philadelphia, Philadelphia; ⁴Cardiology, University of Florida, Shands Hospital, Gainesville; ⁵Cardiology, University of Virginia, Charlottesville; ⁶University of Alabama, Birmingham; ⁷University of Texas, Children's Medical Center, Dallas; ⁸Children's Mercy Hospital and Clinics, Kansas City.

11:54 AM (390) Infant Heart Transplantation: 10 Years and Beyond; V. Krishnamurthy, L. Zaytsev, K. Freier Randall, R. Chinnock. Pediatrics, Loma Linda University Health Care, Loma Linda, CA.

12:06 PM (391) High Titer Donor Specific HLA Antibody Is Complement Binding and Associated with Risk of AMR in Heart Transplant Recipients; A. Zeevi, B. Feingold, J. Lunz, J. Teuteberg, M. Shullo, C. Bermudez, S. Webber. University of Pittsburgh, PA.

12:18 PM (392) Complement Fixation by C1q vs MFI: Detection of Clinically Relevant Antibodies; C.D. Castleberry,¹ C. Chin,² D. Rosenthal,¹ D. Bernstein,¹ S.A. Hollander,¹ D. Tyan.³ ¹Pediatric Cardiology, Stanford University School of Medicine, Palo Alto, CA; ²Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH; ³Pathology, Stanford University School of Medicine, Palo Alto, CA.

12:30 PM (393) Donor Specific HLA Antibodies Arising after Pediatric Cardiac Transplantation; C. Irving,¹ V. Carter,² A. Gennery,¹ G. Parry,¹ A. Hasan,¹ M. Griselli,¹ M. Howell,² B. Kirk.¹ ¹Transplant Institute, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²National Health Service Blood and Transplant, Newcastle upon Tyne, United Kingdom.

11:30 AM – 12:45 PM

CONCURRENT SESSION 46 (MEETING HALL 5)***Mechanisms of Acute Injury and Organ Preservation***

CHAIRS: Tobias Deuse, MD, PhD and James George, PhD

11:30 AM (394) Control of Cardiac Metabolism and Growth by DJ-1; F. Billia,¹ L. Hauck,¹ D. Grothe,¹ F. Konecny,³ V. Rao,² T.W. Mak.¹ ¹Research, Campbell Family Institute for Cancer Research, Toronto, ON, Canada; ²Medicine/Cardiac Surgery, University Health Network, Toronto, ON, Canada; ³Research, Toronto General Research Institute, Toronto, Canada.

11:42 AM (395) Secretome of Apoptotic Peripheral Blood Cells (APOSEC) Attenuates Area at Risk in a Porcine Closed Chest Reperfused Acute Myocardial Infarction Model: Role of Platelet Aggregation In Vitro and In Vivo; K. Hoetzenecker,¹ A. Assinger,² M. Lichtenauer,¹ M. Mildner,³ T. Schweiger,¹ A. Mitterbauer,¹ P. Starlinger,⁴ M. Ernstbrunner,⁵ B. Steinlechner,⁵ M. Gyöngyösi,⁶ I. Volf,² H.J. Ankersmit.¹ ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ²Institute of Physiology, Medical University of Vienna, Vienna, Austria; ³Department of Dermatology, Medical University of Vienna, Vienna, Austria; ⁴Department of Surgery, Medical University of Vienna, Vienna, Austria; ⁵Department of Anaesthesia, General Intensive Care and Pain Management, Medical University of Vienna, Vienna, Austria; ⁶Department of Cardiology, Medical University of Vienna, Vienna, Austria.

11:54 AM (396) Water-Soluble Carbon Monoxide-Releasing Molecule Attenuates Allograft Airway Rejection; T. Ohtsuka, T. Goto, M. Anraku, M. Kohno, H. Nomori. Section of Thoracic Surgery, Keio University, Tokyo, Japan.

12:06 PM (397) Ex Vivo Adenoviral IL-10 Gene Therapy in a Pig Lung Transplantation Survival Model; T.N. Machuca, R. Bonato, M. Cypel, J. Yeung, Z. Guan, S. Juvet, D.M. Hwang, M. Chen, T. Saito, T.K. Waddell, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University Health Network – University of Toronto, Toronto, ON, Canada.

12:18 PM (398) Successful 24-Hour Ex-Vivo Maintenance of Swine Lungs Using the Organ Care System (OCS™); M. Avsar,¹ G. Warnecke,¹ F. Lus,¹ A. Haverich,¹ I. Abdel Fattah,² A. Hasanein,³ M. Iraniha,⁴ H. O'Connor.⁴ ¹Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ²Thoracic and Cardiovascular Surgery, Cairo University Medical School, Cairo, Egypt; ³Thoracic and Cardiovascular Surgery, Ain Shams University School of Medicine, Cairo, Egypt; ⁴Department of Clinical Development, TransMedics, Inc., Andover, MA.

12:30 PM (399) Donor Preconditioning with Carbon Monoxide (CO) Prolongs Lung Graft Survival in Miniature Swine; H. Sahara, A. Shijmizu, M. Tasaki, M. Sekijima, M. Oku, H. Nishimura, K. Setoyama, K. Yamada. Xenotransplantation Surgery Section, Frontier Science Research Center, Kagoshima University, Kagoshima, Japan.

11:30 AM – 12:45 PM

CONCURRENT SESSION 47 (NORTH HALL)*Evolving Infections in a New Era***CHAIRS:** Glen P. Westall, FRACP, PhD and Frauke Mattner, PhD

11:30 AM (400) Ganciclovir-Resistant (GCV-R) CMV Is Common among Lung Transplant Recipients (LTR) Receiving Alemtuzumab Induction and Valganciclovir Prophylaxis (VGC px), and Treatment with Foscarnet (FOS) Is Both Ineffective and Toxic; L. Minces, C.J. Clancy, R.K. Shields, E.J. Kwak, F. Silveira, Y. Toyoda, C. Bermudez, J. Pilewski, M. Crespo, M.H. Nguyen. University of Pittsburgh Medical Center, Pittsburgh, PA.

11:42 AM (401) Differential Distribution and Functional Quality of CMV-Specific T Cell Effector Memory in High-Risk Lung Transplant Recipients; J.A. Akulian,¹ M.R. Pipeling,² E.R. John,¹ J.F. McDyer,² ¹Pulmonary/Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ²PACCM, University of Pittsburgh School of Medicine, Pittsburgh, PA.

11:54 AM (402) Reconstitution of CMV-Specific Immunity after Heart Transplantation Is Modulated by mTOR Inhibition, but Not by Antiviral Strategy; E. Petrisli,² L. Potena,¹ I.G. Bianchi,¹ A. Chiereghin,² M. Masetti,¹ P. Prestinenzi,¹ F. Barberini,¹ F. Angeli,¹ G. Magnani,¹ T. Lazzarotto,² F. Grigioni,¹ A. Branzi.¹ ¹Cardiovascular Department, University of Bologna, Bologna, Italy; ²Clinical Microbiology, University of Bologna, Bologna, Italy.

12:06 PM (403) Chronic Hepatitis E Virus Infection in Lung Transplant Recipients; H.Y. van der Weide,¹ E.B. Haagsma,¹ B.G.M. Niesters,² A. Riezebos-Brilman,² E.A.M. Verschuuren.³ ¹Gastro-enterology & Hepatology, University Medical Centre Groningen, Groningen, Netherlands; ²Medical Microbiology & Virology, University Medical Centre Groningen, Groningen, Netherlands; ³Pulmonary Diseases & Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands.

12:18 PM (404) Impact of Deep-Sequencing for the Identification of Viruses in Pediatric Lung Transplant Recipients; L. Danziger-Isakov,¹ D. Wang,² R. Buller,² S. Mason,² C. Conrad,³ A. Faro,² S. Goldfarb,⁴ D. Hayes, Jr.,⁵ M. Schechter,⁶ H. Spencer,⁷ G. Visner,⁸ G. Storch,² S. Sweet.² ¹Cleveland Clinic, Cleveland; ²Washington University, St. Louis; ³Lucile Packard Children's Hospital, Palo Alto; ⁴Children's Hospital of Philadelphia, Philadelphia; ⁵Nationwide Children's Hospital, Columbus; ⁶Texas Children's Hospital, Houston; ⁷Great Ormond Street Hospital, London, United Kingdom; ⁸Children's Hospital Boston, Boston.

12:30 PM (405) Risk Factors for Invasive Fungal Infection after Lung Transplantation; D.C. Chambers,^{1,2} S.T. Yerkovich,^{1,2} V. Maliyasena,¹ M. Menon,¹ P.M. Hopkins.^{1,2} ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia; ²School of Medicine, The University of Queensland, Brisbane, QLD, Australia.



12:30 PM – 1:30 PM
BOX LUNCH PICK-UP
 (BUFFET – 1ST FLOOR)

12:45 PM – 2:15 PM
COUNCIL AND COMMITTEE REPORTS
TO THE BOARD AND MEMBERSHIP
 (MEETING HALL 4)

2:30 PM – 7:00 PM
ISHLT BOARD OF DIRECTORS MEETING
 (MEETING HALL 2)

SESSION 1

(CONGRESS HALL FOYER)

Presenters will be available on Wednesday from 6pm-7pm to discuss their posters and answer any questions.

[406] *Translational Models: A Humanized Model To Study the Development of Obliterative Airway Disease*; X. Hua,¹ T. Deuse,¹ M. Stubben-dorff,¹ J. Velden,² H. Reichenspurner,¹ R.C. Robbins,³ S. Schrepfer.^{1,3} ¹TSL-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Pathology, University Hospital Hamburg, Hamburg, Germany; ³CT Surgery, Stanford University, Stanford, Germany.

[407] *Regulatory T Cells in Transbronchial Biopsies Compared with FoxP3 mRNA Level in Bronchoalveolar Lavage Fluid*; D. Krustup,¹ C.B. Madsen,² M. Iversen,³ C.B. Andersen.¹ ¹Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ²The Tissue Type Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ³The Heart and Lung Transplantation Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

[408] *The Importance of DC (Dendritic Cell) – T Cell Interplay in Cardiac Transplantation*; T. Ueno,^{1,2} M.Y. Yeung,² K. Jung,³ P. Dutta,¹ M. Nahrendorf,¹ S.H. Yun,³ R. Weissleder.¹ ¹Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ³Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

[409] *Dynamic Changes in the Immunophenotypic Maturation Status of CD19 B Lymphocytes in Patients with Acute Cellular Rejection after Heart Transplantation*; J. Carbone,¹ N. Lanio,¹ A. Gallego,¹ J. Navarro,¹ J. Palomo,² J. Fernandez-Yañez,² E. Sarmiento.¹ ¹Clinical Immunology, Gregorio Marañón Hospital, Madrid, Spain; ²Cardiology, Gregorio Marañón Hospital, Madrid, Spain.

[410] *Can Cross-Reactive Anti-Viral T Cells to CMV Influence Alloreactivity in Lung Transplant Recipients?* O. Nguyen,^{1,2} G.P. Westall,^{1,2} T.C. Kotsimbos,^{1,2} N.A. Mifsud.^{1,2} ¹Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia; ²Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia.

[411] *Epigenetic Analysis Demonstrates That Natural Treg Only Infiltrate the Cardiac Allograft during an Acute Rejection Episode*; K. Boer,¹ A.M.A. Peeters,¹ A.P.W.M. Maat,² K. Caliskan,³ A.H.M.M. Balk,³ W. Weimar,¹ C.C. Baan.¹ ¹Internal Medicine – Transplantation, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; ²Thoracic Surgery, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; ³Cardiology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.

[412] *CMV Reactivation Rather Than Persistent Alloantigen Drives a Specific Cross-Reactive T Cell Receptor Repertoire*; O. Nguyen,^{1,2} K. Kedzierska,³ N. Bird,³ G.P. Westall,^{1,2} T.C. Kotsimbos,^{1,2} N.A. Mifsud.^{1,2} ¹Medicine, Monash University, Melbourne, VIC, Australia; ²Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; ³Microbiology and Immunology, The University of Melbourne, Parkville, VIC, Australia.

[413] *Impact of CD1d+CD5+ B-Cells on T-Dependent and T-Independent Immune Responses in Early Childhood*; Y. Ling,^{1,3} E. Dijke,¹ L.J. West,^{1,2,3} S. Urschel.^{1,3} ¹Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Surgery, University of Alberta, Edmonton, AB, Canada; ³Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.

[414] *Differential Gene Regulation between Brain and Cardiac Death Donor Lungs during Ex Vivo Lung Perfusion*; R. Zamel, X.-H. Bai, J.C.

Yeung, T.N. Machuca, M. Cypel, T.K. Waddell, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada.

(415) Beta-Adrenergic Agonist Infusion during Extracorporeal Lung Perfusion: Effects on Glucose Consumption and Pulmonary Artery Pressure; F. Valenza,¹ L. Rosso,² S. Froio,¹ S. Coppola,¹ J. Colombo,¹ R. Dossi,¹ J. Fumagalli,¹ V. Salice,¹ M. Pizzocri,¹ G. Conte,³ S. Gatti,³ L. Santambrogio,² L. Gattinoni.¹ ¹Anestesia, Terapia Intensiva e Subintensiva e Terapia del Dolore, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy; ²Unità Operativa Trapianti di Polmone, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy; ³Centro di Ricerche Chirurgiche Precliniche, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy.

(416) Hypothermic Machine Perfusion for Lung Preservation: Technical Development in a Canine Model; D. Nakajima, F. Chen, K. Okita, H. Motoyama, K. Hijiya, A. Ohsumi, J. Sakamoto, T. Yamada, M. Sato, A. Aoyama, H. Sakai, T. Bando, H. Date. Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

(417) Evaluating a Novel Albumin Free Lung Perfusion Solution in a Swine Lung Transplant Model; M. Avsar,¹ F. Ius,¹ I.A. Fattah,² M. Iraniha,² A. Hassanein,² W. Sommer,¹ A. Haverich,¹ G. Warnecke.¹ ¹Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Transmedics, Inc., Andover, MA.

(418) The Effect of beta-2 Adrenoreceptor Agonist Inhalation on Lungs Donated after Cardiac Death in a Canine Lung Transplantation Model; J. Sakamoto, F. Chen, D. Nakajima, T. Yamada, A. Ohsumi, H. Sakai, T. Bando, H. Date. Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

(419) Superior Lung Preservation with a Polyethylene Glycol Based Solution in a Porcine Single Lung Transplant Model; A.B. Olland,¹ A. Neyrinck,¹ M. Benahmed,² T. Boogmans,³ A. Stanzi,³ K. Elbayed,² S. Wauters,¹ G. Verleden,⁴ I. Namer,² D. Van Raemdonck.¹ ¹Laboratorium Experimentele Thoraxheelkunde, Katholieke Universiteit Leuven, Leuven, Belgium; ²Service de Biophysique et Médecine Nucléaire, Hôpitaux Universitaires Strasbourg, Strasbourg, France; ³Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium.

(420) Anaplerotic Substrate Replenishes Tricarboxylic Acid Cycle Intermediates during Machine Perfusion Preservation of Donor Hearts; M.L. Cobert,¹ M. Peltz,¹ M.E. Merritt,² L.M. West,¹ M.E. Jessen.¹ ¹Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, TX; ²Advanced Imaging Research Center, University of Texas Southwestern Medical Center at Dallas, TX.

(421) Elevations in Donor Troponin Levels Do Not Predict Worse Outcomes Following Orthotopic Heart Transplant; J.A. Yang,¹ Y. Naka,¹ G. Magda,¹ S. Dizon,¹ B.P. Shulman,¹ T. Horai,¹ T. Ota,¹ N. Uriel,² P. Colombo,² U.P. Jorde,² P.C. Schulze,² D. Mancini,² H. Takayama.¹ ¹Division of Cardiac Surgery, Dept of Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Dept of Medicine, Columbia University Medical Center, New York, NY.

(422) Early Clinical Experience Supplementing Celsior Preservation Solution with Pro-Survival Kinase Agents Glycerol Trinitrate and Erythropoietin Demonstrates Improved Myocardial Recovery Post Cardiac Transplantation; G. Kumarasinghe,^{1,2} A. Iyer,^{1,2} M. Hicks,^{1,2} L. Gao,² A. Doyle,² A.M. Keogh,^{1,2} C.S. Hayward,¹ E. Kotlyar,¹ E. Granger,¹ K. Dhital,¹ P. Jansz,¹ P. Spratt,¹ P.S. Macdonald.^{1,2} ¹Dept of Heart and Lung Transplantation, St. Vincent's Hospital, Sydney, NSW, Australia; ²Cardiac Physiology and Transplantation Laboratory, Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.

(423) Persufflation (i.e., Gas Perfusion) May Extend Allowable Ischemia Time during Donor Heart Preservation; T.M. Suszynski,¹ W.E. Scott III,² B.P. Weegman,¹ J. Li,³ A.S. Lam,³ J.D. Fonger,³ J.M. Ritter,³ M.D. Rizzari,^{1,4}

P.M. Eckman,⁵ L.A. Tempelman,⁶ R. John,⁷ N. Chronos,³ K.K. Papas.² ¹Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN; ²Institute for Cellular Transplantation, Department of Surgery, University of Arizona, Tucson, AZ; ³Saint Joseph's Translational Research Institute, Atlanta, GA; ⁴Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX; ⁵Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN; ⁶Giner Inc, Newton, MA; ⁷Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN.

(424) The Effect of Distance between Donor Hospital and Transplant Center on Survival Following Orthotopic Heart Transplantation; A. Kilic,¹ J.V. Conte,¹ A.S. Shah,¹ W.A. Baumgartner,¹ D.D. Yuh.² ¹Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD; ²Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT.

(425) Evaluation of Patients with Dyspnea with Utilization of Submaximal Exercise Study with SHAPE -HF™ Test Shows Benefits of Cost Saving and Better Patient Care; B. Czerska, A. Pelaez. Transplantation, Florida Hospital, Orlando, FL.

(426) Chagas Cardiomyopathy: The Economic Burden of an Expensive, Neglected Disease, and Cause for Heart Failure; A. Abuhab, E. Trindade, S.M. Fujii, E.A. Bocchi, F. Bacal. Heart Failure, Heart Institute, Sao Paulo, SP, Brazil.

(427) Health Economic Evaluation of Predictive and Diagnostic Biomarkers of Acute Cardiac Rejection; Z. Hollander,^{1,2} T.H.G. Mohammadi,³ M. Co,¹ J.E. Wilson-McManus,¹ R.T. Ng,^{1,4} R. Balshaw,^{1,5} R.W. McMaster,^{1,6} P.A. Keown,^{1,2,7} B.M. McManus,^{1,2,7,8,9} C. Marra.^{1,10,11,12} ¹PROOF Centre of Excellence, Vancouver, BC, Canada; ²Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada; ³Collaboration for Outcomes Research and Evaluation, Vancouver, Canada; ⁴Computer Science, The University of British Columbia, Vancouver, Canada; ⁵Statistics, The University of British Columbia, Vancouver, Canada; ⁶Medical Genetics, The University of British Columbia, Vancouver, Canada; ⁷Medicine, The University of British Columbia, Vancouver, Canada; ⁸UBC James Hogg Research Centre, Vancouver, Canada; ⁹Institute for Heart + Lung Health, Vancouver, Canada; ¹⁰Collaboration for Outcomes Research and Evaluation, The University of British Columbia, Vancouver, Canada; ¹¹Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, Vancouver, Canada; ¹²Arthritis Research Centre of Canada, Vancouver, Canada.

(428) Diffusion Tensor Magnetic Resonance Imaging: A New Tool To Evaluate Cardiac Remodeling Changes in the Failing Human Heart; S.G. Drakos,^{1,2} O. Abdullah,¹ J. Stehlik,² N. Diakos,¹ K. Brunisholz,² B.B. Reid,² C.H. Selzman,² D. Verma,² O. Wever-Pinzon,² C. Myrick,³ G. Russel,³ R. Alharethi,² E.M. Gilbert,² D. Budge,² E. Hsu,¹ D.Y. Li,¹ A.G. Kfoury.² ¹University of Utah Department of Bioengineering & Molecular Medicine, Salt Lake City, UT; ²UTAH Cardiac Transplant Program, Salt Lake City, UT; ³Intermountain Donor Services, Salt Lake City, UT.

(429) Impact of the Severity of End-Stage Liver Disease in Cardiac Remodeling; O.M. Silvestre,¹ F. Bacal,¹ A.G. Farias,² J.L. Andrade,³ M. Furtado,³ V. Pugliese,² W. Andraus,² D.S. Ramos,² E. Belletti,² L.A.C. Albuquerque,² F.J. Carnilho.² ¹Cardiology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil; ²Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil; ³Radiology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil.

(430) The Role of Cardiac Biomarkers in Takotsubo Cardiomyopathy; A. Lahoti,¹ M. Badri,¹ M. Iqbal,² K.S. Mohammed,¹ W. Saeed,² E. Gnall,¹ R. Zolty,² M.R. Sardar.¹ ¹Department of Cardiology, Lankenau Medical Center, Wynnewood, PA; ²Department of Cardiology, Montefiore Medical Center, New York, NY.

(431) Is Improvement in Pulmonary Vascular Hemodynamics in Patients Supported with Continuous-Flow Left Ventricular Assist Devices

Sustained after Heart Transplantation?; A. Saidi, O. Wever-Pinzon, M. Labedi, M. Barakat, J. Stehlik, S. Drakos, C. Selzman, B. Reid, R. Alharethi, A.G. Kfoury, F. Bader. Cardiology, Utah Transplant Affiliated Hospitals, Salt Lake City, UT.

[432] Transmural Heterogeneity and Depressed Function in the Mechanical Properties of Ventricular Tissue from Patients with End-Stage Heart Failure; P. Shekar,¹ M.I. Mitov,² L.F. Ferreira,⁴ S.G. Campbell,¹ S.A. Stasko,¹ A.M. Jarells,¹ B.A. Lawson,¹ M.B. Reid,¹ C.W. Hoopes,³ M.R. Bonnell,⁵ K.S. Campbell.¹ ¹Physiology, University of Kentucky, Lexington, KY; ²Chemistry, University of Kentucky, Lexington, KY; ³Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY; ⁴Applied Physiology and Kinesiology, University of Florida, Gainesville, FL; ⁵Toledo Medical Center, University of Toledo, Toledo, OH.

[433] Relationship between Lead Location and Left Ventricular Remodeling with Peri-Infarct Pacing; C.M. Stolen,¹ L.M. Thackeray,¹ E.S. Chung.² ¹Boston Scientific, St. Paul, MN; ²The Christ Hospital, Cincinnati, OH.

[434] Rest Cerebral Oxygenation Is a Biomarker in Heart Failure Patients; L. Rifai,¹ W. Taylor,¹ K. Key,¹ M.A. Silver.^{1,2} ¹Department of Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, IL; ²Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL.

[435] Use of Vitamin K and Prothrombin Complex Concentrate as Warfarin Reversal Prior to Heart Transplant; T. Mathia,¹ K.E. Pucca,² F. Downey,³ A.J. Boyle,³ Pharmacy, Aurora St. Luke's Medical Center of Aurora Health Care, Inc, Milwaukee, WI; ²Transfusion Medicine, Blood Center of Wisconsin, Milwaukee, WI; ³Cardiothoracic Transplant, Aurora St. Luke's Medical Center of Aurora Health Care Metro, Inc, Milwaukee, WI.

[436] Effect of CYP3A5, CYP3A5 and ABCB1 Genotypes in Tacrolimus Dose and Clinical Outcomes after Heart Transplantation; B. Tavora,¹ B. Diaz-Molina,² J.L. Lambert,² M.J. Bernardo,² C. Moris,² V. Álvarez,¹ C. López-Larrea,³ E. Coto.¹ ¹Molecular Genetics, Laboratory of Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain; ²Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain; ³Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain.

[437] Outcomes in Patients Removed from the Heart Transplant Wait-List Prior to Transplant; C.J. VanderPluym, D. Graham, C. Almond, C. Milliren, T.P. Singh. Children's Hospital Boston, Boston, MA.

[438] Cardiac Transplantation for Chemotherapy Induced Cardiomyopathy: Demographics and Long Term Follow-Up; S.C. McKenzie,^{1,2} A. Sharma,¹ K.-W. Chee,¹ D. Platts,¹ G. Javorsky,¹ M. Brown.^{1,2} ¹Advanced Heart Failure and Cardiac Transplant Unit, The Prince Charles Hospital, Brisbane, QLD, Australia; ²School of Medicine, University of Queensland, Brisbane, QLD, Australia.

[439] Remodeling Risk Prediction with Chronic Heart Rate Variability: Secondary Results from the Myocardial Enlargement and Dilatation Post Myocardial Infarction (MENDMI) Study; D. Dan,² A. Patangay,¹ C.M. Stolen.¹ ¹Cardiology, Rhythm and Vascular, Boston Scientific, St. Paul, MN; ²Piedmont Hospital, Atlanta, GA.

[440] Uric Acid Elevation Is Associated with Severity of Congestion in Advanced Heart Failure; M. Guglin,¹ G. Stewart,² M.M. Kittleson,³ J.A. Cowger,⁴ C.B. Patel,⁵ J.E. Rame,⁶ M.M. Mountis,⁷ P. Patel,⁸ F. Johnson,⁹ J. Teuteberg,¹⁰ J. Testani,⁶ L.W. Miller.¹ ¹Cardiology, University of South Florida, Tampa, FL; ²Medicine, Brigham and Women's Hospital, Boston, MA; ³Sedar Sinai Hospital, Los Angeles; ⁴University of Michigan, Ann Arbor; ⁵Duke University, Durham; ⁶University of Pennsylvania, Philadelphia; ⁷Cleveland Clinic, Cleveland; ⁸UT Southwestern, Dallas; ⁹University of Iowa, Iowa City; ¹⁰University of Pittsburgh, PA.

[441] Exceptional Predictive Ability of the Intermountain Risk Score (IMRS) for Hospital Readmission after Heart Failure (HF) Discharge;

K.D. Brunisholz, A.G. Kfoury, K.D. Rasmussen, T. Bair, D. Budge, R. Alharethi, J. Tuinei, S. Frampton, K.D. Balling, D.P. Nelson, J.L. Anderson, B.D. Horne. UTAH Cardiac Transplant Program, Salt Lake City, UT.

[442] Reoperative Sternotomy Is Associated with Increased Mortality after Heart Transplantation; T.J. George,¹ C.A. Beaty,¹ G.A. Ewald,² A.S. Shah,¹ S.D. Russell,³ J.V. Conte,¹ G.J. Whitman,¹ S.C. Silvestry.⁴ ¹The Division of Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD; ²The Division of Cardiovascular Diseases, Washington University School of Medicine, St. Louis, MO; ³The Division of Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD; ⁴The Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.

[443] Is Heart Transplantation a Reasonable Concept in Patients with Severe Cardiac Amyloidosis?; N. Reiss,¹ A. Kristen,² S. Schoenland,³ U. Heigenbart,³ S. Buss,² F.-U. Sack,¹ P. Schnabel,⁴ C. Roewen,⁵ T. Dengler,² A. Ho,³ A. Ruhparwar,¹ M. Karck,¹ H. Katus.² ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiology, Angiology and Respiratory Medicine, University of Heidelberg, Heidelberg, Germany; ³Department of Hematology, University of Heidelberg, Heidelberg, Germany; ⁴Department of Pathology, University of Heidelberg, Heidelberg, Germany; ⁵Department of Pathology, University of Kiel, Kiel, Germany.

[444] Use of Continuous Home Infusion Milrinone (HIM) in Inotrope Dependent (ID) Patients as a Bridge to Recovery; P. Muthusamy,^{1,2} S. Madan,³ K. Mowers,³ D.E. Langholz,¹ J.D. Call,¹ M.B. Hanrahan,⁴ A.T. Davis,^{2,3} M.G. Dickinson.¹ ¹Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; ²Grand Rapids Medical Education Partners, Grand Rapids, MI; ³Michigan State University/College of Human Medicine, Grand Rapids, MI; ⁴Coram Home Infusion Group, Grand Rapids, MI.

[445] Increased Mortality Following Cardiac Transplantation in Patients with Peripheral Vascular Disease; J.S. Enciso,¹ T.S. Kato,¹ C.J. Chung,¹ J. Yang,² P.C. Schulze.¹ ¹Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; ²Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

[446] A Pilot Study of Screening CRT/ICD Patients for Heart Transplantation and Left Ventricular Assist Device Referral; S. Zabarovskaja, A. Gabrielsen, A. Törnqvist, F. Gadler, C. Linde, L.H. Lund. Cardiology, Medicine, Stockholm, Sweden.

[447] Late Response to Desensitization Therapy; J. Kobashigawa, J. Patel, M. Rafiei, L. Stern, M. Kittleson, L. Czer, F. Esmailian. Cedars-Sinai Heart Institute, Los Angeles, CA.

[448] Heart Transplantation for End-Stage Valvular Cardiomyopathy: A 26-Year Single-Center Experience; C. Pellegrini,¹ S. Nicolardi,² D. Di Perma,¹ P. Totaro,¹ C. Tinelli,³ F. Pagani,¹ A. D'Armini,¹ M. Viganò.¹ ¹Department of Surgical Sciences, Section of Cardiac Surgery and Thoracic Transplantation, Fondazione IRCCS Policlinico "San Matteo" – University of Pavia, Pavia, Italy; ²Department of Surgical Sciences, Section of Surgery, Fondazione IRCCS Policlinico "San Matteo" – University of Pavia, Pavia, Italy; ³Clinical Epidemiology and Biometry Service, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy.

[449] The Outcome of Patients with Idiopathic Non-Dilated Hypertrophic Cardiomyopathy Following Cardiac Transplantation; T.S. Kato,¹ M. Maurer,¹ Y. Naka,² M. Farr,¹ D. Mancini,¹ P.C. Schulze,¹ H. Takayama.² ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

[450] Palliative Care in End Stage Heart Failure: A Single Center Observational Study; M.I. Owen, B.D. DeMoss, D. Gupta. Emory University Hospital, Atlanta, GA.

[451] Kidney Biopsies on Patients Awaiting Heart Transplant: Glomerulomegaly as a Feature; C. Parikh,¹ S. Sandilya,¹ J. Pullman,² J.J.

Shin,³ D. Goldstein,⁴ S. Maybaum,³ M. Melamed,⁵ G. Ladan.⁵ ¹Internal Medicine, Montefiore Medical Center, Bronx, NY; ²Pathology, Montefiore Medical Center, Bronx, NY; ³Medicine, Montefiore Medical Center, Bronx, NY; ⁴Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY; ⁵Nephrology, Montefiore Medical Center, Bronx, NY.

(452) Right Ventricle Impact on Functional Capacity, Cardio Pulmonary Exercise Test and BNP in Chronic Heart Failure; D. Murninkas, A.C. Alba, H.J. Ross. Toronto General Hospital, Toronto, ON, Canada.

(453) The Prevalence of Chronic Kidney Disease before and after Orthotopic Heart Transplant: Does the Degree of eGFR Decline Proportionally Translate into Poorer Patient Outcomes?; J. Jiang,¹ A. Almehty,³ M. Ji,¹ H. Yerebakan,¹ M.A. Farr,² M. Argenziano,¹ C.R. Smith,² H. Takayama,¹ D.M. Mancini,² Y. Naka,¹ P.C. Schulze,² F.H. Cheema.¹ ¹Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Department of Cardiology, Columbia University Medical Center, New York, NY; ³Division of Nephrology, University of Tennessee College of Medicine, Memphis, TN.

(454) Milrinone in Advanced Heart Failure: A Potential Role for Therapeutic Drug Monitoring; D. Charisopoulou,¹ N. Leaver,² N.R. Banner.³ ¹Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom; ²Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom; ³Heart Failure and Transplant, Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom.

(455) U.S. Heart Transplant Rates Vary by Holiday; J.L. Grodin, J.T. Thibodeau, J.D. Mishkin, P.P.P.A. Mammen, D.W. Markham, M.H. Drazner, P.C. Patel. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX.

(456) Regional Distribution of End-Stage Heart Failure Patients in a Single Heart Transplant Center Country; P. Soos, Eva Belicza, D. Becker, L. Kiss, K. Karlocai, Z. Szabolcs, F. Horkay, B. Merkely. Semmelweis University, Budapest, Hungary.

(457) Desensitization Therapy with Immunoglobulin (IVIG) and Rituximab for Patients Awaiting Heart Transplantation; J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, L. Czer, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(458) Endothelial Progenitor Cells Independently Predict Functional Capacity in Heart Failure Patients; A.C. Alba,¹ V. Rao,¹ S. Walter,² G. Guyatt,² H. Ross.¹ ¹Toronto General Hospital, Toronto, ON, Canada; ²McMaster University, Hamilton, ON, Canada.

(459) Monitoring of Respiratory Rate Derived from an Implantable Right Ventricular Pressure Sensor in Patients with Heart Failure; E. Chung,¹ M. Erickson,² V. Torres,³ G. Haas,⁴ A. Magalski,⁵ P. Adamson,⁶ M.R. Costanzo,⁷ J. Murillo.⁸ ¹The Christ Hospital, Cincinnati, OH; ²Medtronic, Inc., Mounds View, MN; ³Loma Linda University, Loma Linda, CA; ⁴The Ohio State University Medical Center, Columbus, OH; ⁵Mid America Heart Institute, Kansas City, MO; ⁶Oklahoma Heart Hospital, Oklahoma City, OK; ⁷Midwest Heart Specialists, Naperville, IL; ⁸Sentara Cardiovascular Research Institute, Norfolk, VA.

(460) Characterization and Functional Implications of Heart Rate Increase at the Onset of Exercise Testing and Heart Rate Recovery in Patients with Advanced Heart Failure; M. White,¹ J. Myers,² M.-C. Guertin,³ M. Cossette,³ A. Ducharme,¹ F. Harel,¹ E. O'Meara,¹ G. Gravel,¹ B. Thibault.¹ ¹Research Center, Montreal Heart Institute/Université de Montréal, Montreal, QC, Canada; ²Research Center, Stanford University, Palo Alto, CA; ³Biostatistics, Montreal Heart Institute Coordinating Center, Montreal, QC, Canada.

(461) Can Clinical Measures Identify Liver Fibrosis in Patients Who Undergo Heart Failure Surgery?; N. Farre, L. Tilling, A. Rice, A.R. Simon, N.R. Banner. Transplant and Circulatory Support, Harefield Hospital, Harefield, Middlesex, United Kingdom.

(462) Effect of Preoperative Dental Foci on Event-Free Survival Post Heart Transplantation; S. Meyer,¹ S. Ohdah,¹ A. von Stritzky,¹ C. Ivanov,¹ T. Deuse,² H. Reichenspurner,² A. Costard-Jäckle.¹ ¹Department of General and Interventional Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Department of Cardiovascular Surgery, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(463) Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for Immune Complication in Heart Transplant; K. Cao,¹ C.-H. Lai,¹ S.V. Flores,¹ M. Rafiei,² J. Mirocha,³ M. Haas,⁴ G. Ong,¹ M. Naim,¹ Q. Wang,¹ L. Constanza,¹ J. Patel,² N.L. Reinsmoen,¹ J. Kobashigawa.² ¹HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ³Biostatistics Core, Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ⁴Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

(464) Preoperative Anti-HLA Antibodies Predict Antibody-Mediated Rejection in Heart Transplant Recipients; T. Gazdic,¹ E. Slimackova,² I. Malek,³ A. Slavcev,² M. Kubanek,³ J. Pirk.¹ ¹Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ³Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(465) A Multivariate Analysis of Clinical Parameters That Affect Gene Expression Profile Assessment of Immune Activation; B. Patterson, B. Springfield, J.A. Hill, J.M. Aranda, R.S. Schofield, A.D. Szady, P.K. Humphlett, D.F. Pauly. Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL.

(466) The Combination of Left Ventricular Torsion and Global Strain Based on Two-Dimensional Speckle Tracking Echocardiography Could Detect Treatment-Requiring Rejection in Heart Transplant Recipients; S. Hashimoto,¹ T.S. Kato,² Y. Sumita,¹ N. Tanaka,¹ I. Nakasone,¹ M. Sano,³ H. Kanzaki,³ T. Ohara,³ M. Kitakaze.³ ¹Department of Clinical Physiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; ²Department of Organ Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; ³Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

(467) Serological Characterization of Cardiac Transplant Patient with Evidence of Antibody Mediated Rejection and Those Without; L.F. Xu,¹ E. Feller,² A.P. Burke,¹ C.I. Drachenberg.¹ ¹Pathology, University of Maryland Medical Center, Baltimore, MD; ²Cardiology, University of Maryland Medical Center, Baltimore, MD.

(468) Are the Levels of Serum CXCL10 Significant for Prediction of Cardiac Allograft Rejection?; L. Kolesár,¹ E. Slimáková,¹ T. Gazdic,² E. Honsová,³ I. Netuka,² A. Slavcev,¹ I. Málék.² ¹Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ³Clinical Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(469) Correlation of Cytomegalovirus (CMV) Serologic Status of Heart Transplant Recipients to Gene-Expression Profiling Scores and Clinical Outcomes: Results from the IMAGE Multicenter Study; W.G. Cotts,¹ M.C. Deng,² B. Elashoff,³ M.X. Pham,^{4,14} J.J. Teuteberg,⁵ A.G. Kfoury,⁶ R.C. Starling,⁷ T.P. Cappola,⁸ A. Kao,⁹ A.S. Anderson,¹⁰ G.A. Ewald,¹¹ D.A. Baran,¹² R.C. Bogaev,¹³ V. Stosor,¹ J.P. Yee,³ H.A. Valantine.⁴ ¹Northwestern University, Chicago, IL; ²Columbia University Medical Center, New York, NY; ³XDx, Inc., Brisbane, CA; ⁴Stanford University Medical Center, Palo Alto, CA; ⁵University of Pittsburgh Medical Center, Pittsburgh, PA; ⁶Intermountain Medical Center, Salt Lake City, UT; ⁷Cleveland Clinic, Cleveland, OH; ⁸Hospital of the University of Pennsylvania, Philadelphia, PA; ⁹American Heart Institute, Saint Luke's Hospital, Kansas City; ¹⁰University of Chicago Medical Center, Chicago, IL; ¹¹Washington University School of Medicine, St. Louis; ¹²Newark Beth Israel Medical Center, Newark,

NJ; ¹³Texas Heart Institute, Houston, TX; ¹⁴VA Palo Alto Health Care System, Palo Alto, CA.

(470) Assessment of Humoral and Cellular Immunocompetence Status Late after Heart Transplantation; E. Sarmiento,¹ A. Gallego,¹ J. Rodriguez-Molina,¹ J. Navarro,¹ J. Fernandez-Yañez,² J. Palomo,² A. Villa,² M. Arraya,¹ J. Gil,¹ E. Fernandez-Cruz,¹ J. Carbone.¹ ¹Clinical Immunology, Gregorio Marañón Hospital, Madrid, Spain; ²Cardiology, Gregorio Marañón Hospital, Madrid, Spain.

(471) IDO Activity May Be a Potential Early Marker of Graft Rejection in Heart Transplantation; N. Suárez-Fuentetaja,² M.J. Paniagua-Martín,¹ N. Domenech-García,² R. Marzoa-Rivas,¹ E. Barge-Caballero,¹ Z. Grille-Cancela,¹ M. Hermida-Prieto,^{2,3} J. Muñoz-García,³ A. Castro-Beiras,^{1,3} M. Crespo-Leiro.¹ ¹Cardiology Department, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; ²INIBIC (CHUAC), A Coruña, Spain; ³Instituto de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain.

(472) Younger Age and Female Gender Are Associated with Higher Gene Expression Profile Values; B.A. Austin,¹ E. Wang,² P.J. Arnold,² A. Kao.¹ ¹Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO; ²Expression Diagnostics, Brisbane, CA.

(473) Echocardiographic Guidance for Endomyocardial Biopsy Reduces the Incidence of Tricuspid Regurgitation Post Cardiac Transplantation; B.A. Boilson, J.A. Schirger, C.J. Bruce, C.S. Rihal, K.S. Sudhir. Division of Cardiology, Mayo Clinic, Rochester, MN.

(474) Successful Use of Gene Expression Profile Testing To Help with Corticosteroid Weaning Post Orthotopic Heart Transplant, the Mid America Experience; K. St. Clair, M. Eaton, J. Linard, C. Knutson, A.M. Borkon, A. Kag. Cardiac Transplant Program, Saint Luke's Mid America Heart Institute, Kansas City, MO.

(475) Correlation of Immunological Markers with Graft Vasculopathy Development in Heart Transplantation; C. Gelpi, C. Roldan, S. Mirabet, V. Brossa, L. Lopez, A. Mendez, J.M. Padro, E. Roig. Immunology, Hospital Sant Pau, Barcelona, Spain; Immunology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain; Cardiac Surgery, Hospital Sant Pau, Barcelona, Spain; Cardiology, Hospital Sant Pau, Barcelona, Spain.

(476) Identification of Immune Profiles That Are Associated with Development of Severe Infection in Heart Recipients; J. Carbone,¹ N. Del Pozo,¹ A. Gallego,¹ N. Lanio,¹ J. Rodriguez-Molina,¹ J. Navarro,¹ J. Palomo,² J. Fernandez-Yañez,² A. Villa,² P. Muñoz,³ M. Ruiz,⁴ J. Hortal,⁵ C. Rodriguez,⁶ E. Fernandez-Cruz,¹ K. Kotsch,⁷ E. Sarmiento.¹ ¹Immunology, Gregorio Marañón Hospital, Madrid, Spain; ²Cardiology, Gregorio Marañón Hospital, Madrid, Spain; ³Microbiology, Gregorio Marañón Hospital, Madrid, Spain; ⁴Cardiovascular Surgery, Gregorio Marañón Hospital, Madrid, Spain; ⁵Anesthesiology, Gregorio Marañón Hospital, Madrid, Spain; ⁶Biochemistry, Gregorio Marañón Hospital, Madrid, Spain; ⁷Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck., Innsbruck, Austria.

(477) Women in a Predominantly African American Population Exhibit Lower Gene Expression Scores Early after Heart Transplant; K.B. Shah, M.P. Flattery, K. Doolin. Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA.

(478) TNF- α and IL-8 Predict Cardiac Vasculopathy after Cardiac Transplantation; N. Heikal,^{1,2} H. Hill,^{1,2,3,4} T. Martins,¹ I. Pavlov,¹ A. Wilson,¹ J. Stehlik,⁴ A. Kfoury,⁴ J. Delgado,^{1,2} F. Bader.⁴ ¹ARUP Institute for Clinical and Experimental Pathology, SLC, UT; ²Department of Pathology, SLC; ³Pediatrics and Medicine, SLC; ⁴Division of Cardiology, University of Utah School of Medicine, SLC.

(479) First-Year Rejection and Cylex Scores Suggest the Importance of Acute Events in the Development of Cardiac Allograft Vasculopathy; M.

Rafiej, J. Patel, M. Kittleson, N. Patel, L. Stern, B. Azarbal, L. Czer, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(480) Donor Specific Anti-HLA Antibody Detection in Heart Transplantation: Comparison of a Donor-Specific Bead-Based Crossmatch Technique with Flow-Crossmatch and Single-Antigen Bead Methodology; A. Chaidaroglou,¹ A. Skoura,¹ A. Gouziouta,² D. Degiannis.¹ ¹Molecular Immunopathology and Histocompatibility Laboratory, Onassis Cardiac Surgery Center, Athens, Greece; ²nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

(481) Surveillance Endomyocardial Biopsies Early after Heart Transplantation Have a Low Yield for Detecting Cellular Rejection in the Modern Era; K.B. Shah, M.P. Flattery, E.H. Sheldon, L. Thacker, K. Doolin, G. Merinar, R.H. Cooke, M.L. Hess. Virginia Commonwealth University, Richmond, VA.

(482) Cellular Rejection on a Non-Routine Biopsy Predicts Poor Long Term Outcome; G.S. Panirath,¹ T. George,¹ S.D. Russell,¹ R.J. Tedford,¹ C. Steenbergen,² J. Scheel,³ D.V. Skojec,¹ M.K. Haluska.² ¹Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD; ²Division of Cardiovascular Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD; ³Division of Pediatric Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD.

(483) Iron Deficiency in Hospitalized Heart Failure Patients; P. Muthusamy,^{1,2} K. Mowers,³ S. Madan,³ A. Bhopalwala,² M. Khan,² C.R. Smith,³ A. Shoemaker,² A.T. Davis,^{2,3} M.G. Dickinson.¹ ¹Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; ²Grand Rapids Medical Education Partners, Grand Rapids, MI; ³Michigan State University/College of Human Medicine, Grand Rapids, MI.

(484) Combined Heart and Liver Transplant Attenuates Cardiac Allograft Vasculopathy with Decreased Coronary Related Cardiac Events Compared to Isolated Heart Transplantation; Y. Topilsky,¹ E. Raichlin,² T. Hasin,¹ B.A. Boilson,¹ J.A. Schirger,¹ N.L. Pereira,¹ B.S. Edwards,¹ A.L. Clavell,¹ R.J. Rodeheffer,¹ R.P. Frantz,¹ M.J. Gandhi,¹ S. Maltais,³ S.J. Park,³ R.C. Daly,³ A. Lerman,¹ S.S. Kushwaha.¹ ¹Cardiology, Mayo Clinic, Rochester, MN; ²Cardiology, University of Nebraska Medical Center, Omaha, NE; ³Cardiac Surgery, Mayo Clinic, Rochester, MN.

(485) Do Significant Daily, Monthly and Seasonal Variations in Thoracic Organ Transplantation Exist?; M.S. Khan,¹ A.X. Samayoa,¹ I. Adachi,¹ B. Shirkey,² J.S. Heinle,¹ D.L.S. Morales.¹ ¹Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²Congenital Heart Surgery, Texas Children's Hospital, Houston, TX.

(486) Thoracic Transplantation Increases during Holidays: Reality or Myth?; A.X. Samayoa,¹ M.S. Khan,¹ B.A. Shirkey,² I. Adachi,¹ W.J. Dreyer,³ J.S. Heinle,¹ D.L.S. Morales.¹ ¹Michael E. DeBakey Department of Surgery, Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX; ²Congenital Heart Surgery, Texas Children's Hospital, Houston, TX; ³Pediatrics, Division of Cardiology, Baylor College of Medicine, Houston, TX.

(487) Oral Sildenafil: A Safe and Effective Treatment of Persistent Pulmonary Hypertension after Heart Transplantation; R. Marzoa Rivas,¹ M.J. Paniagua-Martín,¹ E. Barge-Caballero,¹ Z. Grille-Cancela,¹ J. Balea-Filgueiras,⁴ G. Aldama-Lopez,² M. Garcia-Guimaraes,¹ E. Mendez-Eirin,¹ J.J. Cuenca-Castillo,³ A. Castro-Beiras,¹ M.G. Crespo-Leiro.¹ ¹Advanced Heart Failure and Heart Transplant Unit, University Hospital of A Coruna, A Coruna, Spain; ²Hemodynamic Unit, University Hospital of A Coruna, A Coruna, Spain; ³Cardiac Surgery Service, University Hospital of A Coruna, A Coruna, Spain; ⁴Pharmacy Service, University Hospital of A Coruna, A Coruna, Spain.

(488) Prevalence of Cardiac Allograft Vasculopathy at 1 Year after Heart Transplantation According to the ISHLT Standardized Nomenclature and Its Prognostic Value; O. Prada-Delgado, R. Estévez-Loureiro, A. López-Sainz, M.J. Paniagua-Martín, R. Marzoa-Rivas, E. Barge-Caballero, R. Calviño-Santos, J.J. Cuenca-Castillo, A. Castro-Beiras, M.G. Crespo-Leiro. Heart

Transplant and Advanced Heart Failure Unit, Division of Cardiology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(489) Metabolic Syndrome Is Significantly Associated with Cardiac Allograft Vasculopathy: The Influence of Modifiable Risk Factors on Mortality in Patients Undergoing Orthotopic Heart Transplantation; J. Jiang,¹ O.T. Siddiqui,¹ M. Ji,¹ K. Schaeffle,¹ H. Yerebakan,¹ M.A. Farr,² H. Takayama,¹ C.R. Smith,¹ D.M. Mancini,² M. Argenziano,¹ Y. Naka,¹ P.C. Schulze,² F.H. Cheema.¹ ¹Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Department of Cardiology, Columbia University Medical Center, New York, NY.

(490) Can Strain Echocardiography Be Used as a Noninvasive Method To Predict Cardiac Allograft Stage 3 Vasculopathy in HTx Recipients with Normal Ejection Fraction; L.J.F. Estofan, H.R. Villarraga, B.S. Edwards, F.A. Miller, P.A. Pellikka. Cardiovascular, Mayo Clinic, Rochester, MN.

(491) Differential Effect of Everolimus and Metabolic Risk Factors on Early vs. Late Progression of Allograft Vasculopathy: Dissecting Two Faces of the Same Disease; M. Masetti, L. Potenza, M. Nardoza, P. Prestinzi, V. Pece, N. Taglieri, F. Saia, G. Magnani, F. Coccolo, F. Fallani, F. Grigioni, A. Branzi. Cardiovascular Department, University of Bologna, Bologna, Italy.

(492) Comparison of Predictive Significance of Soluble CD40 Ligand, Pregnancy-Associated Plasma Protein A, and Placental Growth Factor for Graft Failure Development after Heart Transplantation; O.P. Shevchenko,¹ T.A. Khalilulin,¹ A.O. Shevchenko,² Q.V. Orlova,¹ B.L. Mironkov,¹ E.N. Kazakov,¹ A.J. Kormer,¹ S.V. Gautier.¹ ¹Federal Research Center of Transplantation and Artificial Organs Named after Academician V. Shumakov, Moscow, Russian Federation; ²Russian State Medical University, Moscow, Russian Federation.

(493) Declining Incidence of Cardiac Allograft Vasculopathy: A Serial Angiographic Review; R. Khan, K. Morant, P.W. Pflugfelder, W.J. Kostuk. Division of Cardiology, LHSC University Hospital, London, ON, Canada.

(494) Tetranectin Is Associated with Cardiac Allograft Vasculopathy in Heart Transplant Recipients; S. Aharinejad, M. Salama, R. Susanne, A. Zuckermann, G. Laufer. Medical University of Vienna, Vienna, Austria.

(495) A Strong Thigh Can Make VO2 Go High – Predictors of VO2 peak in Heart Transplant Recipients; K. Nytrøen,¹ L.A. Rustad,^{1,2} E. Gude,¹ A.E. Fiane,^{3,5} K. Rolid,¹ I. Holm,⁴ S. Aakhus,¹ L. Gullestad.^{1,5} ¹Department of Cardiology, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; ²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; ³Norwegian School of Sport Sciences, Oslo, Norway; ⁴Department of Cardiothoracic Surgery, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; ⁵Division of Surgery and Clinical Neuroscience, Oslo University Hospital HF Rikshospitalet, Oslo, Norway; ⁶Faculty of Medicine, University of Oslo, Oslo, Norway.

(496) Risk Factors for Nosocomial Infection in the Post-Operative Period after Heart Transplantation; P. Fernández-Ugidos,¹ R. Gómez-López,¹ M.J. Paniagua-Martin,² R. Marzoa-Rivas,² E. Barge-Caballero,² J. Muñoz,³ J.J. Cuenca,⁴ M.T. Bouza-Vieiro,⁵ S. Fojón-Polanco,⁵ Z. Grille-Cancela,² A. Castro-Beiras,² M.G. Crespo-Leiro.² ¹Intensive Care, Complejo Hospitalario Universitario de Ourense, Ourense, Spain; ²Cardiology, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ³Instituto Universitario de Ciencias de la Salud, Universidade de A Coruña, A Coruña, Spain; ⁴Cardiac Surgery, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; ⁵Intensive Care, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(497) Rates of CMV Viremia and Treated CMV in Patients Receiving Alemtuzumab Induction Prior to Cardiac Transplantation; M.A. Shullo,¹ R. Zomak,² C. Grabowski,² M. Navoney,² D. McNamara,² C. Bermudez,² R.L. Kormos,² J.J. Teuteberg.² ¹Pharmacy and Therapeutics, University of Pittsburgh, PA; ²Heart and Vascular Institute, University of Pittsburgh, PA.

(498) Combined Prophylactic and Pre-Emptive CMV Strategy with Valganciclovir in Heart Transplant Patients Is Efficacious and Safe; M. Eriksson,¹ J.J. Jokinen,² P. Hammainen,² J. Lommi,³ K. Lemstrom.² ¹Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland; ²Heart and Lung Transplantation Program, Helsinki University Central Hospital, Helsinki, Finland; ³Cardiology, Helsinki University Central Hospital, Helsinki, Finland.

(499) First Documented Case of Transmission of Mycobacterium Tuberculosis from a Multi-Organ Donor to a Heart Transplant Recipient; J. Weile,¹ U. Fuchs,² H. Eickmeyer,² J.-W. Wittke,³ S. Ruesch-Gerdes,⁴ J.F. Gummert,² C. Knabbe,¹ U. Schulz.² ¹Institute for Laboratory- and Transfusion Medicine, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany; ²Thoracic and Cardiovascular Surgery, Heart- and Diabetes Center NRW, Bad Oeynhausen, Germany; ³Medical Laboratory of Bremen, Bremen, Germany; ⁴Research Center Borstel, German Reference Center for Mycobacteria; Leibniz Center for Medicine and Biosciences, Borstel, Germany.

(500) Non-Invasive Mycoses after Heart Transplantation: Outcome and Long-Term Prognosis; T. Haberl,¹ D. Hutschala,² C. Pelanek,¹ A.Z. Aliabadi,¹ G. Laufer,¹ A. Zuckermann.¹ ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Anaesthesiology, Medical University of Vienna, Vienna, Austria.

(501) Low Infection Rates in Jarvik 2000 LVAD. Are Post-Auricular Cable and Pump Configuration Playing a Positive Effect?; V. Tarzia,¹ U. Livi,² G. Di Giammarco,³ G. Sani,⁴ M. Maccherini,⁵ M. Rinaldi,⁶ F. Alamanni,⁷ M. De Bonis,⁸ F. Gazzoli,⁹ A. Renzulli,¹⁰ G. Mazzei,¹¹ G. Arpesella,¹² G. Di Credico,¹³ M. Zogno,¹⁴ A. Costantino,¹⁵ G. Gerosa.¹⁶ ¹Cardiac Surgery University of Padova, Padova, Italy; ²Cardiac Surgery University of Udine, Udine, Italy; ³Cardiac Surgery University of Chieti, Chieti, Italy; ⁴Cardiac Surgery University of Florence, Florence, Italy; ⁵Cardiac Surgery University of Siena, Siena, Italy; ⁶Cardiac Surgery University of Turin, Turin, Italy; ⁷Cardiac Surgery CCFM University of Milan, Milan, Italy; ⁸Cardiac Surgery San Raffaele Hospital, Milan, Italy; ⁹Cardiac Surgery Policlinico San Matteo, Pavia, Italy; ¹⁰Cardiac Surgery Magna Grecia University, Catanzaro, Italy; ¹¹Cardiac Surgery La Sapienza University, Roma, Italy; ¹²Cardiac Surgery University of Bologna, Bologna, Italy; ¹³Cardiac Surgery Civile Hospital, Legnano, Italy; ¹⁴Cardiac Surgery Carlo Poma Hospital, Mantova, Italy; ¹⁵Cardiac Surgery S. Filippo Neri Hospital, Roma, Italy; ¹⁶Cardiac Surgery University of Padova, Padova, Italy.

(502) Spectrum and Etiologies of Ventricular Assist Device Infections: A Single Center Study; V. Stosor,^{1,2} K. Meehan,^{3,4} R. Gordon,^{1,3} E. McGee.^{3,5} ¹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; ²Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL; ³Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL; ⁴Northwestern Memorial Hospital, Chicago, IL; ⁵Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL.

(503) RSV Prevention and Treatment in Pediatric Lung Transplant Patients: A Survey of Current Practices among the International Pediatric Lung Transplant Collaborative (IPLTC); L.A. Danziger-Isakov,¹ D. Anslan,¹ S. Sweet,² C. Benden,³ S. Goldfarb,⁴ J. Wong.⁵ ¹Cleveland Clinic, Cleveland; ²St. Louis Children's Hospital, St. Louis; ³University Hospital Zurich, Zurich, Switzerland; ⁴Children's Hospital of Philadelphia, Philadelphia; ⁵University of Alberta, Alberta, Canada.

(504) Change in Disability Is a Determinant of Quality of Life in Persons Undergoing Lung Transplant; J.P. Singer,^{1,3} P.P. Katz,⁴ J. Chen,³ T. Golden,³ L.E. Leard,¹ S.R. Hays,¹ J. Kukreja,⁵ D. Sayah,^{1,3} P.D. Blanc.^{1,2,3} ¹Pulmonary and Critical Care Medicine, UC San Francisco, San Francisco, CA; ²Occupational and Environmental Medicine, UC San Francisco, San Francisco, CA; ³Cardiovascular Research Institute, UC San Francisco, San Francisco, CA; ⁴Health Policy Studies, UC San Francisco, San Francisco, CA; ⁵Cardiothoracic Surgery, UC San Francisco, San Francisco, CA.

(505) Overcoming the Tyranny of Distance: Ensuring Equity of Access and Outcome in Lung Transplant; J. Harris, D.T. Keating, S. Hacker, G.I.

Snell, T. Williams. Lung Transplant Service, The Alfred Hospital, Melbourne, VIC, Australia.

(506) The Transbronchial Brush Test Circumvents Sampling Limitation Associated with Transbronchial Biopsy and Has Superior Reproducibility for Assessment of Lymphocytic Bronchiolitis; D.C. Chambers,^{1,2} S.T. Yerkovich,^{1,2} M.E. Tan,¹ K.A. Sinclair,¹ F.D. Kermeen,¹ A. Fiene,¹ P.M. Hopkins.^{1,2} ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia; ²School of Medicine, The University of Queensland, Brisbane, Australia.

(507) IgM Depletion Discovers Undetected Donor Specific Antibodies Associated with Antibody Mediated Rejection after Lung Transplantation; H.W. Ainge Allen,¹ A.P. Havryk,¹ M.A. Malouf,¹ M. Plit,¹ C. Benden,¹ N. Watson,² A.R. Glanville.¹ ¹Department of Cardiopulmonary Transplant, St Vincent's Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.

(508) Experience with Cylex Immune Cell Function Assay in Clinical Immune Monitoring of Lung Transplant Recipients; F. Bini,¹ S. Miserere,¹ M. Morosini,¹ A. Grasso,¹ E. Cova,¹ C. Pellegrini,² A.M. D'Armini,² F. Meloni.¹ ¹Clinic Respiratory Diseases, San Matteo Foundation and University of Pavia, Pavia, Italy; ²Department of Surgery, Section of Cardiac Surgery, University of Pavia and San Matteo Foundation, Pavia, Italy.

(509) Prospective Surveillance and Treatment of De Novo Donor Specific Antibodies after Lung Transplantation Ameliorates 1-Year Risk of BOS; H.W. Ainge Allen,¹ A.P. Havryk,¹ M.A. Malouf,¹ M. Plit,¹ C. Benden,¹ N. Watson,² A.R. Glanville.¹ ¹Department of Cardiopulmonary Transplant, St Vincent's Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.

(510) Cryoprobe Versus Forceps Biopsy for Post-Lung Transplant Surveillance; L. Yarmus, J. Akulian, C. Gilbert, J. Orens, C. Merlo, D. Feller-Kopman. Pulmonary and Critical Care Medicine, The Johns Hopkins University, Baltimore, MD.

(511) Prospective Surveillance and Treatment of Pre-Existing Donor Specific Antibodies Ameliorates 1-Year Risk of BOS after Lung Transplantation; H.W. Ainge Allen,¹ A.P. Havryk,¹ M.A. Malouf,¹ M. Plit,¹ C. Benden,¹ N. Watson,² A.R. Glanville.¹ ¹Department of Cardiopulmonary Transplant, St Vincent's Hospital, Sydney, NSW, Australia; ²NSW Transplantation and Immunogenetics Laboratory, Australian Red Cross Blood Service, Sydney, NSW, Australia.

(512) Lessons from the Lung: 186 Autopsies after Lung Transplantation; M. Malouf, A. Havryk, M. Plit, C. Benden, S. Rainer, A. Glanville. The Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, NSW, Australia.

(513) Extracorporeal Treatment of Antibody Mediated Heart or Lung Transplant Rejection; S. Rummeler,¹ K. Maier,¹ M. Breuer,² T. Sandhaus,² T. Paull,² T. Steinke,² T. Doenst,² D. Barz.¹ ¹University of Jena, Institute of Transfusion Medicine, Jena, Germany; ²University of Jena, Department of Cardiothoracic Surgery, Jena, Germany.

(514) Biopsy-Proven Acute Rejection after Combined Heart and Lung Transplantation; K.L. Dawson,¹ V.P. Doan,² J. Estep,¹ H. Seethamraju.¹ ¹The Methodist Hospital, Houston, TX; ²University of Houston, Houston, TX.

(515) Everolimus for Calcineurin Inhibitor Minimization in Lung Transplant Recipients with Chronic Renal Insufficiency; K. Schoeppler,¹ D. Lyu,² I. Kim,¹ T. Grazia,² J. Crossno,² U. Christians,³ M.R. Zamora.² ¹Pharmacy, University of Colorado Hospital, Aurora, CO; ²Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Aurora, CO; ³Anesthesiology, University of Colorado Health Sciences Center, Aurora, CO.

(516) Plasma Surfactant Protein D Concentrations in Lung Transplant Recipients during Infection and Rejection Events; I. Bejvl,¹ L. Weseslindtner,¹ R. Strassl,¹ P. Jaksch,² M. Kundi,³ W. Klepetko,² E. Puchhammer-Stöckl.¹ ¹Department of Virology, Medical University of Vienna, Vienna, Austria; ²Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ³Institute of Environmental Health, Medical University of Vienna, Vienna, Austria.

(517) Monitoring Warm Ischemic Time Helps Improve Surgeons' Technical Performance; Y. Toyoda,¹ J.K. Bhamra,² N. Shigemura,² A. Bansal,² M. Crespo,² J. Pilewski,² C. Bermudez.² ¹Temple University School of Medicine, Philadelphia, PA; ²UPMC, Pittsburgh, PA.

(518) Incidence and Clinical Course of Barrett's Esophagus Pre- and Post-Lung Transplantation; R. Valia, T.N. Hodges, J.L. Huang, K.A. Varsch, R. Saggari, P.M. Naik, E.Y. Kuo, R.M. Bremner, M.A. Smith. Heart Lung Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ.

(519) Pulmonary Re-Transplantation in the Nordic Countries; P. Wierup,¹ M. Iversen,² G. Riise,³ Ø. Bjørtuft,⁴ P. Hämmäinen,⁵ I. Skog,⁶ S. Lindstedt,¹ A. Fiene,⁷ G. Dellgren.⁸ ¹Dep. of Cardiothoracic Surgery, Lund University Hospital, Lund, Sweden; ²Department of Pulmonary Medicine, Rigshospitalet, Copenhagen, Denmark; ³Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; ⁴Department of Pulmonary Medicine, Rikshospitalet, Oslo, Norway; ⁵Department of Cardiothoracic Surgery, Meilahti University Hospital, Helsinki, Finland; ⁶Department of Pulmonary Medicine, Lund University Hospital, Lund, Sweden; ⁷Department of Cardiothoracic Surgery, Rikshospitalet, Oslo, Norway; ⁸Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

(520) Quality of Life after Lung Transplantation in Patients with Cystic Fibrosis: A Cross-Sectional Study; B. Smeritschnig, P. Jaksch, A. Scheed, W. Klepetko. Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

(521) Does Pulmonary Hypertension Preclude or Impact Outcomes in Single Lung Transplantations for Pulmonary Fibrosis in the Older Recipients; S.L.C. Reddy, M. Hartwig, Z. Hashmi, S. Lin, D.R. Davis. Cardiothoracic Transplant Division, Duke University Medical Center, Durham, NC.

(522) Down-Regulation of CD28 and Up-Regulation of 4-1BB on Peripheral Blood Pro-Inflammatory CD8+ T Cells Is Associated with BOS; G. Hodge,^{1,2} S. Hodge,^{1,2} C.-L. Holmes-Liew,^{1,2,3} P.N. Reynolds,^{1,2} M. Holmes.^{1,2,3} ¹Lung Research and Department of Thoracic Medicine, Hanson Institute and Royal Adelaide Hospital, Adelaide, SA, Australia; ²Medicine, University of Adelaide, Adelaide, SA, Australia; ³South Australian Lung Transplant Service, Royal Adelaide Hospital, Adelaide, SA, Australia.

(523) BOS Is Associated with Increased Peripheral Blood NKT-Like and NK Cell Granzymes, Perforin and Th1 Pro-Inflammatory Cytokines; S. Hodge,^{1,2} G. Hodge,^{1,2} C.-L. Holmes-Liew,^{1,2,3} P.N. Reynolds,^{1,2} M. Holmes.^{1,2,3} ¹Lung Research/Thoracic Medicine, Hanson Institute/Royal Adelaide Hospital, Adelaide, SA, Australia; ²Medicine, University of Adelaide, Adelaide, SA, Australia; ³South Australian Lung Transplant Service, Royal Adelaide Hospital, Adelaide, SA, Australia.

(524) The Role of Lymphotoxin beta Receptor in De Novo Formation of Lymphoid Tissue in Chronic Graft Dysfunction after Lung Transplantation; Y. Matsuda, M. Sato, G. Zehong, M. Cypel, M. Liu, S. Keshavjee. Department of Thoracic Surgery, Toronto General Research Institute, Toronto, ON, Canada.

(525) The Fibroproliferative Chemokine, Eotaxin/CCL11, Is Upregulated in Lung Transplant Recipients Colonized with Aspergillus – A Link to BOS? S.S. Weigt,¹ X. Wang,² C.-H. Tseng,¹ A. Derhovanessian,¹ A. Gregson,¹ R. Saggari,¹ D.J. Ross,¹ A. Ardehali,³ J.P. Lynch III,¹ R.M. Elashoff,² J.A. Belperio.¹ ¹Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

(526) Chronic Allograft Dysfunction after Lung Transplantation. A Comparison of RAS vs. BOS; C.H. Møller,¹ M. Jørgensen,² M. Perch,³ C.B. Andersen,⁴ J. Carlsen,³ D.A. Steinbrüchel,¹ M. Iversen,³ ¹Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark; ²Nephrology, Rigshospitalet, Copenhagen, Denmark; ³Cardiology, Section for Lungtransplantation, Rigshospitalet, Copenhagen, Denmark; ⁴Pathology, Rigshospitalet, Copenhagen, Denmark.

(527) Lung Transplantation in Patients with Pre-Transplant Donor-Specific Antibodies (DSA) Detected with Luminex Technique; O. Brugiere,¹ C. Suberbielle,² G. Thabut,¹ G. Dauriat,¹ A.-C. Metivier,¹ H. Mal,¹ F. Parquin,³ M. Stern.³ ¹Service de Pneumologie et Transplantation Pulmonaire, Hôpital Bichat, Paris, France; ²Service d'Histocompatibilité de l'Hôpital Saint-Louis, Hôpital Saint-Louis, Paris, France; ³Service de Pneumologie et Transplantation Pulmonaire, Hôpital Foch, Hôpital Foch, France, France.

(528) Is Underlying Disease a Risk Factor for RAS after Lung Transplantation (LTx)?; D. Rutters, S.E. Verleden, V. Robin, A. Vaneylen, B.M. Vanaudenaerde, D.E. Van Raemdonck, G.M. Verleden. Lung Transplant Unit, KUL, UZ Gasthuisberg, Leuven, Belgium.

(529) Significance of Anti-HLA Immunization in Lung Transplantation; J. Reeb,¹ P.E. Falcoz,¹ N. Santelmo,¹ Z. Mansour,¹ A.C. Lejay,¹ S. Renaud,¹ A. Parissiadis,² D. Hanau,² R. Kessler,¹ G. Massard.¹ ¹Lung Transplantation Team, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ²Tissue Typing Laboratory, Etablissement Français du Sang, Strasbourg, France.

(530) Detection of Post Lung Transplant Airway Ischemia Using Auto-fluorescence Imaging (AFI) Bronchoscopy; I. Norichika, T. Oto, M. Okada, H. Masaaki, H. Nisikawa, K. Miyoshi, S. Otani, S. Sugimoto, M. Yamane, S. Toyooka, S. Miyoshi. General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University, Okayama, Japan.

(531) Bone-Marrow Derived CCSP+ Epithelial Cells Reside in the Airway Epithelium after Lung Transplantation; S.T. Yerkovich,^{1,2} S. Gilpin,³ K.A. Sinclair,¹ M.E. Tan,¹ A. Fiene,¹ P.M. Hopkins,^{1,2} T. Waddell,³ D.C. Chambers.^{1,2} ¹Queensland Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia; ²School of Medicine, The University of Queensland, Brisbane, Australia; ³Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, Canada.

(532) Remote Ischemic Pre-Conditioning (RIPC) To Improve Lung Transplant (LTx) Outcomes: A Randomized, Placebo-Controlled, Clinical and Mechanistic Trial; E. Lin,² G.J. Snell,¹ B.J. Lewey,¹ L. Mitchell,¹ S. Marasco,¹ T. Kotsimbos,³ N. Mifsud,³ A. Sharland,⁴ P. Myles.² ¹Lung Transplant Service, Alfred Hospital, Melbourne, VIC, Australia; ²Anaesthesia, Alfred Hospital, Melbourne, VIC, Australia; ³Medicine, Monash University, Melbourne, VIC, Australia; ⁴Central Clinical School, University of Sydney, Sydney, NSW, Australia.

(533) Methylprednisolone Regulation of Human Donor Lung Surface Protein A (SP-A) Expression Is Dependent on the SP-A Polymorphism; B. Aramini,¹ C. Kim,¹ D. Lederer,¹ J. Costa,¹ S. DiAngelo,² J. Floros,² S. Arcasoy,¹ J. Sonett,¹ F. D'Ovidio.¹ ¹Columbia University Medical Centre, New York; ²The Pennsylvania State University College of Medicine, Hershey.

(534) Late Decline in Renal Function Following Implantation of Continuous Flow Left Ventricular Assist Devices; T. Hasin, Y. Topilsky, M. Liu, Z. Li, J.A. Schirger, B.A. Boilson, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, B.S. Edwards, N.L. Pereira, L. Joyce, R. Daly, S.J. Park, S.S. Kushwaha. Mayo Clinic, Rochester.

(535) Clinical Predictors and Risks Factors for Left Ventricular Assist Device Thrombosis in HeartMate II Supported Patients; M.R. Labedi,¹ O. Wever-Pinzon,¹ F. Gaqa,¹ R. Alharethi,² C. Selzman,¹ S.G. Grakos,¹ E. Gilbert,¹ D. Budge,² A. Saidi,¹ B. Ried,² A.G. Kfoury,² J. Stehlik,¹ F. Bader.¹ ¹Cardiology/UTAH Heart Transplant Program, University of Utah, Salt Lake City, UT; ²Heart Transplant Program, Intermountain Medical Center, Salt Lake City, UT.

(536) Reduced Antithrombotic Therapy as an A Priori Strategy in HM

II Recipients: A Word of Caution; K.A. Morrison,¹ N. Uriel,¹ P.C. Colombo,¹ H. Takayama,² Y. Naka,² T.S. Kato,¹ U.P. Jorde.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

(537) Non-Cardiac Surgery in Patients with a Ventricular Assist Device; J. Vierecke,¹ M. Schweiger,² T. Krabatsch,¹ A. Stepananko,¹ B. Jurmann,¹ N. Dranishnikov,¹ E. Potapov,¹ R. Hetzer.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Universität Graz, Graz, Austria.

(538) Use of Levitronics Centrimag as a Bridge to Solution beyond 30 Days – Is It Safe?; P.N. Mohite, B. Zych, A.F. Popov, H. Krueger, N.R. Banner, A.R. Simon. Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield NHS Trust, London, Harefield, Middlesex, United Kingdom.

(539) Higher Incidence of Class II Human Leukocyte Antigen (HLA)-Allosensitization in Patients Supported with Pulsatile Ventricular Assist Devices (VAD); M. Askar,¹ A. Zhang,¹ L. Klingman,¹ M. Mastroianni,² A. Nowacki,³ P. Reville,¹ J. Gatto,⁴ S. Bakdash,⁵ N. Smedira,⁶ R. Starling,⁷ G. Gonzalez-Stawinski.⁶ ¹Allogen Laboratoires, Cleveland Clinic; ²Doisy College of Health Sciences, St. Louis University; ³Department of Quantitative Health Sciences, Cleveland Clinic; ⁴College of Arts and Sciences, The Ohio State University; ⁵Clinical Pathology, Cleveland Clinic; ⁶Cardiothoracic Surgery, Cleveland Clinic; ⁷Cardiovascular Medicine, Cleveland Clinic.

(540) Optimized RV Function Prior to LVAD Implantation – Honey-moon Period or Sustainable Success?; T. Butt, F. Özalp, C. Roysam, D. O'Leary, N. Wrightson, J. Schuster, G. MacGowan, T. Pillay, S. Schueler. Mechanical Circulatory Support Programm, Newcastle upon Tyne Hospital NHS FoundationTrust, Newcastle upon Tyne, United Kingdom.

(541) Novel Assessment of Hemolytic Anemia in Patients with Continuous Flow Left Ventricular Assist Devices; W.A. Kay,¹ S. Emani,¹ Y. Ravi,² V. Franco,¹ E. Abel, J. Crestanello,² A. Kilic,² C.B. Sai-Sudhakar.² ¹Internal Medicine, The Ohio State University, Columbus, OH; ²Surgery, The Ohio State University, Columbus, OH.

(542) Recovery of Right Heart Function with Temporary Right Ventricular Assist Using a Centrifugal Pump in Patients with Severe Biventricular Failure; S. Saito, T. Sakaguchi, S. Miyagawa, H. Nishi, Y. Yoshikawa, S. Fukushima, T. Ueno, T. Kuratani, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

(543) An Old Problem with a New Therapy: GI Bleeding in VAD Patients and Deep Bowel Enteroscopy (Double Balloon/Spiral Enteroscopy); K. Sarosiek, L. Bogar, H. Hirose, P. Harrison, B. Ebert, N. Cavarocchi. Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA.

(544) Hemolysis in LVAD: Harbinger of Doom?; A.K. Ravichandran,¹ J. Parker,¹ S. Joseph,¹ E. Novak,¹ H. Craddock,¹ J. Schilling,¹ E. Gregory,¹ S. Silvestry.² ¹Cardiology, Washington University-St. Louis, St. Louis, MO; ²Cardiothoracic Surgery, Washington University-St. Louis, St. Louis, MO.

(545) Changes in Anti-Human Leukocyte Antigen Antibodies after Continuous Flow Left Ventricular Assist Device Implantation; S.S. Desai,¹ M.S. Lefell,² C.M. Rosner,¹ K.P. Schilling,² L.G. Edwards,¹ P. Shah,³ C.W. May,¹ A.J. Rongione,¹ N.A. Burton.¹ ¹Heart Failure/Transplant Program, Inova Fairfax Hospital, Falls Church, VA; ²Immunogenetics Laboratory, Johns Hopkins University, Baltimore, MD; ³Division of Cardiology, George Washington University, Washington, DC.

(546) Platelet Glycoprotein Ibx Shedding: A Novel Marker To Determine the Risk of Bleeding in Recipients of Continuous-Flow Left Ventricular Assist Device (CF-LVAD); J. Hu,¹ E.N. Sorensen,² L. Romar,² N.J. Hiivala,² L. Dees,² E. Feller,² A.C. Watkins,² J.C. Gayden,² B.P. Griffith,² Z.J. Wu.¹ ¹Surgery Department, University of Maryland, Baltimore, MD; ²University of Maryland Medical Center, Baltimore, MD.

(547) An Aggressive Policy of Pump Exchange Can Salvage Most Patients with Pump Malfunction; E. McGee, K. Meehan, J. Brown, R. Gordon, K. Grady, W. Cotts, P. McCarthy. Bluhm Cardiovascular Institute Northwestern Memorial Hospital, Northwestern University's Feinberg School of Medicine, Chicago, IL.

(548) Right Ventricular Failure during Ventricular Assist Device Placement: The Bad Oeynhausen Experience; N. Aissaoui, M. Morshuis, J. Börgemann, M. Schönbrodt, K. Hakim, L. Kizner, J. Gummert. Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.

(549) Tissue Plasminogen Activator (tPA) Assists in the Management of Presumed LVAD Thrombus but Is Not Curative; E. McGee, Jr., K. Meehan, R. Gordon, P. Kansal, W. Cotts, K. Grady, J. Brown, P. McCarthy. Bluhm Cardiovascular Institute of Northwestern Memorial Hospital, Northwestern University's Feinberg School of Medicine, Chicago, IL.

(550) 0 to 60 in under 3 Years: Creating a Regional Referral Network To Grow a New VAD Center; W.H. Perry,¹ K.E. Nelson,¹ J.W. Long,¹ N.M. Chelikani,¹ S.R. Clements,¹ T.A. Snyder,¹ B.V. Bogomilov,² A.M. Kaneshige,³ H. Farhoud,⁴ C. Simpson,⁵ D.A. Horstmanshof.¹ ¹Mechanical Circulatory Support, Integris Baptist Medical Center, Oklahoma City, OK; ²Walker Heart Institute Cardiovascular Clinic, Fayetteville, AR; ³Oklahoma Heart Institute at Hillcrest Medical Center, Tulsa, OK; ⁴Kansas Medical Center, Andover, KS; ⁵Mercy Heart and Vascular Center, Rogers, AR.

(551) Initial Experience – Cost Adjusted Quality of Life Years for Patients Supported by Ventricular Assist Devices for Destination Therapy Indication; T.B. Icenogle,^{1,2} D. Sandler,^{1,2} A.A. Schmitt,¹ D. Sato,¹ J. Bjelkengren,¹ S.A. Schaefer,¹ S. Lewey.¹ ¹Inland Northwest Thoracic Organ Transplant Program, Providence Sacred Heart Medical Center, Spokane, WA; ²Northwest Cardiothoracic & Transplant Surgeons, Spokane, WA.

(552) Are LVAD Support and Cardiac Transplantation Approaching Equipose; R.M. Adamson,¹ B. Jaski,² P. Hoagland,² J. Chammas,¹ V. Norman,¹ V. McCalmont,³ L. Hazard,³ K. Ortiz,³ M. S. Chillcott,³ M. Stahovich,³ W.P. Dembitsky.¹ ¹Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; ²Cardiology, Sharp Memorial Hospital, San Diego, CA; ³Nursing, Sharp Memorial Hospital, San Diego, CA.

(553) Temporal Leukocyte Profiles and Granulocyte Activation in LVAD Recipients; R.L. Kormos,¹ J.R. Woolley,² K.L. Lockard,¹ C. Bermudez,¹ J.K. Bhamra,¹ J.J. Teuteberg,¹ W.R. Wagner.² ¹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ²McGowan Institute for Regenerative Medicine, University of Pittsburgh, PA.

(554) Safety of Discontinuation of Anticoagulation in Patients with Continuous-Flow LVADs; F. Kamdar, P. Eckman, K. Liao, M. Colvin-Adams, R. John. University of Minnesota, Minneapolis, MN.

(555) Nesiritide Improves Urine Output after Ventriculectomy and Placement of the Total Artificial Heart; K.B. Shah, D.G. Tang, V. Kasirajan, K.J. Gunnerson, W.K. Stribling, R.H. Cooke, G.J. Katlaps, M.L. Hess, D.A. Sica. Virginia Commonwealth University, Richmond, VA.

(556) Benefits of Physical Training on Exercise Capacity and Ventricular Pump Function in Patients with Ventricular Assist Devices Long-Term Post Implantation; P. Ganslmeier,¹ H.-J. Schneider,² G. Monika,¹ M. Foltan,¹ C. Diez,¹ D. Camboni,¹ M. Hilker,¹ S. Hirt,¹ C. Schmid.¹ ¹Department of Cardiothoracic Surgery, University Medical Center Regensburg, Regensburg, Bayern, Germany; ²Department of Cardiology, Hospital Barmherzige Brüder Regensburg, Regensburg, Bayern, Germany.

(557) Comprehensive Echo-Doppler Evaluation of Syncardia Total Artificial Heart (TAH); K. Chandrasekaran, C.N. Pierce, R.S. Gopalan, A. Pandit, R.L. Scott, A.V. Kalya, O.E. Pajaro, R.K. Wong, F.A. Arabia. Mayo Clinic, Phoenix, AZ.

(558) Comparative Study between Cavopulmonary Anastomosis Associated with Left Ventricular Assist Device Support and Biventricular Circulatory Assistance in Acute Biventricular Failure; L.A.S. Santos, L.F.P. Moreira, A. Benício, I. Cestari, E. Mattos, Jr., N.G. Stolf. Cardiovascular Surgery Division, Heart Institute (Incor), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., São Paulo, Brazil.

(559) Increased Blood Pressure Variability in Patients Supported by Continuous Flow Left Ventricular Assist Devices: A Novel Vascular Phenotype in the Absence of Pulsatility?; P.C. Schulze,¹ M.N. Bartels,² C.J. Chung,¹ H. Armstrong,² A. Chokshi,¹ M. Jones,¹ Y. Zhao,³ D. Shimbo,⁴ H. Takayama,³ Y. Naka,⁵ D.M. Mancini,¹ R.P. Sloan.³ ¹Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; ²Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; ³Department of Psychiatry, Columbia University Medical Center, New York, NY; ⁴Department of Medicine, Columbia University Medical Center, New York, NY; ⁵Department of Surgery, Columbia University Medical Center, New York, NY.

(560) Institutional Experience with Low Molecular Weight Heparin as an Alternative to Unfractionated Heparin in the Immediate Postoperative Period after Left Ventricular Assist Device Implantation; E. Eskandary,¹ G. Wieselthaler,^{1,3} H. Schima,^{1,2,3} S. Mahr,¹ Z. Hartner,¹ S. Sandner,¹ J. Göklér,¹ G. Laufer,^{1,3} D. Zimpfer.^{1,3} ¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Center of Med. Physics and Biomed. Engineering, Medical University of Vienna, Vienna, Austria; ³Ludwig Boltzmann Cluster of Cardiovascular Research, Medical University of Vienna, Vienna, Austria.

(561) Maintaining Pulsatility or Not with Intermittent Aortic Valve Opening Does Not Appear To Contribute to Formation of AV Malformation in Patients with Continuous-Flow Left Ventricular Assist Devices; A. Bhimaraj,¹ D. Hall,¹ R. Vivo,¹ A.M. Cordero-Reyes,¹ M. Aldieri,¹ G. Torre-Amione,^{1,2} M. Loebe,¹ B. Bruckner,¹ B. Ramlawi,¹ S. Scheinin,¹ J.D. Estep.¹ ¹The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX; ²Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.

(562) Incidence of Major and Minor Mechanical Driveline Failure in Continuous Flow Left Ventricular Assist Devices; E.R. Stephenson, B. Soleimani, C.D. Kline, L.C. Price, C. Brehm, A. El-Banayosy, W.E. Pae. Heart and Vascular Institute, Milton S. Hershey Medical Center, Hershey, PA.

(563) Factors Associated with Lack of Renal Recovery in Patients with Continuous Flow LVADs; A. Mano, J.J. Teuteberg, C.A. Bermudez, J.K. Bhamra, D.M. McNamara, R. Ramani, M. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh.

(564) Use of Novel Thrombosis Index of Risk (TIR) as Indicator for Left Ventricular Assist Device (LVAD) Thrombosis; M. Sobieski, S. Schwartz, J.R. Trivedi, E.J. Birks, K.C. McCants, M.L. Williams, M.S. Slaughter. University of Louisville, Louisville, KY.

(565) Readmissions Following Implantation of Axial Flow Left Ventricular Assist Devices; T. Hasin, Y. Marmor, Y. Topilsky, J.A. Schinger, B.A. Boilson, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, B.S. Edwards, N.L. Pereira, L. Joyce, D. Richard, S.J. Park, S.S. Kushwaha. Mayo Clinic, Rochester.

(566) Clinical Outcomes of Individualized Antiplatelet Therapy in Centrifugal Rotary Blood Pump Recipients; A. Canteli, A. Stepanenko, N. Dranishnikov, E. Hennig, F. Kaufmann, J. Vierecke, B. Jürmann, T. Drews, H.B. Lehmkühl, Y. Weng, M. Pasic, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany.

(567) Renal Dysfunction Following Syncardia Total Artificial Heart Implantation Does Not Affect Survival Following Heart Transplantation; A. Kalya,¹ K. Boyle,¹ R. Goel,¹ F. Arabia,² O. Pajaro,² R. Scott,¹ R. Gopalan,¹ D. Jaroszewski,² D. Kasper,¹ G. Wu,³ L. Staley,² C. Pierce.² ¹Cardiovascular Dis-

eases, Mayo Clinic, Phoenix, AZ; ²Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ; ³Biostatistics, Mayo Clinic, Phoenix.

(568) Outpatient Antiplatelet Therapy in Rotary Blood Pump Recipients: Single-Center Experience; A. Stepanenko, N. Dranishnikov, A. Canteli, J. Vierecke, B. Jurmann, H. Lehmkuhl, T. Drews, E.V. Potapov, T. Krabatsch, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(569) Preliminary Study: Increased Levels of cGMP in Recipients of Continuous Flow LVADs, Implications for Gastrointestinal Bleeding; L. Grosman-Rimon, D.Z.I. Cherney, S. Pollock Bar-Ziv, M.A. McDonald, L. Tumiati, V. Rao. Exercise Sciences, University of Toronto, Toronto, ON, Canada; Medicine, Toronto General Hospital, Toronto, ON, Canada; Heart Transplant, Hospital for Sick Children, Toronto, ON, Canada; Department of Medicine, Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.

(570) Impact of Antiplatelet Therapy on Pump Thrombosis in Axial Flow Devices; D. Abramov, G. Ruiz, R. Chawla, M. Hofmeyer, L.E. Cooper, A.O. Griffin, C. Birther, M. McMenemy, R. Lowery, S.W. Boyce, S.S. Najjar. Department of Heart Failure, Washington Hospital Center, Washington, DC.

(571) Development and Animal Test of the Novel Infection-Resistant Skin-Button for Long-Term VAD Support; T. Mizuno, Y. Nemoto, T. Tsukiya, Y. Takewa, Y. Taenaka, E. Tsumami. Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.

(572) Preoperative Risk Factors for Postoperative Infection after Left Ventricular Assist Device Implantation; A. Raina, ¹ M. Kanwar, ¹ G.G. Sokos, ¹ A. Hopwood, ¹ N. Bhanot, ² R.J. Moraca, ¹ S. Bailey, ¹ S. Murali, ¹ R.L. Benza, ¹ ¹Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA; ²Division of Infectious Disease, Allegheny General Hospital, Pittsburgh, PA.

(573) Improved Surgical Technique of Left Ventricular Assist Device Drive Line Placement; S.M. Yousafzai, T. Butt, F. Oezalp, N. Wrightson, R. Nicola, P. Thasee, M. Guy, G. Parry, A. Siddique, S. Schueler. Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals Foundation Trust, Newcastle upon Tyne, Tyne & Wear, United Kingdom.

(574) Nutritional Status and Left Ventricular Assist Device (LVAD) Outcomes: Is Younger Better?; S.P. McCandless, K.D. Brunisholz, R. Alharethi, R.A. Merchel, D. Budge, B.B. Reid, S. Stoker, S.E. Clayton, A.K. Carter, I.D. Ledford, W.T. Caine, A.G. Kfoury. Utah Artificial Heart Program, Intermountain Medical Center, Murray, UT.

(575) Extra-Corporeal Membrane Oxygenation for Bridge to Heart Transplantation in Adult Recipients. Single Centre Five-Years Experience; C. D'Alessandro, E. Barreda, J.-L. Golmard, M. Laali, S. Varnous, M. Kirsch, P. Leprince, A. Pavie. CT Surgery, La Pitié Hospital, Paris, France.

(576) Left Ventricular Assist Devices for Treatment of Severe Pulmonary Hypertension in Heart Transplant Candidates; Z. Dorazilova, ¹ J. Kettner, ¹ I. Netuka, ² M. Hegarova, ¹ I. Málek, ¹ J. Pirk, ² ¹Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(577) Hemodynamic Efficacy of a Catheter-Deployed Intra-Aortic Micro-Axial Entrainment Pump in Porcine Acute Heart Failure: A Novel approach for an Old Problem; F. Raissi Shabari, ¹ J.K. George, ¹ M. Cuchiaro, ² J.J. Heuring, ² B.A. Hertzog, ² R.M. Delgado. ¹Texas Heart Institute, Houston, TX; ²Procyon, Houston, TX.

(578) Application of the Miniaturized ImaCor Trans-Esophageal Echocardiogram (TEE) Probe in Heart Transplant/Mechanical Cardiac

Support Patients; H. Pitcher, ¹ J.K. Wong, ² C. Kang, ¹ C. Johnson, ¹ K. Sarosiek, ¹ L. Bogar, ¹ H. Hirose, ¹ N.C. Cavarocchi. ¹Division of Cardiothoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA; ²Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA.

(579) Blood Pressure Measurement in Patients with Continuous Flow LVADs: Comparing the Doppler Sphygmomanometer, the Nexfin Device, and the Arterial Line; K.K. Rao, ¹ G.J. Haro, ¹ C.R. Ayers, ³ P.C. Patel, ¹ J. Mishkin, ¹ J.T. Thibodeau, ¹ B.T. Bethae, ² D.M. Meyer, ² P.P.A. Mammen, ¹ M.H. Drazner, ¹ B.D. Levine, ^{1,4} D.W. Markham. ¹Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; ²Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX; ³Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX; ⁴Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Dallas, Dallas, TX.

(580) Investigation of Elemano® Double Cuff Oscillometric Non-Invasive Blood Pressure (NIBP) Measurement in Left Ventricular Assist Device (LVAD) Patients; P. Muthusamy, ^{1,2} T.L. Wainscott, ¹ K.S. McClain, ³ B.D. VanOver, ³ A. Davis, ² M.G. Dickinson. ¹Department of Cardiology, Fredrik Meijer Heart & Vascular Institute/Spectrum Health, Grand Rapids, MI; ²Grand Rapids Medical Education Partners, Grand Rapids, MI; ³Department of Research, Spectrum Health, Grand Rapids, MI.

(581) Physical Therapy for Patients with External Ventricular Assist Device; L.K. Soni, ¹ Y. Naka, ¹ S.R. Cedola, ¹ J. Cogan, ¹ N. Uriel, ² P. Colombo, ² U. Jorde, ² D. Mancini, ² H. Takayama. ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Columbia University Medical Center, New York, NY.

(582) Venous-Pulmonary Arterial ECMO as Temporary Right Ventricular Support in Patients Undergoing Left Ventricular Assist Device Implantation; E.K. Slimani, ¹ C. Soto, ² R. Pye, ³ E. Granger, ¹ D. Robson, ⁴ P.S. Macdonald, ⁴ A.M. Keogh, ⁴ E. Kotlyar, ⁴ K. Dhital, ¹ P. Spratt, ¹ C.S. Hayward, ⁴ P. Jansz. ¹Department of Cardiothoracic Surgery Heart and Lung Transplantation, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; ²Department of Clinical Perfusion, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; ³Department of Intensive Care, Department of Anaesthesia, Saint Vincent's Hospital, Darlinghurst, NSW, Australia; ⁴Heart Failure and Transplant Unit, Saint Vincent's Hospital, Darlinghurst, NSW, Australia.

(583) Post-Cardiac Transplant Survival in the Current Era in Patients Receiving Continuous-Flow LVADs; F. Kamdar, K. Liao, P. Eckman, M. Colvin-Adams, S. Shumway, R. John. University of Minnesota, Minneapolis.

(584) Predictors of Recovery during Combined Pharmacological and Mechanical Unloading with the Heart Mate II Continuous Flow (CF) LVAD; O. Saeed, ¹ S. Patel, ¹ S. Ravishanker, ² J. Patel, ¹ N. Fida, ¹ P. Edwards, ¹ J. Pullman, ² D. Goldstein, ³ S. Maybaum. ¹Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ³Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(585) Temporary Right Ventricular Support in Left Ventricular Assist Device Recipients; A. Loforte, ¹ A. Stepanenko, ² E.V. Potapov, ² N. Dranishnikov, ² A. Montalto, ¹ M. Pasic, ² Y. Weng, ² M. Dandel, ² H. Siniawski, ² M. Kukucka, ² T. Krabatsch, ² F. Musumeci, ¹ R. Hetzer. ²Department of Cardiac Surgery and Transplantation, San Camillo Hospital, Rome, Italy; ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(586) Use of Generic Immunosuppression: Does It Truly Matter?; L. Stern, J. Patel, M. Kittleson, M. Rafiei, D. Dilibero, A. Hage, L. Czer, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(587) Sense of Coherence as a Resource in Relation to Quality of Life in Heart Transplant Recipient; I. Milaniak, ¹ E. Wliczek Ruzyczka, ² K. Wierzbicki, ^{1,2} P. Przybylowski, ^{1,2} J. Sadowski. ^{1,2}Cardiovascular Surgery & Trans-

plantology Dpt, John Paul II Hospital, Krakow, Poland; ²Collegium Medicum, Jagiellonian University, Krakow, Poland.

(588) Does Level of Education Affect Outcome after Heart Transplantation; B. Kearney, W. Chai, J. Patel, M. Kittleson, M. Rafiei, L. Stern, L. Czer, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(589) A Participatory Approach to Online Education and Support Curricular Development for Parents of a Child with a Heart Transplant; D.B. Nicholas,¹ L.J. West,² S. Urschel,³ B. Dodd.³ ¹Faculty of Social Work, Central and Northern Alberta Region, University of Calgary, Edmonton, AB, Canada; ²University of Alberta, Edmonton, AB, Canada; ³Alberta Health Services, Edmonton, AB, Canada.

(590) Long-Term Outcome of Pediatric Heart Transplant Patients with Incidental Subclinical Cellular Rejection during Annual Study; M.A. Kuhn,¹ D.D. Deming,¹ J. Fitts,¹ L.L. Bailey,² R.E. Chinnock.¹ ¹Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA; ²Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA.

(591) Waiting List Risk Factors in Pediatric Heart Transplant Center in the Developing Country; A.S. Cauduro, L.F.P. Moreira, C. Tanamati, L.F. Caneio, J. Penha, M.B. Jatene. Pediatric Cardiac Surgery Unit, Heart Institute of Sao Paulo University School of Medicine, Sao Paulo, SP, Brazil.

(592) Utility of Routine C4d Staining in the First Year after Pediatric Heart Transplantation; Y. Xu,¹ M. Reyes-Múgica,² C. Galambos,² A. Zeevi,³ S.A. Miller,¹ S.A. Webber,¹ B. Feingold.¹ ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ³Pathology, University of Pittsburgh, PA.

(593) Non-PTLD Malignancy in Pediatric Heart Transplantation; H.T. Henderson, K. Laporte, W.T. Mahle. Department of Pediatrics, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA.

(594) A New Glomerular Filtration Rate Estimation Formula Derived from a Pediatric Heart Transplant Population; P. Herrmann,¹ T. Shankel,² S. Sahney,² F. James,² D. Cutler,² R. Chinnock.² ¹Pathology, Loma Linda University Medical Center, Loma Linda, CA; ²Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA.

(595) Relationship of 2D Echocardiographic Strain Imaging in Pediatric Heart Transplant Patients and Healthy Children; L. Wilmot,¹ S. Cupp,¹ T.P. Nguyen,¹ G.H. Dadlani,² S.R. Ghazarian.³ ¹All Children's Heart Institute, All Children's Hospital, Johns Hopkins Medicine, St. Petersburg, FL; ²Department of Pediatrics, University of South Florida, Tampa, FL; ³Johns Hopkins Medicine, Johns Hopkins University, Baltimore, MD.

(596) The Change in B-Type Natriuretic Peptide Levels over Time Predicts Significant Rejection in Pediatric Cardiac Transplant Recipients; D.V. Skojec,¹ S.D. Russell,¹ M.K. Halushka,² J. Wang,¹ J.N. Scheel.³ ¹Medicine, Johns Hopkins Hospital, Baltimore, MD; ²Pathology, Johns Hopkins Hospital, Baltimore, MD; ³Pediatrics, Johns Hopkins Hospital, Baltimore, MD.

(597) Persistence of Human Leukocyte Antibodies in Congenital Heart Disease Late Following Surgery Utilizing Allograft and Whole Blood; M.J. O'Connor,¹ C. Lind,² D. Monos,² J. Weber,¹ R.E. Shaddy.¹ ¹Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA; ²Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA.

(598) Outcomes in Children Removed from the Heart Transplant Wait-List before Receiving a Transplant; C.J. VanderPluym, D. Graham, C. Almond, C. Milliren, T.P. Singh. Cardiology, Children's Hospital Boston, Boston, MA.

(599) NTproBNP as a Marker of Rejection in Pediatric Heart Transplant Recipients; K.R. Knecht,¹ M.L. Alexander,² C.J. Swearingen,³ E.A. Fra-

zier.¹ ¹Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; ²Harding University, Searcy, AR; ³Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR.

(600) Impact of Non-Adherence on Outcomes after Pediatric Heart Transplantation: Analysis of Data from the Organ Procurement and Transplant Network; M. Oliva,^{1,2} C. VanderPluym,^{1,2} K. Gauvreau,^{1,2} K. Campbell,^{1,2} S. Tajinder Pal,^{1,2} P. Wood-Mayer,^{1,2} J. Gilarde,^{1,2} C. Almond.^{1,2} ¹Departments of Psychiatry and Cardiology, Children's Hospital Boston, Boston, MA; ²Departments of Psychiatry and Pediatrics, Harvard Medical School, Boston, MA.

(601) Listing Requirements for a Prospective Crossmatch in Pediatric Heart Transplantation: Analysis of UNOS Data from 1996 to 2009; B. Feingold,¹ S.Y. Park,³ D.M. Comer,³ C.G. Moore,³ C.L. Bryce,² S.A. Webber.¹ ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Health Policy Management, University of Pittsburgh School of Public Health, Pittsburgh, PA; ³Institute for Clinical Research Education, University of Pittsburgh, PA.

(602) Increased Risk of Autoimmune and Severe Atopic Disease in Infant Heart Transplant Recipients; J.H. Mouldedoux, E.L. Albers, D.A. Dodd. Pediatric Cardiology, Vanderbilt University, Nashville, TN.

(603) Outcomes on the Basis of a Prospective XM in Pediatric Heart Transplantation; B. Feingold,¹ D.M. Comer,³ S.Y.L. Park,³ C.G. Moore,³ S.A. Webber,¹ C.L. Bryce.² ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Health Policy Management, University of Pittsburgh School of Public Health, Pittsburgh, PA; ³Institute for Clinical Research Education, University of Pittsburgh, PA.

(604) Status 1B or 2 Pediatric Heart Transplant Listings, a Vanishing Breed; W.T. Mahle,¹ S.A. Webber,³ W.S. Cherikh,² L.B. Edwards.² ¹Emory University, Children's Healthcare of Atlanta, Atlanta, GA; ²United Network for Organ Sharing, Richmond, VA; ³Children's Hospital Pittsburgh, Pittsburgh, PA.

(605) Thrombosis in Pediatric Patients Undergoing Heart Transplantation; C. Manlihot, A.I. Dipchand, R. Vanderlaan, J. Conway, L.R. Brandao, B.W. McCrindle. Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada.

(606) A Reduced Immunosuppressive Protocol in Highly Sensitized Pediatric Heart Transplant Patients with a C1q Negative Virtual Crossmatch; S.A. Hollander,¹ M.W. Anderson,² D. Tyan,² C. Castleberry,¹ D. Bernstein,¹ C. Chin.³ ¹Pediatrics (Cardiology), Stanford University Medical Center, Stanford, CA; ²Pathology, Stanford University Medical Center, Stanford, CA; ³Pediatrics (Cardiology), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

(607) Which T-Cell Crossmatch Method Best Predicts Allograft Loss in Pediatric Heart Transplant Recipients? K.P. Daly,^{1,2} T.P. Singh,^{1,2} G. Piercey,¹ K. Gauvreau,¹ C.S. Almond.^{1,2} ¹Department of Cardiology, Children's Hospital Boston, Boston, MA; ²Department of Pediatrics, Harvard Medical School, Boston, MA.

(608) Outcomes in Pediatric Heart Transplantation in the Second Decade of Survival; M.J. Johnkin,¹ M.H. Madani,² M.C. McGregor,³ P.A. Toole,⁴ A. Kulikowska,⁵ R.K. Ameduri,⁶ C.H. Gumbiner,⁷ C.O. Simon,⁸ K.E. Ward,⁹ A. Asante-Korang,¹⁰ M.T. Kimberling,¹¹ J. Zheng,¹² K.B. Schechtman,¹² C.E. Canter.¹ ¹Division of Pediatric Cardiology, Washington University School of Medicine/St. Louis Children's Hospital, St. Louis, MO; ²Louisiana State University Health Sciences Center, New Orleans, LA; ³Indiana University School of Medicine, Indianapolis, IN; ⁴Meharry Medical College, Nashville, TN; ⁵University of Illinois College of Medicine, Peoria, IL; ⁶University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; ⁷University of Nebraska Medical Center, Omaha, NE; ⁸University Missouri - Kansas City, MO; ⁹The Children's Hospital at Oklahoma University Medical Center, Oklahoma City, OK; ¹⁰All Children's Hospital, St. Petersburg, FL; ¹¹Pediatric Cardiology of Oklahoma, Tulsa, OK; ¹²Division of Biostatistics, Washington University School of Medicine, St. Louis, MO.

(609) Steroid Avoidance in Pediatric Heart Transplantation Results in Excellent Graft Survival; S.R. Auerbach,¹ J. Gralla,² D.N. Campbell,³ S.D. Miyamoto,¹ B.A. Pietra.¹ ¹Pediatrics, Division of Pediatric Cardiology, University of Colorado Denver School of Medicine, Aurora, CO; ²Pediatrics, Children's Hospital Research Institute, University of Colorado Denver School of Medicine, Aurora, CO; ³Pediatric Cardiac Surgery, University of Colorado Denver School of Medicine, Aurora, CO.

(610) Distinguishing Tachycardia-Mediated Cardiomyopathy and Idiopathic Dilated Cardiomyopathy; P.A. Patel, J.P. Moore, G. Perens, J. Alejos. Pediatric Cardiology, UCLA, Los Angeles, CA.

(611) Eosinophilic Esophagitis (EoE) Is a Cause of Morbidity after Pediatric Heart Transplant and Is Associated with Increased Rates of Post-Transplant Lymphoproliferative Disease (PTLD); S.J. Kindel,¹ B.F. Joy,¹ E. Pahl,¹ E.L. Wald.² ¹Division of Cardiology, Department of Pediatrics, Children's Memorial Hospital – Northwestern University Feinberg School of Medicine, Chicago, IL; ²Division of Critical Care, Department of Pediatrics, Children's Memorial Hospital – Northwestern Feinberg School of Medicine, Chicago, IL.

(612) Treatment of Non-Group 1 Pulmonary Hypertension: Results of a Survey of Pulmonary Hypertension Centers in the United States; M.E. Pugh, A.R. Hemnes, J.H. Newman, I.M. Robbins. Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN.

(613) Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Results from the Spanish Registry; M. López-Meseguer,¹ J. Segovia,⁶ P. Morales,⁴ J. Cifrián,⁵ J.A. Barbera,³ A. Roman,¹ P. Escribano.² ¹Respiratory Medicine, H. U. Vall d'Hebron, Barcelona, Spain; ²Cardiology, H. 12 de Octubre, Madrid, Spain; ³Respiratory Medicine, H. Clinic, Barcelona, Spain; ⁴Respiratory Medicine, H. La Fe, Valencia, Spain; ⁵Respiratory Medicine, H. Marqués de Valdecilla, Santander, Spain; ⁶Cardiology, H. Puerta de Hierro, Madrid, Spain.

(614) Simple Echo-Doppler Tool Powerfully Predicts Response to Pulmonary Hypertension Specific Therapy in WHO Group 3 Pulmonary Hypertension; A.V. Fields,¹ S.S. Sinha,¹ R. Sagar,² R. Sagar,³ P.R. Forfia.¹ ¹Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; ²Pulmonary & Critical Care, University of California, Los Angeles, CA; ³Heart-Lung Institute, St. Joseph Hospital, Phoenix, AZ.

(615) Efficacy of Imatinib Mesylate on Scleroderma Associated Pulmonary Arterial Hypertension; H. Maki, M. Hatano, A. Yao, T. Imamura, K. Asada, T. Inaba, T. Shiga, K. Kinugawa, R. Nagai. Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

(616) Bradykinin Targeted Therapy Decreases Mortality in Pulmonary Hypertension; J.N. Salamon,¹ R. Zolty.² ¹Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY; ²Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.

(617) Differences in the Baseline Right Ventricular-Pulmonary Artery Interaction Provides Insight into 'Responders' vs. 'Non-Responders' to PH Specific Therapy in WHO Group 3 Pulmonary Hypertension; S.S. Sinha, A.V. Fields, P.R. Forfia. Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.

(618) Characteristics and Early Outcomes of Patients Requiring Extra Corporeal Life Support after Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension; D. Boulate,¹ O. Mercier,¹ E. Fadel,¹ S. Mussot,¹ D. Fabre,¹ F. Stephan,² P. Darteville.¹ ¹Department of Thoracic and Vascular Surgery, Hopital Marie Lannelongue, Le Plessis-Robinson, France; ²Adult Intensive Care Unit, Hopital Marie Lannelongue, Le Plessis-Robinson, France.

(619) PTEN Is a Therapeutic Target in Pulmonary Hypertension; Y. Ravi,¹ K. Selvendiran,² S. Emami,³ B.K. Rivera,³ P. Kuppusamy,³ C.B. Sai-Sud-

hakar.¹ ¹Surgery, The Ohio State University, Columbus, OH; ²Obstetrics and Gynecology, The Ohio State University, Columbus, OH; ³Internal Medicine, The Ohio State University, Columbus, OH.

(620) Increase in the Adenosine A2B Receptor in Association with Pulmonary Hypertension Secondary to Pulmonary Fibrosis; L.J. Garcia-Morales,¹ H. Karmouty-Quintana,³ T. Weng,³ B.A. Bruckner,¹ S. LaFrancesca,¹ M. Loebe,¹ B. Ramlawi,¹ M.R. Blackburn,³ H. Seethamraju.² ¹Cardiovascular Surgery, Methodist DeBakey Heart & Vascular Center, Houston, TX; ²Pulmonary, Methodist J.C. Walter Jr. Transplant Center, Houston, TX; ³Department of Biochemistry and Molecular Biology, The University of Texas-Houston Medical School, Houston, TX.

(621) Endothelin-1 Levels in Pulmonary Hypertension: A Comparison between Pulmonary Arterial Hypertension and Diastolic Heart Failure-Induced Pulmonary Hypertension; J.A. Mazurek,¹ J.N. Salamon,¹ I. Kelesidis,² W. Saeed,² R. Zolty.² ¹Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

SESSION 2

(CONGRESS HALL FOYER)

Presenters will be available on Thursday from 6:15 pm-7 pm to discuss their posters and answer any questions.

11:45 AM (622) Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but Not Heart Allografts in a Minipig Model – Role of Passenger Leukocytes; G. Buechler,¹ G. Warnecke,¹ M. Avsar,¹ A.-K. Knoefel,¹ K. Dreckmann,¹ W. Sommer,¹ J. Gottlieb,² F. Laenger,³ J. Karstens,⁴ A. Haverich,¹ M. Strueber.¹ ¹Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Clinic for Pneumology, Hannover Medical School, Hannover, Germany; ³Institute for Pathology, Hannover Medical School, Hannover, Germany; ⁴Institute for Radiation Therapy and Special Oncology, Hannover Medical School, Hannover, Germany.

(623) WITHDRAWN

(624) Acute Ethanol Exposure Increases the Susceptibility of the Donor Hearts to Ischemia/Reperfusion Injury after Transplantation in Rats; S. Li,¹ S. Korkmaz,¹ S. Loganathan,¹ A. Weymann,¹ T. Radovits,² E. Barnucz,^{1,2} K. Hirschberg,¹ P. Hegedüs,^{1,2} S. Páli,^{1,2} G. Veres,^{1,3} M. Karck,¹ G. Szabó.¹ ¹Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ²Heart Center, Semmelweis University, Budapest, Hungary; ³Cardiac Surgery, Semmelweis University, Budapest, Hungary.

(625) Dual Blockade of the Renin-Angiotensin System (RAS) Prevents Tacrolimus-Induced Nephrotoxicity in Normotensive and Hypertensive Rats; L. Hoskova,¹ L. Kopkan,² Eva Honsova,³ I. Malek,¹ J. Pirk,¹ L. Cervenka.² ¹Cardio Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ²Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ³Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(626) Vascular Biology: Dichloroacetate Inhibits the Development of Intimal Hyperplasia, but Not Atherosclerotic Lesions; X. Hua,¹ T. Deuse,¹ M. Stubendorff,¹ F. Haddad,² H. Reichenspurner,¹ R.C. Robbins,³ E. Michelakis,⁴ S. Schrepfer.^{1,3} ¹TSI-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²CV Medicine, Stanford University, Stanford, Germany; ³CT Surgery, Stanford University, Stanford, Germany; ⁴Cardiology, University of Alberta, Edmonton, Canada.

(627) Acute Inflammatory Response and Cell Death in Human Epithelial Cells Induced by Hypothermic and Hyperoxic Ischemia Followed

by Normothermic Reperfusion; H. Kim,^{1,2} X. Bai,¹ S.-Y. Fung,¹ W.R. Gao,^{1,2} M. Cypel,^{1,3,4} S. Keshavjee,^{1,3,4} M. Liu,^{1,2,3} ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada; ²Department of Physiology, University of Toronto, Toronto, ON, Canada; ³Department of Surgery, University of Toronto, Toronto, ON, Canada; ⁴Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada.

(628) A Single-Dose Recombinant Glutathione s-Transferase P1-1 Improves Cardiac Function Post Myocardial Infarction in Rats; S. Aharinejad,¹ M. Salama,¹ D. Andrukova,² D. Wiedermann,¹ M. Krssak,¹ L. El-Husseiny,¹ A. Kocher,¹ G. Laufer.¹ ¹Medical University of Vienna, Vienna, Austria; ²University of Veterinary Medicine, Vienna, Austria.

(629) Development of an Experimental Perfusion Model in the Human Placenta; A. Beiras-Fernandez,¹ S. Walther,² A. Beiras,³ E. Thein.² ¹Thoracic and Cardiovascular Surgery, JW-Goethe University of Frankfurt, Frankfurt, Germany; ²LM-University of Munich, Munich, Germany; ³University of Santiago de Compostela, Santiago, Spain.

(904) Impact of Evolving Organ Donation Practices on Lung Transplantation in China; M. Wenjun, J. Chen, Lung Transplant Group, Wuxi People's Hospital, Nanjing Medical University, Management unit for lung transplant registration, Wuxi, China

(631) Increased Red Cell Distribution Width Predicts Poor Stem Cell Mobilization in Advanced Chronic Heart Failure Patients; G. Poglajen,¹ R. Okrajšek,¹ M. Šebeštjen,¹ F. Haddad,² B. Vrtovec.¹ ¹Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; ²Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(632) Clinical Aspects in Regenerative Medicine: Immunobiology of Engineered Heart Tissue; S. Schmidt,¹ L. Conradi,¹ X. Hua,¹ L. Peters,¹ T. Deuse,¹ A. Hansen,² A. Eder,² H. Reichenspurner,¹ R.C. Robbins,³ T. Eschenhagen,² S. Schrepfer.^{1,3} ¹TSL-Lab, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Pharmacology, University Hospital Hamburg, Hamburg, Germany; ³CT Surgery, Stanford University School of Medicine, Stanford.

(633) Use of the Oto Lung Donor Score To Analyze the 2010 Donor Pool of the Nord Italia Transplant Program; G. Porro,¹ F. Valenza,¹ S. Coppola,¹ S. Froio,¹ E. Benazzi,² N. De Fazio,² L. Santambrogio,³ A. D'Armini,⁴ M. Loy,⁵ M. Ravini,⁶ A. Lucianetti,⁷ M.P. Moretti,⁸ S. Vesconi,⁹ M. Scalomogna,² L. Gattinoni.¹ ¹Dipartimento di Anestesia, Terapia Intensiva e Subintensiva e Terapia del Dolore, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy; ²U.O.C. Immunologia dei Trapianti, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy; ³Chirurgia Toracica, Fondazione IRCCS Ca' Granda – Ospedale Maggiore Policlinico, Milano, Italy; ⁴Divisione di Cardiocirurgia, Fond. IRCCS Policlinico S.Matteo, Pavia, Italy; ⁵Chirurgia Toracica, Policlinico Università Padova, Padova, Italy; ⁶Chirurgia Toracica, A.O. Niguarda Ca' Granda, Milano, Italy; ⁷Centro Trapianti di Fegato e Polmone, Ospedali Riuniti, Bergamo, Italy; ⁸Neuroranimazione, A.O. Niguarda Ca' Granda, Milano, Italy; ⁹Coordinatore Regionale al Prelievo, Regione Lombardia, Milano, Italy.

(634) Ex Vivo Evaluation of Brain Dead Donor Lungs: PO2 Is Not Enough; J.C. Yeung, M. Cypel, T. Machuca, T. Koike, D.J. Cook, R. Bonato, M. Chen, M. Sato, T.K. Waddell, M. Liu, A.S. Slutsky, S. Keshavjee. University of Toronto, Toronto, Canada.

(635) Ex-Vivo Lung Evaluation of Pre-Arrest Heparinization in Donation after Cardiac Death; P.G. Sanchez, G.J. Bittle, K. Williams, C. Pasrija, C.R. Cooper, X. Wei, Z.J. Wu, B.P. Griffith. Artificial Organ Laboratory, Cardiac Surgery, University of Maryland, Baltimore, MD.

(636) The 4G/4G Genotype of the Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Polymorphism Is Associated with Decreased Lung Allograft Utilization and Decreased Overall Organ Utilization; A. Sapru,¹ J. Zaroff,² L. Pawlikowska,³ L.A. Baxter-Lowe,⁵ K.K. Khush,⁴ V. Lo,¹ J. Kukreja,⁵ M.A. Matthay.³ ¹Pediatrics, University of California, San Francisco, CA; ²Cardi-

ology, Kaiser Permanente, San Francisco, CA; ³Medicine and Anesthesia, University of California, San Francisco, CA; ⁴Cardiology, Stanford University, Palo Alto, CA; ⁵Surgery, University of California, San Francisco, CA.

(637) Procedure for Solid Organ Recovery Leads to Systemic Inflammatory Response; H. Auråen,^{1,2} T.E. Mollnes,^{1,4} J. Kongerud,^{1,2} Ø. Bjørtuft,² O. Geiran,^{1,3} A.E. Fiane,^{1,3} A.M. Holm.^{1,2} ¹Faculty of Medicine, University of Oslo, Oslo, Norway; ²Dept. of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; ³Dept. of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway; ⁴Dept. of Immunology, University of Oslo, Oslo, Norway.

(638) The Effect of Cocaine Use in Donors for Lung Transplant; T.J. Lee, M.P. Fox, J. Trivedi, V. van Berkel. Department of Surgery, University of Louisville, Louisville, KY.

(639) Extended Criteria Donor in Lung Transplantation: Older Donor's Selection; C. Berutto,¹ T. Krueger,³ M. Gonzalez,³ M.-F. Derkenne,¹ J. Wellinger,³ H.-B. Ris,³ J.H. Robert,⁵ P. Soccia,⁴ T. Rochat,⁴ L.P. Nicod,² J.-D. Aubert.^{1,2} ¹Organ Transplantation Centre, CHUV, Lausanne, Switzerland; ²Pneumology, CHUV, Lausanne, Switzerland; ³Thoracic Surgery, CHUV, Lausanne, Switzerland; ⁴Pneumology, HUG, Geneva, Switzerland; ⁵Thoracic Surgery, HUG, Geneva, Switzerland.

(640) The Administration of Exogenous Surfactant during Cold Preservation Can Improve Pulmonary Function after Lung Transplantation in a Swine Model of Prolonged Ischemia; A. Bertani,¹ L. DeMonte,¹ P. Vitulo,² S. Soresi,² A. Callari,² F. Tuzzolino,³ G. Di Paola,³ A. Arcadipane,⁴ B. Gridelli.¹ ¹Thoracic Surgery and Lung Transplantation, ISMETT-UPMC Italy, Palermo, Italy; ²Pulmonology, ISMETT-UPMC Italy, Palermo, Italy; ³Statistics, ISMETT-UPMC Italy, Palermo, Italy; ⁴Anesthesia and CCM, ISMETT-UPMC Italy, Palermo, Italy.

(641) The Donor Bithermia Preservation: Clinical Experience in Lung Transplantation from Uncontrolled NHBD; P. Gamez,¹ A. Mariscal,¹ I. Martínez,¹ V. Díaz Hellín,¹ C. Marrón,¹ J.C. Meneses,¹ E. López,² F. Hermoso,¹ R. Ávila,¹ J.L. Martín de Nicolás,¹ O. González,² A. de Pablo.³ ¹Thoracic Surgery, Hospital Universitario ¹² de Octubre, Madrid, Spain; ²Anesthesia, Hospital Universitario ¹² de Octubre, Madrid, Spain; ³Pulmonology, Hospital Universitario ¹² de Octubre, Madrid, Spain; ⁴Rehabilitation, Hospital Universitario ¹² de Octubre, Madrid, Spain.

(642) Neutrophil Elastase Inhibitor Improves Lung Function during Ex Vivo Lung Perfusion; M. Harada, T. Oto, M. Okada, H. Nishikawa, N. Iga, K. Miyoshi, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi. General Thoracic Surgery an Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.

(643) Correlation of Differently Defined Warm Ischemic Time in Controlled Donation after Circulatory Death (DCD) with Early Outcome of Lung Transplantation (LTx); B. Zych,¹ P. Mohite,¹ A.F. Popov,¹ A. Moza,¹ A. Wypych-Zych,³ N. Crouchen,¹ H. Krueger,¹ M. Carby,² A.R. Simon.¹ ¹Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ²Department of Pulmonary Medicine, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ³Intensive Care Unit, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(644) The Smoking Donor – Benefit or Hazard to the Potential Lung Transplant Recipient; R.S. Bonser,^{1,3,4} R. Taylor,² D. Collett,^{1,2} H.L. Thomas,^{1,2} J.H. Dark,⁵ J. Neuberger.² ¹UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, London, United Kingdom; ²Statistics and Clinical Audit, NHS Blood and Transplant, Bristol, United Kingdom; ³University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ⁴University of Birmingham, Birmingham, United Kingdom; ⁵Newcastle University, Newcastle Upon Tyne, United Kingdom.

(645) Reconditioning of an Injured Lung Graft from Donation after Cardiac Death (DCD) Donor before Transplantation: Utilization of Ex

Vivo Lung Perfusion System; L. Inci, S. Hillinger, S. Arni, T. Kaplan, B. Leskosek, W. Weder. Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

(646) Donor History of Cigarette Smoking Does Not Adversely Affect Lung Transplant Mortality: A Single Center Experience; R. Hussain,¹ H. Seethamraju,² M. Loebe,² S. Scheinin,² B. Bruckner,² S. LaFrancesca,² S. Jyothula,² A.D. Parulekar.¹ ¹Division of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX; ²Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX.

(647) High Prevalence of Hypertensive Nephropathy in Cardiac Transplant Recipients Selected for Sirolimus Immunoprophylaxis; M. White,¹ A. Boucher,³ R. Dandavino,³ A. Fortier,² G.B. Pelletier,¹ N. Racine,¹ A. Ducharme,¹ S. de Denus,¹ M. Carrier,¹ S. Collette.³ ¹Research Center, Montreal Heart Institute/Université de Montréal, Montreal, QC, Canada; ²BioStatistics, Montreal Heart Institute Coordinating Center, Montreal, QC, Canada; ³Nephrology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada.

(648) Resurgence of Photopheresis for Recalcitrant Cellular and Antibody-Mediated Cardiac Allograft Rejection; J. Patel, M. Kittleson, M. Rafiei, L. Stern, N. Patel, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(649) Study Design and Preliminary Results of the Italian Everolimus Registry CERTIC; F. Parisi,¹ A. Branzi,² R. Fiocchi,³ M. Frigerio,⁴ G. Gerosa,⁵ G. Leonardi,⁶ U. Livi,⁷ M. Maccherini,⁸ C. Maiello,⁹ M. Rinaldi,¹⁰ M. Viganò,¹¹ D. Colombo,¹² R. Brusa,¹² L. Potena.² ¹Ospedale Pediatrico Bambin Gesù, Roma, Italy; ²Policlinico Sant'Orsola-Malpighi, Bologna, Italy; ³A.O. Ospedali Riuniti di Bergamo, Bergamo, Italy; ⁴A.O. Niguarda – Ca' Granda, Milano, Italy; ⁵A.O. di Padova – Università degli Studi, Padova, Italy; ⁶Presidio Ospedaliero Ferrarotto, Catania, Italy; ⁷Dsp. Univ. di Udine – A.O. Santa Maria della Misericordia, Udine, Italy; ⁸A.O. Univ. Senese – Policlinico Santa Maria alle Scotte, Siena, Italy; ⁹AORN Monaldi – II Università di Napoli, Napoli, Italy; ¹⁰A.O.U. S. Giovanni Battista di Torino, Torino, Italy; ¹¹Policlinico San Matteo – Fondazione IRCCS, Pavia, Italy; ¹²Novartis Farma, Origgio, VA, Italy.

(650) High Rate of Discontinuation of a Mammalian Target of Rapamycin Inhibitor Based Regime during Long-Term Follow-Up of Cardiac Transplant Recipients; J. González-Costello, E. Kaplinsky, N. Manito, J. Rocca, M. Nebot, M.J. Barbosa, P. Mañas, J. Salazar, A. Miralles, A. Cequier. Cardiology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.

(651) Impact of Different ATG Dosing Protocols on Long-Term Outcome after Cardiac Transplantation; A.Z. Aliabadi, M. Groemmer, F.A. Eskandary, D. Dunkler, T. Haberl, D. Salameh, S.L. Mahr, D. Wiedemann, D. Zimpfer, G. Laufer, A.O. Zuckermann. Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

(652) Use of m-TOR Inhibitors in Maintenance Heart Transplant Recipients with Renal Failure: Conversion or CNI Minimization? A Propensity Study; F. González-Vilchez,¹ J.A. Vázquez de Prada,¹ M.J. Paniagua,² M. Gómez Bueno,³ J.M. Arizón,⁴ L. Almenar,⁵ S. Mirabet,⁶ J. Delgado,⁷ J.L. Lambert,⁸ F. Pérez-Villa,⁹ M.L. Sanz-Juvé.¹⁰ ¹Cardiology Service, University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain; ²Cardiology Service, Complejo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain; ³Cardiology Service, University Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; ⁴Cardiology Service, University Hospital Reina Sofía, Córdoba, Andalucía, Spain; ⁵Cardiology Service, University Hospital La Fe, Valencia, Spain; ⁶Cardiology Service, Hospital Santa Creu i Sant Pau, Barcelona, Cataluña, Spain; ⁷Cardiology Service, University Hospital ¹² de Octubre, Madrid, Spain; ⁸Cardiology Service, University Hospital Central de Asturias, Oviedo, Asturias, Spain; ⁹Cardiology Service, Hospital Clinic, Barcelona, Cataluña, Spain; ¹⁰Cardiology Service, University Hospital Miguel Servet, Zaragoza, Aragón, Spain.

(653) Heart Rate Reduction for 36 Months with Ivabradine Reduces Left Ventricular Mass in Cardiac Allograft Recipients; A.O. Doesch,¹ C. Erbel,¹

A. Ruhparwar,² P. Ehlermann,¹ T.J. Dengler,¹ C. Zugck,¹ H.A. Katus.¹ ¹Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.

(654) Cardiac Transplantation without Induction Therapy Despite Renal Dysfunction: A Report from the TICTAC Trial; D.A. Baran, C.Y. Guerrero-Miranda, J. Pieretti, N. Hochbaum, M.E. Goldschmidt, M. Camacho, S. Pardi, M.J. Zucker. Transplant Department, Newark Beth Israel Medical Center, Newark, NJ.

(655) Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus; V. Dhungel, M. Colvin-Adams, P.M. Eckman. Department of Medicine, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN.

(656) Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab Versus Basiliximab; S. Martin,¹ T.S. Kato,¹ M. Fam,¹ F. Cheema,² M. Ji,² A. Ross,² H. Yerebakan,² Y. Naka,² D.M. Mancini,¹ P.C. Schulze.¹ ¹Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; ²Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(657) Effects of Heart Rate Reduction with Ivabradine on Cardio-Pulmonary Capacity in Heart Transplant Recipients; U. Radunski,¹ M. Schlüter,¹ S. Ohdah,¹ A. von Stritzky,¹ T. Deuse,² H. Reichenspurner,² A. Costard-Jäckle.¹ ¹Department of General and Interventional Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Department for Cardiovascular Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(658) Lower Lp-PLA2-Activity in Heart Transplanted Patients Treated with Calcineurin Inhibitor Free Therapy Including Everolimus; K. Rosing,¹ J. Stypmann,² M. Fobker,¹ J.-R. Nofer.¹ ¹Center for Laboratory Medicine, University Hospital Münster, Münster, Germany; ²Department for Cardiology and Angiology, University Hospital Münster, Münster.

(659) Perioperative Levosimendan Therapy Affects Short-Term Outcome after Heart Transplantation; G. Pogljajen,¹ R. Okrajšek,¹ M. Šebeščen,¹ I. Knežević,¹ F. Haddad,² B. Vrtovec.¹ ¹Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; ²Stanford Cardiovascular Institute, Stanford School of Medicine, Palo Alto, CA.

(660) Safety Aspects of the Introduction of Everolimus in Cardiac Recipients with Established Allograft Vasculopathy: Results of a Randomized, Multicenter Study; J. Segovia,¹ J. Palomo,² F. González-Vilchez,³ J. Delgado,⁴ V. Brossa,⁵ N. Manito,⁶ F. Pérez-Villa,⁷ G. Rábago,⁸ M. Gómez-Bueno,¹ L. Alonso-Pulpón.¹ ¹Hospital Puerta de Hierro, Madrid, Solomon Islands; ²Hospital Gregorio Marañón, Madrid, Spain; ³Hospital Marqués de Valdecilla, Santander, Spain; ⁴Hospital ¹² de Octubre, Madrid, Spain; ⁵Hospital Sant Pau, Barcelona, Spain; ⁶Hospital de Bellvitge, Barcelona, Spain; ⁷Hospital Clinic, Barcelona, Spain; ⁸Clinica Universitaria de Navarra, Pamplona, Spain.

(661) Virus-Derived Immunomodulatory Therapeutics for Heart Transplantation; M.M.C. Dorotan-Guevara,¹ M. Bartee,² J. Davids,² H. Chen,² D. Zheng,² C. McGinn,² S. Conrad,² J. Hill,² D. Pauly,² J. Aranda, Jr.,² F.J. Fricker,¹ A.R. Lucas.² ¹Pediatric Cardiology, University of Florida, Gainesville, FL; ²Medicine, University of Florida, Gainesville, FL.

(662) Incidence of Rejection after Conversion to Proliferation Signal Inhibitors after Heart Transplantation. Is There any Difference between CNI-Free vs CNI Minimization Regimens?; M.G. Crespo-Leiro,¹ M.J. Paniagua-Martin,¹ R. Marzoa-Rivas,¹ E. Barge-Caballero,¹ Z. Grille-Cancela,¹ J. Pombo-Otero,² C. Naya-Leira,¹ P. Farinas-Garrido,¹ M. Garcia-Guimaraes,¹ E. Mendez-Eirin,¹ A. Castro-Beiras.¹ ¹Advanced Heart Failure and Heart Transplant Unit, University Hospital of A Coruña, A Coruña, Spain; ²Anatomy Pathology Unit, University Hospital of A Coruña, A Coruña, Spain.

(663) Cardiac Allograft Hypertrophy: An Important Prognostic Marker for Cardiac Allograft Vasculopathy; H. Yerebakan,¹ M. Ji,¹ A. Ross,¹ J. Jiang,¹ S. Jones,¹ L. Soni,¹ M. Argenziano,¹ C.R. Smith,¹ H. Takayama,¹ Y. Naka,¹ P.C. Schulze,² F.H. Cheema.¹ ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Columbia University Medical Center, New York, NJ.

(664) Secular Trends of Renal Dysfunction and Its Risk Factors in Heart Transplantation; K. Lachance,^{1,2} M. Carrier,^{1,3} A. Ducharme,^{1,3} N. Racine,^{1,3} M. White,^{1,3} S. de Denuis.^{1,2} ¹Montreal Heart Institute, Montreal, QC, Canada; ²Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada; ³Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.

(665) Combined Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term Development of Cardiac Allograft Vasculopathy; L. Czer, J. Patel, M. Kittleson, M. Rafiei, L. Stern, D. Chang, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(666) Prostate Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry; B. Díaz-Molina,¹ V. Brossa,² G. Rábago,³ L. Alonso-Pulpón,⁴ F. Vilchez,⁵ J. Palomo,⁶ N. Manito,⁷ L. Almenar,⁸ J. Delgado,⁹ J.M. Arizón,¹⁰ E. Lage,¹¹ J.L. Lambert,¹ F. Pérez-Villa,¹² T. Blasco,¹³ D. Pascual,¹⁴ L. Fuente,¹⁵ M. Crespo-Leiro.¹⁶ ¹Hospital Universitario Central de Asturias, Oviedo, Spain; ²Hospital Santa Creu i Sant Pau, Barcelona, Spain; ³Clínica Universitaria de Navarra, Pamplona, Spain; ⁴Hospital Puerta de Hierro, Madrid, Spain; ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain; ⁶Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁷Hospital Universitario de Bellvitge, Barcelona, Spain; ⁸Hospital Universitario La Fe, Valencia, Spain; ⁹Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁰Hospital Reina Sofía, Córdoba, Spain; ¹¹Hospital Virgen del Rocío, Sevilla, Spain; ¹²Hospital Clínico i Provincial, Barcelona, Spain; ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain; ¹⁴Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; ¹⁵Hospital Clínico de Valladolid, Valladolid, Spain; ¹⁶Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.

(667) Development of Serum Lipids in Everolimus Treated Heart Recipients; H. Lehmkuhl, C. Bara, A. Zuckermann, P. Lopez, G. Dong, S. Hirt. A2310 Study Group, Basel, Switzerland.

(668) Primary Graft Failure in Heart Transplantation: Current Characteristics in a Nationwide Cohort; J. Segovia,¹ M.D.G. Cosío,¹ M. Gómez Bueno,¹ L. Almenar,² J. Delgado,³ J.M. Arizon,⁴ F. Gonzalez-Vilchez,⁵ M.G. Crespo-Leiro,⁶ S. Mirabet,¹⁴ F. Perez Villa,⁷ J. Fernández-Yañez,⁸ J.L. Lambert,⁹ N. Manito,¹⁰ L. Fuente,¹¹ M.L. Sanz Julve,¹² D. Pascual,¹³ G. Rábago,¹⁵ L.A.A. Pulpón.¹ ¹Heart Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain; ²Hospital La Fe, Valencia, Spain; ³Hospital 12 de Octubre, Madrid, Spain; ⁴Hospital Reina Sofía, Córdoba, Spain; ⁵Hospital Valdecilla, Santander, Spain; ⁶Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; ⁷Hospital Clínico, Barcelona, Spain; ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain; ⁹Hospital Universitario Central de Asturias, Oviedo, Spain; ¹⁰Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain; ¹¹Hospital Clínico Universitario de Valladolid, Valladolid, Spain; ¹²Hospital Miguel Servet, Zaragoza, Spain; ¹³Hospital La Arrixaca, Murcia, Spain; ¹⁴Hospital Sant Pau, Barcelona, Spain; ¹⁵Clínica Universitaria de Navarra, Navarra, Spain.

(669) The Possibility of Tumor Markers as a Screening Method for De-Novo Malignancies in Heart Transplants; Y. Schneeberger,¹ A. Aliabadi,² D. Dunkler,² H. Reichenspurner,¹ A. Zuckermann.² ¹University Heart Center Hamburg, Hamburg, Germany; ²Medical University of Vienna, Vienna, Austria.

(670) Urinary Biomarkers in Heart Allograft Recipients in Relation to Kidney Function; P. Przybylowski,¹ J. Malyszko,² J.S. Malyszko,² E. Koc-Zorawska,² M. Mysliwiec.² ¹Cardiovascular Surgery and Transplantology, Jagiellonian University, Krakow, Poland; ²Nephrology and Transplantology, Medical University, Bialystok, Krakow, Poland.

(671) Pre-Existing Neoplasms and Risk for Malignancy after Heart Transplantation. Data from the Spanish Post-Heart Transplant Tumors Registry; J.F. Delgado,¹ L. Alonso-Pulpón,² S. Mirabet,³ F. Perez,⁴ L. Al-

menar,⁵ F. González,⁶ A. Villa,⁷ M. Sanz,⁸ M.J. Ruiz,⁹ N. Manito,¹⁰ L. de la Fuente,¹¹ G. Rábago,¹² E. Lage,¹³ D.A. Pascual,¹⁴ B. Diaz,¹⁵ J.M. Arizón,¹⁶ M. Crespo.¹⁷ ¹Cardiology, ² de Octubre Hospital, Madrid, Spain; ³Cardiology, Hospital Puerta de Hierro, Madrid, Spain; ⁴Cardiology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁵Cardiology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain; ⁶Cardiology, Hospital La Fe, Valencia, Spain; ⁷Cardiology, Hospital Marqués de Valdecilla, Santander, Spain; ⁸Cardiology, Hospital Gregorio Marañón, Madrid, Spain; ⁹Cardiology, Hospital Miguel Servet, Zaragoza, Spain; ¹⁰Cardiology, Hospital 12 de Octubre, Madrid, Spain; ¹¹Cardiology, Hospital de Bellvitge, Barcelona, Barcelona, Spain; ¹²Cardiology, Hospital Clínico de Valladolid, Valladolid, Spain; ¹³Cardiology, CH de Navarra, Pamplona, Spain; ¹⁴Cardiology, Hospital Virgen del Rocío, Sevilla, Spain; ¹⁵Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain; ¹⁶Cardiology, Hospital Central de Asturias, Oviedo, Spain; ¹⁷Cardiology, Hospital Reina Sofía, Córdoba, Spain; ¹⁸Cardiology, Hospital Universitario de A Coruña, A Coruña, Spain.

(672) The Incidence of Hematologic Cancer after Heart Transplantation Has Declined in the Last Decade. Data from the Spanish Post-Heart Transplant Tumor Registry; M.G. Crespo-Leiro,¹ F. Gonzalez-Vilchez,² L. Lopez,³ J. Delgado-Jimenez,⁴ L. Alonso-Pulpón,⁵ L. Almenar-Bonet,⁶ M.J. Paniagua-Martin,¹ G. Rábago,⁷ N. Manito,⁸ F. Perez-Villa,⁹ J.M. Arizon,¹⁰ I. Sousa,¹¹ B. Diaz-Molina,¹² D.A. Pascual-Figal,¹³ E. Lage,¹⁴ M. Sanz,¹⁵ L. de la Fuente,¹⁶ J. Muñoz.¹⁷ ¹Hospital Universitario A Coruña, La Coruña, Spain; ²H Marqués de Valdecilla, Santander, Spain; ³H Santa Creu i Sant Pau, Barcelona, Spain; ⁴H 12 de Octubre, Madrid, Spain; ⁵H Puerta de Hierro, Madrid, Spain; ⁶H La Fe, Valencia, Spain; ⁷C de Navarra, Pamplona, Spain; ⁸H Bellvitche, Barcelona, Spain; ⁹H Clínic, Barcelona, Spain; ¹⁰H Reina Sofía, Córdoba, Spain; ¹¹H Gregorio Marañón, Madrid, Spain; ¹²H Central de Asturias, Oviedo, Spain; ¹³H Virgen de la Arrixaca, Murcia, Spain; ¹⁴H Virgen del Rocío, Sevilla, Spain; ¹⁵H Miguel Servet, Zaragoza, Spain; ¹⁶H Clínic, Valladolid, Spain; ¹⁷Universidad de A Coruña, La Coruña, Spain.

(673) Outcomes with Mechanical Support for Early Primary Graft Dysfunction in Heart Transplantation; C.A. Bermudez, R.V. Rocha, D.B. Zaldonis, J.K. Bhamra, R.N. Ramani, J.J. Teuteberg, D.M. McNamara, M.A. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(674) Acute Renal Failure Does Not Predict Long-Term Outcome after Heart Transplantation; O. Kolsrud,¹ S.-E. Ricksten,² V. Sigurdardottir,³ H. Liden,¹ S.-E. Bartfay,⁴ N. Selimovic,⁴ G. Dellgren.³ ¹Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Cardiothoracic Anesthesia, Sahlgrenska University Hospital, Gothenburg; ³Transplant Institute, Sahlgrenska University Hospital, Gothenburg; ⁴Cardiology, Sahlgrenska University Hospital, Gothenburg.

(675) CD19 Monitoring after Rituximab in Patients with Cardiac Transplant Antibody Mediated Rejection (AMR); F. Kamdar, M. Caccamo, C. Martin, C. Masri, P. Eckman, M. Colvin-Adams. Cardiology, University of Minnesota, Minneapolis, MN.

(676) New Onset Atrial Fibrillation and Atrial Flutter after Cardiac Transplant Is Associated with High Mortality and Cardiac Allograft Vasculopathy; L.K. Soni,¹ J. Jiang,¹ M. Ji,¹ S. Cheung,¹ E. Heng,¹ H. Yerebakan,¹ C.R. Smith,¹ M.A. Farr,² H. Takayama,¹ M. Argenziano,¹ D.M. Mancini,² Y. Naka,¹ P.C. Schulze,² F.H. Cheema.¹ ¹Department of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Department of Cardiology, Columbia University Medical Center, New York, NY.

(677) Older Patients with Hemodynamic Compromise Rejection: What Happened to Immunosensescence?; J. Moriguchi,¹ J. Patel,¹ M. Kittleson,¹ M. Rafiei,¹ L. Stern,¹ L. Czer,¹ A. Trento,¹ J. Kobashigawa.¹ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Kaiser Permanente, Los Angeles.

(678) Renalase and Endothelium Function in Heart Transplant Recipients; P. Przybylowski,¹ J. Malyszko,² J.S. Malyszko,² E. Koc-Zorawska,² M. Mysliwiec.² ¹Cardiovascular Surgery and Transplantology, Jagiellonian University, Krakow, Poland; ²Nephrology and Transplantology, Medical University, Bialystok, Poland.

(679) Tricuspid Regurgitation in the 1st Year after Heart Transplant: Does It Lead to Gloom and Doom?; L. Czer, D. Lee, J. Patel, M. Kittleson, M. Rafiei, L. Stern, A. Hage, F. Esmailian, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(680) Prognostic Value of Supraventricular Rhythm Disturbances among Patients Late after Heart Transplantation – Single Center Experience; M. Sobieszczanska-Malek,¹ T. Zielinski,¹ M. Piotrowska,¹ K. Komuda,¹ J. Rozanski,² J. Korewicki.¹ ¹Heart Failure and Transplantation Department, Institute of Cardiology, Warsaw, Poland; ²Cardiosurgery Department, Institute of Cardiology, Warsaw, Poland.

(681) Severe Acute Kidney Injury Is the Most Powerful Predictor of Mortality after Heart Transplantation; J. Shatrov,¹ J. Sevastos,^{1,2} G. Jones,^{1,3} L.T. Lam,¹ C. Hayward,^{4,5,6} A.M. Keogh,^{4,5,6} E. Kotlyar,^{4,6} P.S. Macdonald,^{4,5,6} P.M. Spratt.⁴ ¹Medicine, University of Notre Dame, Darlinghurst, NSW, Australia; ²Renal Medicine, St Vincent's Hospital, Darlinghurst, NSW, Australia; ³Chemical Pathology, St Vincent's Hospital, Darlinghurst, NSW, Australia; ⁴Cardiopulmonary Transplant Unit, St Vincent's Hospital, Darlinghurst, NSW, Australia; ⁵Transplantation Research Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia; ⁶Medicine, University of New South Wales, Darlinghurst, NSW, Australia.

(682) Outcome of Extracorporeal Membrane Oxygenation as Short Term Mechanical Support Following Heart Transplantation: A Single Centre Experience; S.R. Hosmane, R. Venkateswaran, J. Salaia, S. Williams, N. Yonan. Transplant Department, University Hospital of South Manchester, Manchester, United Kingdom.

(683) The Natural History of Biopsy Negative Rejection after Heart Transplantation; J. Patel, M. Kittleson, M. Rafiei, L. Stern, Z. Tang, D. Chang, D. Luthringer, L. Czer, A. Trento, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(684) Risk for Deep Vein Thrombosis and Pulmonary Embolism after Heart Transplantation: Characterization of an Old Problem; J. Moriguchi, J. Patel, M. Kittleson, M. Rafiei, L. Stern, W. Chai, D. Chang, A. Trento, L. Czer, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(685) Anti-HLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft Vasculopathy?; J. Kobashigawa, J. Patel, M. Kittleson, M. Rafiei, L. Stern, L. Czer, N. Reinsmoen, F. Esmailian. Cedars-Sinai Heart Institute, Los Angeles, CA.

(686) Early Detection and Resection of Lung Cancer in Heart Transplant Recipients Yields Similar Survival to Recipients without Lung Cancer; W.A. Teeter,¹ C. Ayers,² D. Rosenbaum,¹ M. Drazner,² M. Peltz,¹ M. Wait,¹ D. Meyer,¹ M. DiMaio.¹ ¹Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, TX; ²Division of Cardiology, University of Texas Southwestern Medical Center at Dallas, TX.

(687) Incidence of Azole Resistance in Aspergillus Fumigatus among Lung Transplant Recipients (LTRs); M.-L. Luong,¹ S. Howard,² S.E. Richardson,³ L.G. Singer,¹ C. Chaparro,¹ S. Keshavjee,¹ Y. Akinlolu,¹ S. Azad,¹ C. Rotstein,¹ T. Mazzulli,⁴ S. Husain.¹ ¹The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada; ²School of Translational Medicine, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; ³Central Provincial Health Laboratory, Ontario Agency for Health Protection and Promotion, Toronto, ON, Canada; ⁴Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.

(688) Effect of Hypogammaglobulinemia after Lung Transplantation on the Incidence of Community Acquired Respiratory Viral Infections; B.C. Noell, K.L. Dawson, H. Seethamraju. The Methodist Hospital, Houston, TX.

(689) Diagnosis of Invasive Aspergillosis (Ia) in Explanted Lung Is Not Associated with Poor Outcome at One Year in Lung Transplant Recipients (Ltr); S.M. Hosseini-Moghaddam, C. Rotstein, L. Singer, C. Chaparro, S.

Azad, S. Keshavjee, S. Husain. MOT, University of Toronto, Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.

(690) Most Effective Antimicrobial Combinations Against Burkholderia cepacia Complex, Stenotrophomonas maltophilia and Pseudomonas aeruginosa Isolated from Cystic Fibrosis Lung Transplant Patients; S.N. Peart, A. Nicholson, F.K. Gould, J.D. Perry, E. Marrs, K. Sands, J.L. Lordan. Microbiology, Freeman Hospital, Newcastle upon Tyne, Tyne & Wear, United Kingdom.

(691) Recovery of VZV-Specific T- and B-Cell Responses by Herpes Zoster Infection after Lung Transplantation; N.M. van Besouw,¹ P.Th.W. van Hal,² J.M. Zuijderwijk,¹ R. de Kuiper,¹ G.M.G.M. Verjans,³ W. Weimar.¹ ¹Internal Medicine – Transplantation, Erasmus Medical Center, Rotterdam, Netherlands; ²Respiratory Medicine, Erasmus Medical Center, Rotterdam, Netherlands; ³Virology, Erasmus Medical Center, Rotterdam, Netherlands.

(692) The Impact of Respiratory Viruses on Acute Rejection and Allograft Function in Lung Transplant Recipients; D.M. Sayah,¹ J.L. Koff,² L.E. Leard,¹ J.A. Golden,¹ J.P. Singer.¹ ¹University of California, San Francisco; ²Yale University, New Haven, CT.

(693) Clinical Spectrum of Sinkania negevensis (Sn) Infection in Lung Transplant Recipients (LTR); M.R. Resende,^{1,2} L.G. Singer,¹ C. Chaparro,¹ C. Rotstein,¹ Y. Akinlolu,¹ A. Sansan,¹ S. Keshavjee,¹ I. McGillvray,¹ S. Husain.¹ ¹Multiorgan Transplant Program – University Health Network, University of Toronto, Toronto, ON, Canada; ²Infectious Diseases – Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil.

(694) The Rise of Clostridium Difficile in Lung Transplantation: Key Predictors in the Modern Era; J.T. Lee,¹ M.I. Hertz,⁴ J.M. Dunitz,⁴ R.F. Kelly,² J. D' Cunha,³ B.A. Whitson,³ S.J. Shumway.² ¹Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis; ²Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis; ³Division of Thoracic and Foregut Surgery, Department of Surgery, University of Minnesota, Minneapolis; ⁴Division of Pulmonary and Critical Care, Department of Medicine, University of Minnesota, Minneapolis.

(695) Association between Sinkania negevensis (Sn) Detection and Acute Cellular Rejection (ACR) in Lung Transplant Recipients (LTR); M.R. Resende,^{1,2} L.G. Singer,¹ C. Chaparro,¹ C. Rotstein,¹ A. Sansan,¹ Y. Akinlolu,¹ S. Keshavjee,¹ I. McGillvray,¹ S. Husain.¹ ¹Multiorgan Transplant Program – University Health Network, University of Toronto, Toronto, ON, Canada; ²Infectious Diseases – Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil.

(696) Recurrent Viral Infection in Idiopathic Pulmonary Fibrosis Patients after Lung Transplantation; F. Calabrese, F. Lunardi, N. Nannini, E. Balestro, E. Rossi, M. Loy, F. Di Chiara, F. Rea. University of Padova, Padova, Italy.

(697) Extended Valganciclovir Prophylaxis (VGC px) Decreases CMV Disease in D+/R- Lung Transplant Recipients (LTR), but Is Limited by Late Onset Infections, Toxicity and Resistance; L. Mlincs, M.H. Nguyen, E.J. Kwak, F. Silveira, J. Pilewski, M. Crespo, Y. Toyoda, C. Bermudez, C.J. Clancy. University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA.

(698) Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Pulmonary Fibrosis; R.V. Rocha,¹ J.K. Bhamra,¹ N. Shiguemura,¹ M.M. Crespo,² J.M. Pilewski,² A. Bansal,¹ M.M. Morrel,² C.J. Gries,² S. Haider,² B.A. Johnson,² C.A. Bermudez.¹ ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(699) Age and Type of Lung Transplant Influence Survival in Pulmonary Fibrosis Patients; T. Motomura,¹ H. Seethamraju,² S. Scheinin,¹ S. La Francesca,¹ M. Loebe,¹ R.R. Bunge,¹ S. Jyothula,² A.D. Parulekar,² B.A. Bruckner.¹ ¹Cardiovascular Surgery & Thoracic Transplant, The Methodist Hos-

pital DeBaKey Heart & Vascular Center, Houston, TX; ²Medicine/Division of Pulmonary Transplant, The Methodist Hospital, Houston, TX.

(700) The Clinical and Histological Characteristics of End-Stage Sarcoidosis Requiring Lung Transplantation; a Three Center Experience; H. Shigemitsu,¹ M. Drent,² B. van den Blink,³ O. Sharma,¹ R. J. van Suylen,⁴ M.A. den Bakker,⁵ M.N. Koss.⁶ ¹Pulmonary & Critical Care Medicine, University of Southern California Keck School of Medicine, Los Angeles; ²ILD Care Center, Maastricht University Medical Center, Maastricht, Netherlands; ³Pulmonary, Erasmus MC University Medical Center, Rotterdam, Netherlands; ⁴Pathology, Maastricht University Medical Center, Maastricht, Netherlands; ⁵Pathology, Erasmus MC University Medical Center, Rotterdam, Netherlands; ⁶Pathology, University of Southern California Keck School of Medicine, Los Angeles.

(701) Rapid Decline in Six Minute Walk Distance Is Associated with Lower Survival to Transplant in the Idiopathic Pulmonary Fibrosis Patient; J.R. Walsh,^{1,2} D.C. Chambers,^{1,2} S.T. Yerkovich,^{1,2} N.R. Morris,^{1,3} P.M.A. Hopkins,^{1,2} ¹Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; ²School of Medicine, The University of Queensland, Brisbane, QLD, Australia; ³Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia.

(702) Growing Single Center Experience with ECMO as a Bridge to Lung Transplantation; N. Wakil,¹ D.P. Mason,¹ S. Murthy,¹ M.M. Budev,² J.J. Yun,¹ D.R. Johnston,¹ K.R. McCurry,¹ G.B. Petterson.¹ ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH; ²Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH.

(703) The Current Role of Extracorporeal Membrane Oxygenation or ECMO for Lung Failure: Bridge to Transplantation and to Recovery for Graft Dysfunction; M.J. Barten, S. Lehmann, J. Garbade, C. Binner, F.W. Mohr, H.B. Bittner. Heart Center University of Leipzig, Cardiovascular Surgery and Thoracic Transplantation, Leipzig, Germany.

(704) Extracorporeal Lung Assist or Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation in Comparison to Patient with Lung Transplantation without Preoperative Assist Device, Single Center Experience; S. Lehmann, S. Leontyev, J. Garbade, M.J. Barten, F.W. Mohr, H.B. Bittner. Heartcenter Leipzig, Leipzig, Germany.

(705) Pre-Operative Cardiac Variables and Clinical Outcomes in Patients with Bilateral Lung Transplants; A. Yadlapati,¹ J. Aboulhosn,¹ J. Belpario,² D. Ross,² A. Ardehali,³ R. Saggat.² ¹Cardiology, UCLA, Los Angeles, CA; ²Pulmonary, UCLA, Los Angeles, CA; ³CT Surgery, UCLA, Los Angeles, CA.

(706) 100% 3-Year Survival after Extracorporeal Membrane Oxygenation (ECMO) Bridge to Lung Transplantation (N=10); M.B. Connellan,¹ Y. Orr,¹ R. Pye,² E. Granger,¹ K. Dhital,¹ C. Soto,¹ M.A. Malouf,¹ P. Spratt,¹ A.R. Glanville,¹ P. Jansz.¹ ¹Cardiopulmonary Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ²Department of Anaesthetics and Intensive Care, St. Vincent's Hospital, Sydney, NSW, Australia.

(707) Pre-Transplant Allosensitization Increases Time to Transplant and Waitlist Mortality in Lung Transplantation; H. Qureshi,¹ H. Seethamraju,² M. Loebe,² S. Scheinin,² B. Bruckner,² S. LaFrancesca,² S. Jyothula,² A.D. Parulekar.¹ ¹Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX; ²Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX.

(708) Percutaneous Coronary Intervention Improves Outcomes in Patients with Coronary Artery Disease Undergoing Lung Transplantation; R.R. Bunge,¹ H. Seethamraju,² S. Scheinin,¹ J. Estep,³ T. Motomura,¹ S. La Francesca,¹ W. Fischer,¹ A.D. Perulakar,² M. Loebe,¹ B.A. Bruckner.¹ ¹Cardiovascular Surgery & Thoracic Transplant, The Methodist Hospital DeBaKey Heart & Vascular Center, Houston, TX; ²Internal Medicine/Division of Pulmonary Transplant, The Methodist Hospital, Houston, TX; ³Internal Medicine/Division of Cardiology, The Methodist Hospital DeBaKey Heart & Vascular Center, Houston, TX.

(709) Single Versus Double-Lung Transplantation in Emphysema; M. Delgado,¹ J.M. Borro,¹ D. González,¹ R. Fernández,¹ S. Campinha,² J.A. García,¹ E. Feira,¹ L. Mendez,¹ M. De La Torre.¹ ¹Thoracic Surgery, University Hospital A Coruña, A Coruña, Spain; ²Pulmonology, Centro Hospitalar de Gaia/Espinho., Vila Nova de Gaia, Portugal.

(710) Survival Stratification in Scleroderma Patients by DeMeester Score; J.P. Gagermeier,¹ P. Patel,² J. Joseph,² P.M. Fischella,³ C.S. Davis,³ C.G. Alex,¹ R.B. Love.⁴ ¹Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; ²Medicine, Loyola University Medical Center, Maywood, IL; ³General Surgery, Loyola University Medical Center, Maywood, IL; ⁴Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL.

(711) Changes in Pulmonary Volumes in Patients Who Underwent Lung Transplantation for Pulmonary Fibrosis; A. Bertani,¹ P. Vitulo,² S. Soresi,² L. DeMonte,¹ F. Tuzzolino,¹ A. Callari,² B. Gridelli.¹ ¹Thoracic Surgery and Lung Transplantation, ISMETT-UPMC Italy, Palermo, Italy; ²Pulmonology, ISMETT-UPMC Italy, Palermo, Italy.

(712) Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant: First Results of the French Experience, 2007-2011; P. Morandant,¹ M. Lafarge,¹ Y. Castier,¹ L. Brouchet,² P.E. Falcoz,³ A. Haloun,⁴ F. Le Pimpec-Barthes,⁵ G. Lesèche,¹ J.-M. Maury,⁶ M. Reynaud-Gaubert,⁷ C. Saint-Raymond,⁸ M. Stern,⁹ H. Mal.¹ ¹Hôpital Bichat – Claude Bernard, Paris, France; ²CHU, Toulouse, France; ³CHU, Strasbourg, France; ⁴CHU, Nantes, France; ⁵HEGP, Paris, France; ⁶CHU, Lyon, France; ⁷CHU, Marseille, France; ⁸CHU, Grenoble, France; ⁹Hôpital Foch, Suresnes, France.

(713) CT Scores Are Predictive of Survival in CF Patients Awaiting Lung Transplantation; M. Loeve,^{1,2} W.C.J. Hop,³ M. de Bruijne,^{2,4} P.Th.W. van Hal,⁵ P. Robinson,⁶ M.L. Aitken,⁷ J.D. Dodd,⁸ H.A.W.M. Tiddens.^{1,2} ¹Pediatric Pulmonology, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid Holland, Netherlands; ²Radiology, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; ³Biostatistics, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; ⁴Medical Informatics, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; ⁵Respiratory Medicine, Erasmus MC, Rotterdam, Zuid Holland, Netherlands; ⁶Pediatric Pulmonology, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia; ⁷Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA; ⁸Radiology, Sint Vincent's Hospital, Dublin, Ireland.

(714) Fluid Balance and Immediate Post Operative Outcomes Following Lung Transplant; L. Munshi,¹ L.G. Singer,³ M. Cypel,² S. Keshavjee,² M. Binnie,³ N.D. Ferguson.¹ ¹Critical Care, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ²Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ³Respirology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.

(715) Right Ventricular Stroke Work Index as a Predictor of One-Year Mortality and Initial Hospital Stay after Lung Transplantation; H.F. Armstrong,¹ P.C. Schulze,² W. Thirapatarapon,³ M.N. Bartels.¹ ¹Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; ²Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ³Department of Rehabilitation Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

(716) Risk Factors for the Development of Cutaneous Squamous Cell Carcinoma after Lung Transplantation; T. Tse,⁴ Z. Klyza,² S.T. Yerkovich,³ P.A. Hopkins,³ D.C. Chambers.³ ¹Pharmacy Department, The Prince Charles Hospital, Brisbane, QLD, Australia; ²The School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia; ³Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; ⁴The Queensland Lung Transplant Service, Brisbane, QLD, Australia.

(717) Increased Distal Airway Nitric Oxide (NO) Release during Acute Complications in Lung Transplant Recipients (LTxR); M.A. Gashouta,¹ Z. Cao,¹ M.R. Pipeling,¹ J.F. McDyer,¹ C.A. Merlo,¹ A.A. Shah,² J.B. Orens,¹ R.E. Girgis.¹ ¹Medicine, Johns Hopkins University, Baltimore, MD; ²Cardiac Surgery, Johns Hopkins University, Baltimore, MD.

(718) Delayed Recovery in Exercise Capacity Post Lung Transplantation Bears No Association with Age or Preoperative Functional Status; J.R. Walsh,^{1,2} D.C. Chambers,^{1,2} S.T. Yerkovich,^{1,2} N.R. Morris,^{1,3} H.E. Seale,¹ P.M.A. Hopkins.^{1,2} ¹Queensland Centre for Pulmonary Transplantation and Vascular Disease, The Prince Charles Hospital, Brisbane, QLD, Australia; ²School of Medicine, The University of Queensland, Brisbane, QLD, Australia; ³Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia.

(719) Sleep-Related Breathing Disorders Development along the First Year Post Lung Transplantation; P. Benavides Mañas, A. Hernandez Voth, R. Díaz Campos, M.D. Hisado Diaz, A. De Pablo Gafas, M.J. Díaz De Atauri Jiménez De Los Rios. Pneumology, ^{1,2} Octubre University Hospital, Madrid, Spain.

(720) Macrolide Resistant BAL Neutrophilia: Role of IL-17?; S.E. Verleden, R. Vos, D. Ruttens, A. Vaneylen, D.E. Van Raemdonck, G.M. Verleden, B.M. Vanaudenaerde. KULeuven, Leuven, Belgium.

(721) Pepsin Concentrations Are Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis after Lung Transplantation; C.S. Davis,¹ D.V. Flint,¹ K. Pelletiere,² E. Lowery,² L. Ramirez,¹ R.B. Love,³ E.J. Kovacs,¹ P.M. Fischella.¹ ¹Department of Surgery, Loyola University Chicago, Health Sciences Campus, Maywood, IL; ²Department of Medicine, Division of Pulmonary and Critical Care Medicine, Loyola University Chicago, Health Sciences Campus, Maywood, IL; ³Department of Thoracic and Cardiovascular Surgery, Loyola University Chicago, Health Sciences Campus, Maywood, IL.

(722) Mycophenolate Mofetil (MMF) as a Cause of Colonic Ischemia Requiring Colectomy in Lung Transplant Recipients (LTR); A. Bansal,⁷ Y. Toyoda,⁶ N. Shigemura,¹ J.K. Bhama,¹ D.J. Hartman,⁴ C.J. Clancy,² R. Shields,³ M. Crespo,³ J. Pilewski,³ C. Bermudez,¹ M.-H.T. Nguyen.² ¹Division of Cardiothoracic Transplant, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Division of Pulmonary Allergy and Critical Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Department of Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁶Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA; ⁷Ochsner Clinic Foundation, New Orleans, LA.

(723) Aspiration after Lung Transplantation: Incidence, Risk Factors, and Accuracy of the Bedside Swallow Evaluation; J.K. Bhama,¹ B.M. Baumann,² S. Byers,² T. Wasserman,² R. Zomak,¹ A. Bansal,¹ N. Shigemura,¹ J.M. Pilewski,³ M. Crespo,³ D. Zaldonis,¹ C.A. Bermudez,¹ Y. Toyoda.⁴ ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Department of Pulmonary, Allergy & Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴Department of Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

(724) Primary Graft Dysfunction (PGD) vs Transfusion-Related Lung Injury (TRLI) in Lung Transplantation (LT): Can These Entities Be Differentiated Based on the Current ISHLT PGD Definition?; M.M. Crespo,¹ C.J. Clancy,² J.M. Pilewski,¹ C. Bermudez,³ V. Jarido,⁴ B. Johnson,¹ S.S. Haider,¹ J. Bhama,³ Y. Toyoda,⁵ M. Morrell,¹ N. Shigemura,³ M.H. Nguyen.² ¹Pulmonary, Allergy and Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Division of Infectious Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Cardiothoracic Surgery, Temple University Medical Center, Philadelphia, PA.

(725) The Importance of Risk-Factor Adjustment When Assessing the Relationship between Voriconazole Utilization and the Development of Non-Melanoma Skin Cancer among Lung and Heart/Lung Transplant Patients, 2002-2009; J.M. McLaughlin,¹ D. Equils,¹ K.T. Somerville,¹ J. Aram,¹ H. Schlamm,¹ V. Welch,¹ J. Mardekian,¹ R.G. Barbers.² ¹Pfizer Inc., New York, NY; ²Adult Asthma and Allergy Center, Lung Transplantation Program, Keck School of Medicine, University of Southern California, Los Angeles, CA.

(726) Endoscopic Treatment of Native Lung Hyperinflation with One-Way Valves in Single Lung Transplant Patients: A Multinational Experience; M. Perch,¹ D.K. Hogarth,² S.C. Springmeyer,³ G.C. Riise,⁴ A.L. Musani,⁵ X. Gonzalez,³ M. Iversen.¹ ¹Cardiology, Section for Lungtransplantation, Rigshospitalet, Copenhagen, Denmark; ²University of Chicago, IL; ³Spiration, Redmond, WA; ⁴Sahlgrenska University Hospital, Göteborg, Sweden; ⁵National Jewish Health and University of Colorado, Denver, CO.

(727) Negative Clinical Outcomes Associated with Postoperative Atrial Arrhythmias after Lung Transplantation; K.R. Branch,¹ B.R. Parmar,¹ M.S. Mulligan,² K.M. Koprivic,⁵ G. Raghu,³ R.W. Rho.⁴ ¹Internal Medicine/Cardiology, University of Washington, Seattle, WA; ²Thoracic Surgery, University of Washington, Seattle, WA; ³Internal Medicine/Pulmonology and Critical Care, University of Washington, Seattle, WA; ⁴Cardiology, Sutter Pacific Medical Foundation, San Francisco, CA; ⁵Biostatistics, University of Washington, Seattle, WA.

(728) The Crossed Wiring Technique, Especially the Parasternal Technique, Is Associated with Less Sterna Dehiscence after Bilateral Lung Transplantation; T.D. Koster,¹ F.Z. Ramjankhan,² E.A. van de Graaf,¹ H.D. Luijk,¹ J.C. Grutters,³ R.C.A. Meijer,² D.A. van Kessel,³ J.M. Kwakkel-van Erp.¹ ¹Division of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, Netherlands; ²Division of Cardio-Thoracic Surgery, University Medical Centre Utrecht, Utrecht, Netherlands; ³Division of Respiratory Medicine, St. Antonius Hospital, Nieuwegein, Netherlands.

(729) Abnormalities of Esophageal Motor Activity Are Highly Prevalent in Lung Transplanted Patients; M. Di Stefano,¹ F. Meloni,² T. Oggioni,² C. Mengoli,¹ F. Briganti,² M. Bergonzi,¹ A. Zanaboni,¹ E. Pagani,¹ E. Miceli,¹ M. Luisetti,¹ G.R. Corazza.¹ ¹1st Department of Internal Medicine, University of Pavia and IRCCS San Matteo Foundation, Pavia, Italy; ²Haematological Pneumological and Cardiovascular Sciences, Section of Pneumology, University of Pavia and IRCCS San Matteo Foundation, Pavia, Italy.

(730) Early Major Neurologic Complications after Lung Transplantation: Prevalence, Risk Factors and Outcome; N. Shigemura,¹ J. Bhama,¹ K. Fujimoto,¹ A. Shiose,¹ A. Ali,¹ H. Kanemitsu,¹ C. Gries,² M. Crespo,² B. Johnson,² J. Pilewski,² C. Bermudez.¹ ¹Cardiothoracic Surgery, Division of Cardiothoracic Transplant, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Medicine, Division of Pulmonary Allergy and Critical Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

(731) Acoustic Analysis of a Mechanical Circulatory Support; L. Hubbert, B. Peterzén, H. Granfeldt, H. Ahn. Heart Centre, University Hospital, Departments of Medicine & Health at Linköping University, Linköping, Sweden.

(732) Preoperative Hypoalbuminemia Predicts Poor Prognosis in Patients Undergoing Left Ventricular Assist Device Implantation; T.S. Kato,¹ Y. Kawano,¹ J. Yang,² H. Akashi,² H. Takayama,² Y. Naka,² M. Farr,¹ D. Mancini,¹ P.C. Schulze.¹ ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY; ²Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

(733) A Retrospective Study of Transcutaneous Energy Transmission in the LionHeart LVAD with Application to Future Wireless Circulatory Support Devices; W.J. Weiss, W.E. Pae, A. El-Banayosy, G. Rosenberg. Department of Surgery, Penn State Hershey Medical Center, Hershey, PA.

(734) Blood Pressure Control in Continuous Flow Left Ventricular Assist Devices – Efficacy and Impact on Adverse Events; B. Lampert,¹ S. Weaver,¹ A. Scanlon,¹ K. Lockard,¹ C. Allen,¹ N. Kunz,¹ C. Bermudez,¹ J.K. Bhama,¹ M. Shullo,² R.L. Kormos,¹ J.J. Teuteberg.¹ ¹Heart and Vascular Institute, University of Pittsburgh, PA; ²Pharmacy and Therapeutics, University of Pittsburgh, PA.

(735) Left Ventricle Assist Device as a Bridge to Transplantation, Comparison of Quality of Life; F. Yliheikkilä,¹ R. Gustafsson,¹ F. Nielsen,² B. Koul,¹ B. Andersson,³ J. Nilsson.¹ ¹Clinical Sciences in Lund, Cardiothoracic Surgery, Lund University and Skåne University Hospital, Lund, Sweden; ²Chemical Engi-

neering, Lund University, LTH, Lund, Sweden; ³Clinical Sciences in Lund, Surgery, Lund University and Skåne University Hospital, Sweden.

(736) Hemodynamic Efficacy of a Novel Catheter-Deployed Intra-Aortic Micro-Axial Entrapment Pump in a Porcine Acute HF Model; F. Raissi, S. Shabari,¹ M.P. Cuchiara,² J.H. Heuring,² B.A. Hertzog,² J.K. George,¹ R.M. Delgado.¹ ¹Texas Heart Institute, Houston, TX; ²Procyonion, Houston, TX.

(737) WITHDRAWN

(738) WITHDRAWN

(739) Integrating Palliative Care in the Management of Patients Considered for Mechanical Circulatory Support; Y. Ravi,¹ S. Emani,² S. Wismann,¹ A.K. Hasan,² E.F. Gafford,² C.B. Sai-Sudhakar.¹ ¹Surgery, The Ohio State University, Columbus, OH; ²Internal Medicine, The Ohio State University, Columbus, OH.

(740) Impact of Reverse Remodeling Following LVAD Implantation on Predicting Long-Term Prognosis during LVAD Support Period; H. Yotsukura,¹ O. Seguchi,² T. Sato,² H. Sunami,² Y. Murata,² M. Yanase,² T. Fujita,³ K. Toda,³ T. Nakatani.² ¹Division of Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan; ²Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan; ³Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.

(741) Endocardial Catheter Based Ablation of Ventricular Tachycardia in Patients with Ventricular Assist Devices; M.W. Winner,¹ E.G. Daoud,¹ Y. Ravi,² J. Ackers,¹ S. Emani,¹ M. Firstenberg,² C.B. Sai-Sudhakar.² ¹Cardiovascular Medicine, The Ohio State University, Columbus, OH; ²Cardiac Surgery, The Ohio State University, Columbus, OH.

(742) Surgical Management of the Inlet Orifice in Explantation of Continuous-Flow LVADs; O.H. Frazier, J.K. Ho, W. Cohn, I. Gregoric. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(743) Role of Echocardiographic Assessment in Staged Weaning and Elective Removal of the HeartMate II LVAD; O.H. Frazier, B. Radovancevic, Z. Demirozu, A.M. Segura, R. Bogaev, W. Cohn, I. Gregoric. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(744) Variability in Fibrosis of Tissue Samples Obtained after Diaphragmatic and Apical LVAD Implantation; A.M. Segura, I. Gregoric, R. Radovancevic, A. Aguayo, L.M. Buja, O.H. Frazier. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(745) Initial Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS); T. Nakatani,¹ K. Sase,² H. Oshiyama.³ ¹Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; ²Clinical Pharmacology, Juntendo University, Tokyo, Japan; ³Japan Medical Devices Manufacturers Association, Tokyo, Japan.

(746) Speed Adjustment and Thrombosis Detection in Continuous Flow Pumps: Utility of Ramp Studies; N. Uriel,¹ P.C. Colombo,¹ K.A. Morisson,¹ T. Kato,¹ S.W. Restaino,¹ M. Yuzefpolskaya,¹ H. Takayama,² Y. Naka,² U.P. Jorde.¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY.

(747) Long-Term Support with a Bi-Ventricular Assist Device – A Single Center Experience; A. Gkouziouta, A. Manginas, D. Zarkalis, A. Thanopoulos, S. Adamopoulos. Heart Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece.

(748) Treatment of Advanced Heart Failure in Cardiac Amyloidosis with Left Ventricular Assist Device Therapy; P.L. Swiecicki,¹ B. Edwards,² S. Kushwaha,² A. Dispenzieri,¹ S. Park,³ M.A. Gertz.¹ ¹Division of Hematology, Mayo Clinic, Rochester, MN; ²Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ³Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.

(749) Support Structure Impacts Outcomes after VAD Implantation; J.W. Entwistle,¹ C. Cassano,² T. Rowe,² S.C. Feitel,³ P. Boateng,¹ S.R. Hankins,⁴ H.J. Eisen,⁴ R.J. Petrucci.⁵ ¹Department of Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA; ²Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA; ³Department of Medicine, Drexel University College of Medicine, Philadelphia, PA; ⁴Department of Medicine, Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA; ⁵Department of Psychiatry, Drexel University College of Medicine, Philadelphia, PA.

(750) Application of New Generation Rotary Pumps and Oxygenators for Venous-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Refractory Cardiogenic Shock (RCS); B. Soleimani, A. Manoskey, L. Baer, E.R. Stephenson, C. Brehm, W.E. Pae, A. El-Banayosy. Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey, PA.

(751) Tricuspid Regurgitation Is a Measure of Right Heart Dysfunction and Is Associated with Event Free Survival in Stage D Heart Failure: Analysis from MEDAMACS; J. Testani,¹ G.C. Stewart,² M.M. Kittleson,³ J.A. Cowger,⁴ C.B. Patel,⁵ M.M. Mounts,⁶ F.L. Johnson,⁷ M.E. Guglin,⁸ P.C. Patel,⁹ J.J. Teuteberg,¹⁰ J.E. Rame.¹ ¹University of Pennsylvania, Philadelphia; ²Brigham and Women's Hospital, Boston; ³Cedars Sinai Heart Institute, Los Angeles; ⁴University of Michigan, Ann Arbor; ⁵Duke University, Durham; ⁶Cleveland Clinic, Cleveland; ⁷University of Iowa, Iowa City; ⁸University of South Florida, Tampa; ⁹University of Texas Southwestern Medical Center, Dallas; ¹⁰University of Pittsburgh.

(752) Should Advanced Age Be a Contra-Indication to LVAD Implant: A Community Hospital Experience; R.M. Adamson,¹ P. Hoagland,² B. Jaski,² M. Stahovich,³ S. Chillcott,³ W.P. Dembitsky.¹ ¹Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; ²Cardiology, Sharp Memorial Hospital, San Diego, CA; ³Nursing, Sharp Memorial Hospital, San Diego, CA.

(753) Low Psychosocial and Financial Assessment Scores Are Not Predictive of Poor Outcomes among Ventricular Assist Device Patients; D.S. Medina,² A.M. Cordero-Reyes,¹ B. Mosele,² K. Fry,² J.D. Estep,¹ A. Bhimaraj,¹ M. Loebe,¹ G. Torre-Amione.^{1,3} ¹The Methodist DeBakey Heart & Vascular, The Methodist Hospital, Houston, TX; ²Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX; ³Cardiology, Hospital San Jose Tec de Monterrey, Monterrey, NL, Mexico.

(754) An Estimate of the Potential Candidates for Mechanical Circulatory Support Based on the Analysis of Heart Failure Hospitalizations; G. Binaghi,^{1,2} C. Vittori,² E. Parravicini,³ L. Martinelli,² R. Paino,² F. Oliva,² M. Cipriani,² G. Masciocco,² F. Turrazza,² A. Garascia,² G. Foti,² A. Verde,² E. Ammirati,² M. Frigerio.² ¹Dipartimento Patologia Cardio-Toraco-Vascolare, Azienda Ospedaliera Brotzu, Cagliari, Italy; ²Dipartimento "De Gasperis", Azienda Ospedaliera – Ospedale Niguarda Ca' Granda, Milano, Italy; ³Dipartimento Direzione – Qualità e Sicurezza Clinica, Azienda Ospedaliera – Ospedale Niguarda Ca' Granda, Milano, Italy.

(755) Reduced Handgrip Strength as a Marker of Patient Frailty Predicts Worse Survival after Implantation of a Left Ventricular Assist Device; C.J. Chung,¹ O. Ferreira,¹ C. Wu,¹ H. Akashi,¹ T.S. Kato,¹ H. Takayama,² Y. Naka,² D.M. Mancini,¹ P.C. Schulze.¹ ¹Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY; ²Department of Surgery, Columbia University Medical Center, New York, NY.

(756) Can Right Ventricular Failure Associated with LVAD Insertion Be Avoided? R.M. Adamson,¹ J. Chammas,¹ V. Norman,¹ B. Jaski,² P. Hoagland,² S. Chillcott,³ M. Stahovich,³ W.P. Dembitsky.¹ ¹Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA; ²Cardiology, Sharp Memorial Hospital, San Diego, CA; ³Nursing, Sharp Memorial Hospital, San Diego, CA.

(757) The Relation of Body Size and Outcome in Patients Using Continuous Flow Left Ventricular Assist Devices; A. Mano, J.J. Teuteberg, C.A. Bermudez, J.K. Bhama, D.M. McNamara, R. Ramani, M. Simon, R.L. Kormos. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.

(758) Outcomes Following Ventricular Assist Device Placement in Patients with Advanced Chronic Kidney Disease; C.T. Gallagher, L.A. Coyle, A. Thomas, G. Bhat, A. Tatooles. Advocate Christ Medical Center, Oak Lawn, IL.

(759) Safety Evaluation of the HeartWare MVAD Pump in the Pericardial Position in an Ovine Model; E. McGee,¹ D. Tamez,² A. Dierlam,² M. Brown,² N. Nunez,² ¹Bluhm Cardiovascular Institute Northwestern Memorial Hospital, Northwestern University's Feinberg School of Medicine, Chicago, IL; ²Clinical Research Division, HeartWare, Inc, Framingham, MA.

(760) Evaluation of the Infant Jarvik 2000 Heart in a Neonate Piglet Model; A.C. Watkins, X. Wei, P.G. Sanchez, H. Ho, P. Zhang, J. Hu, Z. Wu, B.P. Griffith. Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD.

(761) Two CircuLite Pumps as Bi-Ventricular Assist Device (BVAD) in an Ovine Animal Model; J.D. Schmitt,¹ D. Burkhoff,^{2,3} M. Avsar,¹ O. Fey,³ P. Ziehme,¹ G. Buechler,¹ A. Haverich,¹ M. Strueber.¹ ¹Dept. of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ²Dept. of Cardiology, Columbia University, New York, NY; ³CircuLite Inc., Aachen, Germany.

(762) Use of Sealed Grafts in the HeartMate II Inflow and Outflow Conduits; I. Gregoric, R. Radovancevic, M. Patel, L. Fenik, W. Cohn, O.H. Frazier. Center for Cardiac Support, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(763) Extracorporeal Membrane Oxygenation Support after Pediatric Heart Transplantation: Predictors of Survival to Hospital Discharge; J.A. Su, R.B. Kelly, J. Alejos. Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA.

(764) Is There Adequate Knowledge about LVAD Patients among First Responders? A Survey from North Western Italy; A. Muncinò, A. Torriglia, On Behalf of Rete per l'Emergenza-Urgenza. Dept. of Cardiology, Ospedale A. Gallino ASL³ Genovese, Genova, Italy.

(765) Can a Registry Match the Data Quality of a Clinical Trial? Lessons Learned from INTERMACS; D.C. Naftel,¹ J.K. Kirklín,¹ S.L. Myers,¹ M.L. Clark,¹ K.A. Hollifield,¹ S.C. Collum,¹ M.A. Miller.² ¹Surgery, University of Alabama, Birmingham, AL, United Kingdom; ²Cardiovascular Sciences, National Heart, Lung and Blood Institute, NIH, Bethesda, MD.

(766) Echocardiographic and Pathological Correlates of Aortic Regurgitation in Continuous-Flow LVAD Support; S. Murthy,¹ R. Bello,² D. Casazza,¹ S. Maybaum,¹ D. Goldstein.² ¹Cardiology, Montefiore Medical Center, Bronx, NY; ²Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY.

(767) Impact of Left Ventricular Assist Device Implantation upon Native Aortic Valve Regurgitation; K. Rajagopal,¹ M.A. Daneshmand,¹ M.A. Schechter,¹ A.M. Ganapathi,¹ C.B. Patel,² J.G. Rogers,² B.A. Bottiger,³ M. Swaminathan,³ C.A. Milano.¹ ¹Surgery – Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, NC; ²Medicine – Division of Cardiology, Duke University Medical Center, Durham, NC; ³Anesthesiology – Division of Cardiothoracic Anesthesia, Duke University Medical Center, Durham, NC.

(768) Transcranial Doppler Findings in Heart Failure Patients with Left Ventricular Assist Devices (LVADs); Z. Garami, K. Livia, B. Brian, T. Motomura, A. Lumsden, G. Noon, M. Loebe. Cardiovascular Surgery, The Methodist Hospital, Houston, TX.

(769) No Change in Endothelium Dependent Flow-Mediated Dilation Following Continuous Flow Ventricular Assist Device; P.M. Eckman,¹ D. Templeton,² S. Hozayen,¹ P. Baker,³ R. John,⁴ M. Colvin-Adams,¹ D. Dengel.⁵ ¹Department of Medicine, Division of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN; ²Integrative Vascular Biology Lab, University of Colorado, Boulder, CO; ³Clinical and Translational Science Institute, Masonic Clinical Research Unit, University of Minnesota, Minneapolis, MN; ⁴Division of Cardiac

Surgery, University of Minnesota, Minneapolis, MN; ⁵School of Kinesiology, University of Minnesota, Minneapolis, MN.

(770) Cardiac Resynchronization Therapy Does Not Confer Additional Benefit after Implantation of a Left Ventricular Assist Device; B.A. Boilsson, J.A. Schiringer, L.C. Durham, P.A. Friedman, L.D. Joyce, S.J. Park, R.C. Daly, S.S. Kushwaha. Mayo Clinic, Rochester, MN.

(771) Non Invasive Blood Pressure (BP) Measurement with the Terumo Elemeno™ Is More Reliable during Return of Pulsatile Flow in Patients on Continuous Flow (CF) LVAD Support; O. Saeed,¹ J. Patel,¹ C. Nucci,¹ S. Patel,¹ D. Goldstein,² S. Maybaum.¹ ¹Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(772) Normalization of Pulmonary Vascular Resistance after Bridging to Heart Transplantation with the Total Artificial Heart; S.L. Rennyson, M.P. Flattery, G.A. Merinar, D.G. Tang, G.J. Katlaps, R.H. Cooke, M.L. Hess, V. Kasirajan, K.B. Shah. Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA.

(773) Continuous Flow Left Ventricular Assist Device Therapy Deteriorates Systemic Endothelial Function; T. Hasin, A. Lerman, S.J. Park, S.S. Kushwaha. Mayo Clinic, Rochester.

(774) Inflammatory Markers and Cardiopulmonary Exercise Testing in Continuous Flow LVAD Recipients; L. Grosman-Rimon, D.Z.I. Cherney, S. Pollock Bar-Ziv, L. Tumati, M.A. McDonald, I. Jacobs, V. Rao. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Medicine, Toronto General Hospital, Toronto, ON, Canada; Cardiac Transplant, Hospital for Sick Children, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; Department of Medicine, Toronto General Hospital, Toronto, ON, Canada; Exercise Sciences, University of Toronto, Toronto, ON, Canada; Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada.

(775) Axial Flow Left Ventricular Assist Device (LVAD) Support Leads to Progressive Left Ventricular Enlargement and Functional Decline in Normal Hearts; P. Kloepper,¹ C.C. Del Rio,² B. Youngblood,² Y. Ueyama,² P.I. McConnell.¹ ¹Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH; ²Qtest Labs, Columbus, OH.

(776) Incidence and Clinical Significance of Atrial Fibrillation under Mechanical Circulatory Support Systems. Role of Catheter Ablation?; H.A. Welpe,¹ A. Rukosujew,¹ A. Hoffmeier,¹ R.V. Lichtenberg,¹ L. Eckardt,² J. Stypmann,² H.H. Scheld,¹ G. Mönig.² ¹Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Münster, Germany; ²Department of Cardiology, University Hospital Münster, Münster, Germany.

(777) Left Ventricular Assist Device Implantation Significantly Improves Everyday Physical Activity and Quality of Life in Patients with Chronic Heart Failure; A. McDiarmid,¹ G.A. MacGowan,^{1,2} G. Parry,¹ S. Schueler,¹ M.I.I. Trenell,^{2,3} D.G. Jakovljevic.^{2,3} ¹Cardiology and Cardiothoracic Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Institutes for Aging and Health, Genetic Medicine and Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; ³Centre for Brain Aging and Vitality, Newcastle University, Newcastle upon Tyne, United Kingdom.

(778) Monitoring of Heart Rate Variability in Rotary Blood Pump Recipients Is Possible Using the Pump Flow Only; F. Moscato,^{1,3} M. Granegger,^{1,3} M. Edelmayr,¹ D. Zimpfer,² G. Wiesenthaler,² H. Schima.^{1,2,3} ¹Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria; ²Dept. of Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ³Ludwig-Boltzmann-Cluster for Cardiovascular Research, Vienna, Austria.

(779) Quantitative Pre-Operative Risk Assessment of Right Ventricular Failure during Destination Continuous Flow Left Ventricular Assist Device Implantation; P. Atluri,¹ A.B. Goldstone,¹ A.S. Fairman,¹ J.W.

MacArthur,¹ B.W. Ullery,¹ Y. Shudo,¹ W. Hiesinger,¹ M.L. O'Hara,¹ J.R. Fitzpatrick,¹ M.A. Acker,¹ J.E. Rame,² Y.J. Woo.¹ ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; ²Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA.

(780) Impaired 6 Minute Walk Test after Continuous Axial Flow Left Ventricular Device Implantation Is Associated with Reduced Survival; T. Hasin, Y. Topilsky, W. Kremers, B.A. Boilson, J.A. Schirger, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, L. Joyce, R. Daly, S.S. Kushwaha, S.J. Park, N.L. Pereira. Mayo Clinic, Rochester, Mn.

(781) Performance of the Right Ventricular Failure Risk Score in Patients Supported with a Left Ventricular Assist Device; S. Lee,¹ L. Vargas,² S. Rao,³ C. Halley,⁴ Z. Sun,⁵ M.M. Mountis,¹ G. Gonzalez-Stawinski,⁶ N.G. Smedira,⁶ K. Fukamachi,⁷ R.C. Starling.¹ ¹Section of Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic Foundation, Cleveland, OH; ²Vascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; ³Cardiovascular Medicine, SUNY Upstate Medical University, Syracuse, NY; ⁴Cardiovascular Medicine, Mater Misericordiae University Hospital, Dublin, Ireland; ⁵Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH; ⁶Thoracic & Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH; ⁷Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH.

(782) Aggressive Preoperative Optimization Is a Better Determinant of Survival Than Current Risk Models for Acute Cardiogenic Shock; N. Moazami,¹ D. Feldman,² K. Hryniewicz,² M. Lillyblad,² B. Cabuay,² E. Shao,² B. Sun.¹ ¹Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN; ²Cardiology, Minneapolis Heart Institute, Minneapolis, MN.

(783) Severity of End Organ Damage as a Predictor of Outcomes after Extracorporeal Membrane Oxygenator (ECMO) Support for Cardiogenic Shock; B. Soleimani, A. Manoskey, E.R. Stephenson, C. Brehm, W.E. Pae, A. El-Banayosy. Heart & Vascular Institute, Penn State Hershey Medical Center, Hershey, PA.

(784) Clinical Experience with Patients over Age 65 Who Undergo HeartMate II LVAD Placement for Destination Therapy; B.A. Bruckner,¹ M. Loebe,¹ J.D. Estep,³ T. Motomura,¹ I. Gregoric,² W.E. Cohn,² R. Radovancevic,² R.R. Bunge,¹ O.H. Frazier.² ¹Cardiovascular Surgery, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX; ²Cardiothoracic Surgery, Texas Heart Institute, Houston, TX; ³Cardiology, The Methodist Hospital DeBakey Heart & Vascular Center, Houston, TX.

(785) Improved Outcomes in "Crash and Burn" Patients through BiVAD Support; P. Kansara, E. Kransdorf, M. Kittleson, J. Patel, B. Coleman, G. Jamero, C. Runyan, C. Oley, R. Jocsos, L. Czer, A. Trento, R. Kass, F. Esmaillan, J. Kobashigawa, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA.

(786) Isolated Right Ventricular Assist Device Support Does Not Predict Better Survival over Biventricular Support for Primary Graft Failure after Orthotopic Heart Transplant; J.A. Yang,¹ Y. Naka,¹ M.S. Koeckert,¹ B.P. Shulman,¹ J. Jiang,¹ T. Horai,¹ T. Ota,¹ N. Uriel,² P. Colombo,² U.P. Jorde,² D.M. Mancini,² H. Takayama.¹ ¹Division of Cardiac Surgery, Dept of Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Dept of Medicine, Columbia University Medical Center, New York, NY.

(787) Clinical Utility of Percutaneous Mechanical Support Devices in the Bridge to Decision Population; N.K. Kapur, M. Esposito, D.T. Pham, V. Paruchuri, A. Jagannath, M.S. Kierman, M. Schecht, A. Weintraub, A. Majithia, D. DeNofrio. The Cardiovascular Center, Tufts Medical Center, Boston, MA.

(788) Preoperative Optimization Contributes to Sustained Improvement in Renal Function with LVAD Therapy; H.-S. Chiew,¹ B.S. Edwards,² S.J. Park,³ J. Geske,⁴ D.R. Fermin,² S.S. Kushwaha,² W.K. Kremers,⁴ P.A. Geerdes,² J.A. Schirger.² ¹Faculty of Medicine and Dentistry, Charles University at Hradec Kralove, Hradec Kralove, Czech Republic; ²Cardiovascular Diseases, Mayo Clinic, Rochester, MN; ³Cardiovascular Surgery, Mayo Clinic, Rochester, MN; ⁴Department of Biostatistics, Mayo Clinic, Rochester, MN.

(789) Benefit of Tricuspid Repair Concomitant with Left Ventricular Assist Device Implantation; T. Fujita, K. Toda, K. Domae, M. Yanase, O. Seguchi, Y. Murata, J. Kobayashi, T. Nakatani. National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

(790) Experience with Total Artificial Heart Bridge to Transplantation in 15 Women; H. Copeland, J. Copeland. Surgery, University of California San Diego, CA.

(791) Avoiding RVADs: Pre-Operative Optimization Is the Best Predictor of Need for RVADs; K. Hryniewicz, M. Lillyblad, E.S. Shao, D.S. Feldman, B. Cabuay, B. Sun, N. Moazami. Minneapolis Heart Institute, Minneapolis.

(792) Feasibility and Flexibility of Magnetically Levitated Centrifugal-Flow Pump for Patients with Cardiogenic Shock; H. Takayama,¹ L.K. Soni,¹ M. Koeckert,¹ J. Cogan,¹ S.R. Cedola,¹ D. Jones,¹ J. Jiang,¹ T. Horai,¹ T. Ota,¹ N. Uriel,² P. Colombo,² U. Jorde,² D. Mancini,² J. Chen,¹ Y. Naka.¹ ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY; ²Division of Cardiology, Columbia University Medical Center, New York, NY.

(793) Addition of Mitral Valve Repair to Left Ventricular Assist Device Implantation; S. Taghavi,¹ E. Hamad,² L. Wilson,³ R. Clark,⁴ S.N. Jayarajan,¹ N. Uriel,⁵ D. Goldstein,² H. Takayama,⁵ Y. Naka,⁵ A.A. Mangi.³ ¹Department of Surgery, Temple University Hospital, Philadelphia, PA; ²Department of Surgery, Montefiore Medical Center, Bronx, NY; ³Department of Cardiac Surgery, Yale University School of Medicine, New Haven, CT; ⁴Temple University School of Medicine, Philadelphia, PA; ⁵Department of Surgery, NewYork-Presbyterian Hospital/Columbia, New York, NY.

(794) Application of Destination Therapy Risk Score (DTRS) in Recipients of Continuous Flow LVADs; M. Kanwar,¹ S. Bailey,² R.J. Moraca,² S. Murali,¹ A. Raina,¹ G. Sokos,¹ A. Hopwood,¹ R.L. Benza.¹ ¹Advanced Heart Failure and Transplant Cardiology, Allegheny General Hospital, Pittsburgh, PA; ²Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA.

(795) Evidence for Restoration of Glucose Metabolism in Failing Myocardium Following Prolonged Mechanical Circulatory Support; A.M. Cordero-Reyes,¹ A. Gupta,³ K.A. Youker,¹ J.D. Estep,¹ M. Loebe,¹ D.J. Hamilton,³ W. Hsueh,³ G. Torre-Amione.^{1,2} ¹The Methodist DeBakey Heart & Vascular Center, Houston, TX; ²Hospital San Jose TEC de Monterrey, Monterrey, NL, Mexico; ³Center for Diabeter Research, The Methodist Hospital Research Institute, Houston, TX.

(796) Acoustic Monitoring Demonstrates Left Ventricular Systole Is Associated with Transient Speed Reduction of Implanted Rotary Left Ventricular Assist Devices (LVADs); M.R. Noor,^{1,2} S. Morad,³ C.T. Bowles,^{1,2} M.E. Hedger,¹ N.R. Banner,^{1,2} K.H. Parker,³ A. Simon.¹ ¹Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; ²National Heart and Lung Institute, Imperial College London, London, United Kingdom; ³Department of Bioengineering, Imperial College London, London, United Kingdom.

(797) Transcutaneous Energy Transfer with Bidirectional Data Flow for Powering a Novel Partial Circulatory Support Device; J.J. Heuring,¹ M.P. Cuchiara,¹ B.A. Hertzog,¹ R.M. Delgado.² ¹Procyon, Houston, TX; ²Texas Heart Institute, Houston, TX.

(798) Extracorporeal Membrane Oxygenation Support after Pediatric Heart Transplantation: Long-Term Survival Trends; J.A. Su, R.B. Kelly, J. Alejos. Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA.

(799) VAD Competent or VAD Aware?; J.H. Webster, S. Merali, L. Adcock, N.Y. Raval, D.A. Dean. Advanced Heart Failure Center, Piedmont Heart Institute, Atlanta, GA.

(800) Poorer Immediate Memory Predicts Better Self Confidence in Managing Heart Failure; C.M. Murks,¹ M. Gulanick,² S. Penckofer,² S.E. Fedson.¹ ¹Cardiology, University of Chicago, IL; ²Nursing, Loyola University, Chicago, IL.

(801) Improving Community Emergency Medical Services/Emergency Rooms Ability To Care for Mechanical Circulatory Device Patients; M.A. Murray,¹ M.R. Johnson,² J. Blabbaum,¹ L. Lozonschi,¹ W. Biedermann,⁴ N. Robinson,³ T. Kohmoto.¹ ¹Cardiothoracic Surgery and Transplant, University of Wisconsin Hospital and Clinics, Madison, WI; ²Medicine, University of Wisconsin Hospital and Clinics, Madison, WI; ³EMS Department, University of Wisconsin Health, Madison, WI; ⁴Education Department, LifeStar EMS, Columbus, WI.

(802) Transplant Nursing around the Globe: What Are Nurses Reporting; B.L. Coleman, A. Velleca. Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA.

(803) Guidelines for Withdrawal of VAD Therapy at End of Life; N. Wrightson, S. Louw, C. Regnard, S. Clark. Cardiothoracic Surgery and Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and wear, United Kingdom.

(804) WITHDRAWN

(805) LVAD Patient Pack; a Potential Reservoir for Pathogenic Organisms; J. Collins,¹ C. Winter,² N. Wrightson,³ G. MacGowan,³ T. Pillay,³ F.K. Gould,¹ S. Schueler.³ ¹Microbiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; ²Infection Prevention and Control, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; ³Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

(806) Novel Use of Simulation Lab To Educate 'Rapid Response Teams' about Differences in (ACLS) Advanced Cardiac Life Support Algorithms in Patients with HeartMate II Left Ventricular Assist Devices (LVAD); D.H. Karia, K. Parekh, M. Singh, M. Dunlop, M. Morrell, L. Bogar. Cardiology, Albert Einstein Medical Center, Philadelphia, PA.

(807) Outpatient Milrinone Therapy in Young Children with Advanced Heart Failure; E. Liu,¹ A. Lin,¹ M. Ogawa,¹ D. Rosenthal.² ¹Pediatric Cardiology, Lucile Packard Children's Hospital, Palo Alto, CA; ²Stanford University, Palo Alto, CA.

(808) Antibody-Mediated Rejection in Cardiac Transplant Recipients Is a Seasonal Disease; N.E. Hiemann, K. Wassilew, D. Kemper, R. Hetzer. Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

(809) Intraplaque Haemorrhage as a Trigger of Lesion Progression in Cardiac Allograft Vasculopathy; C. Castellani,¹ A. Angelini,¹ O. de Boer,² C. van der Loos,² M. Fedrigo,¹ A. Gambino,³ F. Tona,³ G. Feltrin,³ G. Gerosa,³ G. Thiene,¹ A.C. van der Wal.² ¹Medical-Diagnostic Sciences and Special Therapies, University of Padua, Padua, Italy; ²Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; ³Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

(810) A Prognostic Role for C4d in Surveillance Endomyocardial Biopsies after Heart Transplantation; A.N. Hussain,¹ M.K. Mirza,¹ S.R. Marino,¹ S.E. Fedson.² ¹Pathology, University of Chicago Medical Center, Chicago, IL; ²Medicine, University of Chicago Medical Center, Chicago, IL.

(811) Study of Necropsies of Patients Submitted to Heart Transplantation: NEHTS-Necropsy Heart Transplantation Study; S.M. Ayub-Ferreira, T.N. Valette, L.A. Benvenuti, E.A. Bocchi. Heart Failure Unit, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, SP, Brazil.

(812) Prospective Evaluation of Alveolar and Bronchiolar C4d Expression in Transbronchial Biopsies from Lung Transplanted Recipients; J. Majid,¹ R. Mahida,² N. Thampy,¹ F. Black,¹ G. Meachery,¹ J.L. Lordan,¹ P.A. Corris,¹ A.J. Fisher.¹ ¹Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, England, United Kingdom; ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, England, United Kingdom.

(813) Design of a Smart-Phone App with the Potential To Improve Adherence in Organ Transplantation; B. Kevern,³ J. Marshall,¹ M. Herzer,² T. Apodaca,² R. Johnson,² D. Lynch,⁴ B. Warady,⁵ J. Domen,¹ K. Gandy.¹ ¹Cardiovascular Surgery, Children's Mercy Hospitals and Clinics, Kansas City, MO; ²Developmental and Behavioral Sciences, Children's Mercy Hospitals and Clinics, Kansas City, MO; ³Information Systems, Children's Mercy Hospitals and Clinics, Kansas City, MO; ⁴Adolescent Medicine Department, Children's Mercy Hospitals and Clinics, Kansas City, MO; ⁵Nephrology Department, Children's Mercy Hospitals and Clinics, Kansas City, MO.

(814) Pulmonary Vein Stenosis as a Complication of Infant Lung Transplantation; P.H. Michelson,¹ R.M. Grady,¹ F.V. White,² P. Eghtesady,¹ C.B. Huddleston,³ A. Faro,¹ S.C. Sweet.¹ ¹Pediatrics, Washington University School of Medicine, St. Louis, MO; ²Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; ³Pediatric Cardiothoracic Surgery, Cardinal Glennon Children's Medical Center, St. Louis, MO.

(815) Lung Transplantation for Children in Europe: A 10-Year Multi-Center Austrian-German Experience; N. Schwerk,¹ C. Mueller,¹ G. Warnecke,² M. Griesse,³ J. Ripper,³ S. Gruber,⁴ A. Haverich,² R. Hatz,⁵ W. Klepetko,⁶ T. Frischer.⁴ ¹Department of Pediatrics Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; ²Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ³Children's Hospital, University of Munich, Munich, Germany; ⁴Department of Pediatric and Adolescent Medicine, University of Vienna, Vienna, Austria; ⁵Department of Surgery, Grosshadern Medical Center Ludwig-Maximilians-University, Munich, Germany; ⁶Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

(816) Changes in Body Composition after Lung Transplant in Children; U.G. Kyle,¹ R.A. Orellana,¹ J.K. Johnson,² G.B. Mallory,² M.G. Schechter,² J.A. Coss-Bu.¹ ¹Critical Care Medicine, Baylor College of Medicine/TCH, Houston, TX; ²Pulmonary Diseases, Baylor College of Medicine/TCH, Houston, TX.

(817) ECMO Use in Pediatric Lung Transplantation – The Zurich Experience; A.J. Zuercher,¹ I. Inci,² G. Fretz,¹ W. Weder,² A. Boehler,¹ C. Benden.¹ ¹Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland; ²Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

(818) ABO Blood Group Antigen Sensitization of Infants Exposed to Mechanical Circulatory Support (MCS); A. Guynes,² M. Delaney,³ D. Townsend,¹ M. Kemna,¹ D.M. McMullan,⁴ R. Boucek,¹ Y.M. Law.¹ ¹Pediatrics, Seattle Children's Hospital, Seattle, WA; ²School of Medicine, University of Washington, Seattle, WA; ³Blood Bank and Pathology, Puget Sound Blood Center and Seattle Children's Hospital, Seattle, WA; ⁴Surgery, Seattle Children's Hospital, Seattle, WA.

(819) Human Leukocyte Antibody Production Is Uncommon in a Large Series of Pediatric Patients Supported with the Berlin Heart EXCOR Ventricular Assist Device; M.J. O'Connor,¹ T.O. Harville,² S.E. Pye,¹ K.R. Knecht,¹ E.A. Frazier,¹ M. Imamura,³ W.R. Morrow.¹ ¹Cardiology, University of Arkansas for Medical Sciences/Arkansas Children's Hospital, Little Rock, AR; ²Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR; ³Pediatric Cardiothoracic Surgery, University of Arkansas for Medical Sciences/Arkansas Children's Hospital, Little Rock, AR.

(820) Psychiatric Disorders Following Ventricular Assist Device Implantation in Pediatric Patients; C.R. Pockett, R. LaFrance, J. Moore, H. Wilkes, H. Buchholz. University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada.

(821) Heparin Free VADs: Can It Be Done?; J.V. Cassidy,¹ L. Ferguson,¹ M. Guillen,¹ S.R. Haynes,¹ J.H. Smith,¹ Y. Thiru,¹ R. Kirk,¹ P. Kesteven,² M. Griselli,¹ A. Hasan.¹ ¹Paediatric Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Paediatric Haematology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(822) HLA Sensitization in Pediatric Patients Exposed to Mechanical Circulatory Support; B. Hong,¹ M. Delaney,³ A. Guynes,⁴ G. Cohen,² R.

Boucek,² P. Warner,³ M. Kemna,² Y. Law,² ¹Pediatric Cardiology, Texas Children's Hospital, Houston, TX; ²Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA; ³Puget Sound Blood Bank, Seattle, WA; ⁴School of Medicine, University of Washington, Seattle, WA.

(823) Impact of Pulmonary Venous Hypertension on Prognosis and Outcome after Lung Transplantation for End-Stage Chronic Obstructive Pulmonary Disease; K.H. Andersen,¹ M. Iversen,¹ J. Kjaergaard,¹ J. Mortensen,² J.-E. Nielsen-Kudsk,³ E. Bendstrup,⁴ R. Videbaek,¹ J. Carlsen.¹ ¹Department of Cardiology, Pulmonary Vascular Program, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ²Department of Clinical Physiology, Nuclear Medicine and PET, National University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Department of Cardiology, University Hospital of Aarhus, Skejby, Aarhus, Denmark; ⁴Department of Pulmonary Medicine, University Hospital of Aarhus, Aarhus, Denmark.

(824) WITHDRAWN

(825) Predictors of Six-Minute Walk Distance in Patients with Systemic Sclerosis Associated Pulmonary Hypertension; M.P. Tuppin,^{1,2} D. Chambers,^{1,2} R. Slaughter,³ O. Mohammed,³ F. Kermeen,² ¹School of Medicine, University of Queensland, Brisbane, QLD, Australia; ²Queensland Centre for Pulmonary Transplantation and Vascular Disease, Prince Charles Hospital, Brisbane, QLD, Australia; ³Medical Imaging, Prince Charles Hospital, Brisbane, QLD, Australia.

(826) RePHerral Study: A Multi-Center Study on the Referrals for Pulmonary Hypertension (PH); Left Heart Disease and PH; R.C. Deaño,¹ M. Gombert-Maitland,¹ S. Visovatti,² C. Glassner,¹ V. McLaughlin,² M. Rubenfire,² A. Frost.³ ¹Section of Cardiology, University of Chicago, IL; ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI; ³Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX.

(827) Diastolic Pulmonary Artery Pressure – Pulmonary Artery Occlusion Pressure Difference Is a Good Predictor of Pulmonary Hypertension World Health Organization Group 2; I.R. Preston, K.E. Roberts, S.E. Richter, N.S. Hill. Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center/Tufts University School of Medicine, Boston, MA.

(828) Exercise Testing as a Predictor of Pulmonary Hypertension at Time of Lung Transplant; M.N. Bartels,¹ C.P. Aaron,² H.F. Armstrong,¹ M. Bacchetta,³ ¹Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY; ²Medicine – Pulmonary, Allergy & Critical Care, Columbia University Medical Center, New York, NY; ³Department of Surgery, Columbia University Medical Center, New York, NY.

(829) Care Organisation for Pulmonary Arterial Hypertension in Developed Countries: A Survey; M. Delcroix,¹ Y. Adir,² A. Andreassen,³ A. Boonstra,⁴ B. Ekmeahag,⁵ P. Escribano,⁶ S. Gaine,⁷ N. Galie,⁸ S. Gibbs,⁹ M. Halme,¹⁰ M. Hoepfer,¹¹ P. Jansa,¹² I. Lang,¹³ S. Orfanos,¹⁴ A. Reis,¹⁵ I. Simkova,¹⁶ O. Sitbon,¹⁷ R. Speich,¹⁸ A. Torbicki.¹⁹ ¹Center for Vascular Pulmonary Diseases, Universitaire Ziekenhuizen Leuven, Leuven, Belgium; ²Pulmonary Division, Carmel Medical Center, Haifa, Israel; ³Cardiovascular & Pulmonary Disease, Oslo University Hospital, Oslo, Norway; ⁴Respiratory Diseases, VU Medisch Centrum, Amsterdam, Netherlands; ⁵Heart and Lung Division, Skane University Hospital and Lund University, Lund, Sweden; ⁶Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mater Misericordiae University Hospital, Dublin, Ireland; ⁸Institute of Cardiology, University of Bologna, Bologna, Italy; ⁹National Heart and Lung Institute, Imperial College of Science, London, United Kingdom; ¹⁰Respiratory Medicine, Helsinki University Central Hospital, Helsinki, Finland; ¹¹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; ¹²Department of Cardiology and Angiology, Charles University, Prague, Czech Republic; ¹³Department of Cardiology, Medical University of Vienna, Vienna, Austria; ¹⁴Critical Care & Pulmonary Hypertension Clinic, Attikon Hospital, Athens, Greece; ¹⁵Hospital Santo António, Porto, Portugal; ¹⁶Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia (Slovak Republic); ¹⁷Service de Pneumologie et Réanimation, Hôpital Antoine Bécélère, Clamart, France; ¹⁸Department of Internal Medicine, University

Hospital of Zurich, Zurich, Switzerland; ¹⁹Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Warszawa, Poland.

(830) Heart-Lung or Double Lung Transplantations for Pulmonary Endarterectomy Failure; O. Mercier, E. Fadel, S. Mussot, D. Fabre, F. Leroy Ladurie, F. Stephan, P. Darteville. Thoracic Surgery, Marie Lannelongue Hospital, Le Plessis Robinson, France.

(831) Predicting Survival in Pulmonary Arterial Hypertension in a Single Centre in Latin America; M. Diez, M.L. Talavera, L.E. Favaloro, F. Klein, J.O. Caneva, R.R. Favaloro. Intrathoracic Transplantation, Favaloro Foundation Hospital, Buenos Aires, Argentina.

(832) Determining Clinical Usefulness of the CAMPHOR Questionnaire; C. Glassner, S. Watson, M. Gombert-Maitland. University of Chicago, Chicago, IL.

(833) WITHDRAWN

(834) Circulating Levels of the Stromal Derived Factor 1 in Patients with Pulmonary Arterial Hypertension; N. Selimovic,¹ B. Andersson,¹ N. Bergh,¹ L. Mattsson Hultén,² E. Sakiniene,³ B. Rundqvist.¹ ¹Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Dept of Molecular Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden; ³Dept. of Rheumatology, Sahlgrenska University Hospital, Gotheburg, Sweden.

(835) Neovascularity in Patients with Idiopathic Pulmonary Arterial Hypertension; M.P. Tuppin,^{1,2} D. Chambers,^{1,2} R. Slaughter,³ O. Mohammed,³ F. Kermeen.² ¹School of Medicine, University of Queensland, Brisbane, QLD, Australia; ²Queensland Centre for Pulmonary Transplantation and Vascular Disease, Prince Charles Hospital, Brisbane, QLD, Australia; ³Medical Imaging, Prince Charles Hospital, Brisbane, QLD, Australia.

(836) Pulmonary Arterial Hypertension in Sweden: First Data from a National Registry; N. Selimovic,¹ B. Lövgren Ekmeahag,⁵ K. Jansson,³ F. Larsen,² S. Söderberg,³ G. Wikström.⁴ ¹Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Dept. of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden; ³Dept. of Cardiology, University Hospital Linköping, Linköping, Sweden; ⁴Dept. of Cardiology, Akademiska Hospital University of Uppsala, Uppsala, Sweden; ⁵Dept. of Cardiology, Umeå University Hospital, Umeå, Sweden; ⁶Norråtlje Hospital, Norrtälje, Stockholm, Sweden.

(837) Echocardiographic and Clinical Predictors of Outcome in Patients with Pulmonary Arterial Hypertension; F. Haddad,¹ R. Doyle,¹ A.Y. Denault,² M. Skhiri,¹ E. Spiekerkoetter,¹ V. de Jesus Perez,¹ K. Kudelko,¹ I. Schnittger,¹ R. Zamanian.¹ ¹Medicine, Stanford University, Palo Alto, CA; ²Anesthesia and Critical Care Medicine, Montreal Heart Institute, Montreal, QC, Canada.

(838) Differences in Mortality and Morbidity in Pulmonary Hypertension Secondary to Systolic vs. Diastolic Heart Failure; J.N. Salamon,¹ R. Zolty.² ¹Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY; ²Medicine, Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.

JUNIOR FACULTY CASE REPORT POSTERS

(CONGRESS FOYER TERRACE, 3RD FLOOR)

These posters will be on display Wednesday through Friday

(839) Successful Cardiac Transplantation with Takotsubo Cardiomyopathy Donor; A.P. Nair,¹ L. Murphy,¹ S. Pinney.¹ ¹Mount Sinai Medical Center, New York, NY; ²Mount Sinai Medical Center, New York, NY; ³Mount Sinai Medical Center, New York, NY.

(840) Successful Use of ECMO in a Jehovah's Witness after Complicated Heart Retransplantation; M.J. Russo,¹ P.J. Patel,¹ R. Malyala,¹ S. Fedson,² A. Anderson,² A. Shah,² D. Eton,³ V. Jeevanandam.¹ ¹Section of Cardiac and Thoracic Surgery, Department of Surgery, University of Chicago Medical Center, Chicago, IL; ²Section of Vascular Surgery, Department of Surgery, University of Chicago Medical Center, Chicago, IL; ³Section of Cardiology, Department of Medicine, University of Chicago Medical Center, Chicago, IL.

(841) Pomegranate-Induced Alterations in Tacrolimus Concentration; T. Khuu,¹ A.S. Baas,² R. Cheng,² D. Cruz,² A. Hickey,² B. Kubak,³ A. Nsair,² C. Holt,⁴ M.C. Deng.² ¹Heart Transplant, University of California, Los Angeles, CA; ²Medicine, Division of Cardiology, University of California, Los Angeles, CA; ³Medicine, Division of Infectious Disease, University of California, Los Angeles, CA; ⁴Surgery, Division of Liver & Pancreas Transplantation, University of California, Los Angeles, CA.

(842) Severe Hyperacute Rejection after Cardiac Transplantation Despite Recent Negative Panel of Reactive Antibodies (PRA) Successfully Ameliorated by Utilization of CentriMag Ventricular Assist Devices (VADs) for Biventricular Support and Treatment with Rituximab, Intravenous Immunoglobulin (IVIG), and Plasmapheresis Resulting in Complete Functional Recovery; D.J. Kaczorowski,¹ J. Datta,² M. Kamoun,³ T.A. Mickler,⁴ Y.J. Woo.¹ ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA; ²Department of Surgery, University of Pennsylvania, Philadelphia, PA; ³Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; ⁴Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA.

(843) Successful Heart Transplantation in a Patient with Common Variable Immunodeficiency; M. Sramko, M. Kubanek, J. Vrbska, I. Malek, J. Prik. Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(844) Early Recurrence of Cardiac Sarcoidosis 8 Weeks Post-Heart Transplantation; S.S. Cowan,¹ A. Cheung,² S. Virani,¹ J. Bashir,² A. Kaan,⁴ A. Ostry,³ M. Allard,³ A. Ignaszewski,¹ M. Toma.¹ ¹Department of Medicine, Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; ²Department of Cardiovascular Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada; ³Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; ⁴Department of Nursing, St. Paul's Hospital, Vancouver, Canada.

(845) A Rare Problem in Heart Transplantation: A Case of Haemophagocytic Syndrome; C. Bourgault, J. Morin, M.-H. Leblanc, M. Senechal, B. Cantin. Cardiology, IUCPG, Quebec, QC, Canada.

(846) Atrial Masses Post Cardiac Transplantation: Diagnostic and Treatment Dilemmas; J. Baumwol,¹ D.H. Delgado,¹ R.J. Cusimano,² V. Rao,² S. Kozusko,¹ J. Butany,³ H.J. Ross.¹ ¹Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, ON, Canada; ²Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; ³Division of Pathology, Toronto General Hospital, Toronto, ON, Canada.

(847) Two Young Women with a Soft Tissue Tumor of the Heart; S.I. Lok,¹ M.E.I. Schipper,² J.W.J. Hinrichs,² P.J. van Diest,² J.A.C. Post,³ I.O. Baas,⁴ R.A. de Weger,² N. de Jonge,¹ J.R. Lahpor.⁵ ¹Cardiology, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; ²Pathology, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; ³University Utrecht, Utrecht, Netherlands; ⁴Internal Medicine, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; ⁵Cardiothoracic Surgery, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands.

(848) Sinotubular Junctional Remodeling Aortic Valve Repair Technique To Eliminate Aortic Regurgitation in Donor Cardiac Allograft; D.J. Kaczorowski, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(849) Aborted Sudden Cardiac Death in a Long-Term Survivor after Orthotopic Heart Transplantation; G. Pogljajen, M. Fister, R. Okrajsek, M. Šebestjen, B. Vrtovec. Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia.

(850) Cardiac Transplant Outcomes of 3 Cases with Behcet's Disease; J. Huang,¹ S.S. Hu,¹ H.Y. Song,² W. Wang,² K.Z. Liao.¹ ¹State Key Laboratory of Translational Cardiovascular Medicine, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ²Cardiovascular Surgery, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

(851) Donor-Derived Toxoplasma Infection in a Post-Transplant Patient; K.K. Rao,¹ L.B. Cooper,¹ P.C. Patel,¹ S.Y. Wada.² ¹Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; ²Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX.

(852) Scopulariopsis Infection Following Lung Transplant: Lessons of Organ Procurement; J.L. Castilho,¹ G.G. Miller,¹ E.L. Grogan,² E.S. Lambricht,² J.S. Dummer,¹ J.E. Loyd,³ J. Fosnot,⁴ D.N. Cohen,⁵ I.M. Robbins.³ ¹Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN; ²Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; ³Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN; ⁴Transplant Center, Vanderbilt University Medical Center, Nashville, TN; ⁵Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.

(853) Chagas Disease in a Heart Transplant Patient; E. Blodgett,¹ M. Bowdish,² M. Barr,³ G. Zeger.⁴ ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; ²Surgery, University of California Keck School of Medicine, Los Angeles, CA; ³Pathology, University of California Keck School of Medicine, Los Angeles, CA.

(854) Fever 75 Days after Cardiac Transplantation; A. Muñoz, J. Segovia, M. Gómez-Bueno, M.D. García-Cosío, L. Alonso-Pulpón. Unidad de Trasplante Cardíaco, Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain.

(855) Phaeoacremonium parasiticum as a Cause of Cavitory Native Lung Nodules after Single Lung Transplantation; S.P. Nishi, S.K. Shah, G.A. Lombard, M.A. James, D.L. Beckles, S. Lick, V.G. Valentine. Texas Transplant Center, UTMB Health, Galveston, TX.

(856) Upregulation of Matrix Metalloproteinases and No Evidence of Chromosomal Changes in Mounier-Kuhn Syndrome: Report of a Case; K. Hoetzenecker,¹ A. Mitterbauer,¹ P. Birner,² M. Mildner,³ H. Prosch,⁴ B. Streubel,² S. Taghavi,¹ W. Klepetko,¹ H.J. Ankersmit.¹ ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ²Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; ³Department of Dermatology, Medical University of Vienna, Vienna, Austria; ⁴Department of Radiology, Medical University of Vienna, Vienna, Austria.

(857) Retransplantation for Disseminated Mycobacterium abscessus – How Did We Do That?; A.L. Rigby, R.F. Pearson, A. Havryk, M. Pliit, M. Malouf, A.R. Glanville. St Vincent's Hospital, Sydney, NSW, Australia.

(858) Donor Transmitted Klebsiella Infection Causing Sepsis and Mediastinitis after Heart Transplantation: Early Action Saved the Patient; E. Pektok, E. Oklu, Z.C. Karakoc, N. Arat, B. Ozuekren, F. Ece, D. Eker, C. Cifti, N. Yazicioglu, O. Bayindir, S. Kucukaksu. Heart Transplantation and Mechanical Circulatory Support Center, Florence Nightingale Hospital, Istanbul, Turkey.

(859) Mycobacterium genavense Infection in a Lung Transplant Recipient; V.L. Lorenzen,¹ S. Ohdah,² A. Costard-Jäckle,² T. Deuse,³ H.C. Reichen-spurner,³ ¹Department of Cardiology, Electrophysiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²Department of General and Interventional Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³Department of Cardiovascular Surgery, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

(860) Rapidly Fatal Disseminated Acanthamoebiasis in a Single Lung Transplant Recipient; A. BoydKing,¹ P.M. McFadden,² S. Ganesh,¹ C. Herring-ton,² K. Afshar.¹ ¹Pulmonary and Critical Care, University of Southern California, Keck School of Medicine, Los Angeles, CA; ²Cardiothoracic Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.

(861) Eculizumab for Treatment of Hyperacute Antibody-Mediated Lung Allograft Rejection; K.L. Dawson,¹ A.S. Kirumaki,² G.R. Honeycutt,² A. Parulekar,² H. Seethamraju.¹ ¹The Methodist Hospital, Houston, TX; ²Baylor College of Medicine, Houston, TX.

(862) Novel Approach for Treatment of Bronchial Dehiscence; E.V. Pinelis, N. Arora, P.S. Patel, C. Migliore, N. Shariati. Lung Transplant and Advanced Lung Diseases, Newark Beth Israel Medical Center, Newark, NJ.

(863) Lung Transplant Utilizing Cardiopulmonary Bypass in the Setting of Acute Heparin Induced Thrombocytopenia (HIT); H. Shah,¹ S.R. Knoper,² Y. Raz,² J.C. Daniel,¹ P.E. Nolan,³ M.J. Moulton.¹ ¹Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ; ²Division of Pulmonary and Critical Care, University of Arizona, Tucson, AZ; ³Pharmacy Practice and Science, University of Arizona, Tucson, AZ.

(864) Long-Term Follow-Up of Living-Donor Lobar Lung Transplantation for Diffuse Panbronchiolitis; S. Sugimoto,¹ T. Oto,¹ K. Miyoshi,¹ M. Yamane,¹ A. Nakatani,¹ K. Goto,² S. Miyoshi.¹ ¹Thoracic Surgery, Okayama University Hospital, Okayama, Japan; ²Anesthesiology, Okayama University Hospital, Okayama, Japan.

(865) Combined RV Outflow Tract (RVOT)-Single Lung Transplant: A Novel Approach for the Treatment of Chronic Pulmonary Valve (PV) Disease and Pulmonary Fibrosis (PF); G. Zanotti, M.G. Hartwig, R.D. Davis. Surgery, Duke University Medical Center, Durham, NC.

(866) Double Lumen Bi-Cava Cannula for Venovenous Extra Corporeal Membrane Oxygenation as Bridge to Lung Transplantation in Nonintubated Patient; J. Reeb, P.E. Falcoz, N. Santelmo, G. Massard. Lung Transplantation Team, Department of Thoracic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

(867) Management of Takotsubo Cardiomyopathy in a Lung Transplant Recipient in the Postoperative Setting; T.A. Ni Dhonnchu, A. Anwar, W. Bartosik, L. Nolke, J.J. Egan. Heart and Lung Transplantation, Mater Misericordiae University Hospital, Dublin, Ireland.

(868) Lung Transplant Recipients with a History of Treated Prostate Cancer: A Cedars-Sinai Lung Transplant Program Experience; D.I. Naim, G. Chaux. Pulmonary & Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

(869) Percutaneous Trans-Catheter Closure of the Native Aortic Valve To Treat De Novo Aortic Insufficiency after Implantation of a Left Ventricular Assist Device; A.P. Shah, M.J. Russo, B.H. Freed, J. Paul, V. Jeevanandam, A.S. Anderson, R. Lang. Medicine, The University of Chicago, Chicago, IL.

(870) Use of Membrane Oxygenator for Recurrent Respiratory Failure in Pediatric Berlin Biventricular Support; C.D. Castleberry, D. Bernstein, K. Maeda, S.A. Hollander, G.E. Wright, O. Reinhardt, D. Rosenthal. Stanford University School of Medicine, Palo Alto, CA.

(871) Small Arteriovenous Fistula Causing Persistent Right Heart Failure Symptoms Post Continuous Flow Left Ventricular Assist Device; M.A. Bowman, B. Rosen, M.N. Walsh, C.T. Salerno. Cardiology, St. Vincent Medical Center, Indianapolis, IN.

(872) HeartMate II as a Bridge to Weight Loss; B.C. Lampert, J.J. Teuteberg, R.L. Kormos. University of Pittsburgh Medical Center, Pittsburgh, PA.

(873) Novel Technique for Implanting a HeartMate II Left Ventricular Assist Device in the Presence of a Hostile Ventricle; P. Atluri, D.J. Dymond, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(874) Percutaneous Transcatheter Closure of the Aortic Valve To Treat Cardiogenic Shock in a Left Ventricular Assist Device Patient with Severe Aortic Insufficiency; M.J. Russo,^{1,3} B.H. Freed,² V. Jeevanandam,^{1,3} M. Hashmi,¹ J. Paul,² A. Anderson,² R.M. Lang,² A.P. Shah.^{2,3} ¹Section of Cardiac and Thoracic Surgery, Department of Surgery, University of Chicago, IL; ²Section of Cardiology, Department of Medicine, University of Chicago, IL; ³Center for Aortic Diseases, University of Chicago, IL.

(875) Long Term Efficacy of Long-Acting Octreotide for Recurrent Gastro-Intestinal Bleeding Due to Gastric Angiodysplasia in a Jarvik 2000 Recipient; G. Coutance,¹ V. Saplaçan,² A. Belin,² A. Pellissier,^{1,2} R. Sabatier,¹ M. Massetti.² ¹Cardiology, University Hospital Center of Caen, Normandy, France; ²Cardiac Surgery and Heart Transplantation, University Hospital Center of Caen, Normandy, France.

(876) Transapical Edge-to-Edge Mitral Valve Repair during Insertion of a Left Ventricular Assist Device; M.J. Russo,^{1,3} A.E. Merlo,¹ E.M. Johnson,¹ S.A. Akhter,^{1,3} A. Anderson,² V. Jeevanandam,^{1,3} J. Steiman,⁴ S. McCa-rney,⁵ ¹Section of Cardiac and Thoracic Surgery, Section of Surgery, University of Chicago Medical Center, Chicago, IL; ²Section of Cardiology, Department of Medicine, University of Chicago Medical Center, Chicago, IL; ³Center for Valve Disease, University of Chicago Medical Center, Chicago, IL; ⁴Department of Anesthesiology and Critical Care, University of Chicago Medical Center, Chicago, IL; ⁵Department of General Surgery, Division of Surgery, University of Chicago Medical Center, Chicago, IL.

(877) Improved Systemic Desaturation in Decompensated D-TGA Patient with Fontan Post LVAD Implantation; A.H. Abdul Jabbar,¹ W.J. Franklin,² R. Delgado,¹ O.H. Frazier,¹ L. Simpson, A. Civitello. ¹Advanced Heart Failure and Cardiac Transplant Unit, Texas Heart Institute at St. Luke's Episcopal Hospital/Baylor College of Medicine, Houston, TX; ²Adult Congenital Cardiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX.

(878) Hybrid Approach for Left Ventricular Pump Exchange in a Very High Risk Patient Utilizing Balloon Occlusion of the HeartMate II Left Ventricular Assist Device (LVAD) Outflow Graft; T.A. Timek, T. Wainscott, A. Khaghani, W. Merhi, M. Dickinson, R.L. Hooker. Cardiothoracic Surgery, Fred and Leena Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI.

(879) Explantation of a Temporary Implanted Right Ventricular Assist Device without Necessitating Re sternotomy; D. Saeed,¹ A. Albert,¹ H. Kamiya,¹ R. Westenfeld,² A. Lichtenberg.¹ ¹Clinic for Cardiovascular Surgery,

Heinrich-Heine University Duesseldorf, Duesseldorf, NRW, Germany; ²Clinic for Cardiology, Pneumology and Angiology, Heinrich-Heine University Duesseldorf, Duesseldorf, NRW, Germany.

(880) WITHDRAWN

(881) Catheter Ablation of Atrial Flutter in Patients with HeartMate II Left Ventricular Assist Device Improves Symptoms of Right Ventricular Dysfunction; R.U. Hottigoudar,¹ A.G. Deam,¹ E.J. Birks,¹ K.C. McCants,¹ M.S. Slaughter,² R. Gopinathannair.¹ ¹Division of Cardiovascular Medicine, University of Louisville, Louisville, KY; ²Division of Cardiothoracic Surgery, University of Louisville, Louisville, KY.

(882) Minimally Invasive Insertion of CentriMag Left Ventricular Assist Devices Via a Right Mini-Thoracotomy; D.J. Kaczorowski, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(883) A Rare Disorder Requiring a Left Ventricular Assist Device; R. Hasan, K.D. Aaronson, F.D. Pagani, T.M. Koelling. Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI.

(884) Extended “Temporary” Use of Levitronix CentriMag Right Ventricular Assist Device; D. Saeed, A. Albert, H. Kamiya, A. Lichtenberg. Clinic for Cardiovascular Surgery, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

(885) Berlin Heart EXCOR® Use in Pediatric Restrictive Cardiomyopathy: A Case Report; C.R. Pockett, J.M. Rutledge, D.B. Ross, H. Buchholz. Stollery Children’s Hospital, Edmonton, AB, Canada.

(886) Extracorporeal Life Support (ECLS): The Silver Bullet; E.L. Bush,¹ C.W. Hoopes,² L. Martin,¹ M. Brzezinski,³ J. Kukreja.¹ ¹Department of Cardiothoracic Surgery, University of California San Francisco, CA; ²Department of Cardiopulmonary Transplantation, University of Kentucky, Lexington, KY; ³Department of Anesthesia, University of California San Francisco, CA.

(887) Hemolysis as a Marker for Thrombosis in Centrifugal Flow LVAD and the Role of Thrombolytic Therapy; A.H. Abdul Jabbar,¹ R. Yau,² O.H. Frazier,¹ R. Delgado.¹ ¹Advanced Heart Failure and Cardiac Transplant Unit, Texas Heart Institute at St. Luke’s Episcopal Hospital/Baylor College of Medicine, Houston, TX; ²Cardiology, Baylor College of Medicine, Houston, TX.

(888) Management of Excessive Menorrhagia in a Young Female on the Cardiowest Total Artificial Heart; C. Piercecchi, J. Swan, P. Pomeroy, P. Nolan, R. Smith, M.C. Smith. Cardiothoracic Surgery, University of Arizona, Tucson, AZ.

(889) A Heart Transplant Candidate of Severe Pulmonary Hypertension with Extremely High Pulmonary Vascular Resistance; N. Morikawa,¹ O. Seguchi,² T. Satou,² H. Sunami,² Y. Murata,² M. Yanase,² T. Fujita,³ K. Toda,³ T. Nakatani.² ¹Division of Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan; ²Transplant, National Cerebral and Cardiovascular Center, Osaka, Japan; ³Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.

(890) First Report of Bilateral Epicardial Pulmonary Vein Isolation during Heartmate II Left Ventricular Assist Device Implantation; E.M. Hoenicke,¹ M.B. Cishek,² O.S. Gigliotti,² J. Sanchez.² ¹Cardiothoracic & Vascular Surgeons, Seton Medical Center, Austin, TX; ²Seton Heart Institute, Seton Medical Center, Austin, TX.

(891) Oncologic Challenges in a Patient Supported by Left Ventricular Assist Device (LVAD); E. Ammirati, S. Cantoni, M. Cipriani, A. Garascia, F. Oliva, C. Russo, A. Verde, C. Vittori, F. Milazzo, L. Martinelli, M. Frigerio. Cardiovascular Department, Niguarda Ca’ Granda Hospital, Milan, Italy.

(892) Implantation of a Left Ventricular Assist Device in a Patient with a Concomitant Subcutaneous Implantable Cardioverter Defibrillator; D. Saeed, A. Albert, A. Lichtenberg, J. Winter. Clinic for Cardiovascular Surgery, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

(893) LVAD Outflow Graft Pseudoaneurysm Masquerading as Sepsis; A. Aggarwal,¹ G. Patel,² A. Tatoes,³ P.S. Pappas,³ G. Bhat.¹ ¹Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn; ²Cardiology, Advocate Christ Medical Center, Oak Lawn; ³Cardiothoracic Surgery, Advocate Christ Medical Center, Oak Lawn.

(894) Successful Management of Late Right Ventricular Failure after Heartmate II Implantation with Percutaneous TandemHeart and Tricuspid Valve Repair; R.L. Hooker, T. Wainscott, T.A. Timek, M. Dickinson, A. Khaghani. Cardiothoracic Surgery, Fred and Leena Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI.

(895) Use of BIVAD and ECMO for the Treatment of Peripartum Cardiomyopathy; S. Kumar,¹ D. Jacoby,² A.A. Mangi.¹ ¹Section of Cardiac Surgery, Yale University School of Medicine, New Haven, CT; ²Section of Cardiology, Yale University School of Medicine, New Haven, CT.

(896) Dor Ventriculoplasty with Transventricular Mitral Valve Repair; D.J. Kaczorowski, M. Blank, Y.J. Woo. Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA.

(897) A Novel Way To Identify Donor Specific Antibody in Pediatric Heart Transplant; R.K. Ameduri. Pediatric Cardiology, University of Minnesota Amplatz Children’s Hospital, Minneapolis, MN.

(898) WITHDRAWN

(899) Life-Saving Single Living-Donor Lobar Lung Transplantation for Rapidly Deteriorating Pulmonary Venous Occlusive Disease; K. Takahashi,¹ F. Chen,¹ H. Kayawake,¹ T. Ikeda,² H. Ishii,³ D. Nakajima,¹ J. Sakamoto,¹ A. Ohsumi,¹ H. Motoyama,¹ K. Okita,¹ K. Hijiya,¹ H. Doi,⁴ A. Aoyama,¹ M. Sato,¹ T. Bando,¹ H. Data.¹ ¹Thoracic Surgery, Kyoto University, Kyoto, Japan; ²Cardiovascular Surgery, Kyoto University, Kyoto, Japan; ³Anesthesiology, Kyoto University, Kyoto, Japan; ⁴Pediatrics, Kyoto University, Kyoto, Japan.

(900) A Three Month Course of Pre-Operative Extracorporeal Membrane Oxygenation Culminating in Pediatric Lung Transplantation; Y. Raz,¹ J.C. Daniel,² H. Shah,² P.E. Nolan,³ S.R. Knoper,¹ M.J. Moulton.² ¹Division of Pulmonary and Critical Medicine, University of Arizona, Tucson, AZ; ²Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ; ³Pharmacy Practice & Science, University of Arizona, Tucson, AZ.

(901) An Apparent Case of Undiagnosed Donor Kawasaki Disease Manifesting as Coronary Artery Aneurysms in a Pediatric Heart Transplant Recipient; J.M. Friedland-Little, R. Aiyagari, K.R. Schumacher. Division of Pediatric Cardiology, University of Michigan, Ann Arbor, MI.

(902) Massive Hemoptysis as a Marker of Treprostinil Induced Platelet Dysfunction in a Pulmonary Hypertension Patient; F. Rischard,¹ K. Knox,¹ L. Hanson,¹ S. Knoper,¹ P. Nolan.² ¹Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ; ²Department of Pharmacology, University of Arizona, Tucson, AZ.


(903) Tadalafil Therapy in Exercise Induced Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction; D.C. Ishizawa, M.A. Simon. Cardiology, University of Pittsburgh, School of Medicine, Pittsburgh, PA.

EXHIBITING COMPANIES

Alphabetical List of Exhibitors


Avalon Laboratories	9	Montreal Convention Bureau	13
Bayer Pharma AG	12	Novartis Pharma AG	4
Berlin Heart	19	One Lambda, Inc.	17
CardiacAssist, Inc.	7	Scanlan International, Inc.	25
CircuLite GmbH	26	Sunshine Heart	16
CorMatrix Cardiovascular, Inc.	10	SynCardia Systems, Inc.	14
CSL Behring	31	Therakos	11
Cylex, Inc.	23	Thoratec Corporation	5
Elsevier	6	TransMedics, Inc.	1
Euromacs	32	United Therapeutics Europe LTD	3
HeartWare	2	Vivoline Medical AB	28
IMACS Registry	22	XDx	8
ISHLT Thoracic Transplant Registry	29	XVIVO Perfusion AB	21
Jarvik Heart, Inc.	20		
MicroMed CV	24		

EXHIBIT HALL FLOORPLAN



2ND FLOOR

The Junior Faculty Case Report Posters are located on the 3rd floor of Prague Congress Centre.



LIST OF EXHIBITORS

- | | | | |
|-----------|--------------------------------|-----------|------------------------------------|
| 1 | TransMedics, Inc. | 16 | Sunshine Heart |
| 2 | HeartWare | 17 | One Lambda, Inc. |
| 3 | United Therapeutics Europe LTD | 19 | Berlin Heart |
| 4 | Novartis Pharma AG | 20 | Jarvik Heart, Inc. |
| 5 | Thoratec Corporation | 21 | XVIVO Perfusion AB |
| 6 | Elsevier | 22 | IMACS Registry |
| 7 | CardiacAssist, Inc. | 23 | Cylex, Inc. |
| 8 | XDx | 24 | MicroMed CV |
| 9 | Avalon Laboratories | 25 | Scanlan International, Inc. |
| 10 | CorMatrix Cardiovascular, Inc. | 26 | CircuLite GmbH |
| 11 | Therakos | 28 | Vivoline Medical AB |
| 12 | Bayer Pharma AG | 29 | ISHLT Thoracic Transplant Registry |
| 13 | Montreal Convention Bureau | 31 | CSL Behring |
| 14 | SynCardia Systems, Inc. | 32 | Euromacs |

Avalon Laboratories, LLC

801 Michigan St. NE, Ste 500
Grand Rapids, MI 49503
Web address: www.avalonlabs.com

BOOTH NUMBER: 9

Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite® is the company's premium line of advanced catheters providing important solutions for patients receiving extracorporeal support. With a wide range of sizes, the Avalon Elite Bi-Caval Dual Lumen Catheter is the world's first minimally invasive, kink resistant, veno-venous catheter available for both pediatrics and adults.

Bayer Pharma AG

Mullerstrasse 178
13353 Berlin Germany
Web address: www.bayerpharma.com

BOOTH NUMBER: 12

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 16.913 Billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Berlin Heart

Wiesenweg 10
12247 Berlin
Germany
Web address: www.berlinheart.com

BOOTH NUMBER: 19

Berlin Heart is the only company worldwide that develops, produces and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns children, adolescents, and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow LVAD for adults. INCOR® is the only 3rd generation axial flow pump with CE-mark approval.

The Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric) is approved for use by the FDA under a Humanitarian Device Exemption. All other products are not FDA approved.

CardiacAssist, Inc.

240 Aopha Dr.
Pittsburgh, PA, 15238
Web address: www.tandemheart.com

BOOTH NUMBER: 7

CardiacAssist's TandemHeart System is used by both Cardiologists and Cardiac Surgeons to initiate high flow extracorporeal circulatory support in minutes. Utilizing a femoral venous approach and transeptal cannulation of the left atrium, the TandemHeart system unloads the left ventricle and allows the heart to rest. The system maintains end organ perfusion with flow rates up to 5.0 L/min when placed percutaneously and up to 8.0 L/min with direct surgical cannulation.

Circulite GmbH

250 Pehle Ave.
Park 80 West, Suite 403
Saddle Brook, NJ 07663
Web address: www.circulite.net

BOOTH NUMBER: 26

CircuLite, Inc. (Saddle Brook, NJ and Aachen, Germany) is transforming heart failure treatment with the development of a platform of minimally-invasive, long term partial circulatory support devices. By enabling a proactive and lower-risk treatment approach through supplementing a patient's native cardiac pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients.

CircuLite's Synergy® Micro-Pump, the world's smallest implantable blood pump, weighs 25g and provides up to 4.25 L/min flow.

For more information on CircuLite and the Synergy Micro-pump devices, visit our website at www.CircuLite.net.

CorMatrix Cardiovascular, Inc.

286 S. Main St, Ste 200
Alpharetta, GA 30009
Web address: www.cormatrix.com

BOOTH NUMBER: 10

CorMatrix® Cardiovascular markets its ECM® Technology biomaterial devices for pericardial closure, cardiac tissue repair and carotid repair and is currently conducting preclinical studies to evaluate future applications in heart failure as well as other cardiovascular applications.

CSL Behring

1020 First Ave
King of Prussia, PA 19406
Web Address: cslbehring-us.com

BOOTH NUMBER: 31

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders and immune deficiency disorders. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring-us.com.

Cylex, Inc.

8980-I Old Annapolis Road
Columbia, MD 21045
Web address: www.cylex.net

BOOTH NUMBER: 23

Cylex™ is a global life sciences company developing and manufacturing in vitro diagnostic products that illuminate immunity. Its patented technology provides an innovative platform to assess immune cell function – providing insight for individualized patient management and opportunities for developing additional assays for diseases, and companion diagnostics for treatments affecting the immune system.

ImmuKnow®, Cylex's FDA-cleared product, is a noninvasive biomarker of immune function used by clinicians to manage and optimize immunosuppression in transplant patients.

Elsevier

32 Jamestown Road, London, NW1 7BY, UK
Web address: www.elsevier.com

BOOTH NUMBER: 6

ELSEVIER, a premier worldwide health science publishing company, presents *The Journal of Heart and Lung Transplantation*, the official journal of The International Society for Heart & Lung Transplantation. Please stop by our booth to view the latest issue of the journal and browse our selection of publications in the field of Transplantation.

EUROMACS (European Registry for Patients with Mechanical Circulatory Support)

Augustenburger Platz 1
Berlin, Germany 13353
Web Address: www.euromacs.org

BOOTH NUMBER: 32

EUROMACS unites individual medical professionals and institutions with the goal of running a European registry for data from patients with mechanical circulatory support (MCS) systems. The data collected will be made available for research purposes and facilitate medical studies that will serve to improve the care of patients with MCS. Further, the registry will allow comparison between European and international MCS data.

HeartWare

205 Newbury Street, Suite 101
Framingham, MA 01701
Web address: ww.heartwareinc.com.au

BOOTH NUMBER: 2

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB/IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.

IMACS (ISHLT Mechanically Assisted

Circulatory Support) Registry

701 19th St. S., LHRB 790

Birmingham, AL 35294

Web Address: www.isHLT.org/registries/mcsdDatabase.asp

BOOTH NUMBER: 22

Launched on April 1, 2012, the **ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry** is a new mechanical circulatory support registry designed to capture data on MCS devices from any non-US center. IMACS is an initiative of ISHLT, and is managed by UMACS, a non-profit research group at the University of Alabama at Birmingham, in cooperation with UNOS. IMACS is a high-quality database focused on collecting accurate, complete, and verifiable MCS data. IMACS data will be combined with the INTERMACS dataset to provide “scientific quality” analyses to seek truths in the global application of durable MCS.

ISHLT Thoracic Transplant Registry

700 North 4th Street

Richmond, Virginia 23219

Web address: www.isHLT.org

BOOTH NUMBER: 29

The **ISHLT Thoracic Transplant Registry** was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT Transplant Registry participants. In addition, data screens can be reviewed and we will provide guidance on enrollment, submission of data and data request services.

Jarvik Heart, Inc.

333 West 52nd Street

New York, NY 10019-6238

Web address: www.jarvikheart.com

BOOTH NUMBER: 20

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

MicroMed CV

Erfstraat 10 a

5405 BE Uden

The Netherlands

Web address: www.micromedcv.com

BOOTH NUMBER: 24

HeartAssist 5® LVAD System Description:

At 92 grams and up to 10 Liters/Minute, the HeartAssist 5® LVAD System is one of only 2 full-output, pumps small enough to be consistently implanted above the diaphragm and which provides the ability to accurately measure blood flow through the exclusive, implantable Flow Probe.

This, combined with the unique ability to closely monitor pump operating parameters and flow data remotely over the internet through the exclusive HeartAssistRemote™ Monitoring System, creates an overall superior value proposition to clinicians and patients which is unparalleled in the industry today.

Novartis Pharma AG

Postfach

Basel, CH-4002

Switzerland

Web address: www.novartis.com

BOOTH NUMBER: 4

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas.

In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group.

Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>. Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>.

One Lambda, Inc.

21001 Kittridge St
Canoga Park, CA 91303
Web address: www.onelambda.com

BOOTH NUMBER: 17

Visit **One Lambda's** booth to learn more about the company's revolutionary LABScreen Single Antigen product line. Single Antigen beads serve as the optimal tool to identify Donor-Specific Antibodies (DSA) in transplant patients, which can significantly affect graft survival. Also take the opportunity to collect information on the newest product from One Lambda, the C1Q Screen. This product is designed to distinguish complement-binding antibodies from those that do not bind complement; another important piece of information when analyzing the profile of antibodies. Our experts will be available to discuss the role of DSA in antibody mediated rejection and more.

Scanlan International, Inc.

One Scanlan Plaza
Saint Paul, Minnesota 55107
Web address: www.scanlaninternational.com

BOOTH NUMBER: 25

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN®LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; NEW Axial Handle needle holders and forceps, SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

Sunshine Heart

12988 Valley View Road
Eden Prairie, MN 55344
Web Address: www.sunshineheart.com

BOOTH NUMBER: 16

The C-Pulse Heart Assist System is an extra-aortic balloon pump using counter-pulsation technology to treat moderate to severe heart failure (Class III/IV). It can be performed minimally invasively, is placed outside the bloodstream, and the patient has the ability to disconnect from the system. It is designed to improve heart function by increasing cardiac output, increasing coronary blood flow and decreasing afterload. C-Pulse's goal is to halt the progression of heart failure. The FDA feasibility clinical study results showed promising results with the reduction of NYHA classification in 80% of the patients. CE mark is expected in mid-2012.

SynCardia Systems, Inc.

1992 E Silverlake Rd
Tucson, AZ 85713
Web address: www.syncardia.com

BOOTH NUMBER: 14

The **SynCardia** temporary Total Artificial Heart (TAH-t) is the world's only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom™ portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit our booth for updates on the study, Companion 2 Driver System and the 50cc TAH-t.

Therakos

Pinewood Campus Nine Mile Ride
Workingham, United Kingdom RG40 3EW
Web address: www.therakos.com

BOOTH NUMBER: 11

Therakos Inc., a Johnson & Johnson company, develops and manufactures systems focused on immune cell therapies. Therakos Inc., a pioneer in photopheresis therapy for more than 20 years, currently markets the world's only approved integrated systems for the provision of extracorporeal photopheresis (ECP) – the new THERAKOS™ CELLEX™ Photopheresis System and the THERAKOS™ UVAR™ XTS™ Photopheresis System.

Extracorporeal (outside the body) photopheresis can be used in the treatment of various immune mediated diseases, and is predominantly used for the treatment of cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease (GVHD).

Therakos Inc. is actively engaged in basic research and actively supports innovative independent studies within the academic and medical community.

Therakos Inc. has a commercial presence in 126 centres in 26 countries, with its research and manufacturing headquarters based in the US.

Thoratec Corporation

6035 Stoneridge Drive
Pleasanton, CA 94588
Web address: www.thoratec.com

BOOTH NUMBER: 5

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the Heart-Mate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. For more information, visit the company's website at <http://www.thoratec.com>.

TransMedics, Inc.

200 Minuteman Road, Suite 302
Andover, MA 01810
Web address: www.transmedics.com

BOOTH NUMBER: 1

TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and in pivotal FDA clinical trials in leading global heart & Lung transplant centers comparing the OCS™ to cold storage.

United Therapeutics Europe LTD

Onither House, Curfew Bell Road
Chertsey, Surrey, United Kingdom
Web address: www.unither.com

BOOTH NUMBER: 3

Remodulin® (treprostinil) Solution for Infusion, United Therapeutics, is a prostacyclin analogue indicated to improve exercise capacity and symptoms of patients diagnosed with idiopathic or heritable pulmonary arterial hypertension (PAH) with New York Heart Association (NYHA) functional class (FC) III symptoms.

In much of Europe, Remodulin is available for administration via the subcutaneous route and will be available via the intravenous route in selected European markets in 2012.

United Therapeutics remains committed, through its ongoing R & D activities to assist, support and meet the needs of PAH patients around the world.

Vivoline® Medical AB

Scheelevägen 17
SE – 223 70 Lund
Sweden
Web address: www.vivoline.se

BOOTH NUMBER: 28

VivoLine® LS1.....a new opportunity!

VivoLine® LS1 is intended for reconditioning, evaluation and cold preservation of lungs ex-vivo after lung donation and prior to transplantation. The system provides a simplified method that can perform an ex-vivo evaluation in a safe and controlled way, based on previous research for treating lungs ex-vivo. The possibility to test marginal lungs provides the opportunity to increase the number of organs available for transplantation. It is a compact system which can be set up quickly and easily. The organs can be stored in the system until next day for daytime surgery.

XDx

3260 Bayshore Blvd
Brisbane, CA 94005
Web address: www.allomap.com

BOOTH NUMBER: 8

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.

XDx has one marketed product, AlloMap® Molecular Expression Testing, and other products under development.

XVIVO Perfusion AB

Box 9080
SE - 400 92 Göteborg
SWEDEN
Web address: www.xvivoperfusion.com

BOOTH NUMBER: 21

XVIVO Perfusion AB (Part of the Vitrolife Group) manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve, evaluate and recondition organs and tissues prior to transplantation. Two of our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex-vivo organ evaluation and reconditioning. (*approved in US for research purposes only*).

XVIVO aims to:

- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs and tissues.
- extend the safe ex-vivo preservation time for organs and tissues prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.

FUTURE MEETINGS



MONTREAL

33RD ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS
PALAIS DES CONGRÈS DE MONTRÉAL
APRIL 24-27, 2013



SAN DIEGO

34TH ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS
MANCHESTER GRAND
APRIL 9-12, 2014














See you next year!

Gilead is committed
to expanding
healthcare options
for individuals living with
cardiovascular and pulmonary
disease through innovative
research, access, and
education programs.



14673 Midway Road, Suite 200
Addison, TX75001
P: 972-490-9495
F: 972-490-9499
www.isHLT.org

INSIDE BACK COVER
FOR POSTIION ONLY
PRINTS CMYK



In you, we see the future of transplant medicine.

The future of transplant medicine has always been fuelled by individual efforts and collective experience.

At Astellas Transplant, we continuously seek to improve our knowledge of transplantation. We always look forward to the challenges ahead and strive to work in partnership with you to advance the future of transplantation.

Our goal is to support you in improving the quality of your patients' lives—today and tomorrow. Whether it's with our cornerstone therapies, our innovative compounds in development, or our support of transplant associations, clinical studies, and fellowships, we're continually looking for ways to anticipate and meet your needs, and the needs of your patients.

Together, we can advance the future of transplantation.

BACK COVER
FOR POSITION ONLY
PRINTS CMYK



ADVANCING TRANSPLANTATION—TOGETHER

© 2012 Astellas Pharma Europe Ltd. TX/12/0001/EU January 2012